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SUMMARY 
Background 
The elderly account for an increasing proportion of the population and have a high prevalence of 
coronary artery disease (CAD). Therefore, elderly patients represent an increasing proportion of 
those presenting for investigation and treatment of CAD. Management of CAD is undertaken to 
relieve the signs and symptoms of myocardial ischaemia, making quality of life (QoL) a critical 
consideration in clinical decision making. CAD is associated with both chronological and 
biological ageing processes. However, conflicting evidence exists as to whether leucocyte 
telomere length (LTL) is an appropriate biomarker of ageing in CAD.  
 
Methods 
The thesis comprised four complementary studies. Firstly, secondary data analysis of  the 
Scottish Coronary Revascularisation Register was used to undertake two retrospective cohort 
studies of patients attending for coronary angiography and percutaneous coronary 
revascularization. The aim was to compare case mix and outcomes of elderly versus younger 
patients. A prospective cohort study of 437 patients was then undertaken to assess QoL before, 
and three months after, PCI and to compare QoL changes in elderly versus younger patients. 
Finally a cross sectional study was used to investigate the association between LTL (T/S ratio -
relative ratio of repeat to single copy number) measured using qPCR and CAD (presence and 
severity) in 1,846 patients attending a regional cardiovascular centre for coronary angiography.  
 
Results  
The number and proportion of elderly patients undergoing coronary angiography increased 
from 669 (8.7%) in 2001 to 1,945 (16.8%) in 2010. Among the elderly (≥ 75 years old), 
symptoms were more severe and disease more extensive compared to patients aged <75 
years.  Peri-procedural complications were infrequent irrespective of age: 2.0% of elderly 
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patients suffered complications, compared with 1.6% of young patients (p<0.001). Thirty-
day MACCE were more common in elderly compared with younger patients (2.0% vs 1.6%, 
p<0.001). Elderly patients with evidence of stenosis were less likely to proceed to 
revascularisation (adjusted OR 0.68, 95% CI 0.65–0.71, p<0.001) within one year of 
angiography, irrespective of disease severity. 
There was an increase in the number and percentage of PCIs undertaken in elderly patients, from 
196 (8.7%) in 2000 to 752 (13.9%) in 2007. Compared with younger patients, the elderly were 
more likely to have multivessel disease, multiple comorbidity, and a history of myocardial 
infarction or coronary artery bypass grafting (χ2 tests, all P<0.001). Compared with younger 
patients, the elderly having PCI were more likely to have multivessel disease, multiple 
comorbidity, and a history of myocardial infarction or coronary artery bypass grafting (χ2 tests, 
all p<0.001). The elderly had a higher risk of MACE within 30 days of PCI (4.5% versus 2.7%, 
χ2 test p<0.001) 
Following PCI, mean QoL improved in both elderly and younger patients. Elderly participants 
had higher baseline mental component score (MCS) but lower physical component score (PCS). 
After adjusting for baseline differences, QoL (both physical and mental components) in elderly 
patients improved as much as younger patients, following PCI (SF-12
 v2 MCS 50.0(SD 10.4) to 
53.0(SD 11.9) vs 46.7(SD 11.1) to 49.7(SD 11.1), p=0.652; and SF-12
 v2 PCS 37.6(SD 10.1) to 
41.9(SD 10.1) vs 39.7(SD 10.0) to 45.6(SD 10.8), p=0.373). 
An inverse relationship was found between LTL (T/S ratio) and age. No statistically significant 
difference was found in mean T/S ratio between those with and without CAD (0.87(SD 0.21) vs 
0.89(SD 0.21), p=0.091), even after adjusting for baseline characteristics.  In addition, there was 
no staistically significant difference in relative T/S length by severity of disease in those found 
to have stenosis on cardiac angiography: 0.875 (SD 0.211) vs 0.875 (SD 0.212) vs 0.860 (SD 
0.203) vs 0.867 (SD 0.200), p=0.670 
 
 
 
7 
Conclusions 
This thesis has demonstrated that, in Scotland, elderly patients account for an increasing 
number and proportion of diagnostic coronary angiograms and PCIs.  However, the threshold  
for  investigation  and  subsequent intervention appears to be higher among the elderly, even 
after adjusting for co-morbidities. While elderly patients have a higher risk of early 
complications than younger patients, their absolute risk is, nonetheless, low. This suggests 
that coronary angiography and PCI are safe procedures to perform  in  the  elderly. Following 
PCI, the QoL of elderly patients improves at least as much as in younger patients.  
 
A recognized risk factor for CAD is chronological age, and there is increasing interest in 
whether biological age contributes to the development and progression of disease and can 
explain socioeconomic inequalities in health. However, the current thesis found no association  
between LTL and either the occurrence or severity of CAD, or its severity on cross-sectional 
study. While LTL is considered a useful biomarker of ageing, these findings suggest that LTL 
may not be as useful in CAD.   
Although findings suggest that coronary angiography and PCI are safe procedures in the 
elderly, results of this thesis suggest an age-based inequality in access to coronary artery 
investigation and intervention that is not explained by differences in demographic trends, 
levels of need, potential risk or potential benefit. These findings have significant implications 
for the delivery of cardiovascular clinical services to an increasing elderly population. 
Further investigation should be undertaken upstream of these studies, on patients referred for 
investigation rather than just those receiving it to determine the extent to which there are 
inequalities in referral threshold as well as procedure threshold. Further research is also 
required  to identify those elderly patients who would most benefit from earlier investigation 
and management. There is also a need for longitudinal studies to assess the usefulness of 
LTL as a biomarker of ageing in CAD and to investigate whether LTL is associated with 
adverse outcomes in patients diagnosed with CAD.  
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1.   INTRODUCTION 
1.1. Overview of thesis  
This thesis comprises of four complimentary studies that investigate the association between 
chronological and biological ageing in coronary artery disease (CAD). The elderly (when 
defined in terms of chronological age (time since birth) – see below for further discussion on 
chronological age cut-offs for defining elderly) account for an increasing proportion of the 
population and have a high prevalence of CAD.1 Therefore, elderly patients also represent an 
increasing proportion of those presenting for investigation and treatment of CAD.2 Early 
diagnosis and interventions in CAD are effective at alleviating signs and symptoms of CAD in 
both elderly and younger patients.3 However, there is evidence that elderly patients are subject to 
inequalities in relation to both access to investigations and interventions for CAD, and in 
participating in clinical trials in this context.4 This inequality may be partially explained by 
concerns over adverse outcomes because the morbidity and mortality associated with invasive 
CAD investigations and interventions are known to be strongly associated with chronological 
age.5 In addition, elderly patients have been found to have more advanced disease than younger 
patients when presenting for treatment and investigation of CAD.6 It is unclear whether later 
presentation explains the increased risk of adverse outcomes, or whether it is associated with 
multiple comorbidity. There is, therefore, a need to investigate factors in elderly patients relating 
to outcomes of investigations and interventions of CAD.  
The first two studies in this thesis are secondary data analyses which were undertaken to 
examine whether elderly patients undergo coronary angiography at a more advanced stage of 
disease, whether they are less likely to proceed to revascularisation if CAD is confirmed (see 
Chapter 4.1), and whether any inequalities in management appear justified by a high risk of peri-
procedural complications following percutaneous coronary intervention (PCI) elderly patients 
(see Chapter 4.2).  
In addition, inequalities may be associated with perceived lack of benefits to elderly patients 
following PCI. However, the management of CAD by PCI is primarily undertaken to relieve the 
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signs and symptoms of myocardial ischaemia, rather than survival.7 This makes quality of life 
(QoL) a critical consideration for clinical decision making at all ages. For elderly patients, an 
especially important clinical issue is weighing any increased risk of adverse outcomes in the 
elderly against improvements in QoL. While Study 2 aims to establish if elderly patients do 
indeed have higher risk of adverse outcomes following PCI, Study 3, assesses the impact of PCI 
on QoL in elderly compared with younger patients. This is a prospective cohort study of 437 
patients that assesses QoL before, and three months after, PCI. The main aim was to compare 
QoL changes in elderly versus younger patients (ReQoL: REvacularisation and Quality of Life – 
Chapter 4.3). Together, the findings of these two studies will contribute to clinical decision-
making in relation to interventions for CAD in the elderly. 
The first three studies in this thesis define age as chronological i.e. the number of years a patient 
has lived. However, there is currently much interest in whether biological ageing, rather than 
chronological ageing, may provide a better measurement of age related risks.8 Biological ageing 
involves variable, structural and functional changes that take place at the cellular, tissue and 
organ level; ultimately affecting the overall performance of the body.9 It is thought to vary 
between individuals of the same chronological age and increase susceptibility to ill health and 
disease. If so, biomarkers of biological ageing, rather than chronological age, may provide a 
more effective basis for clinical decision-making in relation to investigation and treatment in 
patients with CAD. A number of biomarkers of ageing have been explored, including telomere 
length.10 However, conflicting evidence exists as to whether leucocyte telomere length (LTL) is 
an appropriate biomarker of ageing in CAD.11 The final study in this thesis aims to provide 
preliminary evidence as to the potential utility of relating telomere length to presence and 
severity of CAD, as a precursor to investigating whether it would be more useful than 
chronological age in predicting clinical outcomes. Therefore, a cross sectional study design was 
used to investigate the association between LTL (gene ratio -relative ratio of repeat to single 
copy number) measured using qPCR (quantitative polymerase chair reaction) and CAD (its 
presence and severity) in 1,846 patients attending a regional cardiovascular centre for coronary 
angiography (see Chapter 4.4).  
 
 
17 
Overall thesis objectives, by individual study: 
Secondary data analysis using the Scottish Cardiac Revascularisation Register: diagnostic 
coronary angiography (Study 1)  
• to explore time trends in numbers and proportion of elderly patients attending for 
diagnostic angiography 
• to assess the baseline chacteristics of patients attending for diagnostic coronary 
angiography 
• to compare baseline case-mix between elderly and younger patients 
• to compare clinical outcomes (revascularisation rates and adverse outcomes) between 
elderly and younger patients attending for diagnostic angiography after adjusting for 
baseline characteristics 
Secondary data analysis using the Scottish Cardiac Revascularisation Register: PCI 
procedures (Study 2) 
• to explore time trends in numbers and proportion of elderly patients attending for PCI 
• to assess the baseline chacteristics of patients attending for PCI 
• to compare baseline case-mix between elderly and younger patients 
• to compare clinical outcomes between elderly and younger patients attending for PCI 
after adjusting for baseline characteristics 
 
ReQoL (Study 3) 
• to assess the baseline QoL in patients undertaking PCI using generic and disease specific 
tools; 
• to assess QoL at 3 months post PCI using generic and disease specific tools; 
• to compare differences between baseline and 3 months QoL 
• to compare differences and changes in QoL between elderly and younger patients 
• to use routine hospital data to assess baseline characteristics (such as demographics, 
comorbidity etc.) and severity of CAD  
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Biological ageing and CAD (Study 4) 
• to use routine hospital data to assess baseline characteristics (such as demographics, 
comorbidity etc.) and severity of CAD in a cohort of patients attending for diagnostic 
angiography 
• to undertake LTL analyses in a cohort of patients attending for diagnostic angiography 
• to compare LTL between those with and without CAD  
The research evidence and theoretical underpinnings in relation to the four studies are discussed 
in the introduction and the literature review. For example, the introduction discusses general 
concepts around ageing (including population ageing, biological and chronological ageing), 
CAD and, QoL. The literature review comprises four main sections, which critically analyse the 
literature relating to: CAD in elderly patients, PCI in elderly patients, QoL in elderly patients 
undergoing PCI, and the use of LTL in CAD. After presentation of each of the four studies, the 
discussion provides a consideration of the results in the context of current literature. The final 
chapter discuss the overall conclusions and recommendations for future research in this area. As 
the population ages, the recommendations from this thesis are likely to be of increasing 
importance for researchers and clinical decision makers.  
 
1.2. Ageing  
1.2.1. Population ageing 
Population ageing is the process through which older individuals make up an increasing 
proportion of the overall population.1 It can also be considered as an increase in the proportion 
of people over a particular age (often 65 years of age) in a population,12 although, an increase in 
median population age has also been used.13 Underlying population ageing is the demographic 
transition from high birth and death rates to low birth and death rates, causing demographic 
change over time. This results in reduced fertility rates and longer life expectancy, on average, at 
any age.14 Driving lower death rates and longer life expectancy is the epidemiological transition: 
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a move from deaths predominantly caused by infectious diseases to chronic/degenerative 
diseases. Reductions in deaths from infectious diseases occurred mainly as a result of advances 
in public health, such as: sanitation; better childhood nutrition; education; and health care 
improvements (such as antibiotics or vaccinations). As infectious diseases disproportionately 
affect younger age groups, reductions in deaths from these resulted in people living long enough 
to develop chronic/degenerative diseases (shift in age at death). In addition, improvements in 
health care and preventive interventions meant that people were living longer with morbidity of 
chronic diseases (for example, chronic angina after surviving a heart attack). Together the 
demographic transition and the epidemiological transition make the “classical” (or “Western”) 
demographic transition model.15  
Latest global population projections suggest that population ageing is a feature of all higher 
income countries and many low-middle income countries. This global trend is likely to continue, 
with the number of people aged 80 years or over, projected to increase from 69 Million in 2000 
to 379 Million by 2050. The proportion of the population aged 80 years or over is also estimated 
to increase by almost fourfold over the next 50 years, reaching 4.1% in 2050 (estimated as ~1% 
currently).16 The 80 years or over age group is the fastest growing of the older population (At the 
global level, the average annual growth rate of persons aged 80 years or over (3.8 per cent) and 
is currently twice as high as the growth rate of the population over 60 years of age (1.9 per cent), 
suggesting that demographic ageing of the older population is also occurring. In addition, global 
population projections suggest that the median age of the world’s population will increase from 
27 years (based on 2000 estimates) to 36 years by the year 2050.17  These projections assume 
that baseline estimates of the world’s population are correct (estimates rather than actual 
numbers are used for many low income countries with less accurate records) and calculations are 
based on continuation of past trends in fertility and mortality.  
 
Scotland, like other post-industrial high-income countries, has undergone a similar population 
change over the last century (Figure 1). The wide based, narrow apex population pyramid of 
1911 has been replaced with the narrow based blunt apex of 2001. The 2031 projection shows 
how the post-war and 1960s baby-boomers are likely to contribute to the ageing population with 
the pyramid becoming skinnier and more top heavy by 2031.  
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Figure 1. Scotland's changing population structure 1911 projected until 2031 
Mortality rates for males and females have continued to decline since the 1960’s, although this 
has been less pronounced in women >75 years of age (Figure 2). 
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Figure 2. Age specific mortality rates as a proportion of the 1981 rate, males (a) 
and females (b) 1981-2005 
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Based on the General Register Office for Scotland (GROS) population projections, deaths are 
projected to continue to decline until at least 2016 (Figure 3), after which slight increases may 
occur, as a result of increasing prevalence of type 2 diabetes, obesity and alcohol-related liver 
disease. 
 
The number of Scots aged 75 years or more is projected to increase by 86% from 418,000 in 
2012 to 779,000 in 2037 (Figure 4).18 With the proportion of the population in Scotland aged 75 
years or over projected to almost double from 7.9% to 13.8%. These projections, by GROS, are 
based on census data and are trend based. They assume that trends in fertility, migration, and 
deaths will continue. However, these assumptions mean that the estimates are less reliable in 
Figure 3. Births and deaths, actual and projected, Scotland, 1951-2033 (ISD) 
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periods of changes, for example, the change in volume of migrants from the EU A8 accession 
countries to Scotland was not picked up by earlier population projections.18  
 
 
 
 
Figure 4. Projected percentage change in Scotland's population by age group, 2006-2031. 
(http://www.gro-scotland.gov.uk/files1/stats/projected-population-of-scotland-2012-based/j896103.htm) 
These projections suggest that population ageing will continue to be an increasingly important 
issue both globally and in Scotland. However, it should be noted that in Scotland ~1:10 people 
die before they reach 65 years of age with marked inequalities in life-expectancy by 
socioeconomic deprivation (Figure 5).9 
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Figure 5. Life expectancy (LE) in Scotland by Scottish Index of Multiple Deprivation (SIMD), 2012.  
 
The potential impacts of population ageing include: an increased dependency ratio (the ratio of 
individuals aged 0-14 years and over 65 years of age to those in the economically active age 
group (16-64 years of age);20 a rise in the prevalence of degenerative disorders such as arthritis, 
chronic obstructive pulmonary disease, and cardiovascular disease (CVD); expansion of 
morbidity (rather than compression) - an increase in the number of years spent living with 
chronic disease morbidity; increased health and social care costs; increase in prevalence of 
multiple morbidity and increasingly complex morbidity; and an increased number of older carers 
who may themselves have degenerative disorders.21  
However, Spijker et al.22 suggest that relative to remaining life expectancy, populations appear to 
be growing “younger.” For example, a 50 year old today is considered younger than a 50 year 
old would have been 40 years ago because they are expected to live for a much longer time. In 
addition, the number of people working after state pension age is rising. Therefore the 
dependency ratio may not be as high, in the future, as initially predicted. Also, improvements as 
a result of early years interventions (as there is growing evidence to suggest that age-related 
chronic diseases have their origin in experiences in early years),23 health care (including 
activities like screening), lifestyle/behavioural modifications (e.g. smoking cessation; and other 
prevention activities may well off-set some of this impact and result in healthy life expectancy 
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(average number of years a person is expected to live to in a healthy state) increasing. Interest is 
growing in investigating the factors which influence healthy life expectancy and healthy ageing,  
While there is no universal definition of elderly, or older persons, most high income countries 
consider it to be 65 years of age24,25 because this age is often associated with eligibility for 
statutory and occupational retirement pensions. However, the WHO acknowledges24 that such an 
arbitrary age cut-off is not necessarily subject to: the social constructions of what it means to be 
elderly, to geographical differences in life-expectancy, or the context in which the term is being 
used e.g. in cardiac patients. The terms “elderly” and “older persons/people” are often used 
interchangeably in the biomedical literature. Th ere is much debate as to the appropriateness of 
using the term elderly, as it is thought to be associated with negative and stereotypical images.26  
In response, some of the biomedical science literature has universally adopted the term “older 
persons “as the standard.27 This is less so in the cardiology literature where elderly patients tends 
to be the term used more often to describe chronologically older patients28,29   For the purposes 
of this thesis, the term older people has been used when discussing population ageing and ageing 
processes; however, the term elderly patient has been used in relation to patients with CAD, or  
attending for investigations of CAD. The choice of chronological age cut-offs for elderly 
patients is also much debated in the cardiology literature with ≥75 years or ≥80 years being 
commonly used in PCI research.30,31  It is also subject to the age at which patients present with 
CAD and, as discussed, variation in life expectancy of a given area  (e.g. Scotland’s life 
expectancy is one of the lowest in Western Europe) has an impact on this. For the purposes of 
this thesis, elderly patients are defined as ≥ 75 years of age for secondary data analyses (Chapter 
4.1 and 4.2), and ≥70 years for ReQoL (following issues with recruitment and a re-analysis of 
the sample size calculation – see Chapter 3.2). The systematic review of QoL following PCI in 
elderly patients focuses on octogenarians to allow comparisons to be made with the systematic 
review of clinical outcomes, which only included octogenarians. In addition, using a more 
focused population in the search strategy excluded those studies which may have presented some 
less elderly focused age related sub-group data (for example using “old” or “old*” in the search 
strategy included studies which used >50 years of age in sub-group analysis), thus allowing 
easier identification of studies on elderly patients.32  
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1.2.2. Theories of ageing 
As discussed, ageing can simply refer to the passage of time since birth (chronological age) or to 
the physical or biological processes of growing old.  Physical ageing is thought to be a complex 
biological process that may not correspond to the chronological ageing of individuals. In 
addition, the rate of biological ageing may vary between individuals in response to internal 
(genetics) and external factors. There are a number of different definitions of the ageing process. 
Rose (1991), in his book on the evolution of ageing, described it as “a persistent decline in the 
age-specific fitness components of an organism due to internal physiological degeneration”.33 It 
has also been defined as a progressive functional decline, or a gradual deterioration of physical 
functioning with age.134 Also as “the intrinsic, inevitable, and irreversible age-related processes 
of loss of viability and increase in vulnerability”.35 
Strehler (1959)36 characterised ageing by 4 main features:-  
• It is destructive – compromising functionality 
• It is progressive and irreversible  
• It is intrinsic i.e. determined by internal rather than external factors 
• It is universal, i.e. all individuals of the same species display a largely uniform ageing 
pattern, with all living beings displaying the ageing phenomenon.  
Of note is that while average life expectancy has increased significantly over the last century, 
maximal longevity (maximal age achieved by any individual) has, shown little or modest 
evidence of increasing.37  However, ONS estimates that there has been a 5-fold increase in the 
number of centenarians. These may go on to live longer than ever before, suggesting that in the 
future maximal longevity may also increase.19  
Human ageing is associated with multiple psychological changes and pathological consequences 
which affect every system, tissue and organ. In ageing, virtually all physiological functions lose 
efficiency. The effects include: 
27 
• appearance: gradual loss of height, muscle and bone mass, and decreased skin elasticity, 
• sensory functioning: reductions in vision acuity and hearing capacity, 
• cognition: memory and cognitive impairment, 
• reduced capacity to maintain homeostasis,   
• deterioration of the force and elasticity of skeletal muscle,  
• increased susceptibility to stress such as external temperature, infections, 
hyperglycaemia, and trauma. 
There is no universally accepted theory of the ageing process; instead, there are numerous 
theories which have attempted to explain the mechanisms involved.  More than 300 of these 
“theories of ageing”39 exist although they are not necessarily mutually exclusive. Generally, they 
can be grouped into 3 main mechanisms:  
• Evolutionary: ageing is part of life’s programming because the old need to remove 
themselves to make room for the next fertile generation, thus sustaining evolutionary 
turnover. 
• Network: that multiple mechanisms of ageing work in parallel and that ageing results 
from the interactions between cells, organs and systems.  
• Causative Mechanisms: ageing can be explained at the cellular level e.g. accumulation of 
cellular waste products, causing cellular senescence (when cells cease to divide with resultant 
impairment of function). 
The free radical theory of ageing is one of the most prominent causative mechanism theories and 
was first proposed by Harman in the 1950’s.40 This theory proposes that accumulation of free 
radicals derived from oxygen is responsible for the decline in biological functions associated 
with ageing. Reactive oxygen species (ROS) within cells are primarily generated by the 
mitochondrial respiratory chain, mainly due to electron leakage. Thus, ROS are viewed as being 
involved in cellular regulation by acting as Redox signals. Over time, the antioxidant systems are 
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unable to counteract all of the ROS (such as superoxide (O2−); hydrogen peroxide (H202); and 
peroxynitrite (OONO−).).41  
These free radicals capture electrons from another molecule, which in turn become unstable and 
reacts with further molecules. This results in oxidative damage to lipids, DNA, and proteins in 
the cells and therefore causes damage to the tissue. This process is called oxidative stress.  There 
is experimental evidence in in-vitro and animal models to support this theory. In animals, 
enhanced oxidative damage by ROS has been shown to lead to shorter lifespans42,43 while 
antioxidants have been shown to extend the lifespan in Drosophila.44 However, recent 
experiments show that, in mice and worms, increases in ROS actually correlate with normal and 
even longer life span, with the harmful effects of ROS seen as a result of compromised 
signalling, rather than direct oxidative damage to sensitive targets.45 The precise relationship 
between ROS induced damage, mitochondrial damage and ageing is unknown.  
 
1.2.3. Healthy ageing 
The prevalence of long-term illness and self-reported ill health increases with chronological age, 
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meaning that gains over time in healthy life expectancy and disability-free life expectancy are 
much smaller than the increase in overall life expectancy. Associated with this is a decrease in 
the proportion of life spent in “favourable health states”.46 The proportion of people reporting 
that they have a limiting longstanding illness is higher in the older population, with 37% of 65-
74 year olds and 48% of those over 75 years reporting that they have such an illness.46 The 
Scottish Health Survey reported that 13% of people aged 70 years and over have both a long-
term illness and disability compared to only 2% of 30-39 year olds.47  Older people were more 
likely to report that poor health affects their activities of daily life, for example: 27% of men 
aged 75 years and over reported that “ill health limited their ability to perform moderate 
activities 'a lot' compared with only 6% of men aged 18-24 years”.47 However, many people in 
older age groups still consider themselves to be in good health, even if they have a long-term 
illness which restricts their daily lives.46 
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Given that the most important risk factor for chronic diseases which limit health in later life is 
age itself, we need to better understand the biological process of ageing and how this relates to 
ageing on an individual and population level.  
Healthy (or successful) ageing can be defined as “optimising opportunities for good health, so 
that older people can take an active part in society and enjoy an independent and high quality of 
life”.48 There are three main components to this: low probability of disease; high cognitive and 
physical functioning; and active engagement in life.  
Recently, recognition has been given to the concept of a life course approach to healthy ageing 
where internal and external (physical and social) environments have been found to affect the 
ageing trajectory.49 Critical periods such as early life or later life experiences; accumulation of 
exposures; and chain of risk (the sequence of linked exposures) throughout life appear to affect 
the ageing process. Observational and experimental evidence increasingly supports a 
relationship between growth and development in early years (a critical period) and health in later 
years.23  
1.2.4. Frailty  
Frailty has been defined as a syndrome of decreased reserve and resistance to stressors causing 
vulnerability to adverse outcomes (based on the French word frêle meaning of little resistance). 
When exposed to such stressors, frail patients are at increased risk of decompensation, adverse 
events, procedural complications, prolonged recovery, functional decline, disability, and 
mortality. Others have suggested that frailty is: “an age-related, biological vulnerability to 
stressors and decreased physiological reserves”;50 or that it is more useful to define frailty as 
“clusters of vulnerabilities, weaknesses, instabilities  and limitations, with shared causes”.51,52 
 
Many such definitions of frailty have commonality to that of ageing and, similar to biological 
age, there appears to be wide variations in frailty between individuals of a similar chronological 
age. Frailty, with its impairment in cognitive and physical function with resultant loss of 
resilience and reserve, may be seen as a consequence of biological ageing; indeed frailty 
measurements have been used as a clinical tool for the assessment of biological ageing. 
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Studies have shown that frailty carries an increased risk of mortality and morbidity associated 
with CVD and heart failure. In addition, it is associated with increased risk of adverse outcome 
following acute coronary syndrome (ACS) and PCI. Clinically, frailty is becoming increasingly 
important, given the ageing population and increasing complexity of care for older patients. 
Innovations in the investigation and management of CAD, for example, have resulted in 
interventions, such as PCI, being able to be used in elderly and frail patients. The current ESC 
guidelines on the management of stable CAD recommends that “frailty should be well assessed 
eventually by means of current available indices”3 However, it is unclear what is meant by “well 
assessed eventually”.  
 
Upward of 20 frailty tools have been developed to measure frailty. 53 Owing to a lack of 
consensus agreement, there is variability among studies and confusion on which tool to use. For 
example, van Iersel et al.54 reported, in a sample of 125 elderly people, a prevalence of frailty 
ranging from 33% to 88% depending on the criteria used. Most tools focus on 1 or more of the 5 
core domains that define the frailty phenotype: slowness, weakness, low physical activity, 
exhaustion, and shrinking (unintentional weight loss), Slowness was measured by a comfortable-
pace gait speed test, weakness by a maximal handgrip strength test (using a dynamometer), and 
other domains by questionnaire or more specialized instruments. These domains may be 
considered individually or combined into a variety of scales. 
 
The Fried scale 55 encompasses slowness, weakness, low physical activity, exhaustion, and 
shrinking, with at least three of the five 5 criteria requiring to be satisfied for a diagnosis of 
frailty. It was developed from measurements in the Cardiovascular Health Study (CHS) and the 
Women’s Health and Aging Studies (WHAS).56 It consists of a total score based on:  
 
1. Shrinking: >10lbs unintentional weight loss in the last year or ≥5% of body weight in 
prior year by direct measurement of weight  
2. Reduced grip strength (tested using a hand held dynamometer): as being in the lowest 
20%, adjusted for gender and BMI 
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3. Self-reported exhaustion 
4. Slowness (measured using time to walk 15 feet adjusted for gender and height): as being 
in the lowest 20%, adjusted for age and gender 
5. Low physical activity level – using kilocalories expended per week.  
A prevalence of 7% in the CHS was found in 4,317 community dwelling adults aged 65 years 
and over, 30% in the sub-group aged 80 years and over, and 28% in the WHAS moderately to 
severely disabled population of 1,002 community dwelling women aged 65 years and over. Fried 
et al.55 concluded that frailty was “not synonymous with either co-morbidity or disability but co-
morbidity is an etiologic risk factor for, and disability is an outcome of, frailty.”55  
 
The Fried Scale is the most frequently cited frailty scale and has been demonstrated to predict 
mortality and disability in large cohorts of community-dwelling elderly people and patients with 
CVD55. Whether cognition and mood should be considered as additional domains of frailty scale 
or as modulating factors (such as having a role in the transition from frailty to overt disability) 
remains an area of discussion. 
 
The Short Physical Performance Battery (SPPB) 57 encompasses slowness, weakness, and 
balance. This is measured by a series of three timed physical performance tests (gait speed, chair 
rises, and tandem balance), each is scored 0 to 4 and frailty is defined as a total score >5 out of 
12. 
 
In contrast to these multi-item frailty scales, five metre gait speed and, to a lesser extent, 
handgrip strength, have been advocated as single-item measures of frailty.58 The gait speed test 
has been shown to have high inter-rater reliability (intraclass coefficient 0.88 to 0.96) and test-
retest reliability (intraclass coefficient 0.86 to 0.91).59 It has been found to be responsive to 
change, with meaningful improvements in gait speed (estimated at 0.05 to 0.2 m/s 59) predicting 
positive outcomes on a population level,60  but not necessarily an individual patient level.61 The 
walking distance used in research studies varies between three and ten metres, although the 
distance appears to have little effect on measured speed.62  A large number of CAD registries 
have adopted the five metre distance as it is thought to be a balance between allowing patients to 
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achieve a steady walking speed without developing angina symptoms.  
 
The Fried scale and the SPPB tools are used to reflect the clinical phenotype of frailty. However, 
an alternative approach reflects the accumulation of deficits.63  Deficits encompass an 
assortment of up to 70 symptoms, signs, comorbidities, disabilities, and frailty traits, which are 
counted and summed. One version is the Frailty index developed by Mitnitski et al.64 They 
propose that a Frailty index, based on 20 deficits, can be used as a proxy measure of ageing and 
mortality as it better reflects physical ageing than chronological ageing, with higher scores being 
associated with a greater risk of adverse outcomes. However, the International Academy on 
Nutrition and Aging Frailty Task Force65 favoured the clinical phenotype approach stating: 
“comorbidities and disabilities should be disentangled from frailty”.  
 
Disabilities, broadly defined as difficulty or dependency in carrying out activities of daily living 
(ADL), are often used interchangeably with frailty. However, disability is more accurately 
considered as an adverse outcome associated with frailty (for example, a frail patient becoming 
more disabled after an acute myocardial infarction (AMI)). Certain scales may be effective at 
screening for frailty, whereas others may be required to focus on specific and potentially 
treatable domains. There is justifiable reason to consider using different scales, more or less 
challenging versions of such scales, or different cut-offs depending on the population being 
studied. In addition, heterogeneity amongst patients suggests that the use of a fixed cut-off for 
frailty may not be appropriate.   
 
A study by Purser et al.,66  was one of the first to prospectively measure frailty, using 3 different 
frailty tools, to assess mortality outcomes in elderly patients with CVD.  In this study, 309 
elderly patients with multivessel disease (MVD) admitted to a coronary care unit, found that the 
prevalence of frailty varied considerably depending on the tool used: 27% using the Fried scale, 
50% using gait speed < 0.65 m/s, and 63% using the Rockwood frailty scale. While increases in 
6-month mortality was associated with each frailty tool and composite scores (developed by the 
authors using all the scales), only gait speed reached statistical significance (odds ratio (OR) 3.8; 
95% confidence interval (CI) 1.1-13.1). However, the CIs were wide and no statistical 
significance was presented. This study was influential in highlighting to clinicians the 
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importance of frailty, in addition to traditional risk factors, for predicting clinical outcomes of 
CVD.  
 
In a study of 629 elderly patients who underwent PCI at the Mayo Clinic, 21% were found to be 
frail, based on administration of the Fried scale before discharge (unintended weight loss (>10 lb 
in the preceding year), exhaustion, physical activity, time required to walk 15 feet, and grip 
strength by Jamar handgrip dynamometer). Patients who were frail had a significantly increased 
3-year mortality: 28% vs. 6%; OR: 2.45; 95% CI 1.33,4.53.67 However, those who did not 
survive until discharge were excluded from the study and only 41% of the eligible participants 
consented; therefore, there is the potential for selection bias as a main limitation of this study. 
QoL was also measured in this study but was not found to be associated with an increased 
hazard for death following PCI. Similarly, cachexia/frailty was found to be the most powerful 
predictor of 18-month mortality (hazard ratio (HR) 14.0 ) in a study of 111 patients undergoing 
PCI for unprotected left main disease in the Kaiser Permanente database.68 All participants were 
considered ineligible for CABG, only 7(13%) of patients were considered cachexil/frail, and 
definition of cachexil/frail was based on case note review.  
 
Gharacholou et al.69 further showed that, despite a similar severity of angina between frail and 
non-frail patients aged ≥65 years and older, those who were frail had lower physical functioning 
and QoL Frailty was found to have a greater impact on QoL than severity of CAD or 
comorbidity. Frail patients were more likely to have MVD and/ or left main stem (LMS) 
involvement, after adjusting for age and gender (p values <0.05 across the groups). Ekerstad et 
al.70 explored the relationship between frailty and comorbidities in patients with non ST 
elevation myocardial infarction and showed that 79% of frail patients had at least one severe 
comorbidity. Frailty was also found to be independently associated with 1-year mortality after 
adjusting for cardiovascular risk and comorbid conditions (HR 4.3, 95% CI 2.4-7.8).  Frailty was 
found to be better at predicting mortality than the presence of comorbidity alone. When the 
comorbidity burden was stratified by severity, moderate to severe frailty was found to be more 
predictive of mortality. Frailty is associated with less aggressive management compared with 
non-frail counterparts. Frail patients were less likely to receive angiotensin-converting enzyme 
inhibitors, and beta-blockers, less likely to be admitted to a coronary care unit, and less likely to 
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be referred for PCI or CABG. 
 
 
 
1.2.5. Biological ageing and biomarkers of ageing 
In contrast to chronological ageing which is easily defined and measured, biological ageing 
involves variable structural and functional changes that take place at the cellular, tissue and 
organ level; ultimately affecting the overall performance of the body.9 It is thought to vary 
between individuals of the same chronological age and increase susceptibility to ill health and 
disease. Biological ageing has also been described as a “steady decrease in physiological ability 
to meet demands that occur with increasing chronological ageing”.71 Biological ageing is 
thought to be due to failure of intracellular and immune system repair mechanisms with resultant 
cellular damage.72 The lack of a universal definition of biological age makes consistent 
measurement, reporting, and comparison of results difficult. 
Biological age (“miles on the clock”)8 appears to be a better reflection than chronological ageing 
of inter-individual variation in rates and expressions of growth and ageing, given the 
heterogeneity of life span and healthy life span. There have been numerous studies which have 
used physical health and various biomarkers to assess biological age,73,74 with particular interest 
in models which can be applied to the clinical setting.75 Biomarkers include biochemical assays, 
genes and physiological characteristics that can indicate the presence, or severity, of an existing 
disease, physiological abnormality (e.g. lens opacity) or psychological condition (or increased 
risk of their future development). Biomarkers of ageing aim to better predict functional capacity 
than chronological age by correlating more closely with “biological age”. In particular, they aim 
to identify individuals who are at greater risk of age-associated disease or disability, or who 
develop it at a younger chronological age.   
Baker and Sprott (1988)76 suggested the following criteria for biomarkers of biological ageing: 
1. The rate of change of the biomarker must, at least in mathematical terms, reflect some 
measurable parameter which can be predicted at a later chronological age. 
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2. The biomarker should reflect some basic biological process of ageing and certainly not 
predisposition toward a disease state or some error in metabolism. 
3. The biomarker should have high reproducibility in cross species comparisons of 
functional or physiological age versus chronological age, particularly within the same 
classes and certainly within the same families of species. 
4. The biomarker should change independently with chronological age and reflect 
physiological (functional) age. 
5. Assessment of the biomarker should be non-lethal in animal systems and should cause 
minimal trauma in humans. 
6. The biomarker should be reproducible and measurable during a relatively short time 
interval compared to the life span of the animal. 
 
Subsequently, a simpler set of criteria for ageing biomarkers was proposed by Miller in Butler et 
al.(2004):77 
1. The biomarker should predict the outcome of a wide range of age-sensitive tests in 
multiple physiological and behavioural domains, in an age-coherent way, and do so 
better than chronological age. 
2. It should predict remaining longevity at an age when 90% of the population is still alive, 
and do so for most of the specific illnesses that afflict the species under study. 
3. Its measurement should not alter life expectancy or the outcome of subsequent tests of 
other age-sensitive tests. 
 
The second criterion suggests that biomarkers of ageing will also be biomarkers of age-related 
diseases rather than merely measures of degenerative changes. This is contentious because  
ageing is thought by others to be a distinct process with specific pathways.78  
The American Federation for Aging Research has proposed the following criteria (reviewed by 
Johnson, 2006):79 
1. The biomarker must predict the rate of ageing. In other words, it should tell exactly 
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where a person is in their total life span. It must be a better predictor of life span than 
chronological age. 
2. It must monitor a basic process that underlies the ageing process, and not the effects of 
disease 
3. It must be able to be tested repeatedly without harming the person, for example, a blood 
test or imaging technique. 
4. It must be something that acts in both humans and laboratory animals, such as mice, so 
that it can be tested in animals before being tested on humans.  
However, even if a potential biomarker could be validated in model organisms, it is still unclear 
whether it would apply equally well to humans.  
 
Physiological biomarkers of ageing, suggested in the literature, include perceived age, systolic 
blood pressure, lipid concentrations, body mass index, cognitive function, and lens opacity.10,74,80 
In addition, at the clinical level, geriatric assessments81 and measurement of frailty82,83 have also 
been suggested as complex biomarkers of ageing. Biological markers that measure inflammation, 
oxidative stress, protein glycation, cellular senescence and hormonal deregulation have all been 
explored.10  
• Inflammatory markers: The immune response in humans is designed as a defence system 
to protect and respond to environmental exposures such as infectious agents. It does this 
via an innate (natural) response and an acquired (adaptive response). Innate immunity 
involves cellular (for example, macrophages and T-cells which secrete interleukin 6 
(IL6)) and non-cellular (C-reactive protein (CRP) and complement cascade 
components).  Therefore, peripheral blood markers of inflammation include IL-6 and 
CRP. Although these are non-specific, abnormal values are thought to indicate clinical 
or subclinical levels of chronic inflammation that contribute to, or are part of, the ageing 
process. In addition, senescent cells have been found to secrete pro-inflammatory 
cytokines (such as interleukins).72 For example, those with elevated IL-6 were 
significantly more likely to develop disabilities of mobility and activities of daily living 
over a four-year period, even after adjusting for multiple potential confounders.83 In a 
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similar cohort, CRP has been shown to be an independent risk factor associated with a 2-
fold risk of death in a cohort of higher functioning elderly patients.84  
• Oxidative stress: In keeping with the free radical theory of ageing,40 a number of 
molecules can be produced as a result of the oxidative stress -  ROS (Reactive oxygen 
species). ROS are constantly being produced in cells and play a role in various signalling 
pathways and immune response.85  ROS are removed from cells by various antioxidant 
defence mechanisms. The imbalance between oxidative metabolism and antioxidant 
defence is called oxidative stress. Cumulative cellular damage by ROS throughout the 
life span has been proposed as an important factor in ageing. A number of potential 
biomarkers of oxidative stress have been developed. For example, 8-hydroxy-
deoxyguanosine  (8-OHdG) is formed when guanine (a DNA nucleotide) is damaged by 
oxidative damage.86 This is excreted in urine and is known to be increased by smoking.87 
Levels have been found to be inversely associated with life span in animal studies.88  
 
Senescent cells are associated with a high level of intracellular ROS and accumulation of 
oxidative damage to DNA and proteins.73 Telomere shortening (DNA caps at the end of 
chromosomes – see Chapter 2.4 for further discussion on telomeres) is considered to be 
one of the major cause of replicative cellular senescence and is increased as a result of 
mild oxidative stress.46  Senescence can be by-passed by the introduction of telomerase 
into human cells.89 
The amino acid homocysteine is derived from dietary methionine. High levels of 
methionine can be found in protein dense food such as eggs, sesame seeds, Brazil nuts, 
fish and meat. Restricting methionine consumption has been shown to increase lifespans 
in some animals.89 Homocysteine is thought to increase production of ROS and the cell’s 
ability to protect itself from the damage caused by ROS.   
DNA methylation: This involves the addition of a methyl group to cytosine or adenine 
(DNA nucleotides).  The pattern of methylation controls protein binding to target sites 
on DNA, affecting changes in gene expression and in chromatin organization. For 
example, it can silence genes responsible for differentiation, or those predisposing to 
cancer. Research involving saliva samples from 34 pairs of identical male twins aged 21 
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to 55 years, identified 88 sites on the DNA where DNA methylation was strongly 
correlated with chronological age.90 Global DNA methylation levels have been found to 
be correlated with frailty status in middle/advanced-aged subjects but not with 
chronological age. A seven-year follow-up study also revealed that worsening in frailty 
status was associated with a significant decrease in global DNA methylation levels91 
 
• Advanced glycation end products (AGEs): These are proteins or lipids that are non-
enzymatically glycated and oxidized after contact with sugars. AGEs can be produced in 
cells or absorbed through the diet (foods high in protein and fat such as meat, cheese or 
egg yolks and food which has been cooked at high temperature, for example, by frying 
or barbecuing). Within cells, complex ROS-dependent reactions occur which lead to the 
formation of AGEs. Cell activation by these AGEs leads to the generation of more ROS 
with resultant oxidative damage. Accumulation of the AGE carboxy-methyl lysine 
(CML) has been associated with chronological age and age related diseases such as 
cataracts.92 CML has been shown to be associated with diabetes disease progression 
where it has been linked with increased risk of developing retinopathy, nephrology and 
cardiac disease.93  
• Cellular senescence and telomeres: Cellular senescence was first described in 1961 when 
Hayflick noted that cell proliferation in a cell culture of human fibroblasts gradually 
declined over time.94 Eventually, all cells in the culture lost the ability to divide, 
although they stayed viable for a long time afterwards (in a state of growth arrest 
described as cellular senescence). He proposed that this resembled the ageing process 
within systems and organisms, as a whole.   
Cellular senescence in primary somatic cells is accompanied by telomere attrition. 
Telomeres are nucleoprotein complexes that cap and protect the ends of chromosomes. 
The DNA component of telomeres consists of repeats of TTAAAGG that shorten as a 
function of replication in most human somatic cells.95 Therefore, telomere length is an 
indicator of a cell’s replicative age. Accelerated telomere attrition has been shown to be 
a feature of many pathologies including cancer, vascular dementia, diabetes, and 
cardiovascular disease.96  
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Cellular senescence is also accompanied by the expression, or appearance of, markers 
such as senescence-associated β-galactosidase and CDKN2A (whose conjugate protein 
is termed P16ink4). It appears to act as a tumour suppressor and maintains cells in a state 
of growth arrest in premature senescence.97  CDKN2A has been associated with cellular 
senescence in cell and animal studies. Increasing levels of CDKN2A  transcriptional 
expression (CDKN2A mRNA levels) have been found to occur with increasing 
chronological age, both in solid organs and peripheral blood leucocytes (PBL). Shiels 
suggests that CDKN2A can better fulfil Baker and Spott’s criteria than other proposed 
biomarkers of ageing.98  
Lamb and Shierls78 also suggest that all these markers operate within the functional 
framework of the MTR (Mitochondrion, Telomere, and Ribosome biogenesis) trinity (of 
ageing), which suggests that ageing is associated with interactions between cellular 
damage responses and any associated fuel utilisation and energy production – the level 
of damage accrued and the level of energy expenditure required to facilitate repair, 
dictates whether a cell will live (functioning or senescent) or die. The more cells die or 
become senescent, correlates directly with organ function and biological age.      
 
• Fetuin-A: This is a serum protein which is secreted by the liver and has multiple diverse 
effects throughout the body. It has been shown to act as an inhibitor of vascular 
calcification, by preventing spontaneous mineral precipitation, and it may be capable of 
attenuating inflammatory processes.99,100 Despite this, it has been shown to induce 
insulin resistance in muscle and fat and has been associated with clinical and sub-clinical 
CVD and type 2 diabetes.101 However, it has also been associated with a decreased risk 
of impaired cognitive functioning and was found to be lower in patients with 
Alzheimer’s disease.102 Maxwell et al. suggest that decreased fetuin-A and telomere 
attrition indicate accelerated biological ageing.103 
• Sitruins(1-7) are a family of proteins found in all living things, whose function is linked 
to cellular metabolism in numerous tissues, including liver, muscle, adipose tissue, heart, 
and endothelium. Accumulating evidence has indicated that sirtuins are not only 
important energy status sensors but also protect cells against metabolic stresses.  In 
addition, they have been implicated in the preservation of genomic stability. A number 
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of studies have shown an association with ageing and they coordinate a wide range of 
cellular responses that are frequently dysregulated during ageing.104,105,106 For example, 
Sirtuin 2 assists in the repair of DNA and regulates genes that undergo altered 
expression with age in yeast;104 overexpression of  Sirtuin 6 in transgenic mice showed 
an increased lifespan of about 15% in males;105 and Sirtuin 1 is thought to behave in 
humans like yeast Sirtuin 2 by regulating mitochondrion biogenesis.84 Sertuins are 
thought to be the mediators of response in the MTR and appear to regulate health-span 
in mammals.107 
While there in increasing and evolving evidence for potential biomarkers of ageing, many 
researchers suggest that no single or simple combination of biological or genetic markers is 
likely to provide a useful clinical estimate of (biological) aging”108,109 This assumes that 
biological ageing is the consequence of the deterioration of more than one system. This 
assumption leads to the conclusion that a ‘‘panel” of biomarkers that reflects the condition of an 
array of critical systems may be needed in order to assess the biological age of any organism. At 
least two important points can be gleaned from this observation. Firstly, the complexity of 
ageing and the ageing processes means that the search for biomarkers is likely to continue unless 
a single or very small number of biological clocks (or  pacemakers  - marker(s) which change 
with biological ageing) actually exist. Secondly, and probably even more important, biomarkers 
may change with chronological age. Biomarkers that are predictive of longevity in early life may 
not be predictive in late life, and vice versa. Rather than selecting a single panel of potential 
biomarkers to measure in early life and then repeating the same panel over the lifespan, it may 
be necessary to measure a very large battery of biomarkers at successive points over the lifespan 
and treating each as a separate, predictive measure. 
 
 
1.2.6. Telomere biology and structure 
Given their association with chronological ageing and role in cell senescence, telomeres are 
thought to be important in assessing biological ageing. As discussed, telomeres are specialised 
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DNA-protein complexes that cap the ends of chromosomes in eukaryotes (organisms whose cells 
contain a nucleus and other structures (organelles) enclosed within membranes). The basic 
structure is that of a nucleoprotein complex consisting of telomeric DNA and a number of bound 
proteins which are vital for the regulation of the telomere length and the functioning of the 
telomere. The DNA component is a repetitive stretch of TTAGGG (made up of the nucleic acid 
sequence: thymine, thymine, adenine, guanine, guanine, and guanine) which is non-coding (not 
translated into proteins). Telomeres safeguard gene integrity during mitosis (cellular division) by 
preventing DNA degradation at the chromosome terminus because the DNA polymerase 
complex is incapable of replicating all the way to the end of the chromosome. Without telomeres 
this would result in loss of vital genetic information which is required to sustain cellular activity. 
Telomere shortening occurs in almost all mitotic tissues, including peripheral blood leucocytes. 
Only germ cells, stem cells, and activated leucocytes maintain their telomere length through 
telomerase enzyme activity (a reverse transcriptase that adds DNA repeats in the telomere 
region), are excluded from the process of telomere shortening. Mice engineered to lack 
telomerase prematurely age and their ageing can be reversed by reactivating the telomerase.110 
Gradual loss of telomeric DNA in dividing cells can result in: cellular senescence (because the 
telomere length has reached a critical level); apoptosis (cellular death); or neoplastic 
transformation, such as occurs in cancer.  
The relationship between ageing and telomere length is still not fully understood; despite being 
first recognised over 20 years ago. Cook and Smith first linked telomeres to the ageing 
process111 and suggested a framework to explain the telomere attrition process and the Hayflick 
limit (the number of times a normal human cell will divide until division stops). Since then 
numerous studies have established the inverse relationship between telomere length and 
chronological ageing.112,113,114,115 A systematic review found that the association between 
telomere length in peripheral blood leucocytes and age was a consistent observation in the 
literature.116 
Olovnikov was the first to suggest that this is a potential mechanism for a biological clock 
determining cellular activity.117 Further research by Vaziri and Allsopp et al.118 demonstrated 
that telomere length could act as a “mitotic clock”. Telomere length fulfils several, but not all, of 
the criteria for a biomarker of human ageing: it decreases progressively with chronological age; 
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varies considerably between individuals and registers the life-cycle of proliferative cells.119 
There is much debate as to whether or not it is a useful biomarker of ageing. 120  
Some studies have shown that shortened telomere length is associated with increased 
mortality121 while others have failed to show an association85 – this is thought to be related to 
methodological issues or multiple confounders in epidemiological studies.97,120 Cawthorn et al121 
studied unrelated residents of Utah, USA aged 60-97 years who donated blood between 1982 
and 1986, and for whom follow up death certification was available. They used the relative ratio 
of telomere repeat copy number to single gene copy number (called T/S ratio) in participant 
samples compared with a single reference DNA sample. This is a commonly used method of 
reporting telomere length (see measurement of telomere length section 1.1.5).   
1.2.7. Measurement of telomere length  
The most commonly used approach in clinical and epidemiological studies is to measure 
telomere length in leucocyte DNA from peripheral blood leucocytes. This is mainly because 
peripheral blood leucocytes are relatively easily obtained from participants and contain an 
excellent source of telomeric DNA in their nuclei. There is some evidence to suggest LTL 
reflects alterations in telomere length in somatic cells such as artery endothelial cells.123 
Recently, Daniali and Aviv et al.124 measured telomere lengths in leucocytes, skeletal muscle, 
skin, and subcutaneous fat in 87 adults aged 19-77 years of age. They found strong correlation 
between age-dependent telomere length shortening in all four tissues; although, telomeres were 
found to be longest in muscle and shortest in leucocytes. Differences between the tissues showed 
no significant change throughout the age range. They conclude that the differences between 
tissues are likely to be established during early life. However, this was a cross-sectional study 
rather than longitudinal measurement of telomere length in the same individuals. Further 
research is likely to be required to confirm this correlation. 
LTL also appears to have important functional consequences that may contribute directly to the 
pathogenesis of CVD. As the leucocyte cells become critically shortened and therefore 
senescent, they secrete pro-inflammatory cytokines.72.125  LTL can be measured as a one-off or 
serial measurements can be used to quantify change over time.  
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Analysis and quantification of the terminal fragments of DNA in PBLs can be undertaken using: 
• Southern Blot – where isolated DNA is cut using a specific restriction enzyme, 
transferred to a gel membrane and separated by electrophoresis according to size.  After 
transfer to a membrane, a labelled probe is added which allows detection of DNA 
sequences. It is very accurate and reproducible. However, it is time consuming, relatively 
insensitive for very short telomere lengths, and requires a large amount of DNA.  
 
• Quantitative fluorescence in situ hybridization (Q-FISH) – this technique uses synthetic 
DNA mimic probes called peptide nucleic acid to hybridise denatured repeat sequences of 
target chromosomal DNA using fluorescent microscopy. Cells or tissue embedded in 
paraffin, rather than extracted DNA, are used. It allows single telomere or cell analysis and 
therefore comparisons between cells can be undertaken. However, as it requires cells to be 
arrested in the metaphasic phase of mitosis, it is unable to measure telomere length in 
senescent cells.  
• Quantitative real-time polymerase chain reaction (RT-PCR) – this is based on the 
quantitative PCR method first reported by Cawthon in 2002.126 It amplifies and 
simultaneously quantifies a targeted DNA sequence compared with that of a single copy 
gene. Therefore, it generates a ratio between telomere and the single copy amplification 
termed T/S ratio. However, some studies report differences in mean base pairs (pb) by 
previous correlations between PCR and Southern blot. While similar to quantitative PCR, 
its key feature is that the amplified DNA is detected as the reaction progresses in “real 
time”. The higher possible throughput and less labour intensive nature of this method have 
led to its widespread use as the method of choice in the majority of studies. While 
concerns exist over reproducibility and variability, if performed with the required precision 
and controls, accurate comparisons with Southern blot are achievable.  
As each method employs different laboratory-based tools and methodologies, comparisons 
between studies have often been difficult. Gardner et al. in their meta-analysis of telomere length 
and gender presented their findings stratified by measurement methodology.127 
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Southern Blotting is considered by many as the ‘gold-standard” assay; however, it requires large 
amounts of intact genomic DNA; is time-consuming; costly; and requires a degree of expertise 
to  undertake the analyses.128 These are less critical for qPCR; however, residual PCR inhibitors 
may still be present in samples even after DNA purification which could contribute to increased 
variability in qPCR.97,127  
Variance is used to describe the level of variability within a population independently of the 
absolute values of the observations. If absolute values are similar, populations can be compared 
using their standard deviations. But if they differ markedly, or are of different variables, then 
you need to use a standardized measure - such as the coefficient of variation. The coefficient of 
variation (CoV) for a sample is the standard deviation of the observations divided by the mean. 
The most common use of CoV is to assess the precision of a technique. It is also used as a 
measure of variability when the standard deviation is proportional to the mean, and as a means to 
compare variability of measurements made in different units.  
Gardner et al.,127 in their systematic review and meta-analysis of telomere length by gender, 
found that the magnitude of the differences between males and females varied by measurement 
method. The summary estimates of effect (using a random effects model) showed longer 
telomeres in women only in the studies which used the Southern Blot method. The authors 
suggested that “smaller measurement error in the Southern blot method as compared with RT-
PCR might explain greater consistency of findings”. The inter-assay coefficient of variance was 
reported as 1.4% to 12% for the studies using Southern Blot methods and 1.7% to 11.1% for 
those using RT-PCR. Aviv et al.129 suggest that the inter-assay CoV measurement for qPCR is 
6.45%, while that of Southern Blots is 1.74%. CoV of qPCR has been reported to be as large as 
27%, which is thought to be so high that drawing any conclusions from such data is “fraught 
with error”.130 However, more recently quantitative Real-Time PCR (RT-PCR) has been 
reported as <1% laboratories including the Shiels lab at the University of Glasgow.8 
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1.2.8. Determinants of telomere length 
Telomere dynamics appear to be complex and strongly influenced by endogenous and 
exogenous factors.  While telomere length appears to be highly heritable and genetically 
determined,137 it can also be affected by many factors including telomerase activity, rate of cell 
division, and degree of oxidative stress which, in turn, is likely to be affected by a number of 
factors which are also considered as social determinants of health, such as: genetics, 
socioeconomic deprivation, environmental factors and life style factors. 8,115 
 
 
 
 
 
 
Figure 6: Schematic representation of factors affecting telomere length and attrition. 
Genetic factors 
Short telomere lengths have been observed in humans with genetic syndromes that are 
associated with accelerated ageing such as: Werner’s syndrome; congenital dyskeratosis; and 
progeria (consistent with a significant genetic component).  
Hereditability of human telomere length has also been demonstrated in several studies131,132 
where it appears to partially explain inter-individual variation,133 with the majority of the 
variance in telomere length between close relatives being accounted for by relatedness.133 In 
1994, Slagboom et al.97 studied 123 human mono- and di-zygotic twin pairs, and calculated 78% 
heritability in telomere length. Monozygotic twins were found to have very similar mean 
telomere lengths, whereas dizygotic twins showed significant differences.  In 2008, Brouilette et 
al.135 found a significant positive correlation in mean telomere length between parents and their 
offspring in 45 pairs where the parent had coronary heart disease (CHD) and 59 control pairs 
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(r=0.37, p=0.002). However, there were significant limitations. Only 67% of parents had 
telomere analysis; “parent” could be either mother or father and the age range was limited. 
Some studies have suggested that telomere length is predominantly inherited paternally rather 
than maternally.131,136 Barrett and Richarson137 suggested that the differences between the sexes 
is due to deleterious recessive alleles on the X chromosome which have no compensatory alleles 
on the Y chromosome. However, a recent study by Broer et al.133 examined father–offspring and 
mother–offspring correlations in telomere length across four different study populations. The 
resultant sample size was threefold larger than all previous individual published studies. Their 
results, contrary to previous findings, showed that the mother–offspring telomere length 
correlation was substantially larger than the father–offspring correlation (P=0.007). This may 
suggest an X–linked component to inheritance. De Meyer et al.138 also found, in keeping with a 
number of other studies, a positive correlation been between the age of fathers (but not mothers) 
and telomere length in their children. This suggests that vertical transmission is important. It 
could indicate that telomere length is not fully re-set after fertilisation and that if paternal 
telomere length is short this is inherited by the offspring. This is a scenario similar to that seen in 
animals created by cloning, in particular when the donor nucleus is harvested from an older 
animal e.g. in Dolly the sheep.139 However, under normal reproductive mechanisms germ cells 
are the source of parental DNA, which retain the ability to maintain TL using telomerase. This 
may mean that genomic imprinting (an epigenetic phenomenon) may be a significant 
mechanism; however the exact mechanism is unknown.  
 
Epigenetics  
Epigenetics can be defined as the study of heritable changes in gene expression that are not due 
to changes in the DNA sequence. Epigenetics was first suggested by Waddington who stated 
that: “between genotype and phenotype, and connecting them to each other, there lies a whole 
complex of developmental processes” – he called this complex the epigenotype.140 Epigenetic 
changes (such as DNA methylation) appear to switch genes on or off and can determine which 
proteins are transcribed by different cells. Epigenetic silencing is one way to turn genes off, and 
it can contribute to differential expression. Silencing might also explain, in part, why genetic 
twins are not phenotypically identical. In addition, epigenetics is important for X-chromosome 
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inactivation in female mammals, which is necessary so that females do not have twice the 
number of X-chromosome gene products as males.141 Thus, there is evidence of significant 
turning off of genes via epigenetic change. Recent experimental data point to epigenetics as a 
fundamental process in telomere length and dynamics.  
 
Within cells, there are three systems that can interact with each other to silence genes: DNA 
methylation (a chemical process which adds methyl to DNA); histone modifications (histones 
are proteins which can influence how chromatin is arranged, which in turn, can determine 
whether the associated chromosomal DNA will be transcribed); and RNA-associated silencing 
(where RNA interference affects gene expression). These are thought to be important in telomere 
attrition.  
Telomere length has been shown to be longest at birth, shortens rapidly until around 5 years of 
age, remains relatively stable until early adulthood, followed by a more gradual reduction 
thereafter.114 This pattern suggests that early life factors may well be an important determinant 
of adult telomere length. While telomerase activity is likely to be high in the rapidly dividing 
foetal cells, little is known about telomere length changes in-utero. Growing evidence suggests 
that antenatal stress and impaired intrauterine growth could lead to accelerated telomere attrition, 
and thus shortened telomeres at birth, which may in turn result in shorter telomeres in 
adulthood.105 Therefore, a one-off measurement of telomere length could represent the combined 
effects of both telomere length at birth and subsequent rate of attrition experienced by the 
individual. This is in keeping with the life-course approach to ageing suggested by Kuh and 
others.23 Barker demonstrated a link between dysfunctional growth in early life and onset of 
atherosclerosis later on in life. The Barker Hypothesis proposes that events leading to restricted 
growth in-utero may programme the foetus for increased risk of adult CVD and other long term 
conditions with resultant premature death.142 This restricted growth is thought to increase ROS 
and oxidative stress. Several studies in animals have reported that intrauterine adversity is 
associated with shorter telomeres in cells of different tissues. Entringer et al. measured telomere 
length in 94 healthy adult subjects, 45 of who were offspring of mothers who had experienced 
severe stress during the pregnancy.143 After adjusting for available potential confounders, stress 
during pregnancy was associated with shorter telomere lengths in adult life. However, further 
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research is required to investigate this. 
 
 
Sex  
 
While female sex is associated with a higher life expectancy and longer life span in a number of 
different populations, inconsistencies exist in the literature regarding longer telomere length and 
gender. Some studies have found LTL to be longer in women than men.144,145,146 while others 
found no difference;146 or even the reverse147 to be the case.  A recent meta-analysis127 has been 
conducted in accordance with PRISMA guidelines. It included data from 36,230 participants (40 
datasets from 32 separate studies) and showed that, on average, females had longer telomeres 
than males (age-standardised difference in telomere length of: 0.09, 95% CI: 0.015, 0.16). There 
was no evidence that this association varied by age group (defined as above or below the median 
age of 55.6 years); however, significant heterogeneity between studies was detected. Only two of 
the included studies assessed gender differences in LTL at birth. 148,149 Okuda et al.148 found no 
difference between the genders at birth, while Aubert et al.149 found that female newborns had 
longer telomere lengths than males.  These contradictory studies led the authors to state that it 
was “not clear if gender dependant differences are present at birth” and therefore it is unclear 
whether or not differences in telomere length between adult men and women occur at birth, or 
are due to increased attrition throughout the lifespan. Okuda et al.148 suggest that the lack of 
evidence for differences at birth indicates that factors which contribute to telomere maintenance, 
or accelerate attrition, are likely to accumulate throughout an individual’s lifetime.  
There is evidence from studies of adults to support this.  The Bogalusa Heart Study (participants 
aged 19-37 years) found no difference in telomere length between men and women, while the 
Family Heart Study with its older participants  (30-93 years) did.150,151,152  The Bogalusa Heart 
study and Bakaert et al.152 found that telomere attrition was slower in women compared with 
men. Bekaert et al. used a cross-sectional study design with 2509 participants to estimate yearly 
telomere attrition rate, while the Bogalusa Heart Study used a longitudinal study design. Njajou 
et al.,153  demonstrated that men have shorter overall TL and faster rates of telomere attrition 
over the 2.5 years they studied. However, in all of the studies, the association was not found to 
49 
be strong. 
 
Several hypotheses have been suggested to account for  sex difference later in life. These include 
the effects of oestrogen exposure on telomere length. Lin et al.,156 reported that increased 
endogenous oestrogen exposure was associated with greater LTL, suggesting oestrogens may 
decelerate cellular ageing. Exogenous hormone replacement of oestrogen and progesterone have 
also been associated with greater LTL in post-menopausal women.157 In a molecular context, an 
oestrogen-responsive element is present in telomerase transcriptase and therefore oestrogen may 
up-regulate telomerase activity with a concomitant increase in telomere length.158 As discussed, 
telomere length is sensitive to oxidative stress and women have been found to produce less ROS 
than men;144 this may also be mediated by oestrogen.  
Lifestyle 
 
The literature suggests that telomere length is associated with similar lifestyle factors to those 
associated with CVD. For example, smoking has been shown to be associated with accelerated 
telomere attrition in a number of studies159,160. Valdes et al.159 observed that telomeres shortened 
linearly with age by 27 bp (base pairs) per year in a study of 1,122 white women aged 18 to 76 
years.  Age-adjusted telomere length was found to be ∼5 bp shorter for every pack-year smoked, 
with 40 pack-years of smoking corresponding to 7.4 years of age-related shortening in telomere 
length.  However, while this study adjusted for age, other confounders may be responsible for 
the association. Morla et al.160 observed a dose–response relationship between cumulative 
lifetime exposure to tobacco smoking and shorter LTL in a case-control study of from 26 never-
smokers, 24 smokers with normal lung function and 26 smokers with moderate-to-severe airflow 
obstruction (forced expiratory flow in one second 48±4% predicted). Both of these studies are 
cross-sectional in nature, making causual inferences difficult.  
It is thought that smoking acts by amplifying tissue inflammation through oxidative stress,161 
therefore augmenting the link between ageing and CVD. The mechanism underlying this has 
been studied at a cellular level, using cultured endothelial cells isolated from the internal 
mammary artery of smoking and non-smoking patients with CAD. They suggest that cellular 
senescence appeared to be independent of telomere length, but was strongly related to oxidative 
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damage and markers of inflammation.162 Despite this, the exact mechanism is unclear.  
Weischer et al. investigated whether lifestyle factors were associated with telomere length 
change in 4,576 healthy individuals from the general population.163 Individuals had relative LTL 
measured twice with a 10-year interval, and were then followed for a further 10 years after the 
second measurement. They found that LTL shortening was associated with smoking cross-
sectionally but not over the 10 years of follow-up. However, these findings may be subject to 
survivor bias. In addition, the findings could be partly explained by regression towards the mean, 
ie. the combined effect of biological and analytical variability will push the highest levels to a 
lower level on retesting and vice versa for those with the lowest levels.  
Obesity has been associated with increased oxidative stress and DNA damage. 164 Although the 
precise mechanisms linking obesity to age-related disorders remain largely unknown, it has been 
suggested that biological ageing driven by telomere shortening plays a central role.165 In cross-
sectional epidemiological studies, shorter LTL has been associated with body mass index (BMI), 
waist-to-hip ratio (WHR) and visceral fat.166 Also in an intervention trial of 521 subjects, 
reduction in adiposity indices corresponding to a Mediterranean diet intervention was 
accompanied by increased LTL,167 attributed to telomere maintenance.168 Weight loss induced 
by calorie-restricted diets was also found to be associated with increased telomere length in 
rectal mucosa of obese men.169 However, these findings, in the literature, were primarily derived 
from relatively small subgroups of patients or research subjects, and results were inconsistent 
across study populations.170,171,172,173  
It has been suggested that biological ageing reflected by shortened telomere length is also 
associated with diabetes.174,175,176 Proposed pathophysiological mechanisms include a reduction 
in insulin secreting beta-cell mass in the pancreas, impaired insulin secretion and adipocyte 
insulin resistance elicited by cellular senescence. Studies on South Asian populations have 
shown shorter LTL in individuals with either non-insulin dependent diabetes mellitus (NIDDM) 
or impaired glucose tolerance compared to healthy controls.174,175,176 Harte et al174 compared 
LTL in South Asians with (n=142) and without (n-=76) Type 2 diabetes (T2DM). This case-
control study found an association between LTL and Type 2 diabetes in men only (only 56 cases 
and 43 controls). They also found that reduced LTL observed in T2DM South Asian males was 
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inversely associated with total cholesterol and triglycerides. However, no association was found 
between LTL and age, BMI, or waist circumference, which maybe as a result of the small 
numbers included in the study Adaikalakoteswari et al175 also found an association between LTL 
and type 2 diabetes in south Asians. While this study did show an association between LTL and 
age, it included only 40 cases and 40 controls. Jeanclos et al. demonstrated similar findings in a 
case-control study (54 with type 1 diabetes, 74 with type 2 diabetes , and 106 healthy controls) 
for insulin dependent diabetes mellitus (IDDM) but not for NIDDM, in Caucasian men.176  
However, LTL was not associated with duration of type 1 diabetes. While diverse in aetiology, 
there is a strong genetic susceptibility to type 1 diabetes, which may also affect telomere length 
and attrition.  The studies by Harte et al.,174 Adaikalakoteswari et al.,175 and Jeanclos et al.176 are 
cross-sectional in nature, precluding causal inferences. However, Zhao et al.177 used the Strong 
Heart Family Study to investigate the association of leukocyte telomere length at baseline with 
future risk of diabetes over an average follow-up period of over 5 years. They found that 
individuals in the lowest quartile of leukocyte telomere length were at almost twice the risk of 
developing diabetes compared with those with longer telomeres. Notably, they highlight a 
nonlinear association between telomere length and diabetes risk in which the increased risk is 
largely confined to those with the shortest telomere length – consistent with the hypothesis that 
there is a critical limit of telomere length that induces cellular senescence. A key strength of the 
study is the prospective design, which should minimize the possibility of reverse causality. 
There are, however, some important limitations, particularly given the long latency that can 
precede diabetes diagnosis. Even with a 5.5-year follow-up period, many of those who went on 
to develop type 2 diabetes were likely to be experiencing subclinical metabolic changes at 
baseline.  
 
In the Helsinki Businessman Study, there was a dose-dependent, linear, inverse relationship 
between LTL and alcohol consumption in 622 men followed up over 38 years to a mean of 78 
years of age178 Alcohol intake was assessed by self-report at the beginning of the study and LTL 
was assessed in old age, thus restricting the study to survivors, and did not contain data on 
changes in LTL with time.  In addition, data on type of alcohol and pattern of use was limited. 
While the statistical adjustments were applied for measured potential confounders, the authors 
acknowledge that they could  not exclude residual confounders such as genetic and 
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environmental factors. Again the mechanism of telomere shortening associated with alcohol 
intake is currently unknown; however, possible explanations include alcohol-induced oxidative 
stress and inflammation. 
 
Ornish et al.178 undertook a small pilot study which showed for the first time that improvements 
in diet, exercise, stress management and social support may result in longer LTL. The study 
included 35 participants who all had biopsy-proven low-risk prostate cancer and had chosen to 
undergo active surveillance rather than conventional treatment. The intervention group (n=10) 
underwent a lifestyle intervention. This was the first controlled (but non-randomised) trial to 
show that a lifestyle intervention may lengthen LTL over time (the difference remained 
significant at 5 years). It also demonstrated a dose response correlation between degree of 
lifestyle change and increase in LTL. However, the generalizability of the study findings is 
limited because all participants had prostate cancer.  In addition, debate exists as to whether this 
apparent lengthening of telomere length may be a result of changes in peripheral blood stem 
cells or shifting patterns of leucocyte sub-populations rather than being an actual increase.  
Environment 
Hoxha et al.179 evaluated telomere length in the leucocytes derived from 57 office workers and 
77 traffic police officers exposed to traffic pollution. Exposure to pollution was assessed by 
levels of toluene and benzene measured using a personal passive sampler over 1 work shift. 
After adjusting for available confounders, the within each age-band telomere length was shorter 
in traffic police officers than office workers. However, the non-random selection of participants 
and potential residual confounders are limitations of this study.  
A number of studies have examined the association between area, socio-economic status, 
deprivation and LTL.8,180 Robertson and Shiels et al.180 found that the rate of age-related 
telomere attrition was significantly associated with low relative income, housing tenure and poor 
diet. Notably, telomere length was positively associated with LDL and total cholesterol levels, 
but inversely correlated to circulating IL-6. However, no such association was found with area-
based measures. However, this meta-analysis of 29 study populations found weak evidence for 
an association between SES (when measured by education) and biological ageing (as measured 
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by telomere length), although there was a lack of consistent findings when different SES 
measures investigated.180 This meta-analysis was conducted following the robust PRISMA 
guidelines and different SES measures were included in the same analysis (social class, income, 
and employment status), which allowed each of the meta-analyses to be maximized in terms of 
size. In addition, a wide range of sensitivity analyses were conducted to investigate the effect of 
different aspects of study heterogeneity on the findings. While the studies were limited to 
English language only, there was little evidence of publication bias based on the funnel plots and 
rank correlation results.  
1.3. Coronary artery disease  
1.3.1. Definition 
CVD are diseases relating to the heart, blood vessels, or the circulatory system.  Historically, 
they comprised of various diseases including: heart failure, CHD, stroke – ischaemic and 
haemorrhagic, arrthymias, and peripheral artery disease. The International Classification of 
Disease (ICD) is the accepted standard to classify diseases and other health problems; recorded 
on many types of health and vital records including death certificates and health records (ICD 10 
is the current version in use). In this classification, CVD also includes: rheumatic heart disease; 
valvular heart disease; disorders of the venous and lymphatic system; hypertension; pulmonary 
artery disease; peri-, myo- and endo-cardial disorders; blood vessel aneurysms; and intracranial 
haemorrhages.   
CHD, ischaemic heart disease (IHD), and CAD are often used interchangeably; however, CAD 
usually refers more specifically to atherosclerotic involvement of the coronary arteries. In 
contrast, IHD most commonly refers to the presentation of clinical symptoms and CHD often 
includes other causes of inadequate blood flow to muscles, such as valvular heart disease or 
pulmonary hypertension. For the purposes of this thesis, CAD will used to denote atherosclerosis 
of the coronary arteries.   
Atherosclerosis is a complex process affecting the coronary artery vessels walls. The endothelial 
cells that line arteries provide a semi-permeable barrier between the blood stream and the artery 
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wall. Their main function is to regulate the exchange of fluid, nutrients, gases, and waste 
products between the blood and tissues. Endothelial cells also regulate constriction and 
relaxation of vessels by releasing vasodilatory molecules (e.g., nitric oxide (NO) and 
prostacyclin (PGI2)) and vasoconstrictive molecules (e.g., endothelin and angiotensin-II). They 
provide a unique surface that normally allows the cellular elements of blood to flow without 
adhering to the vessel lining.   
Atherosclerosis is a disease process which is sometimes triggered by quite subtle physical or 
chemical insults to the endothelial cell layer of arteries. The "Response to Injury Theory" now 
has widespread acceptance in the literature.181 This theory suggests that the earliest event in 
atherogenesis is injury to the endothelium, which can be triggered by any number of insults, 
either alone or in combination. These include: 
• Physical injury or stress as a result of direct trauma or hypertension 
• Turbulent blood flow, for example, where arteries branch 
• Circulation of reactive oxygen species (oxidative stress) 
• Inflammation 
• Hyperlipidemia (high blood concentrations of Low Density Lipoprotein (LDL) or Very 
Low Density Lipoprotein (VLDL) 
• Chronically elevated blood glucose concentrations 
• Homocysteinaemia, in which an inherited metabolic defect leads to very high levels of the 
homocysteine, a metabolite of methionine, high concentrations of which are toxic to the 
endothelium 
In response to these insults, perturbation occurs where the endothelial cells secrete cytokines 
which then trigger and maintain an inflammatory response. The endothelial cells begin to 
produce cell surface adhesion molecules, causing monocytes and T-lymphocytes (specific types 
of leucocytes which play a central role in cell-mediated immunity) to adhere to the endothelium 
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and then migrate beneath it, by squeezing between the endothelial cells. Circulating monocytes 
and T-lymphocytes are attracted to the sites of injury by the cytokines. 
The endothelial cells also change shape, causing the tight junctions between endothelial cells to 
loosen, increasing the permeability to fluid, lipids, and leucocytes. Lipoprotein particles, and 
especially LDL, enter the artery wall and undergo oxidation. Oxidation of LDL in the artery wall 
occurs as a result of its exposure to nitric oxide, macrophages, and some enzymes such as 
lipoxygenase. Once they have migrated into the intima layer, monocytes differentiate into 
macrophages and begin to take up oxidized LDL that has entered the intima. Macrophages retain 
the lipid they take up, and as they become more lipid-laden, they are referred to as "foam cells." 
Eventually, the foam cells will undergo apoptosis and die, but the lipid will remain and 
accumulate in the intima. 
Fatty streaks are the first signs of atherosclerosis that are visible without magnification. A fatty 
streak consists of lipid-containing foam cells in the artery wall just beneath the endothelium. It 
appears as a yellow discoloration in the artery's inner surface and occurs in the aorta and 
coronary arteries of most people by age 20. Over time, these fatty streaks can evolve into 
atherosclerotic plaques or they can remain stable or even regress.182  
Slowly growing plaques expand gradually due to the accumulation of lipid in foam cells and the 
migration and proliferation of smooth muscle cells. These plaques tend to stabilize and are not 
prone to rupture. The so-called fibrin cap on the lesion matures. These plaques can build up and 
harden causing narrowing with reduction of blood flow to the heart. This can cause symptomatic 
(angina) or asymptomatic ischaemia.  
In contrast, other plaques grow more rapidly as a result of more rapid lipid deposition. These 
have thin fibrin caps that are prone to rupture.  Once a plaque ruptures, it can trigger an acute 
thrombosis (clot) by activating platelets and the clotting cascade. This blood clot can cause 
partial or complete blockage. This results in an ACS.13.183 
ACS is a spectrum of events which include:- 
• STEMI (ST elevation MI) – elevation of the ST segment is seen on the electrocardiogram 
(ECG) – this is often referred to as an acute myocardial infarction (AMI) or heart attack 
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and usually involves complete blockage of the artery. Cardiac enzymes are raised. 
(Cardiac enzymes are proteins produced by the damaged heart muscle and released into 
the blood stream). 
• NSTEMI (Non-ST elevation MI) – is where there is an AMI but ST elevation does not 
occur on the ECG. This is usually associated with partial rather than complete blockage 
of the culprit artery. Cardiac enzyme blood tests are also raised in NSTEMI (although 
often not as high as in STEMI), indicating that damage is occurring to heart muscle.  
• Unstable angina – this is where there is partial blockage of the artery but the severity is 
insufficient to cause release of cardiac enzymes. However, this is also thought to be  
caused by coronary artery spasm where there may be partial and temporary blockage of 
arteries.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Coronary artery disease morphology 
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Stable CAD is characterised by episodes of reversible ischaemia or hypoxia (transient imbalance 
between blood oxygen supply and myocardial demand) usually induced by exercise, emotions or 
other stressors, although it can occur spontaneously. Traditionally the underlying mechanisms 
are thought to be plaque related obstruction of coronary arteries. However, more recently, focal 
or diffuse spasm of normal or plaque diseased arteries, microvascular dysfunction and left 
ventricular dysfunction have been shown to also cause symptoms of CAD.3 These mechanisms 
are thought to be able to act singly or in combination.  
Stable CAD and ACS are not considered to be distinct entities, rather they are part of a 
continuum; although stable CAD lesions less commonly show erosion or rupture of the 
endothelial layer.3  
1.3.2. Epidemiology of coronary artery disease 
CVD is the leading cause of death worldwide; the World Health Organisation (WHO) estimates 
that globally 17.3 million people die from CVD each year.184 Of these deaths, an estimated 7.3 
million were due to CAD. CVD is projected to remain the leading cause of death with the 
number of people who die from heart disease and strokes increasing to 23.3 million by 2030. 
WHO statistics are often the most complete, comparable, or often the only data available on a 
global scale. However, the quality of the data collected varies substantially across countries. 
Many high income countries have highly evolved health surveillance and death certification 
record systems. However, in many countries—especially in low and middle income countries—
health statistics are often based on surveillance that does not cover all areas of the country, is 
incomplete in the areas it does cover, or is collected by undertrained staff who may not 
accurately report the pertinent data.  
 
In the United Kingdom (UK), there are around 180,000 deaths recorded each year from CVD, 
with  CAD being the most common cause (45%). Mortality rates for CAD have been falling in 
the UK since the early 1970s; although this has fallen more slowly in younger age groups, with 
CAD being the leading cause of premature mortality. Despite these declines, mortality rates 
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from CVD and CAD in the UK remain amongst the highest in Western Europe. Declining 
mortality rates have been attributed to reductions in major risk factors, advances in treatments 
(such as improved management of AMI resulting in a reduced case fatality rate), and to 
secondary prevention.185  
 
Within the UK, mortality rates from CAD are highest in Scotland and the North of England and 
lowest in the South of England. For example, the premature mortality rate from CAD for men 
living in Scotland is 65% higher than in the South West of England and 112% higher for 
women.186,187 Within Scotland itself there are also geographic variations in mortality rate 
declines.142 Reductions have been slower in the most deprived areas of Scotland than elsewhere, 
meaning that relative inequality has increased slightly over the long-term while the absolute 
inequality gap has narrowed. However, there are signs that relative inequality has begun to 
stabilise in recent years.2 
 
Incidence of AMI has also been declining, with the most recent Scottish estimates (based on 
hospital and death certification) suggesting around a 25% decrease from 2002 to 2010. However, 
the absolute number of people who have had an AMI has actually increased since the 1960s. 
This is because incidence of AMI increases with age and Scotland has an increasingly ageing 
population.  Age-sex standardised incidence rates for AMI decreased by 22.3% between 2003/04 
and 2007/08 but increased by 12.9% between 2007/08 and 2010/11. This increase is thought to 
be due to the introduction of more sensitive tests for diagnosis (such as cardiac enzymes), 
meaning that more cases are being diagnosed with an AMI.  
 
Data on CAD morbidity are harder to collect. In Scotland the incidence of CAD has been 
tracked using the Information and Statistics Division (ISD) linked data set (based on national 
hospital discharge records). Incidence of CHD has decreased over the past decade, with the 
standardised incidence rate falling by 27.3% from 361.7 per 100,000 in 2003/04 to 262.8 in 
2012/13. Between 1994 and 2003 incidence fell by 14% in men (from 585 to 501 per 100,000) 
and by 19% in women (449 to 366 per 100,000). Incidence rates for CHD also show regional 
and socioeconomic variations within Scotland. For example, the age-sex standardised rates were 
238.0 per 100,000 in 2012/13 in the NHS Lothian Health Board area compared with 286.9 per 
59 
100,000 in the more deprived Greater Glasgow and Clyde Health Board area. Although the 
premature death rate has fallen across all social groups for both men and women in the UK, the 
decline has been greater in people in higher socio-economic groups.186 The incidence of CAD 
increases sharply with age. In Scotland, the standardised incidence rate for the under 75 age 
group in 2012/13 was 197.5 per 100,000 compared with 1,829.2 in the 75 and over group.  
 
Data on prevalence of CAD in Scotland can be obtained from a number of sources including: the 
Scottish Health Survey, and ISD (which uses inpatient hospital discharge and day case procedure 
data). The self-reported prevalence of CAD was found to be 7.3% (8.2% of men and 5.7% of 
women) in the 2012 Scottish Health Survey, with this showing little change since the 2003 
survey. However, this rose to 30.7% in men and 21.2% of women, for those aged 75 years and 
over. ISD estimates the prevalence of CAD in Scotland to be 3.3% (4.2% in men and 2.5% of 
women) and that 16% of the Scottish population aged 75 years and over is living with CAD. 
Similar to incidence, ISD found marked socioeconomic variations in prevalence, for example, in 
some more deprived areas around 25% of men aged 75 years and over are living with CAD.  
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1.3.3. Symptoms of coronary artery disease 
The main symptom of CAD is chest pain. It is often described as feeling like a dull, heavy, or 
tight pain. It can also spread to the left arm, neck, jaw, or back. However, the presentation of 
CAD chest pain is variable. The traditional classification of chest pain is:  
 
Typical angina Meets all three of the following characteristics: 
• Sub-sternal chest discomfort of            
characteristic quality and duration 
• Provoked by exertion of emotional stress 
• Relieved by rest and/or nitrates within 
minutes 
Atypical angina (probable) Meets two of these characteristics 
Non-anginal chest pain  Lacks or meets only one or none of these 
characteristics. 
 
The Canadian Cardiovascular Society (CCS) classification is widely used as a grading system 
for severity of stable angina.188 It quantifies the threshold at which symptoms occur in relation to 
physical activities. The Rose Angina Questionnaire is similar and can also used for this purpose, 
although it is usually used as a screening tool for CAD in epidemiological studies.189  
 
CCS classification Description 
Class I Ordinary activity does not cause angina such as walking and climbing stairs. 
Angina with strenuous or rapid or prolonged exertion at work or recreation. 
Class II Slight limitation of ordinary activity. Angina on walking or climbing stairs 
rapidly, walking or stair climbing after meals, or in cold, wind or under 
emotional stress, or only during the first few hours after wakening. Walking 
more than two blocks* on the level and climbing more than one flight of 
ordinary stairs at a normal pace and in normal conditions. 
Class III Marked limitation of ordinary physical activity. Angina on walking one to two 
blocks on the level or one flight of a stairs in normal conditions and at a normal 
pace. 
Class IV Inability to carry on any physical activity without discomfort' – angina 
syndrome may be present at rest'. 
*Equivalent to 100-200m 
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Sometimes CAD chest pain can be difficult to distinguish from other causes of chest pain (such 
as oesophageal pain) and therefore further investigation may be indicated. The latest European 
Society of Cardiology (ESC)3 guidelines on the management of stable CAD have recommended 
applying a well-validated prediction rule (to determine risk of CAD) containing the five 
determinants: 
 
• male ≥ 55 years or female ≥ 65 years);  
• known vascular disease;  
• patient assumes pain is of cardiac origin;  
• pain is worse during exercise; and 
• pain is not reproducible by palpation.  
According to the guideline, using one point for each determinant can be used to rule-out CAD at 
a specificity of 81% (for ≤2 points) and a sensitivity of 87% (for 3–5points). However, they 
emphasise that this rule should be used in the context of other clinical information, such as the 
presence of cough or stinging pain (making CAD more unlikely). In contrast, clinical features 
such as radiation of pain into the left arm, known heart failure and diabetes mellitus make CAD 
more likely. Some people with angina also become breathless when they exert themselves.  
 
1.3.4. Investigation of coronary artery disease  
After considering general health, co-morbidities and quality of life (QoL), non-invasive testing 
for CAD includes: 
• Resting electrocardiogram (ECG) to look for evidence of ischaemia (such as ST/T 
changes) which may show other abnormalities, such as conduction defects which may 
contribute to symptoms. A normal resting ECG is not uncommon in stable CAD and can 
occur irrespective of severity of angina. All patients with suspected CAD have ECGs 
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undertaken prior to more advanced or invasive investigations. In addition, ECGs are 
sometimes carried out in routine clinical situations (for example prior to surgery). If the 
ECG changes are consistent with CAD, irrespective of symptoms, this may prompt a 
diagnosis of CAD (for example. if the ECG is consistent with previous AMI) and/or 
further investigation.   
• ECG exercise testing is useful in patients with suspected CAD and an intermediate risk 
based on the pre-test probability (PTP) (see below for more discussion on PTP). ECG 
monitoring is undertaken while the patient is exercising using a treadmill or bicycle to 
look for evidence of ischaemia – either during or in the recovery phase. Positive finds 
can also lead to more advanced or invasive investigations.  
• A chest X-ray is useful in patients where there is suspicion of a pulmonary cause and to 
assess if the heart appears enlarged - indicative of cardiomyopathy or heart failure.  
• Echocardiography at rest is generally undertaken to assess cardiac structure and function. 
The diagnostic yield of resting echocardiography is mainly in sub-groups with murmurs, 
previous MI or symptoms/signs of heart failure. However, as left ventricular function is 
now an important risk predictor, the current ESC guidelines recommend that it is 
performed in all patients presenting with symptoms suggestive of angina. Therefore 
patients attending for invasive investigations in the future will have had an 
echocardiography. This allows an assessment of the thickness of the heart muscle to look 
for hypertrophy. Measurement of the left ventricular ejection fraction (volumatic fraction 
of blood pumped out of the left ventricle with each contraction of the muscle) can also be 
undertaken using echocardiography. This is used to assess left ventricular function.  
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• In ACS, biomarkers of myocardial injury, such as troponin, should be measured. 
Troponin can be raised in patients with stable CAD; however, the levels are usually 
below the cut-off for being defined as elevated and the level provides no additional 
diagnostic or prognostic benefit in stable CAD. Therefore, it is usually reserved for 
patients presenting as an emergency with suspected AMI.  
Invasive coronary angiography 
Coronary angiography is an invasive diagnostic procedure which is generally considered as the 
“gold standard” in diagnosing CAD.190 It is used to visualise the coronary arteries. It involves 
the injection of an iodine based contrast into the coronary arteries. The contrast absorbs X-rays, 
making the blood vessel lumen radio opaque, and producing a sharp contrast with the 
surrounding cardiac tissue. An image intensifier converts the X-ray shadow into a visible light 
displayed on fluoroscopic monitors or a flat panel detector can be used to produce a direct digital 
image signal from the original visible light fluorescence.   
After introduction of local anaesthesia, percutaneous access to a large peripheral artery (such as 
the femoral, radial or brachial artery) is achieved by puncturing the skin. A sheath is then 
inserted into the artery.  Heparin (an anticoagulant used to inhibit thrombus formation during the 
procedure), nitrates (a vasodilator) or other adjuvant drugs may be inserted into the blood stream 
via this sheath. Through this, a small catheter is fed, via a guide wire, to the coronary ostia of the 
aorta, where the coronary arteries originate. Contrast can then be injected into coronary arteries 
and X-ray films are taken rapidly (Cine images) to show the vessels filling with blood and the 
sites of any stenosis (narrowing of the arteries) can be seen.  
The heart is supplied by the right coronary artery and left coronary artery. The left coronary 
artery is wider. The first part, termed the left main stem (LMS) is around 1cm in length. It then 
divides into the left anterior descending artery and the circumflex artery. The left coronary artery 
and its branches are most commonly found to be stenosed in CAD. In around 70% of people, the 
right coronary artery supplies the posterior descending coronary artery. This is described as 
being right-dominant, while around 20% are left dominant (where the left coronary artery 
supplies the posterior descending artery), and around 10% have co
the right and the left coronary arteries. Three
stenosis, significant stenosis of t
been associated with higher mortality rates.
 
 
 
Figure 8. Anatomy of the coronary arteries
 
The severity and manifestation of CAD generally depends on the degree of stenosis and on the 
type and number of arteries affected. However, paradoxically, severe stenosis can result in no, or 
mild symptoms, and conversely severe symptoms can occur in patients with mild stenosis. 
Currently, the ESC defines significant stenosis as 
angiographic views when there is no evidence of ischaemia) or 
major coronary arteries (although 
areas of the world). Single vessel disease (SVD) is defined as a significant stenosis in one of the 
64 
-dominant supply from both 
-vessel disease (involving 3 arteries) with proximal 
he LMS and proximal anterior descending artery lesions, have 
191
  
 
≥ 50% in the LMS (or <90% in two 
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≥ 50% has been used in the past and is currently used in other 
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major coronary arteries, other than the LMS. Multivessel disease generally refers to significant 
stenosis in two or more vessels. Involvement of the LMS is often classified as multivessel 
disease or as “MVD with LMS” involvement to distinguish it from MVD without significant 
LMS stenosis. The term triple vessel disease is also used to describe MVD where there is 
involvement of the right coronary artery, left descending, and left circumflex.  
However, classification of angiographic appearance of the coronary arteries has evolved over 
time based on evidence  from clinical trials. One such classification is the SYNTAX scoring.149 
The SYNTAX score is an angiographic grading tool to determine the complexity of CAD. The 
SYNTAX score was developed by Serruys and colleagues at the Thoraxcenter, Erasmus Medical 
Center in The Netherlands and was published in 2005.192 The SYNTAX score was derived from 
pre-existing classifications, including  the American Heart Association (AHA) classification; the 
Leaman score; the American College of Cardiology (ACC)/AHA lesion classification system; 
the total occlusion classification system; the Duke and International Classification for Patient 
Safety (ICPS) classification system for bifurcation lesions; and a consensus opinion from among 
the world’s experts. The coronary artery tree is divided into 16 segments according to the AHA 
classification (Figure 8). Each lesion is given a score of 1 or 2 based on the presence of disease 
and this score is then weighted based on a chart, with values ranging from 3.5 for the proximal 
left anterior descending artery to 5.0 for left main, and 0.5 for smaller branches. The SYNTAX 
score is the sum of the points assigned to each individual lesion identified in the coronary tree 
with >50% diameter narrowing in vessels >1.5mm diameter. The ESC currently recommends 
that the SYNTAX score is derived and used for diagnostic and management decision making. 
For example, it recommends that a patient with a SYNTAX score ≥33 with LMS plus 2 or 3 
other vessel involvement, undergo CABG (as long as they have a low risk of surgical 
complications) rather than PCI. However, decision making is also influenced by a number of 
factors including: patient preference, assessment of potential risks from surgery, clinical factors, 
and clinical team decisions.  
As with any invasive procedure, coronary angiography is associated with a number of potential 
complications such as: access site complications (bleeding, pseudoaneurysms, fistulas, or 
infection); renal failure resulting from contrast medium damage; stroke; AMI; cardiac 
arrhythmias; aortic aneurysms; and damage to the coronary vessels (perforation, embolism, or 
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dissection). However, the risk of any complication during coronary angiography is said to be 
1%-2%, with the risk of death, AMI or stroke around 0.1%- 0.2% 193 
 
The methods used to perform coronary angiography have improved substantially since its 
introduction, with, for example, vascular closure devices (medical devices used at access sites to 
achieve haemostasis). This is especially true for radial access rather than via the traditional 
femoral artery route.  Since its introduction by Lucien at the Montreal Heart Institute, radial 
access has been increasingly used, particularly in the UK (with recent BCIS audit suggesting that 
65.3% of procedures are now undertaken using radial access). It requires less contrast medium151 
and carries a lower overall risk of complications, fewer access site complications,194,195,196 fewer 
bleeding episodes and a reduced likelihood of renal damage.  Because there is better collateral 
circulation, there is less chance that an access site complication will result in limb-threatening 
damage. Collateral circulation can be assessed prior to coronary angiography, by measuring the 
time for the hand’s circulation (colour) to return to normal following compression of the radial 
artery (known as Allan’s test).  Despite the radial artery having a smaller diameter than the 
femoral artery, the success rate (defined as successful balloon dilatation with or without stent 
placement and <30% residual stenosis) associated with radial access is well over 90%.152 Radial 
access, with its lower complication rate and the possibility for early ambulation, has facilitated 
the use of day case and rapid discharge protocols for patients who have had a successful PCI and 
are at low risk of complications (following the Amsterdam criteria for same day discharge).197  
Guidelines for investigating CAD have evolved based on emerging evidence and innovations in 
non-invasive techniques (see below). Currently a two-stage approach is recommended based on 
clinical assessment of risk of CAD followed by assessment of the likelihood of benefiting from 
invasive management for those found to be at increased risk of CAD. Risk is assessed using the 
PTP. The PTP is influenced by the background prevalence of CAD in the population and the risk 
factors and clinical features of the individual, including age, gender and nature of the symptoms. 
Points are assigned to the presence of these factors, enabling patients to be classified into four 
categories based on their likelihood of having CAD: low-likelihood (PTP < 15%), low-
intermediate likelihood (PTP 15-65%), high-intermediate likelihood (PTP 65-85%), and high-
likelihood (PTP > 85%). Low-likelihood patients are not recommended for further investigation. 
High likelihood patients (defined as a PTP >85%) are assumed to have CAD without need for 
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further non-invasive testing. Those with an intermediate risk should be referred for further 
investigations, such as non-invasive testing or coronary angiography (depending on the 
availability of non-invasive testing and severity of symptoms).  
Coronary angiography has a sensitivity of is 95-99%, and specificity of only 64-83%3 and is 
associated with a risk of a major complication (albeit low). Therefore it is recommended to 
be used in those who would most benefit from revascularisation, for example, high PTP, 
where it is used to assess the severity of CAD to inform future management options (such as, 
PCI  or  coronary  artery bypass grafting (CABG)); in patients where the findings of non-
invasive testing are inconclusive or in those where optimal medical management fails to 
control symptoms (also in some professions for regulatory reasons). However, severity of 
clinical symptoms, the patient’s risk of adverse events from coronary angiography, and 
patient preferences, are also taken into consideration in determining investigation of CAD. In 
addition, while coronary angiography  is  an important invasive investigation to assesses the 
presence and severity of coronary artery stenosis, current understanding of angina 
demonstrates that clinical symptoms can be more severe than suggested by the degree of 
stenosis and that angina can be caused by other mechanisms (such as microvascular 
dysfunction).  
Additional imaging procedures, such as intra-vascular ultrasound (IVUS) and fractional flow 
reserve (FFR), may be performed along with coronary angiography in some cases to obtain 
detailed images of the walls of the blood vessels. Both of these imaging procedures are currently 
only available in specialized hospitals and research centres. With IVUS, a miniature sound-probe 
(transducer) is positioned on the tip of a coronary catheter. High-frequency sound waves produce 
detailed images of the inside walls of the arteries. Therefore, IVUS produces a more accurate 
picture of the location and extent of plaque. With FFR, vasodilator medication is used to perform 
a very high quality stress test over a short segment of the artery.  
Prior to recent guidelines, coronary angiography was considered a first-line investigation among 
patients at high risk of CAD.193  All men and women older than 70 years with typical or atypical 
symptoms were considered to be at “high  risk”. Therefore, in the past, elderly patients were 
more likely to have undergone coronary angiography. In spite of being at higher risk, previous 
studies have suggested that elderly patients may receive less aggressive investigation and 
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management of CAD.199,200 Having a higher threshold for investigation among the elderly 
results in diagnostic coronary  angiography being delayed until the disease and symptoms are 
so  severe that they are less amenable to PCI.   
The literature suggests that elderly patients may be at increased risk of complications 
following coronary angiography. 3,201 However, elderly patients have historically been 
underrepresented in large epidemiological and clinical studies.202  
Non-invasive investigations 
Non-invasive imaging includes multi-detector computed tomography, cardiac magnetic 
resonance imaging, or myocardial perfusion scintigraphy (such as,single-photon emission 
computed tomography or positron emission tomography). These use contrast or isotopes injected 
into a peripheral vein (intravenous injections) to visualise the coronary arteries. Therefore, 
unlike coronary angiography, which requires artery access for a catheter to inject contrast 
directly into the coronary arteries, these non-invasive imaging techniques are not associated with 
access site bleeding or coronary artery damage. Availability of these tests varies across the UK.  
Stress testing can also be undertaken in conjunction with non-invasive imaging and can provide 
an assessment of coronary artery function. Sensitivities and specificities for these techniques 
vary depending on the test. Further discussion on non-invasive imaging techniques is outwith the 
scope of this thesis.  
 
1.3.5. Management of coronary artery disease 
The management of CAD has improved significantly over the last few decades resulting in 
improved life expectancy and survival.3 It can be managed using either medical therapy or 
revascularisation. As discussed, revascularisation can be achieved via PCI or CABG. In addition 
to these, lifestyle (and environmental) modification should always be addressed e.g. diet, 
exercise, smoking, exposure to second hand smoking. Medical therapy includes statins to 
maximise blood lipids, ACE inhibitors to manage blood pressure and left ventricular function, 
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anti-anginals (e.g. nitrates) for symptomatic relief, and antiplatelets (where indicated) which are 
used to prevent the formation of blood clots.   
 
Percutaneous coronary intervention  
PCI is a non-surgical procedure used to open narrowed coronary arteries to improve blood flow 
to the heart. PCI is also known as balloon angioplasty, or percutaneous transluminal coronary 
angioplasty (PTCA). PCI can be performed as an immediate follow-on procedure if significant 
stenoses are identified during coronary angiography or it may be performed as a separate 
procedure. PCI can be used to treat patients with stable CAD or patients presenting with AMI. In 
relation to the latter, it can be used as the first-line treatment (primary PCI) or following failure 
of anti-thrombotic medication (rescue PCI). PCI encompasses a number of techniques including: 
balloon angioplasty (sometimes described as “Plain old Balloon Angiography” (POBA)), 
insertion of a coronary stent, rotablation, a cutting balloon or a combination of these. 
 
Balloon angiography: during balloon angiography a small balloon at the tip of the catheter is 
inflated within the stenosed lesion, compressing the fatty plaque and dilating the vessel lumen 
and increasing blood flow to the heart. This procedure is sometimes complicated by vessel 
rupture, aneurysm formation, and acute occlusion. As discussed, angiographic appearance (for 
example, which vessels are involved, SYNTAX score), patient preference, clinical factors, and 
clinical team decisions, all influence whether patients have a PCI undertaken.  
 
Balloon angioplasty with stenting: Increasingly, balloon angioplasty is often used in 
combination with insertion of a coronary stent in order to reduce the risk of requiring repeat 
revascularisation. A stent is a small, metal mesh tube that acts as a scaffold to provide support 
inside the coronary artery. Coronary stents can be either bare metal or drug-eluting. A balloon 
catheter, placed over a guide wire, is used to insert the stent into the narrowed artery. Once in 
place, the balloon is inflated and the stent expands to the size of the artery and holds it open. The 
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balloon is deflated and removed, and the stent stays in place permanently. Over a period of 
several weeks, the artery heals around the stent.  
Drug-eluting stents: Drug-eluting stents contain a medication that is actively released at the 
stent implantation site and reduces the risk of stent thrombosis as a result of delayed 
development of endothelial layer cover. Concern was raised in 2006 regarding the safety of 
drug-eluting stents due to the risk of late stent thrombosis causing AMI. In 2007, the Food and 
Drug Administration stated that drug eluting stents, when used according to approved 
indications, are safe and effective.203 However, longer post PCI antiplatelet use is advised with 
drug eluting compared with bare metal stents to reduce the risk of late thrombosis. The majority 
of stents deployed during PCI procedures in the UK are now drug eluting.3  
Rotablation: In rotablation, also known as percutaneous transluminal rotational atherectomy, a 
special catheter, with an acorn-shaped, diamond-coated tip, is guided to the point of narrowing 
in the coronary artery. The tip spins at high speed and grinds away the plaque on the artery 
walls. This process is repeated as needed to remove the blockage and improve blood flow. The 
microscopic particles enter the bloodstream and are filtered out by the liver and spleen. 
Cutting balloon: The cutting balloon catheter has a balloon tip with small blades. When the 
balloon is inflated, the blades are activated. The small blades score the plaque, then the balloon 
compresses the fatty matter into the artery wall. This type of balloon may be particularly useful 
in treating the build up of plaque within a previously placed stent (restenosis). 
 
While medical therapy remains the cornerstone of the management of chronic stable angina, 
randomized trials have consistently demonstrated greater symptomatic relief from coronary 
revascularization compared with medical therapy alone.204,205,206,207 Since the introduction of PCI 
in the UK in 1991, there has been a major shift in the proportion of patients treated with PCI 
compared to CABG. The number of CABG operations performed each year rose until 1997 then 
remained relatively static until falling again after 2007.  
 
  
Figure 9 UK Time trends in percutaneous coronary intervention and coronary artery bypass grafting: 1991
2010 
In Scotland, the number of CABG operations decreased from 2,032 
2009/10. This follows a slight increase between the years 20009/10 and 2010/11. However, 
overall there is was general downwards trend in the numbers of CABG operations which, again, 
is thought to reflect the increased use of PCI. The
2008/09 to 6,583 in 2009/10.  
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Figure 10. Scottish time trends for percutaneous coronary intervention and coronary bypass grafting: 
2003/04-2012/13 
 
Risks associated with percutaneous coronary intervention 
 
Similar to coronary angiography, PCI is associated with a number of potential complications 
such as: access site complications (bleeding, pseudoaneurysms, fistulas, or infection); 
myocardial infarction; cardiac arrhythmias; aortic aneurysms; and stroke. Damage to the 
coronary vessels (perforation, embolism, or dissection) is more likely with the balloon inflation 
or stent deployment of PCI. Risk of renal failure resulting from contrast medium damage is also 
more likely in PCI as larger amounts of contrast may be utilised to guide balloon inflation, stent 
deployment, and to assess their effects on lumen patency. Early stent thrombosis is a risk until 
the stent becomes covered with an endothelial layer. This presents more frequently during the 
first month, occurs in 1-2% of patients, usually presents as an AMI, and is associated with high 
mortality. To reduce the risk of stent thrombosis, antiplatelet therapy is given to patients 
following PCI. Restenosis of the artery lumen is also possible which can may result in a angina 
symptoms, AMI, sudden death, or need for repeat revascularisation.  In patients with three-
vessel disease, the evidence suggests that, while there is no over all difference in mortality 
between management by CABG or PCI, CABG is associated with a lower requirement for repeat 
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revascularisation. Further discussion on the risks of PCI in relation to elderly patients can be 
found below in Chapter 2.1.  
 
 
1.4. Health related quality of life  
The World Health Organization defines health as "a state of complete physical, mental and 
social well-being and not merely the absence of disease or infirmity."208 This definition 
highlights that health is not simply the absence of pathology but is a multidimensional concept 
that captures several domains of well-being simultaneously. Similarly, health related quality of 
life (HRQOL) has evolved as a multi-dimensional concept which includes domains related to 
physical, mental, emotional and social functioning. HRQOL has been studied for at least 40 
years with no commonly accepted definition of the concept. Often HRQOL is synonymously 
referred to as simply quality of life (QoL) in contexts including health research and will be used 
in this way throughout this thesis.   
The Central Union for the Welfare of the Aged defines QoL as “an individual’s understanding of 
his/her life situation with respect to his/her values and cultural context, as well as in relation to 
his/her goals, expectations and concerns”.209 Material well-being (income, level of housing, 
availability of services, environment), close relationships (social relationships, social well-being, 
support, societal involvement), health (physical health, fitness, ability to move, symptoms of 
illness, ability to work), emotional well-being (emotions, self esteem, spirituality, cognitive 
functions) and productivity (satisfaction with ability to work, competence, autonomy, 
meaningful roles) have been viewed as essential dimensions of QoL  
QoL is used to imply an individual’s experience of his or her health status and health-related 
well-being. QoL is usually examined in terms of impacts of illness on an individual - as negative 
deviations from health. However, the concept of QoL is value-laden and attached to social norms 
defined by healthy individuals, according to whom QoL is always weakened when a person is 
sick. QoL measurements are usually used to examine the effectiveness of treatments. QoL is 
thought to be an equivalent to a meme, which is "an idea, behaviour or style that spreads from 
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person to person within a culture.“210 A meme acts as a unit for carrying cultural ideas, symbols 
or practices, which can be transmitted from one mind to another through writing, speech, 
gestures, rituals or other imitable phenomena. Supporters of the concept regard memes as 
cultural analogues to genes in that they self-replicate, mutate and respond to selective pressures. 
This idea of a meme was coined by Dawkins.211 
 QoL tools have been developed to document experience of illness and healthcare and to 
measure what effects of treatment are deemed to be of greatest importance to patients. They can 
also act as a proxy for measuring health needs within assessment.  In health economics, QoL 
tools are used to develop QALYs (quality-adjusted life year) for use in cost–utility analyses. 
QALYs are overall measures of health outcome that weight the life expectancy of a patient with 
an estimate of their QoL score.212 QALYs are widely recognised as a useful approach for 
measuring and comparing the efficiency of different health interventions.  
QoL is particularly important in long term conditions (such as CAD) where prevention, 
rehabilitation and other disease management strategies have resulted in an increase in the 
number of people living and growing older with these conditions.  It is also important for 
treatments such as PCI which are intended to improve symptoms rather than increase life 
expectancy. Studies have shown that CAD imposes a substantial burden on QoL213, 214 though 
this can be improved significantly by interventions.215, 216 Consequently there has been a 
significant growth in the measurement of QoL as a prime indicator of health outcome and 
therapeutic benefit in patients with CAD. 
QoL instruments should be “comprehensive, reliable and valid, easy to score and interpret, and 
minimise respondent burden in order to quantify the impact and burden of disease”.217 The real 
value of QoL instruments in research and in clinical practice is to show that changes are not just 
statistically significant but are also clinically meaningful. This is particularly important for 
assessing the impact of an intervention such as revascularisation, which is primarily undertaken 
to relieve symptoms of CAD. 
The instruments selected should measure the health dimensions relevant to that particular patient 
cohort. For instance, an instrument intended for use in a patient with CAD should take into 
account the individual's responses to living with the disease, in terms of recreational, 
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occupational, social, personal, emotional and sexual aspects, as well as the acute and chronic 
physical consequences of the disease.  
There are two types of QoL instruments: ‘generic’ and ‘disease-specific’. Generic tools are 
designed to address multiple aspects of QoL across a range of different patients or disease 
groups218 and include the Short-Form 36-item (SF-36, SF-12, SF-24) health survey219 and the 
EuroQoL (EQ-5D)220. They assess multiple aspects of patients’ experience without focusing on 
specific features of a particular disease.  
The EQ-5D is a widely used simple and validated general instrument to measure QoL in a 
standard way. It has been used to assess QoL in a wide range of conditions, treatments and 
interventions.221 In addition, it is used extensively in health economics to derive a quality 
adjusted life year (QALY). The EQ-5D was originally designed to complement other 
instruments, although, is increasingly used as a “stand alone” measure. While it has a condensed 
format and assigning values to health states is straight forward, a limiting factor is its restricted 
ability to discriminate small to moderate differences in health states. In addition, evidence 
suggests that there is a ceiling effect i.e. patients who start with a higher quality of life than the 
average patient do not have much room for improvement. This could compromise accurate 
conclusions in relation to a treatment's effectiveness or lack thereof. 222 
The SF-36 was designed as a generic indicator of health status for use in population surveys and 
evaluation of the impact of health policy.223 However, it has also been used in a wide range of 
clinical research areas - on its own, and in conjunction with, disease specific measures. It 
measures both physical and mental health components including behavioural functioning and 
role limitations, such as questions on work, self-care, and mobility. Evidence from studies 
suggests that the SF-36 has been found to be more sensitive to change than the EQ-5D and has 
less of a ceiling effect.224 However, it is much longer for participants to complete and creating a 
utility score for assessing QALYs is much more complex.  
Disease specific instruments measure the multiple aspects of QoL relevant to a specific disease 
group and, for patients with CAD, include the Seattle Angina Questionnaire (SAQ)225 and the 
MacNew questionnaire.226 Disease-specific instruments are generally considered to be more 
clinically sensitive and potentially more responsive in detecting change,227 though each type has 
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its own particular strengths and weaknesses and there is “established merit in using both”.217 For 
example, a generic instrument might ask if someone has problems walking about (such as in the 
EQ-5D), while a disease specific questionnaire would ask if a person’s disease has limited their 
walking (such as in the MacNew).   
The SAQ is a disease-specific instrument designed to assess the functional status of patients with 
angina. It comprises 19 questions that quantify five clinically relevant domains: physical 
limitation, anginal stability, anginal frequency, treatment satisfaction and disease 
perception/quality of life. It is often used as a QoL instrument because 7 of its 19 items relate to 
emotional health (psychological/emotional health being important for QoL in patients with a 
chronic disease such as CAD229) and because it has been shown to be demonstrably valid, 
reproducible, and sensitive to clinical change.230 In addition, SAQ score has been found to be 
strong predictor of 1-year mortality and hospitalization for ACS.231 It is used extensively in 
research trials to quantify the symptoms, functional limitations, and QoL of patients with stable 
heart disease in the previous 4 weeks. Use of the SAQ can help healthcare providers identify 
patients at high risk for morbidity and mortality and can also help identify those patients who 
may require more aggressive medical therapy or revascularization. However, it is specific to 
angina symptoms, making comparisons with other heart conditions difficult.  
 
The MacNew Heart Disease Health-Related QoL Questionnaire was designed to evaluate the 
effect of heart treatments on daily activities and physical, emotional, and social functioning. This 
self-administered questionnaire generates an overall score from 27 questions that cover physical 
limitations, emotional and social function, and angina symptoms experienced in the previous 2 
weeks. It has been used in multiple clinical studies in patients with different types of heart 
disease (rather than being specific to CAD). It has also been shown to be valid, reproducible, and 
sensitive to clinical change and performs well in comparison to the SAQ.232 In addition, the 
reading level required to understand the MacNew Questionnaire was found to be on average to 
be 1 year lower than the SAQ.233 Also, the MacNew questionnaire is the only disease-specific 
instrument that contains a question regarding sexual functioning.  
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1.4.1. Measurement of quality of life in older people   
Despite increasing interest, the concept of QoL in older people is still inadequately defined and 
the measures exploring it have been studied insufficiently among this group. With the existing 
QoL measurements, the meaningful aspects of QoL for older people may not be measured 
comprehensively.234 For example, effects of environment on older people’s well-being and 
functional status, meanings of social contacts, and adaptation to changing situations, are of 
particular importance and may not be covered by some QoL tools. Research undertaken in 
lonely older people’s group rehabilitation indicated that these issues are significant for an 
individual’s health, well-being and prognosis.235  
 
In measuring the QoL of older people, the strengths and weaknesses of the measurement tools 
should be recognized. QoL measurements tend to involve only few, if any, positive aspects of 
well-being (e.g. satisfaction with life) where elderly may do better than younger respondents.  
In addition, groups with special requirements, such as demented persons or frail older people 
living in institutions, need their own measurements since other people cannot “objectively” 
define their QoL on the basis of their own values. 
 
WHOQOL-BREF was developed, using international collaborations, by the WHO to be a 
universal tool.236 It is thought to be one of the most comprehensive measurement tools and 
comprises 26 items, which measure the following broad domains: physical health, psychological 
health, social relationships, and environment. It defines QoL as an individual’s understanding of 
his/her life situation with respect to his/her values and cultural context, as well as in relation to 
his/her goals, expectations and concerns. In addition to breadth of coverage, it has been showed 
to be sensitive to change with respect to rehabilitation interventions designed to improve QoL in 
elderly people. However, it has been criticised for its subjective approach and that few items 
directly assess functional limitations or disability: suggesting it may not be universally 
applicable. In addition, there is limited evidence for its use in assessing improvements in QoL 
following interventions such as PCI. Recently, the WHOQOL-OLD add-on module for the 
WHOQOL-BREF has been developed which has been designed for use in older adults.237 While 
it appears to perform well against other QoL tools such as the SF-36 with less ceiling effect ,238 
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completion rates have been an issue and using the module as a “stand alone’ has still to be 
assessed fully.  
 
The 15D measurement tool discriminates very well between older people receiving various 
levels of health and social care and with different functional status or need of help (for example, 
community-dwelling, hospital and nursing home patients). It can predict mortality and utilisation 
of hospital care to a moderate extent. A great benefit is its ability to show change as a result of 
an intervention. In addition, its ability to quantify QoL in the form of a single number is an 
advantage compared to several other QoL measurements. However, its limitations – such as the 
absence of certain aspects of QoL important for older people (for example, sensory abilities, 
autonomy, attitudes to death and dying) – should be considered when interpreting the results. 
 
The SF-36 and 15D QoL measurement tools appear to explore the QoL and well-being of lonely 
older people from different perspectives. SF-36 takes better account of an individual’s subjective 
opinion of his or her health status. It is also better at measuring psychological and social well-
being. The disadvantage of SF-36 is that older people may have difficulties in understanding the 
measurement items and it takes longer to complete than the EQ-5D. In several international 
studies, completion of SF-36 was found to be low. 239,240 The advantage of using generic tools, 
like these, is that they allow comparisons to be made between groups, such as comparing elderly 
and younger patients having PCI. They also allow comparisons with normative data and are used 
to generate QALYs.  
 
A number of QoL measurement tools have been developed for use in older people.  For example, 
the Older People’s Quality of life (OPQOL) was developed from lay person views (using a 
constructivist approach), while the WHOQOL-OLD is largely expert led.241 These are increasing 
being used in older populations; however, their use in the context of CAD is limited. 
P 141  In addition further explanation has been given for the choice of QoL instrument: 
 
EQ-5D: This is a widely used simple and validated general instrument to measure QoL in a 
standard way. This instrument is used in a wide range of conditions, treatments and 
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interventions. It is also used extensively in health economics to derive a quality adjusted life year 
(QALY). The EQ-5D descriptive system consists of five dimensions (mobility, self-care, usual 
activities, pain/discomfort, anxiety/depression) with three levels each (no problem, some 
problems, extreme problems), thus defining 243 distinct health states. Low scores on the 5 items 
of EQ-5D reflect a favourable assessment of each component. Responses were used to derive the 
single index value based on the algorithm provided by EuroQoL. This single index represents 
the overall health status by applying preference weights to participant responses. The index-
based score is typically interpreted along a scale where 1 represents best possible health and 0 
represents dead, with some health states being valued as worse than dead (<0). In addition, EQ-
5D contains a visual analogue scale (VAS). The endpoints of the VAS are labelled ‘best 
imaginable health state’ and ‘worst imaginable health state’, at 100 and 0, respectively. 
Respondents were asked to indicate how they rated their health by drawing a line from an anchor 
box to the point on the VAS which best represented their own health that day. Permission to use 
the EQ-5D was obtained from EuroQol(www.euroqol.org). This widely used QoL tool was 
chosen because it is simple for researchers to administer, score and interpret. It also imposes 
minimal burden on participants, as it is a brief, simple measure to understand and to complete 
(with resultant high completion rates. In addition, the generation of the utility index based health 
status are useful for both clinical outcomes and economic evaluation.  
 
SF-12: This is a commonly used health status questionnaire and is a shortened version of the SF-
36. It appears to be more sensitive to differences in health status for people with less morbidity. 
Like the SF-36, summary scores for physical and mental health status can be derived from the 
SF-12, referred to as the Physical Component Summary (PCS-12) and the Mental Component 
Summary (MCS-12), respectively. The summary scores of the SF-12 have also been shown to 
closely represent the summary scores of the SF-36.343The PCS-12 and MCS-12 scores have also 
been found to be virtually identical to the equivalent SF-36 summary scores in indicating the 
level of health and are equally sensitive to changes in health status among patients with various 
conditions. Permission to use the SF
-
12v2 was obtained from QualityMetric Incorporated 
(www.qualitymetric.com).  This is the most commonly used generic QoL tool for assessing QoL 
following PCI in both young and elderly patients (see Chapter 2.3). This was chosen, rather than 
other instruments that are thought to be more appropriate to use in older people, because the 
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questionnaire will be used for both elderly and younger patients. In addition, it allows multiple 
comparisons to be made with existing literature on QoL outcomes following PCI.  
 
 
MacNew: Disease specific QoL was assessed using the MacNew health-related QoL 
questionnaire. It was designed to assess how heart disease affects daily physical activities and 
emotional and social functioning. It has been widely used and validated in cardiology patients 
with AMI, angina and heart failure at the time of designing the ReQoL study. It was chosen 
because it had not been utilised for assessing QoL following PCI in the UK; therefore, providing 
an opportunity to address a gap in the literature. It also allows validation of the questionnaire, by 
comparing it to both the EQ-5D and SF-12, in this population (see Chapter 4.3). In addition, the 
MacNew questionnaire has been used to assess QoL following PCI outwith the UK e.g.  SipÖtz 
et al.,372 providing evidence for its use in this context. It contains 27 items (questions), the 
responses to which, map to 3 domains: physical limitations, emotional function, and social 
functioning. Global QoL score and individual domain subscale scores can be calculated. Scores 
are from 1 (low QoL) to 7 (high QoL). In addition, MacNew has an established the minimal 
important difference (MID) of ≥0.5. Permission to use the MacNew questionnaire was obtained 
from MacNew (www.macnew.org).  
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2. LITERATURE REVIEW  
 
2.1. Management of coronary artery disease in elderly 
patients 
 
As discussed in Chapter 1.2.5 CAD may be managed using medical therapy or with 
revascularization techniques such as PCI or CABG.  Medical therapy remains the cornerstone of 
the management of chronic stable angina, but randomized trials have demonstrated greater 
symptomatic relief from coronary revascularization compared with medical therapy alone.241,242 
However, PCI treatment for stable CAD has shown no evidence of an effect on death or AMI 
when compared with medical therapy.3,241 As described in Chapter 1.2.2, CAD incidence and 
mortality are strongly associated with chronological age, and, due to the ageing population, the 
elderly account for an increasing proportion of those requiring investigation and management of 
CAD. In spite of this, the trials have tended to exclude or under-represent elderly patients.202  
One important study specifically undertaken in elderly patients was the Trial of Invasive versus 
Medical therapy in Elderly patients (TIME) study in which 305 patients aged over 75 years with 
stable angina were randomized to either an invasive strategy (n=153) or optimal medical therapy 
(OMT) (n=148).243 The patients all had angina, resulting in at least mild limitation of their usual 
ordinary activity (scoring CCS Class II or worse) that was refractory to two or more types of 
medication. At baseline, patients had a mean age of 80 years. In the interventional group (CABG 
or PCI), all patients underwent coronary angiography (dye injected into the heart to assess 
degree of stenosis), with the clinician then deciding whether or not to proceed to 
revascularization and which approach to use. At 6 months follow-up, both groups reported 
improvements in both angina severity and QoL.243 The improvement was significantly greater in 
the revascularization group compared with OMT alone. OMT was associated with an increased 
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risk of major adverse cardiac events (49% vs 19%; p<0.0001) and, in particular, with subsequent 
hospital admission for ACS with or without the need for emergency PCI. At 1 year follow-up,244 
using intention-to-treat analysis, improvements in angina and QoL were maintained in both 
groups but the differences between them were attenuated and no longer statistically significant. 
However, major adverse cardiac events continued to be more common in the OMT group 
(64.2% vs 25.5%, p<0.001) and importantly 46% of this group ultimately required 
revascularisation (most commonly by PCI) due to refractory symptoms.244 When re-analysed on 
the basis of actual treatment received, the differences in angina symptoms and QoL between the 
groups were significant at one year follow-up. This suggests that the negative results using 
intention to treat reflected the high cross-over from medical therapy to revascularization.245 
Subsequent follow-up over a median of 3.1 years, demonstrated that long-term survival was 
similar for both groups. Irrespective of which treatment arm patients were assigned to initially, 
revascularization within the first year was associated with better survival.246  
A pre-specified sub-group analysis of the COURAGE (Clinical Outcomes Utilizing an 
Aggressive druG Evaluation) study assessed the proportion of elderly patients (defined in this 
study as aged 65 and over) who were angina free at 60 months following PCI in combination 
with OMT group verses OMT alone. This study recruited only 6.4% of the screened population; 
there was low representation of women (15%) and drug eluding stents were  used in only 2.7% 
of PCIs. Nevertheless, the proportion of elderly patients who were angina free at 60 months was 
found to be higher following the addition of PCI to OMT (80% vs 73%, p=0.01). Despite this, 
the authors suggest that PCI in addition to OMT “does not reduce clinical events or improve 
angina relief during long-term follow up” of elderly patients.247   
 
2.2. Coronary revascularization in the elderly 
A large number of randomized trials have demonstrated comparable survival rates following PCI 
and CABG for most patient populations.7,248,249,250 Again, elderly patients have tended to be 
excluded from these trials. As yet, no randomized controlled trials comparing PCI and CABG 
have been undertaken in elderly patients. Therefore, the choice of type of revascularisation in the 
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elderly has to be based on evidence from observational studies and a limited number of non-
randomised studies. Whilst observational studies are more likely to include elderly patients than 
clinical trials, they still suffer from age-dependent bias as elderly patients are less likely to 
receive evidence-based and guideline–recommended care including coronary angiography and 
PCI. 251,252,255,256,257 A meta-analysis of these observational studies reported that peri-procedural 
and long-term outcomes in elderly patients were equivalent for PCI and CABG.258 Thirty day 
case fatality was 7.3% (95% CI 6.3% - 8.2%) following PCI, compared with 5.4% (95% CI 
4.4% - 6.4%) following CABG. One year survival was 86% (95% CI 83% - 88%) and 87% 
(95% CI 84% -91%) respectively, suggesting that comparable survival seen across younger age-
groups extends to the elderly. However, the authors acknowledge that differences in survival 
between PCI and CABG in the elderly could still exist in view of the low level of the evidence 
available, use of group-level data (rather than meta-regression), and because of differences in 
baseline case-mix found in the studies.  
Over the past decade there has been a major shift in treatment patterns, whereby the number of 
CABG operations performed each year has decreased whilst PCI procedures have increased in 
number and now account for an increasing proportion of revascularization procedures.256 PCI is 
now the most common form of revascularization in both young and elderly patients in both acute 
and elective settings.256,258 Elderly patients tend to present greater technical challenges in 
relation to PCI due to heavier coronary calcification, tortuous anatomy in both coronary and 
peripheral arteries and reduced tolerance to bleeding problems.252 They also tend to have a 
greater risk profile due to more severe coronary disease and multiple co-morbidities.5 
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2.2.1. Outcomes of percutaneous coronary intervention in the elderly   
Previous studies have shown that elderly patients have higher in-hospital (death, MI, bleeding) 
and long term complication rates (mortality and MACCE – major cardiac and cardiovascular 
complications (or MACE – major cardiac events which excludes non-cardiac cardiovascular 
events, such as strokes) than younger patients following revascularisation procedures. 
5,32,253,254,255
 
As discussed, clinical trials tend to exclude elderly patients.  However, there are a number of 
retrospective cohort studies which have examined outcomes in elderly patients undergoing 
PCI.5,234,258,259,260,261,262,263,264,265 One of the largest of these studies examined outcomes in 82,140 
consecutive PCI cases undertaken in New York State in 2000 and 2001.5 This multicentre study 
reported in-hospital mortality and major adverse cardiac events following elective and 
emergency procedures in three age-groups: <60, 60-80 and >80 years. In-hospital mortality was 
1%, 4.1% and 11.5% respectively (p<0.05) and in-hospital major adverse cardiac events were 
1.6%, 5.2% and 13.1% respectively (p<0.05). This study found that, after adjusting for patient 
co-morbidities and severity of coronary disease, age remained the strongest predictor of in-
hospital complications in elective procedures and the second strongest in emergency procedures.  
As previously discussed, thirty day and long-term survival rates in elderly patients were 
examined in a 2003 systematic review, which included only those studies that separately 
reported baseline characteristics and outcomes for patients aged >80 years and included elective 
and emergency procedures collectively in the pooled analysis.32 The pooled estimate suggests 
that octogenarians were found to have acceptable short and long term outcomes following PCI. 
A number of the studies included in the review reported in-hospital rather than 30-day outcomes 
following PCI, possibly resulting in an under-estimate of the pooled risk of adverse events.32   
 
A study comparing the safety and efficacy of second-generation coronary stents utilized pooled 
data from six major clinical trials.267 This found, that despite more complex coronary lesions, 
stenting could be performed safely in patients aged over 80 years; with low rates of early and 
late restenosis. After one year, the incidence of clinically evident restenosis was similar to that in 
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patients aged under 80 years (11.2 vs 11.9%, p=0.78). However, it was observed that elderly 
patients had higher rates of major bleeding complications (5.0 vs 1.0%; p < 0.001), in-hospital 
mortality (1.3 vs 0.1%; p = 0.001) and 1-year mortality (5.7 vs 1.4%; p < 0.001). Their increased 
risk of mortality remained statistically significant after adjustment for higher baseline risks 
(more complex lesions, comorbid conditions and higher prevalence of multi-vessel disease 
(MVD) – defined in their study as involvement of 3 vessels or more).  
 
Elderly patients do have an increased risk of procedure-related complications that are associated 
with increased early mortality. Almost all of the studies have demonstrated increased risk for 
vascular access complications and associated major bleeding events in elderly patients, with 
chronological age being the strongest predictor of vascular complications.268,269,270,271,272,273 
Bleeding events and transfusion requirement after PCI have been associated with increased 
mortality during follow-up.261 Several studies have also shown increased risk for in-hospital 
stroke in elderly patients.267,269 This excess risk of vascular and bleeding complications in the 
elderly is probably due to a higher prevalence of non-cardiac vascular disease and a greater 
susceptibility to the risk associated with adjuvant medical therapy.266,270 In addition, elderly 
patients have an increased risk of contrast-induced nephropathy following PCI. This is 
particularly important as elderly patients are more likely to have the complex lesions and 
tortuous vasculature which require greater amounts of contrast utilization during the procedure. 
Age related changes in renal function, particularly glomerular filtration rate and tubular function, 
are also important.270 Contrast nephropathy has been associated with both early and late 
mortality.271 
A multi-centre European registry of 47,407 consecutive patients from 2005 to 2008 included 
over 8,000 patients aged 75 years and older.272 PCIs undertaken for ACS and stable angina were 
examined separately. Patients aged 75 years and older were at significantly greater risk of in-
hospital death, especially those presenting with ACS, and age remained an independent risk 
factor following statistical adjustment for baseline characteristics, including co-morbidities and 
severity of CAD. This study has the lowest ever reported in-hospital mortality rates (ACS ≥75 
years 5.2% and <75 years 1.7%; unstable angina ≥75 years 0.5% and <75 years 0.2%). The 
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authors suggest that this low rate is related to advances in PCI, such as adjuvant medical 
therapies, drug eluting stents and operator experience. However, in a retrospective analysis of 
observational data it is impossible to rule out residual bias.  
 
2.2.2. Reducing the risk of percutaneous coronary revascularization in 
the elderly 
 
In the last decade, a series of technological and therapeutic developments have reduced in-
hospital complications following PCI including adjuvant drug therapies, drug eluting stents and 
trans-radial access.229,260,273,274,275 Historically, PCI has been carried out via the femoral artery. 
Over the last decade, radial access for PCI has become increasingly popular in many countries, 
with 42.8% of all PCI procedures in the UK now undertaken using this approach.276 This route is 
still uncommon in some countries, such as the United States of America, where less than 2% of 
PCI procedures are undertaken via radial artery access.277 It has been suggested that the slow 
adoption of the trans-radial approach in USA may be due to a lack of operator familiarity and 
limited availability of training.279  
The major advantages of using a radial, rather than a femoral, approach are reduced access site 
complications,248 earlier ambulation of patients,250 increased patient satisfaction280 and reduced 
costs.278,279 The benefits of early ambulation are particularly important for elderly patients who 
have a higher baseline risk of venous thromboembolism, healthcare acquired infection and 
oesteoarthritic problems. The risk of access site complications is reduced using transradial 
access because the hand has a dual blood supply via the ulnar artery, the radial artery is accessed 
distal to major nerves and veins and the superficial location of the radial artery makes it easier to 
achieve hemostasis using local compression. Again, these benefits are particularly important for 
elderly patients who have a significantly higher baseline risk of artery access complications.265 
Elderly patients are more likely to have heavily calcified coronary lesions257 and therefore are 
more likely to require complex PCI strategies such as high-speed rotational atherectomy 
87 
(HSRA). The transradial approach for HSRA in has been shown to be feasible, safe and effective 
281,282 in a number of small studies which included younger and older patients.  
In a meta-analysis249 of studies comparing radial and femoral routes of access, the former was 
associated with a 73% reduced risk of major bleeding following elective or emergency PCI 
(0.05% vs 2.3%, OR 0.27, 95% CI 0.16, 0.45, p<0.005). Using radial access, the length of stay 
in hospital was shorter, with a weighted mean difference of -0.4 days (95% CI -0.2 to -0.5, 
p<0.001). However, only two of the randomised controlled trials in the meta-analysis focused on 
elderly patients.273,283 In a study by Achenbach et al.,273 307 patients over the age of 75 years 
presenting with suspected CAD, or worsening of existing CAD, were randomized to either the 
transfemoral or transradial approach. Sixty three patients (16%) were excluded because of 
clinical contraindications to using a transradial approach; including 37 patients who were 
excluded because of a positive Allen’s test using pulse oximetry. Allen’s test is used to assess 
the collateral circulation in the hand, but there is a lack of evidence that it can predict hand 
ischemia after radial artery occlusion (a possible vascular complication of PCI) and therefore its 
use may have excluded patients unnecessarily.284 In the Achenbach et al.273 trial, the data were 
analysed according to intention-to-treat principles. Among the 152 patients randomized to 
transradial access, this approach was successful in 91%, with the remaining 9% having to 
undergo transfemoral access. None of the patients with transradial access suffered major adverse 
events (defined as death, periprocedural infarction, stroke, vascular access complications that 
required surgical intervention, blood transfusion or a fall in haemoglobulin of more than 3g/dl) 
compared with five (3.2%) patients with transfemoral access. Only two (1.3%) transradial 
patients suffered minor bleeding complications, compared with 9 (5.8%) transfemoral patients.  
A similar sized, but multi-centre, study of octogenarians reported comparable cross-over rates 
from radial to femoral access (8.9%) as from femoral to radial access (8.1%). Analysis according 
to intention to treat, again demonstrated a significantly lower risk of vascular complications 
following radial (1.6%) compared with femoral (6.5%) access (p=0.03).283 
 
Jaffe et al.285 assessed the safety and efficacy of the approach in an observational study of 228 
consecutive, octogenarian patients undergoing PCI for either chronic stable CAD or ACS. The 
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initial choice of approach was at the operator’s discretion and the transradial approach was 
chosen in 97 (42.5%) patients. There was a cross-over rate of 11% in the transradial group 
compared with only 4% in the transfemoral group (p=0.03). Procedural success rates were 
comparable. However, the transradial approach was associated with shorter cannulation and 
procedure time, reduced use of contrast media, fewer vascular complications (5% versus 20%, 
p<0.001) and shorter time to ambulation (5.2 ±3.1 versus 11.6±6.3 hours, p<0.001). The mean 
lengths of stay were 1.7 days for transradial access and 3.1 days for transfemoral access. A 
single–centre, observational study conducted in China recruited 2,058 consecutive patients 
undergoing PCI with transradial access.286 Of these, 719 (35%) were aged 65 years and over. 
Procedural success rates were high (94.7%). Vascular complications occurred in 4.9% of 
patients with no statistically significantly difference between elderly and younger patients.  
2.2.3. Antithrombotic therapy in elderly patients undergoing elective 
percutaneous coronary intervention 
The development of newer antithrombotic strategies has markedly reduced cardiovascular 
mortality and ischemic complications in patients undergoing percutaneous coronary intervention. 
However elderly patients have age-related changes in haemostasis and drug metabolism, 
distribution and clearance as well as non-cardiac comorbidities and resultant polypharmacy, all 
of which are associated with an increased risk of bleeding with antithrombotic therapies.287  
Current guidelines recommend that dual antiplatelet therapy (DAPT) with aspirin and 
clopidogrel be used prior to and after percutaneous coronary intervention in all patients, 
irrespective of age.287 The duration of DAPT is dependent on the type of stent deployed. 
Following bare metal stent (BMS) deployment the recommended duration of DAPT is 1 month 
compared with 6-12 months for drug eluting stents. The extended period of DAPT is necessary 
because drug eluting stents are associated with delayed or incomplete re-endothelialization 
which can result in an increased risk of late stent thrombosis. Prolonged DAPT is a concern in 
elderly patients who, as discussed above, have an increased risk of bleeding. Concurrent 
warfarin therapy for atrial fibrillation (which is more common with age) is an additional 
problem.288 The elderly also have a higher risk of requiring non-cardiac surgery and an increased 
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risk of falls. All of these factors need to be considered when deciding on the choice of stent 
during PCI for elderly patients. 
Heparin is currently the standard peri-procedural antithrombotic therapy to provide 
anticoagulation during elective PCI, with GPIIb/IIIa inhibitors being used only for high risk 
lesions or “bail out” situations (thrombus, slow flow, acute occlusion).288  GPIIb/IIIa inhibitor 
use during PCI generally precludes same day discharge. Direct thrombin inhibitors (e.g 
Bivalirudin) have been used as an alternative to Heparin. Randomised controlled trials (RCTs) 
comparing Heparin and Bivalirudin have tended to include mainly younger patients or to recruit 
patients with ACS.289,290 Meta-analysis shows that Bivalirudin is associated with a significant 
reduction in major bleeding complications (1.7% vs 3.4%, p<0.0001), but no difference in 
mortality (1.73% vs 1.67%, p=0.15).290 The largest individual study is the ACUITY (Acute 
Catheterization and Urgent Intervention Triage Strategy)291 trial which demonstrated an absolute 
reduction in bleeding events with the use of Bivalirudin instead of Heparin. This was most 
pronounced in patients aged ≥75 years, with no significant differences in efficacy between the 
groups. A large observational study of elective PCI in 2,766 octogenarians found that the use of 
Bivalirudin was associated with a decreased risk of in-hospital bleeding (HR 0.41, 95% CI 0.23 
– 0.73, p=0.003) and 6 months MACE (adjusted HR 0.5, 95% CI 0.4 – 0.7, p=0.001). Whilst this 
provides supportive evidence for the use of Bivalirudin, further studies are required to clarify its 
use in elderly patients in the elective setting – particularly in light of the increased use of the 
radial approach with its reduced risk of bleeding.292  
 
2.2.4. Outpatient percutaneous coronary intervention in the elderly 
 
Increased use of transradial access, with its reduced ambulation time and vascular complications, 
has facilitated the introduction and expansion of outpatient PCI. Outpatient PCI is an attractive 
option as it reduces procedural cost, decreases bed utilization, and addresses the demand for  
increasing numbers of PCI procedures. It has been shown in numerous randomized and 
observational studies to be both safe 293,294,295,296,297,298,299,300,301,302,303,304,305 and preferred by the 
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majority of patients.303 In some centres, outpatient PCI has become the preferred method for 
managing patients with chronic stable angina who have no medical contraindications (such as 
comorbid conditions), good angiographic results and an uncomplicated immediate observation 
period. The Criteria for Overnight Hospital Stay developed by Slagboom et al. has been widely 
used (and modified) to inform decision making 197 However, some operators remain concerned 
about the safety of outpatient PCI, in light of possible delayed bleeding complications and acute 
coronary occlusion following discharge. In the UK only17.4% of all (elective and emergency) 
PCIs are undertaken on an outpatient basis, but this ranges from 0% to 85% across sites.248  
Only two studies have compared the outcomes of outpatient PCI in elderly and younger 
patients.30,306 The first involved only 117 patients aged 75 or over,  attending for transradial PCI 
between 1998 and 2001. Thirty six (31%) patients reported one or more access site 
complications during the first 24 hours, including pain, bleeding, numbness, bruising, 
haematoma, swelling and infection. However, only 3 of these 36 patients consulted their doctor 
and none had to attend hospital. There were no major access site complications reported in this 
group. One patient reported chest pain within 24 hours but did not require investigation or 
intervention, and one further patient had stent thrombosis 37 hours after the procedure. Whilst 
this retrospective, observational study may suffer from selection bias and minor complications 
may be subject to reporting bias, secondary data analysis ensured that major complications were 
identified even in patients who did not respond to the questionnaire. No difference in rates of 
entry site complications were found between younger and elderly patients in this study.  
A more recent study which included 212 patients aged 75 years and older in New Zealand 
demonstrated that same-day discharge following a 6 hour observation period is possible in the 
majority of elderly patients (84%).306 This study did, however, show that elderly patients were 
more likely to be excluded from consideration for outpatient PCI compared with younger 
patients (4.5% vs 1.2%, p=0.02). Patients were excluded for a number of reasons including 
inadequate social circumstances, further intervention or testing planned the next day and 
previous contrast reaction. In those who were put forward for outpatient PCI, it was successfully 
achieved as often as in younger patients. Suboptimal angiographic results, evidence of 
periprocedural myocardial ischaemia or infarction, access site complications, late sheath removal 
and glycoprotein 11b/11a inhibitor infusion were cited as the primary reasons for the failure of 
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same-day discharge. In this study, only 19 (9%) procedures were undertaken using the 
transradial approach. All of the elderly patients who had a transradial approach were 
successfully discharged on the same-day. Despite the low utilization of transradial access, there 
were no deaths in the 24 hours following discharge and 24 hour readmission rates were very low 
(0.5%). Since only hospital data were used in this study, the investigators did not have access to 
information on minor complications in the elderly that were managed without recourse to 
hospital. Whilst there is a general dearth of literature, it appears that outpatient PCI is feasible 
and safe in elderly patients who are at low risk of complications and following an uneventful 
period of post-procedural observation.  
In conclusion, the elderly account for an increasing proportion of the population in many 
countries and the prevalence of CAD is known to increase with age. Therefore elderly patients 
account for an increasing number and proportion of patients attending for PCI. This trend is 
likely to continue and should be reflected in the recruitment of more elderly patients into clinical 
trials to allow for improved evidence-based decision making.  
The transradial approach for PCI is associated with fewer vascular complications, reduced bed 
utilization and reduced time to ambulation. Even in elderly patients, in whom the baseline risk of 
vascular complications is higher, the transradial approach is safe, effective and associated with 
less bleeding from the access site. The transradial approach has facilitated the introduction and 
expansion of outpatient PCI which has been shown in two small studies to be as safe and 
effective in elderly patients as it is in younger patients. Whilst this area would benefit from 
further research, outpatient PCI appears to be a realistic option for many elderly patients. Over 
the next decade the proportion of PCI undertaken on an outpatient basis is likely to increase for 
both younger and elderly patients, becoming the routine choice for patients without 
contraindications.  
PCI is now a routine treatment for both acute and chronic CAD in both elderly and younger 
patients. In the elderly, it has been associated with a greater risk of in-hospital, 30-day and long 
term complications. However the improvements in QoL are at least as significant as those 
observed in younger patients. Potential improvements in QoL following PCI are likely to 
become increasingly important in decision making, rather than chronological age per se.  
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2.3. Systematic review of quality of life in elderly 
patients following percutaneous coronary 
intervention 
Although in-hospital and late mortality following PCI are important, the effect on symptom 
relief and QoL are critical considerations and inform patient decision-making. This is 
particularly pertinent in the elderly population as “the longevity benefits are frequently limited 
by multiple competing risks and the goals of therapy are often to maintain independent living 
with reasonable comfort” 29. There has been a previous systematic review which assessed 
clinical outcomes following PCI in octogenarians (e.g. death or major adverse cardiac events). 
This did not assess any impact on QoL;32 however, it demonstrated that PCI in octogenarians 
was well tolerated and associated with acceptable short-term and long-term outcomes. However, 
the authors described the evidence as of ‘low quality’ because of small study sizes or 
observational nature—despite containing some large well conducted observational studies. 
As previously discussed, the TIME study demonstrated an improvement in QoL following 
revascularization in elderly patients which appeared to be maintained long-term244 and initially 
superior to that achieved by OMT alone. There are a number of studies which have shown that 
PCI produces improvements in QoL measures in the elderly that are equivalent to, or even better 
than, those observed in younger patients. Spertus and colleagues307 concluded that age was an 
independent predictor of QoL benefit while Seto et al.308 concluded that QoL improvements 
after PCI were not age-dependant. However, no systematic review of the evidence on QoL 
outcomes in elderly patients undergoing PCI has been undertaken.  
A systematic review of the literature was undertaken in accordance with the Preferred Reporting 
Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines (http://www.prisma-
statement.org/). Systematic reviews are used due to their ability of synthesizing, selecting and 
appraising all high quality evidence from relevant studies to answer the research question, and to 
extract the required data for a meta-analysis. Furthermore, systematic reviews are considered to 
be updatable, accountable and replicable pieces of work which follow distinctive steps.282 The 
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PRISMA (Preferred Reporting Items for Systematic reviews and Meta-analysis 
http://www.prisma-statement.org/) checklist was created as an instrument for ensuring 
transparent and comprehensive reporting of systematic reviews.  
The aim of the search was to identify articles reporting QoL outcomes in older patients aged 80 
years or older who underwent PCI and, where possible, compare results with younger patients. 
Eighty years and older was chosen to reflect the findings of the systematic review of clinical 
outcomes and to allow for easier identification of studies on elderly patients.32  
 
2.3.1. Search Strategy and selection criteria 
Four journal databases were used: 
• Ovid Medline 1948 to September week 1 2011, 
• Ovid Embase 1996 to 2011 week 36,  
• Science Direct, and  
• Cochrane Library of Systematic Reviews from 1995 to 2010 inclusive  
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The following search terms and Boolean connectors were applied. 
1 “coronary” OR “heart” OR “cardi*” OR “myocardi*” 
2 “stent” OR “PCI” OR “revascularisation” OR “percutaneous coronary” OR “percutaneous 
intervention” OR “angio*” OR “percutaneous transluminal” 
3 “quality of life” OR “psychological adaptation” OR “attitude to health” OR “health status” 
OR “life change events” OR “EQ-5D” OR “ED5D” OR “SF*36 OR “SF*12” OR “SF*24” OR 
“DASI” OR “HRQOL” OR “Seattle Angina Questionnaire” OR “RAND 36” OR “DASI” 
4 “octogen*” OR “*80 year*” 
5 1 AND 2 AND 3 AND 4  
 
The search was limited to studies conducted on humans and those which were available in 
English and was last run on 15.09.2011. In cases where studies had duplicate publications, the 
most recent publication was used.  
Inclusion criteria:  
Only studies which reported QoL and outcomes in cohorts older than 79 years were included.  
Exclusion criteria:  
• Reviews, editorials, studies of procedures other then PCI and those which reported 
clinical outcomes only (e.g. death or major adverse cardiac events)  
• Non-English language papers  
• Papers with non-human subjects 
The reference lists of relevant articles (including reviews and editorials) were reviewed to 
identify additional articles that were potentially relevant.  Titles and then abstracts were 
reviewed to exclude articles that did not satisfy the inclusion criteria.  
95 
The full texts of the remaining articles were obtained and reviewed by two people independently 
(PhD student and supervisor) in detail to determine their eligibility for inclusion. Methodological 
quality scores were independently assigned and compared. During the review process, all 
included studies were appraised against a list of specific criteria as suggested by CASP 
guidelines (http://www.casp-uk.net/). The criteria for critical appraisal included these main 
points;  
• The presence of clear study questions, which focused on the relationship between PCI 
and QoL outcomes in elderly patients. 
• The usage of valid epidemiological methods in conducting the study. 
• The presence of any kind of bias either in the methodology part of study or in the results 
section. 
• The presence of clear description of the sampling method and whether the sample was  
truly representative of the population from which it was drawn. 
• The presence of proper definition of the outcome, such as QoL  
• Controlling for confounding factors (e.g. gender) 
The data extracted from eligible articles included the publication date, indication for PCI, study 
setting, study population size and characteristics, intervention details, QoL measurement, length 
of follow-up, results and measures of statistical significance (Table 1). Corresponding authors 
were contacted to obtain any missing information and to request sub-group data where 
appropriate: only 1 such author provided additional information.  
Meta-analysis was attempted using the "metan" command in Stata software version 11. The 
purpose of using this statistical technique is to combine the effect sizes from different eligible 
studies to obtain a pooled estimates of the overall effect of PCI procedures on QoL in elderly 
patients. There are two statistical models which are considered as a fundamental for meta-
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analysis, the fixed effects models or random effects models. The assumptions used in the two 
models are different. The fixed effects models assumes that all the studies included in the meta- 
analysis will have one true effect size and that the sampling error is the underlying cause of the 
all variations in the observed effects. 309 In contrast, the random effects model assumes that the 
true effect may vary from study to study. This model assumes that the heterogeneity is attributed 
to the diversity of the underlying factors in different studies.  
Eligible studies for the systematic review were conducted in different years and countries. In 
addition, they used different QoL tools, with measures applied at different time intervals 
following PCI. These differences resulted in much variability between the studies. Therefore, the 
random effect model was used to attempt to calculate the combined effects of PCI on QoL in 
elderly patients.309 The I2 quantifies the effect of heterogeneity and provides a measure of the 
degree of inconsistency in studies’ results.310  Negative values of I2 are put equal to zero so that 
I2 lies between 0% and 100%. A value of 0% indicates no observed heterogeneity, and larger 
values show increasing heterogeneity. Ioannidis et al. suggests that I2 values >75% should be 
considered high.311  
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Figure 11. PRISMA flow diagram. 
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2.3.2. Findings 
One hundred and thirty-one articles were identified by the electronic search, of which 28 were 
discarded as duplicates (Figure 11). Title review resulted in the exclusion of a further 61 articles. 
The abstracts of the remaining 42 were screened and an additional 18 were excluded. The full 
manuscripts of the remaining 24 were reviewed and 9 were judged eligible for inclusion in the 
review. The eligible studies were published between 1993 and 2011 (inclusive). They included a 
total of 671 older patients within the 9 studies, with a mean age of 82.9 (ranging from 82.1 to 
83.9 years) across the studies. The oldest patient was reported as 96 years of age. Four studies 
reported separate results for both older patients and their younger counterparts, with three of 
them making direct comparisons. Four studies provided before and after comparisons.  
 
Six studies included patients with a mixture of stable and unstable angina; one included only 
elective PCIs and two had only PCIs undertaken following acute events. Follow up of Qol 
ranged from to five to 40 months following PCI. The SF-36 was the most commonly used tool 
and was used in three studies, followed by Seattle Angina Questionnaire (SAQ) in three studies. 
The EQ-5D (EuroQol 5 Domains) and the RAND 36 (a 36-Item Health Survey from RAND 
Health) were used in only one study each. (One study assessed QoL using two different 
assessment tools in the same population). Two studies did not use a validated QoL instrument 
but asked patients to classify their own QoL following PCI as either excellent, good, fair or poor; 
or score it on a 0 – 10 scale, with no pre-intervention measurement.  
 
  
Table 1: Summary of studies: study design, sample, and instruments: quality of life following percutaneous coronary intervention in 
octogenarians.  
Authors/Country 
(publication year) 
Study Design Quality 
 Score*  
Sample  PCI indication  Mean Age (years) 
(age range or SD) 
Instruments  Intervals of testing  
and number of  
patients 
 in each interval  
Before and after comparisons 
Agarwal et al.  
(2009), UK 
Prospective cohort  
Multiple  
measurements 
        3 74 patients 
(50♂) ≥80 yrs 
 
51 ACS 
23 Chronic  
stable 
82.5 ± 2.1 (80 to 96) SF-36  
SAQ 
Baseline n=74 
6 months n=73 
12 months n=71 
Graham et al.  
(2006), USA 
Prospective cohort/ 
register of cardiac 
catheterisation 
Patients. Compares  
medical, PCI and 
CABG 
        4 137 ≥80 yrs 
(819 70-79 yrs) 
(2698 <70 yrs) 
13 Stable 
43 Unstable 
56 AMI 
26 Other 
82.1 SAQ 1 year n=118 
3 years n=94 
Kähler et al. (1999), 
Germany 
 
Prospective cohort  
with external  
comparison group 
 
       3 34 ≥80 (24♂)  
yrs (34 <80) 
Elective 83± 3 (80-89) SF-36 Baseline n=34 
6 months n=34 
Li et al.  (2010) 
China 
 
Prospective cohort 
 
       3 23 ≥80 yrs 
(132 60-79 yrs) 
(78 <60 yrs) 
ACS ** SF-36 Baseline 
6 months  
Yan et al. (2012) 
(conference abs) 
 
Prospective cohort         3 64 ≥80 yrs 
(476 60-70 yrs) 
(255 <60 yrs) 
Stable & AMI ** EQ-5D  
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QoL Quality of Life; PCI Percutaneous Coronary Intervention; CABG Coronary Artery Bypass Grafting; AMI Acute Myocardial Infarction; ACS Acute Coronary Syndrome; SF-36 Short Form Health Survey; SAQ Seattle Angina Questionnaire; EQ-5D EuroQol 5 Domains; 
RAND-36 Rand Health’s quality assessment tool; WHOQOL-BREF World Health Organisation Quality of Life shortened questionnaire – Maltese version.   
*Quality score 1-5 (5 denoting best score) ** missing data.  
Authors/Country 
(publication year) 
Study Design Quality 
 Score*  
Sample  PCI indication  Mean Age (years) 
(age range or SD) 
Instruments  Intervals of testing  
and number of  
patients 
 in each interval  
QoL assessed post procedure only 
Krumholz (1993), 
USA 
Cross-sectional         1 41 (23♂) ≥80  
yrs 
AMI 83.9 ± 0.5 Excellent,  
good, fair or 
poor  
No baseline 
12 months 
Günal et al. (2008), 
Netherlands 
Cross-sectional QoL  
compared to general  
population 
 
        2 98 patients 
(39♂) ≥80 yrs 
63 elective 
35 acute/stable 
82.7 ± 2.9 RAND-36 No baseline 
1 year post PCI N=68 
 
Kamiya et al. (2007),
Japan 
Observational,  
comparison of 
PCI, CABG &  
medical 
        3 100 PCI  
patients(63♂)  
 ≥80 yrs 
56 emergent 
44 elective 
83.3 ± 2.8  SAQ No baseline 
39.9 ± 30.1  
months n=58 
Little et al. (1993), 
USA  
Cross-sectional  
comparing to 
Patients <80 yrs  
        2 118  patients 
(67♂) ≥80 yrs 
102 AMI 
16 Other  
83 (80-91) Self ranked on 
a 0-10 scale 
No baseline 
18.1 ± 10 months 
 
  
Krumholz et al.312 in 1993 was one of the first studies to report QoL outcomes following PCI in 
octogenarians. They compared 41 patients undergoing PCI with 18 undergoing coronary artery 
bypass grafting and 34 managed medically. They used a simple self-rating system where patients 
graded their average QoL after discharge as: excellent, good, fair or poor. At one year follow-up, 
86% of patients treated by PCI rated their QoL as good or excellent, compared with 89% treated 
by CABG and 44% of those managed conservatively. No tests of statistical significance were 
reported but post hoc analyses suggests that the outcome following PCI was comparable to 
CABG and better than medical management alone. However, five patients who underwent PCI 
died prior to follow-up, making generalisation of the findings problematic.   
 
A simple self-rating scoring system was also used by Little et al. in 199331 to compare outcomes 
of PCI in 118 octogenarians to that of 500 younger patients. There were significant baseline 
differences between the groups in sex, left ventricular dysfunction, indication for PCI, severity 
of angina and complexity of PCI. QoL outcomes were measured between 6 and 48 months later 
in 110 of the 112 octogenarian hospital survivors, but not in the younger patients. Among long-
term survivors, QoL was rated as 8.3 ± 2.0 using a 10 point scale, with 95% stating that they felt 
their QoL had improved following the procedure. No baseline scores were undertaken to assess 
improvement from baseline.  
 
Four additional studies assessed QoL after PCI without formal baseline comparisons. Günal et 
al.313 assessed outcomes at one year follow-up using the RAND-36 instrument in 68 of the 75 
octogenarians recruited to the study. These patients rated their general health as 57±19 points on 
a 0-100 scale. The authors stated that “at follow-up the general health was rated as fairly good 
and better than before PCI,” but provided no data to support this statement. Older patients had 
fewer symptoms of angina at follow up, assessed using the CCS classification. RAND-36 scores 
were compared with octogenarians from the Netherlands general population and no differences 
were demonstrated in the scores for either physical or mental well-being. In a retrospective 
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study, Kamiya et al. used a modified SAQ in 58 PCI patients aged ≥ 80 years who survived to 
follow up (39±20.4 months).314 Favourable QoL scores were obtained for the physical and 
mental domains. Both univariate and multivariate analyses of the predictors of unsatisfactory 
QoL were undertaken. This showed that left ventricular dysfunction was the only significant 
factor that influenced QoL scores were also found to be comparable with optimal medical 
therapy or coronary artery bypass grafting.  
Martin et al.315 compared QoL outcomes of minimally invasive direct coronary artery bypass 
(MIDCAB) and PCI for left anterior descending artery (LAD) revascularisation. The SF-36 was 
used in 330 patients (172 MIDCAB, 158 PCI). No baseline measurements were undertaken, 
however follow-up was continued up to 84 months (average follow-up to 38 months). The 
authors concluded that QoL was better in patients aged <80 years who had undergone MIDCAB 
compared with PCI, but not in those aged ≥80 years. The number of patients aged ≥80 years is 
not presented. While propensity score matching was used to select the PCI patients, baseline 
QoL is not included.  
Cassar et al316 used the WHOQOL-BREF (Maltese version) tool to assess QoL in 228 patients 
following PCI to examine differences between sub-groups. Patients aged ≥40 years were chosen 
randomly to receive the questionnaire; a response rate of 64% was achieved. Only 11 patients 
were aged ≥80 years and no statistically significant difference was found by age group.  Agarwal 
et al.317 assessed QoL in 74 consecutive octogenarians undergoing PCI using both the SAQ and 
the SF-36. Baseline measurements were undertaken. Functional status and QoL of life, at both 6 
and 12 months, were found to be lower than the age-specific general population norms, but 
substantially improved compared with baseline measurements. The use of both SAQ and SF-36 
enabled the researchers to assess both disease-specific and general health status. The consecutive 
nature of recruitment resulted in mainly patients with ACS and MVD being included in the 
study.  
 
Graham et al.318 used the Alberta Provincial Project for Outcomes Assessment in Coronary 
Heart Disease (APPROACH) register to assess QoL in patients undergoing PCI compared with 
optimal medical therapy and coronary artery bypass grafting. Revascularisation patients reported 
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better QoL scores than those treated medically over the full three year follow-up period. Overall 
response rates for patients aged ≥80 years was reported as 77.7% at one year. Sixty-nine percent 
of those responding at one year also completed a SAQ questionnaire at 3 years. Non-responders 
were much more likely to have received medical therapy alone suggesting possible over-
estimation of the QoL benefit in older patients. They were also more likely to have missing data, 
particularly their exertional capacity scores.  No patients ≥80 years of age who were managed by 
optical medical therapy subsequently underwent revascularisation.  
 
Kaehler et al.319 compared QoL, measured using the German translation of the SF-36 at 6 
months following PCI (in only 34 patients aged 80 years and over) with the same number of  
younger patients. Immediately following PCI, physical functioning and general health were 
worse in those ≥80 years. However, all other SF-36 domains were better in patients aged ≥80 
years at baseline. They found that the benefits of PCI were at least equal, and for some measures 
were even more pronounced, in the older patients.  
 
More recent studies have also demonstrated greater improvements in QoL among octogenarians 
than younger patients, following PCI. In 2010, Li et al.320 reported the results of a prospective 
study of 624 patients who underwent PCI or medical therapy for acute coronary syndrome in a 
single centre. Older patients reported lower QoL scores at baseline but reported greater 
improvements in physical health following PCI than younger patients (using the validated SF-36 
Chinese version) (p<0.001). Eighty percent of patients were followed-up to six months, which is 
comparable with other PCI follow-up studies. However, longer-term QoL was not assessed.  
 
An abstract presented orally at the Cardiac Society of Australia and New Zealand conference 
2010321 reported the results for 647 consecutive patients in Hong Kong who were managed by 
PCI for stable angina or acute coronary syndrome. The EQ-5D was used to assess QoL at 
baseline and six months following PCI and compared with medical therapy across 3 age groups 
(<60, 60-79 and >80 years). EQ-5D scores at baseline and at 6 months showed no significant 
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differences between the age groups, with 86%, 84% and 73% (p=0.32) respectively of patients in 
each age group experiencing improvements in QoL following PCI.   
2.3.3. Conclusion 
This systematic review identified 9 studies which have examined the impact of PCI on QoL 
among 671 octogenerian patients. The mean age was 82.9 years (ranged from 82.1 to 83.9 
years).  The evidence, to date, suggests that the QoL for octogenarians does improve following 
PCI. The benefits are found to be greatest in the first 6 months but may continue for at least 3 
years. Older patients improve at least as much as younger patients and appear to gain more in the 
areas of physical functioning and angina status.  
This is the first systematic review to assess QoL after revascularisation by PCI in octogenarians. 
The results are in keeping with other studies which demonstrate improved QoL in younger and 
older patients following PCI.244,322,279,281,308,320 For example, The TIME study (Trial of Invasive 
versus Medical therapy in Older patients) demonstrated significant improvements in QoL 
following revascularisation compared with baseline.244 These QoL improvements in older 
patients (defined as ≥75 years rather than as octogenarians), as measured by the SF-36 and 
DASI, appeared to be maintained at one year follow-up and were found to be initially superior to 
optimal medical therapy alone. Improvements in QoL in the optical medical therapy group were 
thought to be the result of a high cross-over rate (46%) to revascularisation. While this small 
selective randomised controlled trial may not necessarily be generalisable, it did consider QoL as 
a primary end point and therefore included it in the power calculation. In addition, CABG and 
PCI have been reported together as “revascularisation” making it difficult to assess the 
improvement following PCI alone.  
 
There have been a number of other studies that have shown that PCI produces improvements in 
QoL measures in older patients that are equivalent to, or even better than, those observed in 
younger patients. Spertus and colleagues307 assessed this and concluded that age was an 
independent predictor of QoL benefit in 1,518 consecutive patients in the United States of 
America. Seto281 and colleagues assessed QoL using the SF-36 and angina symptoms with the 
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SAQ during 1-year follow-up in 295 patients aged over 70 years compared with 1,150 younger 
patients (maximum age 89 years). At baseline, older patients reported lower scores for physical 
functioning but similar scores for mental health, when compared with younger patients. At six 
month follow-up, both older and younger patients reported significant improvements in mental 
health, physical health and angina status. Similar to the findings of this study, the benefits 
persisted and, at one year follow-up, 60% of each group reported no angina. The conclusion was 
that QoL improvements after PCI were not age-dependant. 
The studies included in this systematic review were heterogeneous in nature: 4 studies included 
differences between older patients and their younger counterparts; 6 provided before and after 
comparisons and 8 included a mixture of stable and unstable patients; 1 included only elective 
patients and 2 included only PCIs undertaken following acute events. Follow up of QoL 
following PCI ranged from to 6 to 39.9 months. QoL was assessed using 5 different validated 
QoL tools or by informal self-reported QoL. Studies were from 6 different countries (including 3 
from the USA, 2 from the UK, and 2 from China). The quality score of the studies (which 
included the number of participants in the study) varied from 1-5 (5 denoting the best score 
possible), with the majority of studies scoring 3 and no studies scoring 5.  
As discussed, QoL tools can be generic (e.g. SF-36) or disease specific (e.g. SAQ). Generic 
instruments address multiple aspects of patients’ experience following interventions rather than 
focusing on specific features of a particular disease. There is much debate in the literature as to 
which tool is most appropriate to measure improvements following PCI or to assess QoL in 
older people,218,241,323 disease specific instruments (e.g. SAQ) are considered more appropriate to 
assess QoL directly in the presence of CAD. 
 
This systematic review concentrated on octogenarians as representative of much older patients. 
There are numerous studies in the literature which assess clinical outcomes in octogenarians 
following PCI.5,6,32,259 The ageing population and increased life expectancy has resulted in more 
octogenarians presenting for PCI, suggesting that investigating outcomes in this group is 
important and hence the choice of age cut-off. Authors of individual studies, which were 
identified through the search strategy as likely to contain participants >80 years were contacted 
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with requests for sub-group data. Only one study was able to provide such data – the RITA 
study.216 This has not been included in this systematic review as it contained only 1 participant 
aged ≥80 years.   
 
As with all systematic reviews, publication bias may be important because negative studies are 
less likely to be published. Publication bias is particularly important in this field, given that the 
number of published studies is small. The possibility of confounding and bias is a likely issue 
within the studies included in this review because only one study reported statistical adjustment 
for confounding variables, such as baseline QoL and participant characteristics. The studies also 
used widely different selection criteria, making it difficult to generalise the results. The search 
strategy excluded non-English language studies, which may have excluded some studies. 
However, English tends to be the language used in cardiology interventional studies, therefore 
there is likely only to be a very small number of studies which report in another language. 
Heterogeneity (I2 >75%) amongst the populations and the QoL tools utilised, plus the missing 
QoL scoring data from most of the studies meant that meta-analysis was inappropriate. This high 
degree of statistical heterogeneity is in keeping with what is known about differences in the 
studies in: country of origin, study designs, quality of the studies, sample size, election criteria, 
range of time of follow-up, and QoL measuring tools.  
The benefits of this systematic review are that it used a robust search strategy, which used 
multiple databases and followed the PRISMA guidelines - making it unlikely that relevant 
studies were missed. Two independent reviewers were used to assign quality scores to each of 
the studies.  
Overall, this systematic review shows that QoL following PCI in octogenarians improves at least 
as much as younger patients. Given the small number of studies with only 750 octogenarians, 
further studies would be useful in determining those octogenarian patients who are likely to 
derive the greatest benefit from the procedure and to investigate a consensus in the measurement 
tool utilized to measure QoL following PCI in older patients. This is particularly important as we 
have an ageing population; this will result in an increase in the number and proportion of 
octogenarians likely to undergoing PCI in the future.  
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2.4. Review of the literature: telomere length and 
coronary artery disease  
As discussed, there is emerging evidence of an association between telomere length and 
attrition with age-related diseases such as CVD. Many such studies explore telomere length 
as a biomarker of ageing, with the potential to better predict CVD incidence and prognosis 
than chronological age.  Shorter LTLs have also been associated with: CVD risk factors 
(see Chapter 1.1.4); atherosclerosis;11 chronic heart failure;329 peripheral artery disease;330 
degenerative aortic valve stenosis;331 intima-media thickness of the carotid artery; coronary 
artery calcification; and CAD, independent of age. 
Two main hypotheses exist (these are not necessarily mutually exclusive) to explain this 
association: 
• Telomere attrition, caused by ageing, is accelerated by cardiovascular risk factors 
and disease, and reflects the overall burden of inflammatory, oxidative, and 
mechanical stress induced by increased heart rate on the cardiovascular system.329 
• The Telomere Hypothesis of CVD 330 suggests that shorter inherited telomere 
length is the primary abnormality and is causally associated with atherosclerosis 
and CVD.  
However, there is no consensus in the literature as whether or not telomere attrition is 
causally linked to CAD,331 although there is growing evidence to support an association.  
Brouilette et al.332 evaluated whether shorter TL is the primary abnormality in healthy 
offspring of subjects with, and without, a family history of CAD. Their study design 
eliminated potential baseline effects: because TL and CVD risk are to an extent inherited, 
they measured the TL of healthy young adults. Results from this pilot study of 104 subjects 
indicated shorter telomeres in the offspring of CAD patients, suggesting that shorter 
inherited telomeres predispose to CAD. This finding supports the Telomere Hypothesis of 
CVD implying that shorter telomeres are a primary abnormality. This finding has been 
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partially confirmed in a study that showed shorter LTL in the offspring of patients with 
ischaemic heart failure than in the offspring of healthy controls, but no difference between 
the two groups in telomere length in CD34+ mononuclear cells or buccal cells.333 A small 
study by Dei Cas et al.334 (82 offspring), the larger Bruneck study (800 offspring),334 and 
the European Atherosclerosis Research Study II (EARSII)21335 (765 offspring) have shown 
a similar association. However, results were often only borderline significant, and could be 
prone to confounding effects.  
Although experimental evidence in support of the role of telomere length in cardiovascular 
disease is compelling, there is much less epidemiological evidence. The majority of 
epidemiological studies have shown an association with age, cardiovascular disease and its 
risk factors. However, as most studies are cross-sectional, case controls or disease cohorts 
(rather than prospective cohort studies in those without CAD) there is less evidence to 
support a causal association. While important, these findings could equally suggest either 
hypothesis is appropriate - that CAD causes telomere attrition rather than vice versa. Or, 
alternatively, that both telomere attrition and cardiovascular disease might be caused by 
common risk factors (smoking, hypertension, high total cholesterol level, obesity, physical 
inactivity), which contribute to inflammation and oxidative stress. 331  
Several studies have identified an increased risk for AMI and heart disease in subjects with 
shorter telomeres,336,337,338,339 although it is unclear to what extent telomere length might 
have already been affected by subclinical disease status or by confounding variables at 
baseline. 
De Meyer et al.138 assessed the association between atherosclerosis and telomere length in 
the large Asklepios Study population (2509 subjects). They concluded that LTL is not a 
substantial underlying determinant of preclinical atherosclerosis. The only marginally 
significant finding was observed in women, where combined atherosclerotic plaque 
(carotid and femoral) prevalence was increased in those with shorter telomere length.  It 
has also been shown that LTL is shorter in patients with carotid plaques compared with 
those without.315 
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While a meta-analysis has been undertaken by Chen and Zeng in 2012340 exploring the 
relationship between telomere length and CAD, it has only been presented as a conference 
abstract in Heart. They used telomere length data from 13 publications consisting of 1985 
cases and 3435 controls in a pooled meta-analysis to assess the association between CAD 
and telomere length. They suggest that telomere length is associated with CAD 
(WMD=−0.26, 95% CI −0.29 to −0.23). This association between the telomere length and 
CAD was statistically significant in studies from European-American countries 
(WMD=−0.25, 95% CI −0.29 to −0.22), and Asian countries (WMD=−0.83, 95% CI −1.21 
to −0.45), with the authors stating there was no publication bias (no indication is given to 
how this was assessed in the abstract). Given the limited evidence and the absence of a full 
publication of the Chen systematic review and meta-analysis, a literature review was 
undertaken following systematic review processes to assess the literature on the link 
between CAD and telomere length in peripheral leucocytes. This was primarily undertaken 
to provide background and a basis for comparison of results, for the biological ageing in 
CAD study in Chapter 4.4. 
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2.4.1. Search strategy and search criteria 
 
Three journal databases were used (Ovid Medline 1948 to September week 1 2013, Ovid 
Embase 1996 to 2013 week 36, and Science Direct 1996 –present (31.12.2013)) with the 
following search terms and Boolean connectors applied:  
 
1 “coronary” OR “heart” OR “cardi*” OR “myocardi* OR ”submyocard*” OR 
“arter*” 
2 “disease*” OR “infarct*” OR “ischaem*” OR “ischem*” OR “athero*” OR 
“angina” OR “steno* 
3 “telomere*” OR “*telomere length” OR “telomere shortening” 
4 “leucocyte* OR “peripheral white blood cell” OR “white blood cell*” OR “TL” 
OR “LTL” 
5 1 AND 2 AND 3 AND 4  
 
The search was limited to studies conducted on humans and those that were available in 
English and was last run on 16.01.2014. Only studies that reported the association between 
telomere length in peripheral blood leucocytes and CAD were included. Exclusion criteria 
included: reviews, editorials, studies which included CVD other than CAD or only CVD 
risk factors. The reference lists of relevant articles (including reviews and editorials) were 
reviewed to identify additional articles that were potentially relevant.  In cases where 
studies had duplicate publications, the most recent publication was used. 
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The data extracted from eligible articles included the publication date, study setting, study 
design, study population size and characteristics, LTL measurement method, main outcome 
of interest, and main findings (see Table 2) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. PRISMA Flow diagram of studies 
  
Records identified through 
database searching (Medline, 
Embase and Science Direct) 
n = 1051    
Duplicate studies removed 
n =248 
Titles screened 
n =803    
Irrelevant studies excluded 
n =554   
Abstracts screened  
n =   249 
Abstract articles excluded 
n = 181 
Studies included in literature 
review  
(n =26) 
Full text assessed 
n =  68 
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Lead author/ 
Country 
(publication year) 
Study 
Design 
Number of 
participants 
Age of participants  
years 
(age range or SD) 
Telomere 
Measurement 
method  
Main Outcome 
indicator  
Main Findings 
Carquist  
(2013) 
USA 
Conference abstract 
Cohort 3,569 patients 
undergoing 
angiography.  
63.2% found to 
have CAD 
62.9 Multiplex 
qPCR  
Evidence of CAD 
and survival 
(follow up 9.2 
years) 
Univariate-longer LTL associated with decreased 
risk CAD and death. No association with MI or 
stroke.  
Multivariate – only association with death 
remained.  
Ye  
(2013) 
Canada 
 
Cohort 1,917 
Population 
based 
Shortest tertile – 41.7 ± 
18.0 
Middle tertile – 46.1±17.8 
Longest – 51.8±18.1 
PCR 
CoV 5% to 8% 
Fatal/Non fatal 
CAD events 
(based on hospital 
discharges) 
No association found. Non fatal CAD associated 
with the middle tertile (OR 1.63, 95%CI:1.07-
2.51, p=0.02) 
Small number of CAD events.  
Perez-Rivera 
(2012) 
Spain 
Cohort 203 males with 
ACS 
50-74 (mean 62±7) n=150 
>75 (mean 82±5) 4=53 
qPCR Death 
Revascularisation 
Recurrent angina 
Heart failure 
Composite end 
point 
Short telomere length is associated with a worse 
prognosis in men aged 50-(OR  2.56, 95% CI: 
1.03-6.39, p=0.04) – note inflame markers 
Ruff  
(2012) 
USA 
Conference abstract 
Cohort 5,057 ACS Unknown qPCR MACE Strong independent association between LTL and  
MACE 
Russo  
(2012) 
Italy 
 
C-C 199 cases 
190 controls 
18-48  
(period of most flattened 
LTL loss) 
qPCR 
CoV 1.46% 
AMI No significant difference on univariate or 
multivariate analysis  
Weischer 
(2012) 
Denmark 
Cohort 19,284 
Population 
based 
36-74 RT-PCR 
CoV 2% 
 
MI 
IHD 
Death 
 
Short LTL is associated with only modest 
increases I in risk of MI, IHD, and Death. 
HR MI: 1.10(1.01-1.19) 
IHD: 1.06 (1.00-1.11) 
 
Fyhrquist 
(2011) 
USA 
Cohort 
With HBP 
& LVH 
1271   Southern Blot CAD 
Framingham 
score  
MACE  
Short LTL associated with CAD in males: OR 
0.61, 95% CI 0.39–0.95), and transient ischemic 
attack in females (OR 0.62 95% CI 0.39–0.99). 
Proportion of short telomeres was associated with 
combined cardiovascular mortality, stroke or 
angina pectoris (HR 1.04, 95% CI 1.01–1.07) 
Table 2: Summary of studies: study design, sample, instruments, and main findings: leucocyte telomere length and coronary artery disease.   
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Lead author/ 
Country 
(publication year) 
Study 
Design 
Number of 
participants 
Age of participants  
years 
(age range or SD) 
Telomere 
Measurement 
method  
Main Outcome 
indicator  
Main Findings 
Wang  
(2011)  
China 
C-C CAD 163 
Controls 112 
CAD – 57.7±11.6 
Controls 56.3±9.2 
RT-PCR 
CoV 
1.5%±1.2% 
CAD 
Carotid femoral 
pulse wave 
velocity (PWV) 
LTL shortening associated with PWV 
Correlation between LTL and PWV with CAD 
was stronger than in controls 
Fitzpatrick  
(2011) 
USA  
Cardiovascular Health 
Study 
Cohort 1,136 
Population 
based  
19.0% had 
CHD 
73.9(4.7) Southern Blot 
CoV 1.7% 
Cause specific 
mortality 
“Borderline” association for cardiac deaths  
1.82 (95%CI:0.95-3.49, p=0.07) 
Calvert 
(2011) 
UK 
C-S 
PCI patients 
170 stable 
angina or ACS 
Upper tertile 59.9(11.0) 
Lower tertile 63.1(10.2) 
qPCR Plaque severity on 
virtual histology 
ultrasound 
Shorter LTL is associated with high-risk plaque 
morphology but not total 3-vessel plaque burden.  
Willeit  
(2010) 
Italy 
Cohort 800 Population 
based 
45-84 in 1995 qPCR 
intra-assay CoV 
1.2%; 
interassay CoV 
2.4% 
Composite CVD 
endpoint 
Baseline LTL is a significant and independent 
risk factor for composite CVD endpoint but not 
IC or stable CAD 
Maubaret  
(2010) 
Europe 
C-C 598 white 
patients who 
survived AMI 
653 age-
matched 
controls 
<60  RT-PCR CAD Those with CAD had shorter LTL than controls 
Spyridopoulos 
(2009) 
Germany 
C-C 25 CAD 
27 Controls 
65  Flow-FISH 
Interindividual 
variability 5.5% 
and 
intraindavidual 
variability 1.0%  
CAD LTL negatively associated with CAD 
Njajou  
(2009) 
USA  
Health ABC study 
Cohort  2,721 
Population 
based 
Multi site  
70-79  qPCR 
CofV 5.8% 
Survival 
CAD mortality 
LTL not associated with overall survival or CAD 
mortality 
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Lead author/ 
Country 
(publication year) 
Study 
Design 
Number of 
participants 
Age of participants  
years 
(age range or SD) 
Telomere 
Measurement 
method  
Main Outcome 
indicator  
Main Findings 
Yang  
(2009) 
China 
Cohort 388 patients 
with 
hypertension 
379 healthy 
controls 
30-80 qPCR 
Average SD for 
the triplicate 
measurement 
was 6.8% 
CAD Shorter LTL and hypertension are independent 
risk factors for developing CAD within 5 years 
Mukherjee 
(2009) 
India 
C-C 238 CAD 
(attending for 
CAD 
investigation or 
management) 
238 Controls  
29-82  RT-PCR 
CoV 1.5% 
Confirmed CAD  
CAD severity 
After adjustment T/S ratio was significantly lower 
in patients with a history of CAD. 
No association was found between CAD severity 
and LTL 
Epel 
USA 
(2009) 
Cohort 
McArthur 
Healthy 
ageing study 
236 Population 
based 
70-79 qPCR 
CoV 5% 
 
CVD mortality 
over 3.5 years 
Baseline LTL “weakly” predicted cardiovascular 
mortality, p<0.10 
In men, LTL change (shortening) associated with 
greater mortality from CVD  OR 3.0, 95%CI:1.1-
8.2, p<0.04 
In women, baseline LTL was associated with 
greater mortality from CVD  OR 2.3, 95%CI: 1.0-
5.3, p<0.05 
Zee 
(2009)  
USA 
Nested C-C 337 white 
males AMI 
337 Controls 
(USA 
physicians) 
Cases 60.1±8.7  
Controls 60.2±8.7 
Modified qPCR 
CoV<5% 
 
AMI After adjustment (no lipids in model) LTL was 
significantly associated with the risk of MI (OR 
1.6, 95%CI:1.14-2.30, p=0.007) 
Farzaneh-Far 
(2008) 
USA 
 
Cohort  780 with Stable 
angina 
Quartitle 1 – 70±10 
2 – 68±11 
3 – 67±11 
4 – 65±11 
qPCR  
(single 
measurement) 
CoV 9.5% 
Mortality 
MACE  
Heart failure 
Inflammatory 
markers 
After adjustment lowest LTL quartile associated 
with significant increase in death, heart failure 
admissions but not MACE.  
Starr 
(2007) 
UK 
Nested C-C 620 patients 
with ischaemic 
heart failure  
183 Controls 
40-80 qPCR 
 
Ischaemic heart 
failure 
Univariate analysis – shorter LTL in ischaemic 
heart failure  
Shorter according to the severity of 
atherosclerosis  
Shorter LTL predicts death and hospitilisation 
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ACS acute coronary syndrome; AMI acute myocardial infarction; CAD coronary artery disease; C-C case control; CI confidence interval; CoV coefficient of variance; CVD cardiovascular 
disease; Flow-FISH fluorescence in situ hybridization; HBP hypertension/high blood pressure; HR hazard ratio; LTL leucocyte telomere length; LVH left ventricular hypertrophy; MACE 
major adverse cardiac events; OR odds ratio; qPCR quantitative polymerase chain reaction; SD standard deviation; T/S ratio relative ratio of repeat to single copy number; WOSCOPS West 
of Scotland Coronary Prevention Study
Lead author/ 
Country 
(publication year) 
Study 
Design 
Number of 
participants 
Age of participants  
years 
(age range or SD) 
Telomere 
Measurement 
method  
Main Outcome 
indicator  
Main Findings 
Brouilette  
(2007) 
UK 
Nested C-C 
WOSCOPS 
study  
 
484 Patients 
with CAD 
1,058 controls 
Cases 56.9(5.1) 
Controls 56.7(5.2) 
qPCR CAD Individuals in lowest tertile of LTL more likely to 
have future CAD. Risk was attenuated by use of 
Pravastatin.  
Kurz 
(2006) 
Switzerland  
C-C 64 patients with 
calcific aortic 
stenosis 
>=70 Southern Blot 
Interassay 
variability 
7.8%±7% 
Calcific arotic 
stenosis 
CAD 
No association found between CAD and LTL in 
neither cases or controls 
Brouilette  
(2003) 
UK 
C-C 203 premature 
AMI 
180 Controls  
Cases 46.8(6.2) 
Controls 47.2(5.9) 
Southern Blot 
“Interassay 
variance in 
estimate of 
mean TRF was 
3.3+/-2.7%” 
Premature AMI After adjustment – shorter quintile associated 
with 2.8-3.2 fold increase in premature MI 
Obana  
(2003) 
Japan 
C-C 78 CAD with 
hypercholestero
lemia 
62 No CAD 
with  
hypercholestero
lemia 
30 Controls 
CAD 66±7.8 
No CAD 64±7.1 
Controls 64±46.4 
Southern Blot 
Interassay CoV 
2/1% 
CAD CAD had significantly shorter LTL compared 
with controls 
Cawthon  
(2003) 
USA 
Cohort 143 Population 
based 
60-97 qPCR 
5.8% 
 
Death 
Death from CVD 
3.18 fold higher mortality from heart disease 
(95% CI:1.36-7.45, p=0.0079) 
Samani 
(2001) 
UK 
C-C 10 Severe CAD 
20 Controls 
39-72 Southern Blot 
Interassay 
variation was 
0.8% (SD 
1.5%) 
CAD Cases had mean terminal restriction fragments 
303 (SD 90) base pairs shorter. Equivalent to 
those 8.6 years younger.  
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2.4.2. Findings 
One thousand and fifty-one articles were identified by the electronic search, of which 248 
were discarded as duplicates (Figure 12). Title review resulted in the exclusion of a further 
554 articles. The abstracts of the remaining 249 were screened and an additional 181 were 
excluded. The full manuscripts of the remaining 68 were reviewed and 26 were judged 
eligible for inclusion in the review. The eligible studies were published between 2001 and 
2013 inclusive. They included a total of 23,452 participants within the 26 studies. The 
oldest patient was reported as 97 years of age and the youngest as 18. Nine studies were 
case-controls, 3 were described as nested case-controls, 13 were cohorts, and one was 
cross-sectional. Of the cohort studies: 7 included population based participants; 2 had only 
participants who had recently had an AMI or ACS; 1 included participants with and 
without hypertension; 1 included participants with hypertension and left ventricular 
hypertrophy; 1 included participants attending for investigations or management of stable 
angina; 1 had participants who were undergoing PCI, and only 1 had participants who were 
undergoing angiography where some 63.2% were found to have CAD and were followed 
up for 9.2 years. Six studies used Southern Blot to measure LTL; 19 studies used some 
form of PCR (RT-PCR, qPCR, or “modified” PCR); and 1 study used “multicolor flow 
cytometry-fluorescent in situ hybridization”.  
Of the 10 case-control and 2 nested case-control studies, 10 found an association between 
LTL and CAD. The first of these studies was a very small pilot study undertaken in 2001 
by Samani et al.341 They measured LTL, using the Southern Blot method (with interassay 
variation of 0.8 SD 1.5%), in 10 cases with severe CAD and 20 controls. The cases were 9 
men and 1 woman with angiographically detected severe (>75% stenosis) triple vessel 
CAD. The controls were 10 men and 10 women with normal arteries on angiography 
which was preformed to investigate valvular heart disease (n=9) or chest pain of uncertain 
origin (n=11). An age-related decrease in mean telomere restriction fragment in blood 
leucocytes of 30-40 bb/year was found in individuals with CAD. On average, mean 
telomere restriction fraction was similar to controls who were 8.6 years older. The small 
numbers and sex difference between the groups was a major limiting factor in this study; 
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although the difference remained significant (p<0.001) when the analysis was restricted to 
males. The inter-assay variation of the LTL measurement was 0.8% (SD 1.5%).  
The unselected consecutive cases in Mukherjee et al.’s342 study also attended for coronary 
investigations or treatments of CAD (74% for diagnostic angiography, 20% for PCI, and 
6% for CABG) to a single centre in India. They comprised of 195 males and 57 females 
aged 29-82 years. Controls were recruited from the general population of people living and 
working in the neighbourhood next to the hospital and were free of CAD (based on self-
reported history, Rose’s angina questionnaire and medications list). Real-time PCR was 
used to determine the T/S and the CoV was reported as being 1.5%. Correlations from a 
previous study were used to relate differences in T/S ratio to differences in mean telomere 
length. They found that the mean LTL in cases was significantly shorter after adjustment 
for clinical characteristics 1.34bp (95%CI:1.27bp – 1.42bp, p=0.002) with no relationship 
between T/S ratio and severity of disease. However, they did not find an association 
between LTL and age in either the cases nor the controls. This may be due to the wide age 
range or the Indian ethnicity of participants.  
In 4 of the case control studies, all of the included cases had had an AMI.  (Maubaret et 
al.,336 Russo et al,343 Zee et al,339 and Brouilette et al (in their 2003 study)344 Russo et al,343 
Maubaret et al.,336 and Brouilette et al.344 used cases that had premature AMIs. However, it 
is possible that LTL may adversely affect immediate prognosis following AMI meaning 
that survivors of AMI may have differences in LTL compared with those who died.  
Maubaret et al.336 in the HIFMECH (hypercoagulability and impaired fibrinolytic function 
mechanisms predisposing to myocardial infarction) study showed a significant relationship 
between LTL and AMI in patients <60 years of age. The study compared male survivors of 
AMI (598 white males <60 years of age) with population based controls of the same age 
and region of North or South Europe (598 white male patients (<60 years) who survived a 
first MI and 653 age-matched control subjects from across Europe). In addition, 413 
coronary artery bypass graft patients and 2 groups of 461 patients with familial 
hypercholesterolemia (FH), of whom 162 had premature CHD, were recruited. LTL was 
measured using a real-time q-PCR. It was reported that LTL was significantly shorter in 
patients (7.85 kb) compared with control subjects (8.04 kb, P = 0.04). In the coronary 
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artery bypass graft sub study, LTL was also significantly shorter compared with control 
subjects. In the FH patients, LTL was shorter in those with CHD (overall, 8.68 kb) 
compared with the non-CHD subjects (9.23 kb, P = 0.012). On the other hand, LTL was 
not associated with any measured CHD risk factors except for age. These data confirm that 
subjects with CHD have shorter telomeres than control subjects, and extends this to those 
with monogenic and polygenic forms of CHD, such as FH. 
Brouilette et al.344 in 2003 also found a statistically significant association between mean 
terminal restriction fraction in 203 cases of AMI <50 years of age and 180 controls. 
Controls were recruited from 3 primary care practices in the same geographical area. Cases 
were 3/12 post AMI matched for age, sex and current smoking status. All participants were 
white and of Northern European origin. Southern Blot interassay variance in estimate of 
mean TRF was 3.3+/-2.7%. They found that having shorter than average mean leucocyte 
TRF length increased the risk of MI approximately 3-fold (2.79, 95%CI:1.53-5.11, 
p=0.001). No correlation was found between age and LTL; however, the participants in the 
study were aged 18-48 years old. As discussed, this is thought to be the age range with the 
cardiovascular event. During multivariate regression analysis, the LTL determined at 
enrolment did not predict major cardiovascular events. The authors concluded that LTL did 
not represent a marker of acute MI in young patients and was not predictive during follow-
up.36 This could, however, have been influenced by the narrow age range (18-48 years is 
consistent with the most flattened area of the LTL age curve) and low number least 
telomere length attrition which may explain this finding.  
In contrast, Russo et al.343 compared LTL in 199 consecutive patients admitted to an Italian 
coronary care unit with a first diagnosis of AMI at ≤48 years of age to 190 age and sex 
matched controls. They describe their study as a prospective case-control, with cases being 
followed up for a median of 9±5 years. No significant differences were observed in LTL 
between cases and controls (0.81±0.14 vs 0.77±0.2, p=0.46). Real time quantitative PCR 
with a CoV of 1.46 5 was used to determine LTL. Little information is provided on 
controls and in all, 171 patients completed the average follow-up of 9 years, during which 
time 92 of them presented with a major of study participants as well as other 
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methodological shortcomings. For example, no correlation with chronological age and LTL 
was shown, as would have been expected. 
Zee et al.339 employed a nested-case-control design within a randomised, double blind, 
placebo-controlled trial of Aspirin and beta-carotene (a precursor of vitamin A). The study 
was initiated in 1982 among predominantly white male US physicians who were free of 
CVD at the time of enrolment. Unlike the other studies, incidence of AMI was assessed in 
337 case-control pairs. The prospective nature of the original study reduces recall and 
confounding bias which is a common issue in case-control studies. A modified qPCR 
method was used to determine the LTL with a CoV of <5%. After adjustment, an 
association was found between LTL shortening and risk of incident AMI (OR MI 1.621 
95%CI 1.14-2.304, p=0.007). As the participants were US physicians, there are issues with 
generalisability. In addition, potential confounders such as Triglycerides, LDL cholesterol, 
HDL cholesterol, glucose, and homocystine were not examined.  
Similar to Zee et al,339 Brouilette et al.(2007)11 used a nested case-control design within the 
randomised controlled placebo controlled trial (WOSCOPS). All participants were from 
the West of Scotland, aged 45-64 years of age, had raised cholesterol at recruitment, and 
were statin-naive. They were randomised to receive either a statin (Pravastatin 40mg daily) 
or placebo. The 484 cases had either a primary endpoint (non-fatal AMI or death from 
CHD) or underwent coronary revascularisation. They were matched on the basis of age, 
duration of follow-up and smoking status with two controls that remained event free for the 
duration of the study (mean follow-up period of 4.9 years). LTL was measured at 
recruitment using qPCR based technique which was shown to be correlated (r=0.65) with 
Sounthern Blot in a random sample of 18 participants. They found that individuals in the 
middle and lowest tertiles of LTL were more at risk of developing a CHD event than were 
individuals in the highest tertile (OR 1.51, 95%CI:1.15-1.98, p=0.0029 for the middle 
tertile and 1.44, 95%CI: 1.10-1.90, p=0.009 for the lowest). In addition, they reported that 
this risk was found not to be significant in those participants who had been randomised to 
receive the statin, suggesting an attenuation of risk. However, the end points used in this 
study meant that not all CAD could have been captured e.g. those being medically 
managed.  
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Case-control studies which included cases known to have CAD were also conducted by 
Wang et al.,345 Obana et al.,346 Syridopoulos et al.,323 and Mukherjee et al.318 Wang et 
al.321 included 163 male Chinese Han patients with CAD attending a single centre hospital 
in Qingdao, China. They measured LTL and pulse wave velocity of large arteries (as a 
biomarker of ageing of the artery system which measures artery stiffness via the carotid 
and femoral arteries). The age range of participants was 40-73 years of age (less restrictive 
than in the WOSCOPS study) and quantitative PCR was used to measure LTL (CoV 
1.5%±1.2%). All cases had CAD confirmed on coronary angiography: this was defined as 
having ≥50% diameter narrowing 1 coronary artery or its major branches. Age and sex-
matched controls were recruited from the same hospital (n=112). They attended for routine 
health examinations and were judged free of hypertension and cardiovascular disease 
according to history, clinical examination, ECG, and treadmill test. Therefore they may not 
be representative of the general population of Chinese Han. The T/S ratio as found to be 
significantly shorter (p<0.001) in patients with CAD (0.79±0.26) than in control subjects, 
after adjustment for baseline characteristics including lipids and CRP.  
Obana et al.346 in Japan compared TL in patients with hypercholesterolaemia (n=91) and/or 
diabetes (n=84) (35 had both), according to the presence or absence of CAD. Controls were 
30 healthy volunteers who were older than 50 years to adjust the mean age to be that of the 
patient’s group. Cases were those with hypercholesterolaemia and/or diabetes found to 
have CAD by ECG or coronary angiography (n=62). LTL was measured using Southern 
Blot with an interassay coefficient of variance of 2.1%. LTL was significantly shorter in 
those with CAD than controls using ANOVA (6.1±0.9 vs 6.9±1.5, p=0.0014). However, 
little information is given about the recruitment of controls or why only 30 were used. Of 
the baseline characteristics (age, gender, smoking status, BMI, systolic and diastolic blood 
pressure, total cholesterol) only serum glucose was found to be significantly different on 
using unpaired ttests (usually used to compare the means of a continuous variable between 
2 unrelated groups – not the 3 (CAD+ with hypercholesterolaemia and/or diabetes, CAD – 
with hypercholesterolaemia and/or diabetes, and controls) used here. In addition, 64% of 
cases with CAD were male compared with 73% of controls, suggesting the small numbers 
may be an issue with statistical significance and that larger numbers with statistical 
adjustment may have been necessary. 
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Spyridopoulos et al347. cases included 25 men who had: coronary angiographic confirmed 
CAD; healed AMI (at least 3 months after infarction) and impaired left ventricular systolic 
function. Controls were 14 young (mean age 26.7±1.8 years) and 13 older (65.1±2.1 years) 
healthy male volunteers. Medical history and blood tests were used to assess the health 
status of controls; with additional echocardiography and stress ECG testing in elderly 
controls. This was the only study that used Flow-FISH to determine LTL which had an 
inter-individual variability of 5.5% and an intra-individual variability of 1.0%. LTL was 
determined separately for all relevant leucocyte subtypes (n=12). A power calculation (to 
detect an 80% probability at the 5% significance level) was undertaken to determine 
sample size and cases were matched for age. However, no reference is provided for the 
expected difference between the groups. They found that LTL in cases was 500bp shorter 
than in age-matched healthy controls.  
Mukherjee et al.342 examined the association of LTL and CAD in Indian subjects (known 
to have a higher prevalence of CAD). Cases were 238 consecutive patients (aged 29-82 
years) admitted to a single centre hospital for coronary investigation or treatment of CAD 
and controls were drawn from the general population (residing in the hospital catchment 
area) without a history of AMI, stroke or CAD. Presence of ≥50% stenosis on coronary 
angiography was considered diagnostic of CAD with severity classified according to the 
American Heart Association guidelines (33 cases did not fulfil this criteria). Cases were 
matched for: age, sex, BMI, and smoking history, with no statistically significant 
differences found between cases and controls in fasting lipids. LTL was measured using 
Real-time PCR with differences in T/S ratio matched to bp using their previous correlation 
of LTL measured by PCR and by Southern Blot.344 Mean LTL was significantly shorter in 
cases compared with controls (1.21, 95% CI:1.16-1.42 vs 1.33, 95%CI:1.28-1.38, 
p=0.0003) even after adjustment for baseline characteristics  and excluding cases without 
significant CAD on coronary angiography. There was no relationship between LTL and the 
number of stenosis vessels (p=0.327). However, no association was found between LT and 
age (despite the substantial age range in the study) in cases or controls. The authors suggest 
this may be related to the sample size or the ethnicity of participants (which the study was 
not designed to assess) rather than imprecision of the assay (CoV 1.5%).  
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In the nested case control study by Starr et al.,348 participants were recruited from the 
Scottish Mental Survey and were all born in 1921. LTL measurement was undertaken in 
190 participants at age 79 years using qPCR - mean LTL were determined following the 
Cawthon et al. (2003) method. Selection bias towards inclusion of participants from 
professional and semi-professional social classes and survivor bias were major limitations 
of this study. Heart disease was classified as definite, possible (e.g. possible angina), or 
absent (based on history and normal ECG). Definite or possible heart disease was reported 
in 33% of participants. Associations were examined by type of abnormality: conduction 
defect, ischaemia, and left ventricular hypertrophy. No association (F=0.021, p=0.88) was 
found between LTL shortening and with evidence of ischaemia on ECG.  
Elderly participants (193 aged ≥70 years) were also used in Kurtz et al.’s349 study. All 
participants were recruited prospectively from patients undergoing elective coronary 
angiography. Cases (n=64, mean age 77.2±5.2 years) were those undergoing investigation 
of CAD prior to valve replacement surgery for critical calcific aortic valve stenosis (CAC). 
Controls (n=129) were those without CAC on direct measurement of the aortic valve 
pressures during coronary angiography (mean age 75.9±4.3 years). LTL was measured 
using Southern Blot with an interassay variability of 7.8%±7%. While there was an 
association between LTL and CAC, no significant association was found between CAD 
and LTL, in cases or controls, even after “investigating for possible confounding” (results 
not presented in the paper).  
Of the 7 cohort studies which used population based participants, 4 restricted the age range 
to only elderly participants.352,353,354,355,356,357,358 Epel et al.350 measured telomeres in 236 
elderly subjects at baseline and 2.5 years later (available in 134 participants). They 
measured both LTL and telomere attrition and studied their association with cardiovascular 
mortality (which included CAD) over 12 years. They state that baseline LTL “weakly” 
predicted cardiovascular mortality; however, this was not found to be statistically 
significant, p<0.10. In men, LTL change (shortening) was associated with greater 
cardiovascular mortality OR 3.0, 95%CI:1.1-8.2, p<0.04. In women, baseline LTL was 
associated with greater cardiovascular mortality OR 2.3, 95%CI: 1.0-5.3, p<0.05. The 
participants were a small atypical sample of white elderly men and women (restricted to 
age 70-79 years) from Boston, USA (all had good cognitive and physical functioning). 
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Analysis was performed using quantitative PCR and following Cawthon’s process with 
reliability and validly being described as “high” – Cawthon suggests a CoV of 5%.121 This 
study used CVD deaths as an outcome which did include CAD deaths; however, no details 
are provided on the breakdown of CVD deaths or how they were defined (e.g.  inclusion of 
PAD or heart failure not stated). It is however, one of the few studies which assess 
telomere attrition over time.  
 
Njajou et al.352 also had an equally restrictive age group (70-79 years of age). This large 
(n=2,721) multi-site population based study assessed the association between LTL and 
cause-specific mortality as part of the Health ABC Study.  Participants were all from the 
USA and eligible for Medicare (a national social insurance program, administered by the 
U.S. federal government). Similar to Epel et al., exclusion criteria included deficits in 
physical and cognitive functioning. Baseline LTL was undertaken using qPCR with a high 
CoV of 5.8%. Multivariate linear regression was used to assess the mean terminal 
restriction fraction length based on the reference DNA sample. The mean follow up time 
was 8.2±2.3 years. Average LTL was marginally shorter in the 47% who were African 
Americans compared with white (4.77±1.3kbp vs 4.87±1.3kbp).  
In contrast, Fitzpatrick et al.’s351 USA study (Cardiovascular Health Study cohort (CHS)) 
had only 15% African American participants. However, they were less homogeneous in 
nature, had less physical and cognitive exclusions, and a less restrictive age group (65 
years and over) than Njajou et al.352 In addition, LTL measurement in the CHS, was 
undertaken by Southern Blot with a CoV of 1.7%. Cause of death was classified 
independently by physicians using medical records and death certification data, thus cause 
of death was more specific than in Njajou et al.’s study.352  A “borderline” association 
between risk of death due to cardiac causes and shortest LTL quartile was found (HR 1.82, 
95%CI:0.95-3.4). However, the p value was reported as p=0.07 and there was limited 
adjustment for traditional cardiovascular risk factors. Cardiac causes of death included: 
congestive heart failure, arrhythmia, cardiovascular procedures, or multiple mechanisms. 
No statistically significant associations were found for deaths from congestive heart failure 
or arrhythmias.  
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The first population based cohort to be undertaken was published in 2003 by Cawthon et 
al.121 and was also conducted in USA citizens. Shorter leucocyte telomere length was 
associated with an increased age-adjusted risk for cardiovascular mortality in a 
convenience sample of 143 initially healthy subjects over the age of 60 years (3.18-fold 
higher mortality from heart disease (95CI:1.36-7.45, p=0.0079)). This was based on Cox’s 
Proportional Hazard regression models for shortest half of telomere distribution after 
adjustment for age. No other adjustments were made for traditional cardiovascular risk 
factors. This was also the first to use qPCR to measure LTL (CoV 5.8%).353 The vast 
majority of PCR techniques employed since then were based on (with subsequent 
modification) this initial approach. LTL was found to be associated with age with every 1 
year of age being associated with a 0.0048 decrease in the relative T/S ratio.  
Population based cohorts have also been undertaken with less restrictive age ranges. One of 
the most important studies in this area was undertaken by Ye et al.354 with 1,917 healthy 
subjects aged >18 years. In univariate analysis participants with shorter telomeres appeared 
to have greater risk of incident CAD than those with longer LTL. Nevertheless, after 
adjustment for traditional cardiovascular risk factors and inflammatory markers, the risk of 
new ischaemic events was not linearly associated with LTL (HR 1.25 95%CI:0.82-1.90, 
p=0.30 - shortest tertile of LTL compared with the longest). Subjects were relatively young 
(mean age 41.7(±18.0)-51.8(±18.1) depending on tertile of LTL) and the incidence of CAD 
in this group is low, with only 8.56% of participants presenting with events (fatal and non-
fatal CHD events) which were assessed using robust hospitalisation data.  
One of the largest population based cohorts was conducted by Weischer et al.337 in 
Copenhagen, Denmark. Randomly invited participants numbered 19,383 with a follow up 
of median 17 years assessing incident AMI (n=929) and CAD (n=2038). LTL decreased 
linearly with age; although, age explained only 6% to 11% of the variation. Per 1000 bp 
decrease in LTL with the adjusted HR for AMI and CAD was: 1.10 95%CI:1.01-1.19 and 
1.1.06 (1.00-1.11) respectively, suggesting only modest increases. Follow up was complete 
and the 100% interassay coefficient was 2%. All participants were white and of Danish 
descent and participants diagnosed with an end point were excluded from that particular 
analysis.  
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Willeit et al.355 included 800 men and women aged 45-84 years (in 1995) in the Bruneck 
Study (South Tyrol, Italy) of prevention of cardiovascular and cerebrovascular disease.  
Participants were also randomly chosen from the general population and were exclusively 
white but of heterogenous origin – Italian, German and Austrian background. During the 
10 years follow up, 43 participants experienced an AMI. Hospitalisation data was used to 
assess endpoints. Each 1-SD decrease in loge –transformed relative to T/S ratio was 
associated with 41% increase risk of AMI (95%CI:.1.02-1.96). Intra-assay CoV of 1.2% 
and interassay of 2.4% was reported.  
The association between LTL and adverse outcomes in populations known to have CAD 
were explored in Farzaneh-Far et al.,356 Perez-Rivera et al.,357 and Ruff et al.335 Both Ruff 
et al. and Perez-Rivera et al. used populations who presented with ACS and used qPCR. 
While Farzaneh-Far included outpatients with stable CAD. The Spanish cohort357 consisted 
of 150 males aged 50-75 years and 53 aged >75 years of age and used the same primers for 
the qPCR telomere length analysis as Cawthon et al.121 Cardiovascular prognosis was self-
reported at interviews. In men aged 50-75 years there was a statistically significant worse 
prognosis in patients with shorter LTL (log-rank: 5.22, p<0.05). Cox’s analysis was used to 
confirm the independence of this relationship:  HR 2.56  95%CI:1.03-6.39, p=0.04. Ruff et 
al.358 followed up 5,057 participants who were enrolled in the MERLIN-TIMI 36 and 
PROVE-IT TIMI 22 ACS trials, for 1.2 years. After adjustment for baseline characteristics, 
short LTL was strongly associated with a subsequent AMI (HR 1.81 95%CI:1.36-2.42, 
p<0.001). While Farzaneh-Far et al.356 in the San Francisco, USA based Heart and Soul 
Study also used self-reported outcomes; This study also reviewed medical records, death 
certification and coroners’ reports. Seven hundred and eighty participants were followed up 
for a mean time of 4.4 years. Exclusions included previous history of AMI in the last 6 
months, those who deemed themselves unable to walk 1 block, or those who were planning 
to move out of the area. After adjustment for clinical, inflammatory, and echocardiographic 
risk factors, participants in the lowest quartile of LTL remained at significantly increased 
risk of death and heart failure admission, but not a subsequent cardiovascular event (which 
included MI, stroke or CVD death) Adj HR 1.5 95%CI:0.9-2.6, p=0.11). The CoV of the 
qPCR was reported as 9.5%.  
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The only cross-sectional study was undertaken by Calvert et al.359 and included 170 
patients with stable and unstable angina who were referred for PCI and underwent 3-vessel 
virtual histology intravascular ultrasound.  Shorter LTL was found to be associated with 
high-risk plaque morphology but not total 3-vessel burden, adding to the evidence that 
leucocyte ageing is involved in vulnerable plaque formation.  
To examine how shorter LTL might be associated with unstable plaques, age- and sex-
matched healthy controls were also used as an extension of the cross-sectional study. 
However, no further information is provided on the controls. LTL was significantly shorter 
in CAD patients vs controls ~0.45kb, p<0.01. qPCR was used to measure LTL and 
compared to a reference DNA of known telomere length (by Southern Blot). This is a 
highly selective patient group and exclusion criteria included: previous PCI, unsuitability 
for virtual histology intravascular ultrasound, active inflammation, and any form of surgery 
3 months before the procedure.  
Two of the cohort studies were focused on patients with hypertension. Fyhrquist et al.360 
measured LTL in 1271 subjects (aged 55-80 years) with hypertension and left ventricular 
hypertrophy participating in the Lifestyle Interventions and Independence For Elders 
(LIFE) study. This was a post hoc analysis of participants who were in a randomised 
double blind controlled trial which was set up to compare different medical treatments. 
Southern Blot (CoV reported as 3.70%) was used to measure LTL at recruitment. At 
baseline, short mean LTL was associated with CAD in males (OR 0.61 95%CI:0.39-0.95) 
but not in females. During the 4 year follow up, development of angina, but not AMI, was 
associated with short mean telomere length. Antihypertensive medication given in the trial 
(adjustments were only made for age and sex although differences in LTL were noted 
between the treatment arms noted between LTL and treatment ). Lack of controls and the 
post hoc nature of the study may have influenced the baseline mean LTL.  
Hypertensive patients in a study of 767 30-80 year olds,337 were found to have 7 shorter 
LTL than healthy controls (0.57 vs 0.67, p<0.001). Exclusion criteria were history of 
alcohol abuse, diabetes, secondary hypertension, and renal disease. After 5 years follow up 
of 411 subjects, those with shorter LTL wre at higher risk of developing CAD than 
individuals with longer LTL (OR 3.315 95%CI:1.662-6.609, p<0.001). Multivariate 
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analysis showed that LTL and hypertension were independent risk factors for developing 
CAD (adjusted for age and gender OR 6.413, p=0.008). LTL measurement was undertaken 
using qPCR with a CoV of 6.8%. Follow up drop out participants were similar interms of 
age, gender, and conventional risk factors.  
In 2013, Carlquist et al.361 presented a poster on the association between LTL and 
cardiovascular outcomes in 3,569 patients attending for coronary angiography at a singe 
centre in Utah, USA. LTL was measured using multiplex qPCR with patient information 
being extracted from electronic records and survival status being verified by the National 
Death Index. Some 63.2% of patients had CAD on coronary angiography nd the mean age 
was 62.9 years; 91.3% were white and 63.8% were male. LTL was found to be correlated 
with age (r=-0.244, p<0.001). After adjustment for: severity of CAD; traditional 
cardiovascular risk factors; and heart medication use, LTL was associated with risk of 
death but not AMI during follow up (median 9.2 years). Longer LTL was associated with a 
decreased risk of CAD (OR=0.54, p<0.0001) but not after adjustment.  
2.4.3. Conclusion 
In 2003, Cawthon et al.121 first reported that shorter LTL was associated with an increase 
in age-adjusted risk for cardiovascular mortality in a population based sample. Since then 
there have been a number of studies which have reported discordant findings, with some 
studies reporting a weak or non existant association between LTL and CAD in population 
based cohorts. Others have reported a modest association. Many of the studies have notable 
limitations such as restricting enrolment to the very elderly, leading to possible survival 
bias; the inclusion of participants with previous CVD; and limited adjustment for 
traditional cardiovascular risk factors. Further studies are needed to explore the link 
between LTL, and CAD and its subsequent adverse outcomes.  These should include 
longitudinal studies which can provide evidence for a causal association and whether or not 
LTL could be used to predict adverse outcomes in patients with CAD. Comparison 
between the different methods of measuring LTL is difficult; therefore, consensus on the 
most appropriate way of analysing LTL would be useful. Alternatively, the development of 
a statistical method which produces a common scale could be explored.  As there is still 
128 
debate as to whether LTL reflects telomere length in arterial endothelial cells, additional 
studies in this area are warranted.  
This literature review could be described as “near” systematic review362 because it was 
undertaken following the PRISMA guidelines for searching and synthesising the literature 
on LTL and CAD. In addition, it was undertaken to identify, critically appraise, and 
synthesise the existing literature relating to LTL and CAD. This is to provide background 
and a basis for comparison of results for the biological ageing in CAD study in Chapter 
4.4. In addition, a near systematic review does not include 2 independent reviewers 
assessing the studies against the inclusion/exclusion criteria or independently reviewing the 
quality of the studies using a formal checklist. Therefore, a meta-analysis has not been 
undertaken at this stage. However, this is a potential area for future research.  
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3. METHODS 
3.1. Secondary data analysis  
CAD remains the most commonly reported limiting longstanding illness and accounts for 
around a quarter of deaths in men and women. Morbidity and mortality from CAD are 
strongly associated with chronological age. A secondary data analysis was undertaken to 
examine whether elderly patients undergo coronary angiography at a more advanced stage 
of disease, whether they are less likely to proceed to revascularisation if CAD is confirmed 
and whether any inequalities in management appear justified by a high risk of peri-
procedural complications in elderly patients.  
 
3.1.1. Data sources and study population 
3.1.1.1 Scottish Coronary Revscularisation Register (SCRR) 
Since 1997, the Scottish Coronary Revascularisation Register (http://www.scs-
online.org.uk/cardreg.php) has routinely collected detailed information prospectively on all 
coronary angiographies, PCIs, and CABGs performed in Scottish hospitals. Data are 
entered prospectively by a combination of clinical and administrative staff according to a 
predefined set of standardised data definitions, and centrally collated to form the Scottish 
Coronary Revascularisation Register. The database is annually validated for completeness 
and consistency. Information collected includes: demography (including age, gender, and 
deprivation); comorbidity (e.g. previous history of MI, stroke, chronic lung disease, 
diabetes, and hypertension); clinical presentation (e.g. indication for PCI, procedural 
priority); CAD severity (using CCS); procedural details (type of lesion, length of lesion, 
diameter of treated vessel, type of stent) and in-hospital/in-catheter lab complications. In 
Scotland, relatively few angiographies or revascularisation procedures are performed in the 
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private sector. Therefore, the analysis was restricted to the publicly funded NHS hospitals 
that performed angiographies or coronary revascularisation procedures during the period of 
study.  
Consecutive patients who underwent diagnostic coronary angiography in Scotland between 
April 2001 and March 2010, and PCI between 1998 and 2008 were included in the 
secondary data analysis. These were the most recent database downloads available from 
the SCRR system, prior to it being decommissioned. Decommissioning of the SCRR 
system was undertaken in stages (related to funding) and the coronary angiography 
database was the last to return from ISD with linked follow up. This resulted in more 
recent data being available for the coronary angiography analyses, compared with PCI. 
Informed consent to collate and use data for audit and research purposes is routinely 
obtained from patients prior to angiography or coronary revascularisation.  Both studies 
were approved by the Scottish Coronary Revascularisation Registry Steering Committee 
and the NHS Privacy Advisory Committee. All patient and operator data were stripped of 
unique identifiers prior to analysis.  
 
3.1.1.2 Scottish Morbidity Record (SMR01) 
The Scottish Morbidity Record (SMR01) collects information on all discharges (and 
therefore admissions) to acute hospitals in Scotland, including disease and procedure 
codes (http://www.datadictionaryadmin.scot.nhs.uk/isddd/9065.html).  SMR01 has 
episode-based patient records that relate to all acute inpatient and day cases. Every record 
in SMR01 data reflects one episode of care. An SMR01 record is generated every time a 
patient completes an episode of inpatient or day case care. Completion of an episode 
includes: discharge home; transfer to another consultant in either; the same or a different 
hospital; a change of specialty under either the same or a different consultant; or death. The 
data that are collected to describe each episode include clinical (diagnoses and procedures) 
and non-clinical (demographic information, episode management details) information. 
Details of diagnoses on discharge are recorded, by a clinician, in the patient’s medical 
notes. These are then translated into codes using the ICD-10, Office of Population 
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Censuses and Surveys’ Classification of Surgical Operations version-4 (OPCS-4) codes, 
and National Interim Clinical Imaging Procedure Codes.  
 
3.1.1.3 General Register Office for Scotland (GROS) 
The GROS collates death certificate data across Scotland, including cause of death. 
Diseases are recorded using the International Classification of Diseases (ICD) and 
procedures using the Operating Procedure Codes (OPCS). It has since merged with 
the National Archives of Scotland to become the National Records of Scotland (NRS). 
Any death which occurs in Scotland must be registered within eight days of the date of 
death by the Registrar of Births, Deaths and Marriages. 
The SCRR is linked annually to the SMR01 and death certificate data at  an  individual  
level, providing information on fatal and non-fatal events that occur following 
discharge. The last linkage, available via the SCRR system prior to it being 
decommissioned, provided follow-up events up to 31 March 2007 for the PCI data, and 
31st March 2011 for the diagnostic angiography data, inclusive. 
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3.1.2. Definitions 
Elderly was defined as ≥75 years of age, and the younger group as <75 years of age. 
Angina  severity  was  graded  using  the  CCS classification: (from 0 (no symptoms) to 4 
(most severe). CAD was defined in the register as angiographic evidence of significant 
stenosis (≥70% diameter stenosis of at least one major epicardial artery segment or 
≥50% diameter stenosis in the left main coronary artery). MVD was defined as significant 
stenoses in two or more coronary arteries.  MVD with left main stem (LMS) 
involvement was allocated  to a separate category. Current smoking was defined in the 
registry as regular smoking of one or more cigarettes per day in the month preceding 
coronary angiography. Obesity was defined as a body mass index (BMI) >30. The 
Scottish  Index of Multiple  Deprivation   
(SIMD; www.scotland.gov.uk/Topics/Statistics/SIMD)  was used to measure  
socioeconomic status.  This  ranks  data  zones  of  residence  (mean  population  of  
750)  to  produce deprivation quintiles for the general population. These were applied to 
the study cohort using  their  postcode   of  residence.   Diabetes   included   both  type  
1 and type 2. Hypertension  was  defined  as  a systolic  blood  pressure  ≥140mmHg,  
diastolic  blood pressure ≥90mmHg or use of anti-hypertensive therapy. Extra-cardiac 
arteriopathy included  peripheral  artery  disease,  previous  stroke,  recurrent  transient  
ischaemic attacks  and  carotid  stenosis  ≥70%.  Impaired  renal  function  was  defined  
as  serum creatinine >200mmol/l or use of renal replacement therapy. Impaired left 
ventricular function was  defined  as  an  ejection  fraction  of  <50%.  Multiple co-
morbidity was defined as the presence of two or more of these conditions.
 
 
Follow on PCI were procedures which were undertaken immediately (with the patient still 
on the catheterization table) following diagnostic coronary angiography, rather than a 
staged procedure performed during a different session - these are also known as ad hoc 
PCIs. Any revascularization within 30 days included follow on PCI. Isolated coronary 
angiography was defined as an angiogram that was not associated with follow-on PCI. 
Data for outcomes are presented by diagnostic coronary angiography, follow-on PCI, and 
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any revacularisation within 30 days, given the increased risks associated with 
revascularisations.3 In addition, data are broken down by presences and severity of CAD 
(SVD, MVD, LMS) because this influences how patients are subsequently managed.3 
Peri-procedural complications were defined as adverse events (including: death; abrupt 
closure of a coronary  artery;  anaphylaxis;  coronary  artery  perforation  or dissection; 
cardiac    arrhythmias;    cardiopulmonary    arrest;    bleeding;    and   peripheral    vessel 
haematoma) that occurred during or following the procedure, but prior to leaving the 
catheter laboratory. Thirty-day outcomes were defined as events that occurred during 
the procedure or up to 30 days follow-up, and included events that occurred both in 
hospital and post discharge. The binary outcomes studied were: PCI; CABG; coronary 
revascularisation (PCI or CABG); all cause death; fatal/non-fatal AMI, fatal/non-fatal 
cerebrovascular event (stroke or transient ischaemic attack) and a composite outcomes of 
major adverse cardiovascular event (MACE) comprising death, AMI or cerebrovascular 
event. 
The coverage of troponin measurement varied by hospital and over time; therefore peri- 
procedural  AMI  was  defined  as  electrocardiographic  evidence  of  a  Q  wave  AMI 
rather than including those with the more recent definition of ACS: STEMI, NSTEMI or 
unstable angina.   
 
 
3.1.3. Statistical analyses 
All statistical analyses were undertaken using STATA 11. Baseline characteristics were 
compared between elderly and younger patients using: Pearson’s Chi-Squared tests χ2  
tests for binary variables; independent t tests for continuous variables; and Cuzick’s 
non-parametric test for trend for ordinal data.363   
Thirty-day outcomes were compared using univariable and multivariable binary 
logistic regression models, and longer-term outcomes using Cox’s proportion 
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regression hazard model.364 Logistic regression was used as the outcomes of interest 
were binary in nature e.g. death/no death. Logistic regression models the relationship 
between a dependent and one or more independent variables, and allows us to look at 
the fit of the model as well as at the significance of the relationships (between 
dependent and independent variables). The goodness of  fit  of  the  models  was  
assessed  using  Hosmer  and  Lemeshow’s  test365 applied to 8, 10 and 12 groups of 
observed and predicted binary outcomes. Logistic regression, being based on the 
probability of an event occurring, allows us to calculate odds ratios (OR). OR is defined 
as the odds that an outcome will occur in one group, compared to the odds of the 
outcome occurring in another.  Where odds is the ratio of the probability of an event 
occurring to the probability that it does not.  
Cox proportional regression hazard model was used to determine the unadjusted and 
adjusted hazard ratio (HR) for elderly versus younger patients, with the younger patient 
group forming the referent population. HR is a measure of how often a particular event 
happens in one group compared to how often it happens in another group, over time. It 
assumes that hazard ratio is constant over time. The proportional hazard assumption 
was tested using a residual based inference method.366 The assumptions of the test were 
met for all models presented in the results section (Chapter 4.1).  
The multivariable models provided a method for adjusting for the potential  
confounding  effects  of  sex,  smoking  status,  diabetes,  hypertension,  extra- cardiac 
vascular disease, renal impairment, impaired left ventricular function, disease 
severity, SIMD deprivation quintile, urgency of the procedure, access site, year of 
procedure and hospital.  
An interaction term between year of procedure and age-group was introduced, in 
order to determine whether the association between age-group and outcome changed 
over  time  after  adjusting  for  the  potential  confounding  factors  listed  above.  
This was thought to be a possible likely interaction given the advances in coronary 
angiography and PCI over the time period.    
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In addition, the MACCE and revascularisation outcomes following coronary 
angiography analyses were re-run using imputed variables with missing data and 
using multiple imputation by chained equations. The chained equations used the same 
variables as the full models and included outcome variables. Five imputed datasets 
were created using the ICE package in STATA.367 Multiple imputation is a statistical 
technique which has been used for missing data in observational studies using 
secondary data.368 However, as it assumes that the data is missing randomly and 
normally distributed, this technique is less useful with missing binary variables such 
as diabetes status. In addition, it been considered less useful with large datasets where 
power is often not an issue.369  
Multiple imputation was used to explore the effects of missing data in the coronary 
angiography outcomes study, as missing values were higher in this dataset. Most 
common variables with missing data were BMI (44.6%), diabetes status (23.6%) and 
left ventricular dysfunction (25.4%). Goodness of fit was assessed using a plot of 
observed versus expected values as well as Hosmer-Lemeshow tests. Where the tests 
showed that the models were an adequate fit for the data, the multiple logistic 
regressions were re-run. However, using the imputed dataset resulted in little change 
in the association between age group and MACE or revascularisation outcomes. 
Therefore, multiple regression models are presented with complete cases.  
General population   age-group   specific rates were calculated using the 2006   mid-
census population estimates from General Registrar for Scotland. This was used 
because the study used PCI data from 2000 – 2010 inclusive. This estimate can be 
applied to all the years and was more likely to best reflect the breakdown of the 
population than the 2001 census.  
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3.2. Methods for Revascularisation and Quality of 
Life (ReQoL) 
3.2.1. Aims and objectives 
As discussed, PCI is generally undertaken in elderly patients to alleviate the signs and symptoms 
of CAD. The systematic review of the literature, in Chapter 2.3, suggested that QoL in older 
patients improves at least as much as younger patients and they may gain more in the areas of 
physical functioning and improved angina status. The benefits appear to be greatest in the first 6 
months and may continue until at least 3 years. However, only a small number of studies were 
included in the systematic review (11 studies with a total of 700 octogenarians). Therefore, 
assessing the benefits of PCI on QoL for elderly patients is an important area for further study.   
In addition to undertaking secondary data analysis to investigate the risk of peri-procedural 
complications and MACCE outcomes in elderly patients, QoL improvements following PCI were 
also assessed as part of this thesis as the ReQoL study.  
The main objectives were: 
• To assess the baseline QoL in patients undertaking PCI using generic and disease specific 
tools; 
• To assess QoL at 3 months post PCI using generic and disease specific tools; 
• To compare differences between baseline and 3 months QoL 
• To compare differences and changes in QoL between elderly and younger patients 
• To assess the impact of frailty on outcomes.  
• To use routine hospital data to assess baseline characteristics (such as demographics, 
comorbidity etc.) and severity of CAD  
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3.2.2. Participants 
Patients undergoing non-emergency PCI for CAD were recruited from the West of Scotland 
Regional Heart and Lung Centre at the Golden Jubilee National Hospital (GJNH). The GJNH is 
one of the largest regional centres undertaking PCIs in the West of Scotland; with around 5,000 
diagnostic angiograms and 2,000 PCIs undertaken per annum. The majority of patients attend as 
day cases (68%) rather than inpatients, with some (96%) being undertaken using the radial 
approach rather than via the femoral or brachial artery. This allows many patients to be 
discharged as “rapid discharge” (~ 4 hours) following the modified Amsterdam criteria.154  
The study group comprised consecutive patients attending for non-emergency PCI with CAD 
who did not have the following exclusion criteria: 
• Emergency admission 
• Attending for investigation/management following ACS 
• Unable to read/write in English (as QoL questionnaires were validated in English) 
• Unwilling or unable to provide informed consent  
Potential participants were identified through the GJNH procedure list. The Cardiac Research 
Nurses approached potential participants after routine admission to the unit to discuss 
potential involvement in the study. They were provided with participant information leaflets 
and given sufficient time to consider their involvement. Following written, informed consent 
participants undertook a baseline questionnaire in the unit with face-to-face support by the 
cardiac research nurses. The 3-month questionnaires were sent to the participant’s contact 
address using a pre-paid reply envelope. Participants were sent reminders 1 month following 
a non-returned questionnaire. 
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3.2.3. Ethical considerations 
Ethical approval for this study was granted from the West of Scotland Ethics Committee (REC 2) 
and was supported by the GJNH Research and Development department (see Appendix 7.1). 
Ethical considerations for patients were carefully considered and these included: 
• Taking part in this study had no impact on clinical care as it involved self-reported QoL 
questionnaires;  
• The research involved NHS patients and included administration of questionnaires; 
• Participation in this research did include an additional burden for patients as completion 
of the questionnaires took between 20 and 30 minutes;  
• Sensitive questions – no sensitive questions were included in the QoL questionnaire; 
• Confidentiality – The top sheet of the questionnaire, which included the participant 
contact details, was detached and stored separately from the questionnaires. 
Questionnaires contained only the study number (and no other identifiable data) which 
was not available to the researcher. Contact details were exclusively used for follow-up 
and only an experienced and professionally qualified administrator had access to them. 
All data was kept separately and password protected on University of Glasgow computers 
in the Department of Public Health.  
• Informed consent – Information about studies being undertaken at the GJNH are provided 
in the pre-admission information provided by the GJNH. It routinely states that: “As a 
regional centre for the West of Scotland in the treatment of heart disease, the Golden 
Jubilee Hospital participates in a number of research studies’ and “During your stay, you 
may be approached by a member of the Cardiology research team and invited to take part 
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in such a study. Participation in research is entirely voluntary and will not affect the 
standard of care you receive”. The cardiology research nurses provided potential 
participants with a participant information leaflet (see Appendix 7.2) and sufficient time 
to decide whether or not to take part in the study. Informed consent was gained using a 
consent form (see Appendix 7.3). 
3.2.4. Power calculation 
Seto et al.281 assessed QoL in 1445 patients following PCI using SF-36 and SAQ. They compared 
QoL at baseline, 6 months and at 1 year between elderly (≥70 years of age) and non-elderly (<70 
years of age). The demonstrated that elderly patients had an increase of 8.6 points in the median 
SF-36 physical functioning score compared with a 10.5 increase in non-elderly. If we wish to 
demonstrate a statistically significant difference at the 5% level and achieve a power of 95%, 
with a conservative difference of only median of 1.9 points, we need at least 360 in each group.  
Initially, age groups were defined as elderly (≥75 years of age) and non-elderly (<75 years of 
age) to be consistent with the secondary data analysis in Chapter 4.2. However, following slow 
recruitment, a revised sample size calculation was undertaken based on the analysis of the first 
100 participants, revised age groups (elderly as ≥70 years of age and non-elderly as <70 years of 
age), and a power of 90%. This suggested 252 in each group should be sufficient to demonstrate 
statistical significance.  
3.2.5. Questionnaire 
Following informed written consent, all eligible patients attending for non−emergency 
revascularisation procedures are asked to complete a questionnaire on admission to the GJNH 
(see Appendix 7.4). The questionnaire included: 
Two generic QoL instruments: 
EQ-5D: This is a widely used simple and validated general instrument to measure QoL in 
a standard way. This instrument is used in a wide range of conditions, treatments and 
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interventions. It is also used extensively in health economics to derive a quality adjusted 
life year (QALY). The EQ-5D descriptive system consists of five dimensions (mobility, 
self-care, usual activities, pain/discomfort, anxiety/depression) with three levels each (no 
problem, some problems, extreme problems), thus defining 243 distinct health states. 
Low scores on the 5 items of EQ-5D reflect a favourable assessment of each component. 
Responses were used to derive the single index value based on the algorithm provided by 
EuroQoL. This single index represents the overall health status by applying preference 
weights to participant responses. The index-based score is typically interpreted along a 
scale where 1 represents best possible health and 0 represents dead, with some health 
states being valued as worse than dead (<0). In addition, EQ-5D contains a visual 
analogue scale (VAS). The endpoints of the VAS are labelled ‘best imaginable health 
state’ and ‘worst imaginable health state’, at 100 and 0, respectively. Respondents were 
asked to indicate how they rated their health by drawing a line from an anchor box to the 
point on the VAS which best represented their own health that day. Permission to use the 
EQ-5D was obtained from EuroQol(www.euroqol.org). This widely used QoL tool was 
chosen because it is simple for researchers to administer, score and interpret. It also 
imposes minimal burden on participants, as it is a brief, simple measure to understand and 
to complete (with resultant high completion rates. In addition, the generation of the utility 
index based health status are useful for both clinical outcomes and economic evaluation.  
 
SF-12: This is a commonly used health status questionnaire and is a shortened version of 
the SF-36. It appears to be more sensitive to differences in health status for people with 
less morbidity. Like the SF-36, summary scores for physical and mental health status can 
be derived from the SF-12, referred to as the Physical Component Summary (PCS-12) 
and the Mental Component Summary (MCS-12), respectively. The summary scores of the 
SF-12 have also been shown to closely represent the summary scores of the SF-36.343The 
PCS-12 and MCS-12 scores have also been found to be virtually identical to the 
equivalent SF-36 summary scores in indicating the level of health and are equally 
sensitive to changes in health status among patients with various conditions. Permission 
to use the SF
-
12v2 was obtained from QualityMetric Incorporated 
(www.qualitymetric.com).  This is the most commonly used generic QoL tool for 
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assessing QoL following PCI in both young and elderly patients (see Chapter 2.3). This 
was chosen, rather than other instruments that are thought to be more appropriate to use 
in older people, because the questionnaire will be used for both elderly and younger 
patients. In addition, it allows multiple comparisons to be made with existing literature on 
QoL outcomes following PCI.  
 
 
MacNew: Disease specific QoL was assessed using the MacNew health-related QoL 
questionnaire. It was designed to assess how heart disease affects daily physical activities 
and emotional and social functioning. It has been widely used and validated in cardiology 
patients with AMI, angina and heart failure at the time of designing the ReQoL study. It 
was chosen primarily because it had not been utilised for assessing QoL following PCI in 
the UK. However, it has been used to assess QoL following PCI outwith the UK e.g.  
SipÖtz et al.372 It contains 27 items (questions), the responses to which, map to 3 
domains: physical limitations, emotional function, and social functioning. Global QoL 
score and individual domain subscale scores can be calculated. Scores are from 1 (low 
QoL) to 7 (high QoL). In addition, MacNew has an established the minimal important 
difference (MID) of ≥0.5. Permission to use the MacNew questionnaire was obtained 
from MacNew (www.macnew.org).  
 
 
Frailty questions were devised based on Rockwood’s 4 levels of progressive impairment in the 
Rockwood frailty index.187 This is a brief clinical instrument that was originally developed to 
target patients in hospital, who may be eligible for specialised geriatric intervention. However, it 
has subsequently been used in community dwelling residents who self-report deficits. The 4 
Rockwood levels are:  
 
(0) Those who walk without help, perform basic activities of daily living (eating, 
dressing, bathing, bed transfers), are continent of bowel and bladder, and are not 
cognitively impaired 
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(1) bladder incontinence only 
(2) one (two if incontinent) or more of needing assistance with mobility or activities 
of daily living, has cognitive impairment with no dementia, or has bowel or 
bladder incontinence 
(3)  two (three if incontinent) or more of totally dependent for transfers or one or 
more activities of daily life, incontinent of bowel and bladder, and diagnosis of 
dementia 
 
 
This was used rather than the Fried Frailty Index because it does not include variables which  
require an independent physical assessment e.g. grip strength and walk test. There were a number 
of reasons for excluding physical assessments in this study, including: these assessments were 
not part of routine admission to day care (would require additional assessment); difficulties for 
patients who may wish to complete the questionnaire following their PCI (dominant hand may 
well be used to gain radial artery access) and concerns raised by clinicians that the walk test may 
not be appropriate to assess a patient attending for PCI (potential to produce angina sysmptoms).  
Therefore, the self-reported questions included in the study questionnaire were  
 1. During the past 2 weeks, how much of the time did you:  
Have difficulty reasoning and solving problems, for example: making plans, 
making decisions, learning new things?  
All of the time/ A good bit of the time/ Some of the time/ A little of the time/ None 
of the time 
Forget, for example things that happened recently, where you put things, your 
appointments?  
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All of the time/ A good bit of the time/ Some of the time/ A little of the time/ None 
of the time 
Have difficulty doing activities involving concentration and thinking?  
All of the time/ A good bit of the time/ Some of the time/ A little of the time/ None 
of the time 
2. Have you ever been diagnosed with dementia? Yes/No/Don’t Know 
3. How would you describe your current living arrangements?  
Living alone, living with partner or spouse, living with family, living in a nursing home, 
living in supported accommodation? 
4. When you need help with tasks, can you count on someone who is willing and able to 
meet your demands? Yes/No/Don’t Know 
5. Have you fallen in the last 3 months? Yes/No/Don’t Know 
6. Do you have a problem with losing control of urine or your bowel when you don’t 
want to? Yes/No/Don’t Know 
7. Have you recently lost weight such that your clothing has become looser? 
Yes/No/Don’t Know 
8. At times do you forget to take your prescriptions?  Yes/No/Don’t Know 
 
Questionnaire administration was facilitated by 2 cardiac research nurses in the Golden Jubilee 
National Hospital. Facilitation included identifying eligible participants, explaining the study, 
gaining informed consent, giving out questionnaires, and assisting in completing the 
questionnaires (from answering questions about the completing the questionnaire to completing 
the questionnaire for participants unable to complete it themselves due to issues like iv access or 
radial catheter on dominant hand).  Further questionnaires were posted to patients at 3 months 
with a pre-paid addressed return envelope for self-completion.  
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3.2.6. Statistical analysis 
Descriptive analysis included frequencies, means, medians, Pearson’s Chi-Squared tests χ2, t 
tests or Mann-Whitney for non-parametric values. Paired ttests or Willcoxon signed rank tests 
were used to compare before and after QoL scores in both groups. The Spearman rank 
correlation coefficients of the QoL score were calculated. The association between MacNew total 
scores and the EQ-5D index score, and the MacNew emotional and physical scores and the MCS 
and the PCS respectively, were assessed using Spearman’s correlation by constructing a 
correlation matrix of the QoL questionnaire. Internal consistency reliability of the scales was 
assessed by calculating Cronbach’s alpha coefficient using Nunnally’s criterion of 0.7 or greater 
to indicate good internal consistency.369 Test re-test reliability was not assessed as the 
questionnaire was completed before and after PCI; an intervention designed to have an effect on 
QoL. Multivariate linear regression was used to assess the differences in change of QoL 
following PCI between elderly and younger patients after adjusting for baseline characteristics. 
For this, the absolute change in QoL following PCI was used (QoL at 3 months – QoL at 
baseline). An alternative is to use the percentage change from baseline as a measure of relative 
change in QoL. While this method takes account of the baseline score and can increase 
comparability across subjects, it normalises the data, which may alter its distribution and may 
introduce additional complexity to the analysis.370  
Multivariate models were developed with and without the inclusion of baseline QoL 
measurements as debate exists in the literature as to which is the most appropriate approach.371 
Models, which include baseline scores, take account of the variation in 3 months scores that arise 
from the variation in baseline scores. In addition, baseline QoL score is a potential confounder as 
it is associated with both age and changes in QoL. However there are concerns that this method 
may introduce regression-to-the mean bias if baseline function is measured with error.371 
Adjusting for baseline QoL score is the most common method used in the literature.31,291,292, 
Interactions were explored and goodness of fit of models were assessed using the likelihood ratio 
test. A p-value of <0.05 was considered statistically significant.  
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3.3. Methods for Biological Ageing 
CAD is associated with both chronological and biological ageing processes. However, 
conflicting evidence exists as to whether LTL is an appropriate marker of biological ageing in 
CAD. 
3.3.1. Participants 
Participants were recruited from consecutive patients attending the West of Scotland Regional 
Heart and Lung Centre at the GJNH for non-emergency coronary angiography between October 
2011 and August 2012.   
Inclusion criteria were: patients attending electively (as in-patients or day cases) for coronary 
angiography.  
As ACS is associated with an acute inflammatory response, which could have an effect on 
measurement of biomarkers and inflammatory markers, patients were excluded if they were <48 
hours following an acute ACS event. Additional exclusion criteria included: patients who were 
unwilling or unable to provide informed consent and those with insufficient English 
comprehension to complete the consent form.  
Potential participants were approached by the interventional cardiologist to answer any questions 
regarding the study and to complete the consent form; this was undertaken at the same time as 
routinely consenting the patient for the coronary angiogram. Participant information was collated 
and transferred to the Western Infirmary and via the hospital postal system. Manual collection 
from the Western Infirmary to the University of Glasgow Public Health Department was 
undertaken on a weekly basis. Participant details were imputed into an access database held on 
the University of Glasgow secured server by an experienced professional administrator.  
Baseline participant characteristics were retrieved by data linkage with the Cardiac, cardiology 
and Thoracic Health Information system (CaTHI). Data linkage was deterministic in nature. A 
deterministic data linkage requires a high quality formal identifier common to both datasets to 
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exactly match between the datasets. In this study CHI was used as the unique identifier. In 
addition, date of procedure allowed collection of information for the correct coronary 
angiography event (given that participants may have multiple entries). Where deterministic 
linkage was unable to match for CHI; manual case record search was undertaken by the cardiac 
research nurses (n=3). CaTHI provides clinical information for all cardiac surgery, cardiology, 
and thoracic specialties. It captures data throughout the full patient journey from assessments, 
surgical procedures to discharges, and follow-ups. It is used for administrative processes and 
assists with the monitoring of clinical performance, waiting times, and facilitates 
research. CaTHI collects data similar to the SCRR.  
Data are entered prospectively by a combination of clinical and administrative staff according to 
a predefined set of standardised data definitions. Information collected includes: demography 
(including age, gender, and deprivation); comorbidity (e.g. previous history of MI, stroke, 
chronic lung disease, diabetes, and hypertension); clinical presentation (e.g. indication for PCI, 
procedural priority); CAD severity (using CCS).  
 
3.3.2. Definitions 
Baseline definitions were the same as those within SCRR (see Chapter 3.1.2).  
Severity of CAD was assessed in 2 different ways. The first was similar to SCRR where CAD 
was defined as angiographic evidence of significant stenosis (≥70% diameter stenosis of at 
least one major epicardial artery segment or ≥50% diameter stenosis in the left main coronary 
artery). MVD was defined as significant stenoses in two or more coronary  arteries.  MVD with 
left main stem (LMS) involvement was allocated to a separate category.  
The second used the SYNTAX score.149 Two independent interventional cardiologists reviewed 
and coded the angiographies using the SYNTAX scoring system. They were both blinded to the 
study outcomes.  
In addition, if a follow on PCI was undertaken then procedural details (type of lesion, length of 
lesion, diameter of treated vessel, type of stent) are also recorded in the CaTHI system.  
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3.3.3. Power calculation 
Aviv et al.92 used data from the UK Twins Study to study sample size and power issues with 
regard to telomere attrition rates. Their study provides sample sizes for research into ageing 
involving telomere attrition. Their results suggest that for patients in the age-group of those 
undergoing coronary angiography, if we wish to demonstrate as statistically significant at the 5% 
level and achieve 95% power, with a conservative difference of only 10 base pairs per annum we 
require at least 525 patients in each group. Applying a 25% margin of error produces a figure of 
656 in each group. From the Scottish Coronary Revascularisation Register we know that ~40% 
of patients undergoing elective diagnostic coronary angiography will be found to have normal 
coronary arteries. Therefore, we planned to recruit 1802 patients prior to catheterisation with a 
view to analysing the blood samples of 656 with normal coronary arteries and the first 656 of the 
1,531 with CAD. From the register, we knew that there are 5392 coronary angiograms performed 
per annum at the Golden Jubilee National Hospital. Some 2476 are recorded as being “elective” 
and therefore would be eligible for recruitment (given that the inclusion criteria for this study 
includes  >48hrs post ACS - this is a conservative estimate as these aren’t usually defined or 
coded as “elective”). Therefore, assuming a recruitment rate of 88%, we estimated that it would 
take around one year to recruit the required number of participants.    
However, recruitment reached the appropriate predetermined sample size by 11 months.  
 
3.3.4. Telomere length determination 
Participant blood was drawn by the interventional cardiologist, after artery sheath insertion 
and before administration of any drugs e.g. heparin. A 20 ml syringe was used, which was 
handed to the assisting catheterisation laboratory nurse. From this syringe, 4 vacutainer 
tubes were filled (to allow for analysis of DNA (EDTA), plasma, RNA, and serum) and 
mixed well by inverting the samples 10 times. Samples were labeled using patients CHI 
sticky labels and transferred to a dedicated research fridge. On a twice-daily basis, the 
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cardiology research nurses checked the participant blood samples for labeling accuracy and 
centrifuged the serum and plasma samples prior to transferring them to a dedicated 
research -20o freezer. All samples were transferred from the GJNH to the Shiels lab on a 
weekly basis in specialized containers to maintain sample temperatures. The EDTA tube 
containing 5mls of blood was used for the LTL analysis. 
Laboratory analysis of telomere length was undertaken by Shiels lab based in the 
University of Glasgow department at the NHS Western Infirmary. The lab was blinded to 
the outcomes of participants for analysis and only age and sex was provided post analysis 
for validation purposes.  
DNA was extracted from peripheral blood leucocytes using the Maxwell automated 
purified system (Promega, WI, USA). Telomere length determination was performed 
blindly using a Roche Light Cycler LC480 (Roche Diagnostics, Indianapolis, Indiana, 
USA) by qPCR. Analyses were undertaken in triplicate for each sample, using a single-
copy gene amplicon primer set (acidic ribosomal phosphoprotein, 36B4) and a telomere-
specific amplicon primer set. A standard deviation (SD) of 0.15 of the threshold cycle (Ct) 
for sample replicates was used as a cut-off for quality control parameters for the 
amplifications. The Ct is the intersection between an amplification curve and an 
amplification threshold line. Its value indicates the fractional PCR cycle number for which 
the fluorescence is greater than the threshold. Samples were reanalysed at a SD above 0.15. 
The average SD across plates was 0.05. When telomere and control gene assays resulted in 
similar amplification efficiencies, relative telomere length was estimated from Ct scores 
using the comparative Ct method. This method determined the ratio of telomere repeat 
copy number to single copy gene number (T/S) ratio in experimental samples relative to a 
control sample DNA. The normalized T/S ratio was used as the estimate of relative 
telomere length (Relative T/S). The interassay variation was tested by comparing relative 
T/S ratios across assays for the positive controls on every assay plate. The average inter-
assay CoV was 0.51% for telomere length and 0.18% for 36B4. The average of triplicates 
was used for further analysis. This has shown to be an effective measure of the average 
telomere length. For a copy of the full laboratory protocol see Appendix 7.5.  
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3.3.5. Statistical analysis 
Using the Categorical baseline data displayed in Table 16 were analysed using the 
Pearson’s χ2 test or Fisher’s exact test where any cell had an expected count of <1 or  
>20% of cells <5. Those with and without CAD were analysed using t-tests for independent 
samples assuming unequal variance. Comparisons between patients with one-, two- and 
three-vessel disease were made using one-way analysis of variance (ANOVA). Adjusted 
mean differences in T/S ratio were calculated using multiple linear regression models. 
Models were constructed and interactions explored using dependent variables e.g. age, sex, 
current smoking status, deprivation, comorbidities, angina severity, obesity, andfamily 
history. The data were inspected visually; with the assumption of parallel lines for the 
relationship between the dependent variables and covariates. Thus the values quoted are the 
coefficients for the difference between those with and without CAD after adjustment for 
age, sex, smoking status, and level of deprivation. All continuous results are expressed as 
mean (standard deviation) unless otherwise stated. Statistical significance was accepted 
when P <0·05. 
 
3.3.6. Ethical considerations 
Ethical approval for this study was granted from the West of Scotland Ethics Committee 
(REC 5) and was supported by the GJNH Research and Development department (see 
Appendix 7.6).  
Ethical considerations for patients were carefully considered and these included: 
• Taking part in this study had no impact on clinical care as it involved taking 20mls of 
blood through the artery access sheath which is used routinely for coronary 
angiography.  
• The research involved NHS patients and included taking a blood sample 
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• Participation in this research did not include an additional burden for patients as blood 
was drawn at the same time as artery access; therefore, no additional needles were 
required.  
• Confidentiality – A top sheet containing participant details (name, date of birth, date 
of procedure, and CHI number) was sent directly to the University of Glasgow Public 
Health Department via the NHS internal mail system and collected in person on a 
weekly basis. This information was entered into a Microsoft Access database by a 
qualified professional administrator. This allowed continuous monitoring of 
recruitment levels. It also provided the information required for data linkage to both 
the Shiels lab data and the CaTHI system. The Access database was password 
protected on University of Glasgow computers and kept secure in the department of 
Public Health. Following linkage, CHI and participant names were removed prior to 
statistical analysis using STATA.  
• Informed consent – Information studies being undertaken at the GJNH are provided in 
the pre-admission information provided by the GJNH. It routinely states that: “As a 
regional centre for the West of Scotland in the treatment of heart disease, the Golden 
Jubilee Hospital participates in a number of research studies’” The interventional 
cardiologist who was undertaking the coronary angiography explained the study and 
gained written consent (Appendix 7.7). All participants were provided with a 
participant information sheet (see Appendix 7.8).  
 
  
4. RESULTS  
4.1. Diagnostic coronary angiography among elderly 
versus younger patients
4.1.1. Number of coronary angiogram
Over   the   nine-year   period (2001
were performed on 101,057 patie
101,057  first  procedures  13,344 
number of angiograms  performed 
2007 (Figure 13).  
 
Figure 13: Number of angiography
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Thereafter, the number fell slightly to 11,567 in 2010 mainly due to a reduction in angiograms 
among younger patients (a similar trend was found when patients with multiple coronary 
angiograms were included). The absolute number of coronary angiograms performed on elderly 
patients increased from 669 in 2001 to 1,945 in 2010. The elderly accounted for an increasing 
proportion of  coronary  angiograms:  from  8.7%  in  2001  to  16.8%  to  2010  (χ2   test  for  trend, 
p<0.0001).   The   incidence   of   coronary   angiography   among   the   elderly   general population 
increased three-fold from 198/100,000  per annum in 2001 to 629/100,000 per annum in 2008. In 
comparison, among the general population aged 35 to 74 years, the incidence of coronary 
angiography increased by only 56% from 284/100,000 per annum to 444/100,000 per annum. 
 
 
4.1.2. Case-mix 
Compared with younger patients, the elderly were more likely to be female, have severe (CCS grade IV) 
angina, have multiple co-morbidities and have a past medical history of AMI, PCI or CABG (Table 
3).  
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Table3. Characteristics of patients undergoing diagnostic coronary angiography by age-group
 
 ≥75 years 
 
<75 years
 
 
 n (%) 
 
n (%) 
 
 
 n=13,344
 
n=87,713
 P value*
 
 
 
 
 
Male 7,507 (56.3) 55,758 (63.6) <0.001 
Current smoker 3,820 (37.8) 33,823 (52.6) <0.001 
CCS angina score 
 
 
 
0 (none) 1,730 (18.8) 10,205 (17.1) <0.001 
      I 1,632 (17.7) 16,480 (27.5)  
      II   2,033 (22.1) 14,064 (23.5)  
      III   1,264 (13.7) 6,571 (11.0)  
      IV (severe) 2,542 (27.6) 12,514 (20.9) <0.001 
Procedural urgency 
 
 
 
 
      Urgent 5,240 (38.5) 25,928 (29.1) 
 
 
      Routine 8,103 (60.7) 61,774 (70.4) <0.001 
Obese 1,359 (18.1) 15,853 (33.1) <0.001 
Diabetes mellitus 1,510 (14.7) 9,553 (14.6) 0.911 
Hypertension 5,753 (55.7) 30,019 (46.1) <0.001 
Extra-cardiac arteriopathy 1,551 (15.4) 5,979 (9.4) <0.00 
Renal impairment 294 (2.9) 949 (1.5) <0.001 
 
Left ventricular dysfunction 
 
2,246 (50.4) 
 
12,386 (40.3) 
 
<0.001 
 
Multiple comorbidity 
 
2,714 (20.3) 
 
12,981 (14.8) 
 
<0.001 
 
Previous AMI 
 
3,053 (29.6) 
 
15,784 (24.1) 
 
<0.001 
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In addition, elderly patients were less likely to live in the most deprived SIMD quintile,  be a 
current smoker,  be obese; or report a family history of CAD. At coronary angiography, elderly 
patients were more likely to have significant coronary stenoses detected (76.1% vs 63.51%, p<0.001) 
and more likely to have MVD with or without LMS (39.3% vs 27.1%, p<0.001 and 13.0% vs 
5.9%, p<0.001, respectively) (Table 4). 
                                                                
                                                                
 
 
   
 ≥75 years 
 
<75 years
 P value* 
 
n (%) 
 
n (%) 
 
 
 n=13,344
 
n=87,713
  
 
Previous PCI 
 
814 (8.0) 
 
3,036 (4.7) 
 
<0.001 
 
Previous CABG 
 
1,121 (10.7) 
 
4,633 (7.0) 
 
<0.001 
 
Family history CAD 
 
1,945 (14.6) 
 
23,493 (26.8) 
 
<0.001 
 
Deprivation (SIMD) 
 
        Most deprived quintile 
 
 
 
2,333 (17.9) 
 
 
 
22,001 (25.6) 
 
 
 
<0.001 
 
        Least deprived quintile 
 
2,800 (21.4) 
 
13,496 (15.7) 
 
<0.001 
 
*Pearson’s χ2 test 
CCS Canadian Cardiovascular Society scoring; AMI: acute myocardial infarction; PCI percutanteous coronary intervention; 
CAD  coronary  artery  disease;  SIMD:  Scottish  Index  of  Multiple  Deprivation.  CABG:  coronary  artery  bypass  
grafting 
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4.1.3. Adverse outcomes 
Overall (diagnostic only plus follow-on),   angiography   was   associated   with   a   low   crude   rate   of   
peri-procedural complications which  occurred  in  1.7%  of  patients.  By  30  days  follow-up,  1.1%  of 
patients  had suffered  a MACE;  0.5% had suffered  an AMI, 0.1% a cerebrovascular event,   and   1.0%   
had  died.   The  elderly   were   more   likely,   than   their   younger counterparts,  to have a peri-procedural  
complication  (2.0% vs 1.6%, p<0.001) and a MACE ( 2.9% vs 0.8%, p<0.001) within 30 days of their 
angiogram.  
Among all patients who underwent isolated coronary angiography, the elderly group experienced similar rates 
of peri-procedural complications (1.4% vs 1.2%, p=0.168) but higher rates of AMI (1.1%  vs 0.2%,  
p<0.001),  death  (2.3%  vs 0.6%,  p<0.001)  and MACE (2.6% vs 0.7%, p<0.001) within 30 days. In those 
without significant CAD at angiography, peri-procedural complications and adverse 30-day outcomes were 
rare but still more common in the elderly (peri-procedural complication: 1.9% elderly vs 1.1% young, 
p<0.001; and MACE: 1.2% vs 0.4%, p<0.001). In those with significant CAD, peri-procedural 
complications following isolated angiography were generally no more common in elderly patients regardless 
of severity of disease. However, adverse 30-day outcomes were more common (Table 4). 
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Table 4. Comparison of crude thirty day outcomes by type of procedure, age-group and coronary angiographic findings. 
 Diagnostic coronary angiography only, 
no PCI /CABG within 30 days. 
 
Follow on PCI 
 
 
Any revascularization within 30 days 
 
 n=36,115   n=19,857  n=26,230   
                            
     n (%)       n (%)         n (%)   
 ≥75   <75 P 
value 
≥75 <75 
    P 
value* 
≥75 <75 P value* 
 
        
NO CAD  
 
 
  
 
  
 
Peri-procedural complications 59 (1.9) 363 (1.1) <0.001       
All-cause death 34 (1.1) 107 (0.3) <0.001       
AMI 11 (0.4) 15 (0.1) <0.001       
CVA/TIA 4 (0.1) 28 (0.1) 0.355       
Death, AMI or CVA/TIA 38 (1.2) 129 (0.4) <0.001       
SVD  
 
 
  
 
  
 
Peri-procedural complications 17 (1.0) 363 (1.1) 0.258 45 (4.2) 262 (2.4) <0.001 51 (3.9) 297 (2.4) 0.001 
All-cause death 29 (1.7) 107 (0.3) <0.001 13 (1.2) 41 (0.4) <0.001 24 (1.9) 64 (0.5) <0.001 
AMI 14 (0.8) 15 (0.1) <0.001 8 (0.8) 31 (0.3) 0.011 12(0.9) 42 (0.3) 0.001 
CVA/TIA 10 (0.6) 28 (0.1) <0.001 1 (0.1) 12 (0.1) 0.674 1 (0.1) 15 (0.1) 0.554 
Death, AMI or CVA/TIA 38 (2.2) 129 (0.4) <0.001 13 (1.2) 51 (0.5) 0.001 24 (1.9) 77 (0.6) <0.001 
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Diagnostic coronary angiography 
only, no PCI /CABG within 30 days. Follow on PCI 
    Any revascularization within 30 days 
 
 
n=36,115 
n (%) 
 
  n=19,857 
n (%) 
n=26,230 
n (%) 
MVD without LMS  
 
 
 
 
 
 
 
 
 
 
 
 
 
Peri-procedural complications 44 (1.3)  0.343 60 (4.7) 212 (3.5) 0.033 65 (3.6) 252 (3.0) 0.199 
All-cause death 90 (2.7) 119 (0.8) <0.001 49 (3.8) 79 (1.3) <0.001 66 (3.7) 114 (1.4) <0.001 
AMI 46 (1.4) 55 (0.4) <0.001 25 (2.0) 56 (0.9) 0.001 35 (2.0) 75 (0.9) <0.001 
CVA/TIA 6 (0.2) 21 (0.1) 0.629 8 (0.6) 7 (0.1) <0.001 10 (0.6) 7 (0.1) <0.001 
Death, AMI or CVA/TIA 95 (2.9) 139 (1.0) <0.001 57 (1.9) 85 (1.4) <0.001 76 (4.3) 120 (1.5) <0.001 
LMS 1,145(25.6|) 3,334(74.4)  157(31.3) 344(68.7)  548(24.7) 1,670(75.3)  
Peri-procedural complications  
13 (1.1) 
 
45 (1.3) 
 
0.579 
 
10 (6.4) 
 
22 (6.4) 
 
0.991 
 
17 (3.1) 
 
50 (3.0) 
 
0.898 
All-cause death  
63 (5.5) 
 
82 (2.5) 
 
<0.001 
 
13 (8.3) 
 
16 (4.7) 
 
0.107 
 
38 (6.9) 
 
46 (2.8) 
 
<0.001 
AMI  
31 (2.7) 
 
49 (1.5) 
 
0.006 
 
11 (7.1) 
 
14 (4.1) 
 
0.161 
 
21 (3.9) 
 
31 (1.9) 
 
0.008 
CVA/TIA  
1 (0.1) 
 
8 (0.2) 
 
0.463 
 
1 (0.2) 
 
0 (0.0) 
 
0.313 
 
1 (0.2) 
 
1 (0.1) 
 
0.433 
Death, AMI or CVA/TIA 64 (5.6) 89 (2.7) <0.001 14 (9.0) 16 (4.7) 0.062 39 (7.2) 47 (2.9) <0.001 
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Diagnostic coronary angiography 
only, no PCI /CABG within 30 days. Follow on PCI Any revascularization within 30 days 
 
n=36,115 
n (%) 
  n=19,857 
n (%) 
n=26,230 
n (%) 
Overall 
 
         
Peri-procedural complications 133 (1.4) 728 (1.2) 0.049 115 (4.6) 496 (2.9) <0.001 133 (3.7) 599 (2.7) <0.001 
All-cause death 216 (2.3) 363 (0.6) <0.001 75 (3.0) 136 (0.8) <0.001 128 (3.5) 224 (1.0) <0.001 
AMI 102 (1.1) 144 (0.2) <0.001 44 (1.8) 101 (0.6) <0.001 68 (1.9) 148 (0.7) <0.001 
CVA/TIA 21 (0.2) 65 (0.1) 0.002 10 (0.4) 19 (0.1) <0.001 12 (0.3) 23 (0.1) <0.001 
Death, AMI or CVA/TIA 235 (2.5) 422 (0.7) <0.001 84 (3.4) 152 (0.9) <0.001 139 (3.9) 244 (1.1) <0.001 
*Pearson’s χ2  test . AMI: acute myocardial infarction; PCI: percutanteous coronary intervention; CVA/TIA: cerebrovascular accident/transient ischaemic attack; CABG: coronary artery bypass grafting; MVD 
multi-vessel disease; SVD: single vessel disease; CAD: coronary artery disease 
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Overall follow-on PCI was associated with a higher crude risk of adverse outcomes than isolated 
coronary angiography (peri-procedural complications 3.1% vs 1.4%, p<0.001; 30 day MACE 
1.5% vs 1.2%, p=0.012). In those undergoing follow-on PCI for SVD and MVD without LMS, 
differences in adverse outcomes between elderly and younger patients were similar to that seen for 
isolated coronary angiography. Elderly patients experienced higher rates of AMI, MACE and all-
cause death within 30 days of follow-on PCI. While crude 30-day MACE outcomes appeared 
more common among elderly, compared with younger, patients with LMS (9.0% vs 4.7%, 
p=0.062), this was not found to be statistically significant. 
In the univariable logistic regression analysis (Table 5), being elderly was associated with  an  
increased  risk  of  peri-procedural  complications  in  those  patients  with  no significant stenosis 
(OR 1.64, 95% CI:1.24, 2.17, p<0.001), but this did not persist after adjustment for potential 
confounding factors (Table 1) (adjusted OR 0.86, 95% CI: 0.34, 2.05, p=0.159). Potential 
confounders included in the model were those, which were prospectively collected by the SCRR, 
and were associated with age and the outcome of interest: sex, smoking status, diabetes, 
hypertension, non-cardiac vascular disease, renal impairment, left ventricular dysfunction, 
cardiogenic shock, co-morbidity, disease severity, deprivation quintile, and year of procedure. The 
covariates which reduced the estimates of the risk of peri-procedural in patients with no significant 
stenosis, for elderly compared to younger persons when included in the model as potential 
confounders, were left ventricular dysfunction, renal disease, and final access site.  In those with 
SVD or LMS, univariable analysis suggested that being elderly was associated with an increased 
risk of all-cause death, AMI and having a MACE. However, after adjusting for potential confounders 
(see above), being elderly was not found to be associated with adverse outcomes in these patients. 
In those with MVD, being elderly was associated with an increased risk of all-cause death, AMI, 
CVA/TIA and composite outcomes. Risk of all-cause death, CVA/TIA and composite outcomes 
remained statistically significant following adjustment. The covariates which reduced the estimates 
of the risk of MACE outcomes in patients with SVD stenosis, for elderly compared to younger 
persons when included in the model as potential confounders,  were left ventricular dysfunction, 
renal disease, and diabetes. In MVD and LMS left ventricular dysfunction, renal disease, diabetes, 
and smoking reduced the estimates most.  
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Table 5. Complication rates and any revascularisation rates for those with CAD: Overall (elderly referent to young): 
 
 
Univariable Multivariable* 
OR/HR 95% CI P value OR/HR 95% CI P value 
 
 
No significant stenosis <75% 
 
Peri-procedural complications 1.64 1.24, 2.17 <0.001 0.86 0.34, 2.05 0.159 
All-cause death within 30 days 3.21 2.18, 4.73 <0.001 1.49 0.56, 3.53 0.155 
AMI within 30 days 2.01 1.24, 2.77 <0.001 1.82 0.85, 4.48 0.916 
CVA/TIA within 30 days 1.67 0.58, 4.83 0.341 1.04 0.02, 47.51 0.984 
Death, AMI or CVA/TIA within 30 days 2.98 2.07, 4.29 <0.001 2.20 0.32, 15.08 0.422 
SVD 
Peri-procedural complications 1.22 0.94, 1.58 0.126 1.47 0.91, 2.38 0.114 
All-cause death within 30 days 3.66 2.64, 5.08 <0.001 1.57 0.52, 4.76 0.420 
AMI within 30 days 3.17 2.01, 5.00 <0.001 2.12 0.58, 7.77 0.256 
CVA/TIA within 30 days 3.31 1.64, 6.69 0.001 0.30 0.02, 5.47 0.415 
Death, AMI or CVA/TIA within 30 days 3.60 2.66, 4.86 <0.001 1.14 0.39, 3.36 0.811 
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Univariable Multivariable* 
OR/HR 95% CI P value OR/HR 95% CI P value 
SVD 
 
MVD without LMS 
Peri-procedural complications 1.17 0.95, 1.45 0.144 1.00 0.62, 1.63 0.978 
All-cause death within 30 days 3.05 2.48, 3.74 <0.001 1.82 1.03, 3.20 0.038 
AMI within 30 days 2.82 2.13, 3.73 <0.001 1.68 0.81, 3.47 0.163 
CVA/TIA within 30 days 2.55 1.38, 4.72 0.003 5.01 1.09, 22.9 0.038 
Death, AMI or CVA/TIA within 30 days 3.03 2.49, 3.68 <0.001 2.05 1.21, 3.46 0.007 
PCI within 30 days 0.92 0.86, 0.99 0.020 0.91 0.78, 1.06 0.242 
CABG within 30 days 1.07 0.94, 1.21 0.317 0.97 0.64, 1.45 0.868 
Any revascularisation within 30 days 0.95 0.89, 1.01 0.088 0.90 0.77, 1.06 0.208 
PCI within 1 year 0.82 0.77, 0.87 <0.001 0.92 0.79, 1.08 0.331 
CABG within 1 year 0.72 0.67, 0.77 <0.001 0.73 0.60, 0.89 0.002 
 
PCI within 30 days 0.66 0.61, 0.71 <0.001 0.70 0.56, 0.86 0.001 
CABG within 30 days 0.71 0.66, 0.76 <0.001 0.55 0.13, 2.34 0.424 
Any revascularisation within 30 days 1.93 1.55, 2.40 <0.001 0.69 0.56, 0.86 0.001 
PCI within 1 year 0.71 0.66, 0.76 <0.001 0.62 0.50, 0.78 <0.001 
CABG within 1 year 1.93 1.55, 2.40 <0.001 0.90 0.59, 1.39 0.643 
Any revascularisation within 1 year 0.69 0.64, 0.75 <0.001 0.55 0.43, 0.71 <0.001 
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Univariable Multivariable* 
OR/HR 95% CI P value OR/HR 95% CI P value 
 
MVD without LMS 
Any revascularisation within 1 year 0.62 0.58, 0.66 <0.001 0.70 0.58, 0.85 <0.001 
LMS 
OR:  odds  ratio, used for 30 day outcomes;  HR:  hazards  ratio, used for 1 year outcomes;  CI:  confidence  interval;  AMI:  acute  myocardial  infarction;  PCI:  
percutanteous  coronary  intervention;  CVA/TIA:  cerebrovascular accident/transient ischaemic attack. 
*adjusted for sex, smoking status, diabetes, hypertension, non-cardiac vascular disease, renal impairment, left ventricular dysfunction, cardiogenic shock, co-morbidity, disease 
severity, deprivation quintile, year of procedure, and final access site. 
 
Peri-procedural complications 
      
All-cause death within 30 days 2.41 1.85, 3.16 <0.001 1.80 0.61, 5.28 0.288 
AMI within 30 days 1.95 1.37, 2.78 <0.001 1.06 0.27, 4.17 0.935 
CVA/TIA within 30 days 0.66 0.14, 3.04 0.592 0.73 0.03, 15.17 0.837 
Death, AMI or CVA/TIA within 30 days 2.32 1.79, 3.01 <0.001 1.46 0.50, 4.25 0.488 
PCI within 30 days 1.40 1.18, 1.67 <0.001 1.59 1.09, 2.34 0.018 
CABG within 30 days 0.79 0.69, 0.90 <0.001 0.97 0.60, 1.59 0.912 
Any revascularisation within 30 days 0.96 0.85, 1.07 0.448 1.48 1.05, 2.10 0.027 
PCI within 1 year 1.07 0.92, 1.26 0.367 1.30 0.90, 1.89 0.163 
CABG within 1 year 0.51 0.45, 0.57 <0.001 0.49 0.34, 0.70 <0.001 
Any revascularisation within 1 year 0.50 0.44, 0.56 <0.001 0.58 0.38, 0.89 0.012 
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4.1.4. Management of patients with confirmed coronary artery 
disease 
In the univariable analyses, among those patients in whom angiography demonstrated 
evidence of CAD, the elderly were less likely to proceed to follow-on PCI than younger 
patients (24.9% vs 31.4%, p<0.001) and less likely to undergo revascularisation within one 
year, irrespective of the severity of CAD found at diagnostic angiography (60.1%  vs 68.8%,  
p<0.001) (presented by SVD, MVD, and LMS in Table 6).  As shown in Table 6, those with 
SVD, elderly patients were more likely to undergo CABG by 1 year than younger patients but 
this was offset by a lower number undergoing PCI; resulting in a lower overall use of 
revascularisation (61.9% vs 70.1%, p<0.001 at 1 year). Among those with LMS, elderly 
patients were more likely to undergo early but not later PCI than younger patients (11.1% 
vs 8.0%, p<0.001 at 30 days and 13.8% vs 13.0%, p=0.429 at 1 year).  This was offset by 
a lower percentage undergoing CABG, resulting in a lower overall use of revascularisation 
at 1 year (61.2% vs 76.0%, p<0.001) (presented by SVD, MVD, and LMS in Table 6).  
Among those with MVD excluding LMS, elderly patients were less likely to undergo both 
PCI and CABG. 
In the multivariable analyses, elderly patients with evidence of CAD were less likely than 
younger patients to have had a revascularisation procedure by one year (OR 0.68, 95% CI 
0.65–0.71, p<0.001) even after adjusting for baseline characteristics  (adjusted OR 0.60, 
95% CI 0.52–0.69, p<0.001) (data not shown in Table 6). This was found to be the case 
regardless of severity of disease (Table 6). 
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Table 6. Comparison of revascularization rates following diagnostic coronary angiography by age-group and angiographic findings 
 
≥75 years <75 years  Total P value 
n=9,853  n=52,492 62,345 
 
SVD 3,035 (11.0) 24,625 (89.0) 27,660 
Follow on PCI 1,067 (35.7) 10,881 (44.2) 11,948 <0.001 
PCI within 30 days (including FO) 1,076 (35.5) 11,267 (45.8) 12,343 <0.001 
Any revascularization within 30 days 1,296 (42.7) 12,635 (51.3) 13,931 <0.001 
PCI within 1 year (including FO) 1,379 (45.4) 14,568 (59.2) 15,947 <0.001 
CABG within 1 year 414 (13.6) 2,060 (8.4) 2,474 <0.001 
Any revascularization within 1 year 1.880 (61.9) 17,263 (70.1) 19,143 <0.001 
 
MVD without LMS 5,125 (18.3) 22,863 (81.7) 27,988 
Follow on PCI 1,279 (25.0) 6,129 (26.8) 7,408 0.007 
PCI within 30 days (including FO) 1,327 (25.9) 6,370 (27.9) 7,697 0.004 
Any revascularization within 30 days 1,793 (35.0) 8,288 (36.3) 10,081 0.088 
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≥75 years <75 years  Total P value  
n=9,853         n=52,492 62,345 
                                 MVD without LMS 
PCI within 1 year (including FO) 1,736 (33.9) 8,949 (39.1) 10,685 <0.001 
CABG within 1 year 1,257 (24.5) 7,102 (31.1) 8,359 <0.001 
Any revascularization within 1 year 3,077 (60.0) 16,177 (70.8) 19,254 <0.001 
LMS 1,693 (25.3) 5,004 (74.7) 6,697 
Follow on PCI 157 (9.3) 344 (6.9) 501 0.001 
PCI within 30 days (including FO) 188 (11.1) 402 (8.0) 590 <0.001 
Any revascularization within 30 days 548 (32.4) 1,670 (33.4) 2,218 0.448 
PCI within 1 year (including FO) 233 (13.8) 651 (13.0) 884 0.429 
CABG within 1 year 803 (47.4) 3,201 (64.0) 4,004 <0.001 
Any revascularization within 1 year 1,036 (61.2) 3,801 (76.0) 4,837 <0.001 
 
 
*Pearson’s χ2  test . AMI: acute myocardial infarction; PCI: percutanteous coronary intervention; CVA/TIA 
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Strengths and Limitations 
 
Data for this study was based on a national register and, therefore, included all patients who 
underwent coronary angiography over the study period. The registry data are detailed and 
comprehensive,373 and are collected prospectively by staff at the patient's hospital. In 
Scotland, the data on outcomes are obtained via linkage to routine hospital and death records 
which have been shown to be as complete and accurate as those obtained using conventional  
follow-up  methods.   The vast  majority  of  patients  were  successfully linked to the 
follow-up databases (99%), which is in keeping with similar studies using similar registry 
data.256 Previous studies and quality assurance exercises, suggest that systematic bias is 
unlikely. Only 1% could not be linked and there was no reason to suspect a systematic 
bias in successful linkage. In addition, post hoc analysis confirmed no significant 
statistical differences according to whether or not linkage was achieved. 
This section of the thesis utilised statistical methods to adjust for known differences in 
baseline characteristics  between  elderly  and younger  patients.  However, residual 
confounding due to unknown or unrecorded differences cannot be excluded. This is a 
recognised limitation of all observational studies. In any cohort study, there is always the 
potential for loss  to follow-up  due  to,  for  example,  emigration  from  Scotland.  Linkage 
with SMR01 and GROS would not provide admission data for events and deaths occurring 
outside Scotland. However, this is unlikely to impact significantly on the early (30 day) 
complications reported here. 
Age-stratified general population incidence rates were based on a single year being used as the 
denominator – 2006. This could have resulted in a modest underestimate of the incidence rate 
as the elderly probably increased in the overall population during the study period. 
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4.1.5. Discussion of the main findings 
The total numbers and rates of coronary angiography undertaken in Scotland have increased 
until the mid 2000s. This may be  expla ined  by increasing prevalence of CAD and 
changes in the threshold for investigation by coronary angiography. Elderly patients 
accounted for an increasing number and proportion of first diagnostic coronary angiograms, 
over this time period. Age-stratified general population incidence rates of coronary 
angiography increased more in the elderly group, suggesting the threshold for investigation 
by coronary angiography may have decreased over time. Compared with younger patients, 
the elderly were more likely to have severe angina, angiographic evidence of any CAD, or 
MVD with or without LMS, suggesting that the threshold for investigation is probably higher.  
Elderly patients had a higher risk of early complications but their crude risk was nonetheless 
low (2.0% of elderly patients suffered complications, compared with 1.6% of young patients 
(p<0.001) suggesting that coronary angiography is a safe procedure to perform in the elderly. 
This suggests that concerns about investigating elderly patients with suspected CAD using 
coronary angiography may not be justified.  
Elderly patients were less likely to proceed to revascularisation, either as a follow-on 
procedure, or over the subsequent year, suggesting a higher threshold for intervention even 
among those investigated. Further investigation of this apparent higher threshold for 
revascularisation in elderly patients has been undertaken in this thesis by examining PCI data 
from the SCRR in more depth (the findings of which are presented below in Chapter 4.2). In 
addition, trends have been examined to assess changes over time in case-mix in patients 
undergoing PCI.  
 
 
 
  
 168
4.2. PCI in the elderly: changes in case-mix and 
periprocedural outcomes  
Overall comparison  
Of the 46,774 patients who underwent PCI in Scotland between 1998 and 2008, 40,933 (87.6%) 
were classed as non-emergencies. Of these, 4,544 (11.1%) were performed in elderly patients and 
36,387 (88.9%) in younger patients. Compared with younger patients, the elderly were more likely 
to be female, have MVD disease, have multiple comorbidity, and have a past medical history of 
AMI or CABG (Table 7).  
 
Figure 14. Numbers of non-emergency percutaneous coronary interventions per annum by age-
group.        
 
Of the 40,933 patients, 5,912 (14.4%) were excluded from the outcome analysis because of missing 
or incomplete follow-up data. There were no significant differences between those included and excluded 
in terms of age, sex, SIMD quintile, disease severity or presence of comorbidities. In the remaining cohort 
of 35,021 (85.6%) patients, the overall crude risk of MACE within 30 days of PCI was 4.5% in the elderly 
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compared with 2.8% in younger patients (χ
2 
test, p<0.001). In the logistic regression model, the increased 
risk among the elderly (unadjusted OR 1.61, 95% CI 1.30–1.91, p<0.001) was attenuated after adjustment 
for differences in case-mix, but remained statistically significant (adjusted OR 1.36, 95% CI 1.07–1.75, 
p<0.001). 
 
 
Time-trends  
The overall number of non-emergency PCI procedures performed each year tripled, from 2,009 in 
1998 to 6,244 in 2006 (Figure 14). Thereafter, the number fell slightly to 6,180 in 2008, mainly 
due to a reduction in procedures among younger patients. The absolute number of PCIs performed 
on the elderly increased from 101 in 1998 to 792 in 2008. The incidence of PCI among the elderly 
general population increased from 29/100,000 per annum in 1998 to 219/100,000 per annum in 
2008. Among the general population aged 35-74 years, the incidence of PCI increased from 
71/100,000 per annum to 173/100,000 per annum.  
The elderly accounted for an increasing proportion of non-emergency PCIs, from 2.5% in 1998 to 
11.1% in 2008 (χ
2 
test for trend, p<0.0001). Among elderly patients, there was a significant 
increase in the prevalence of all comorbid conditions, other than obesity (Table 8).  
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Table 7. Comparison of characteristics of patients undergoing non-emergency percutaneous coronary 
intervention by age-group.   
 ≥75 years <75 years P value* 
 n (%) n (%)  
Male 2,702 (59.6) 25,900 (71.2) <0.001 
Current smoker 1,415 (34.8) 10,873 (32.8) 0.013 
MVD 2,480 (56.3) 14,628 (41.5) <0.001 
Obese 569 (18.9) 7,595 (30.6) <0.001 
Diabetes mellitus 817 (18.8) 6,342 (18.0) 0.202 
Hypertension 2,303 (55.8) 15,150 (45.4) <0.001 
Extra-cardiac arteriopathy 602 (13.3) 2,757 (7.6) <0.001 
Renal impairment  120 (3.0) 409 (1.25) <0.001 
Left ventricular dysfunction  2,063 (51.8) 13,651 (42.1) <0.001 
Multiple comorbidity 821 (18.1) 4,841 (13.3)   <0.001 
Previous PCI 603  (14.5) 5,294 (15.7) 0.060 
Previous CABG 681 (16.1) 3,644 (10.7) <0.001 
Previous AMI 1,679 (39.8) 12,233 (35.4) <0.001 
Family history 1,022 (25.4) 14,034 (42.6) <0.001 
*χ2  test 
n number, PCI percutaneous coronary intervention, CABG coronary artery bypass grafting, AMI acute 
myocardial infarction, MVD multivessel disease 
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Table 8. Time trends in case-mix of patients undergoing non-emergency percutaneous coronary intervention by age-group.  
   
1998 
 
1999 
 
2000 
 
2001 
 
2002 
 
2003 
 
2004 
 
2005 
 
2006 
 
2007 
 
2008 
 
  n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) P value* 
≥75 years 
 male 64 (63.5) 92 (71.3) 124 (63.3) 130 (59.6) 141 (52.2) 212 (54.5) 257 (60.2) 340 (61.1) 418 (61.1) 440 (58.5) 484 (61.1) 0.790 
 current smoker 34 (37.4) 52 (48.6) 65 (44.5) 84 (42.9) 85 (35.6) 127 (38.8) 130 (31.9) 208 (38.0) 310 (33.9) 213 (32.0) 207 (28.5) <0.001 
 MVD  48 (51.1) 56 (54.4) 85 (59.0) 115 (55.6) 140 (52.4) 212 (55.5) 244 (55.6) 312 (56.0) 384 (56.6) 407 (54.5) 477 (60.5) 0.090 
 obesity 13 (16.0) 18 (18.0) 39 (30.2) 30 (18.1) 31 (16.2) 53 (21.5) 51 (19.0) 68 (17.3) 87 (17.7) 98 (19.5) 81 (18.1) 0.193 
 diabetes mellitus 10 (9.9) 35 (27.1) 61 (31.4) 31 (14.8) 44 (16.5) 64 (17.3) 86 (20.0) 77 (13.8) 121 (18.4) 147 (21.0) 141 (19.0) <0.001 
 hypertension 27 (28.4) 35 (32.4) 46 (31.3) 78 (39.4) 103 (43.6) 177 (51.5) 212 (51.5) 327 (59.6) 403 (64.2) 434 (63.9) 461 (62.8) <0.001 
 extra-cardiac arteriopathy - - 11 (5.6) 33 (15.1) 33 (12.2) 60 (15.7) 48 (10.8) 66 (11.7) 103 (15.1) 124 (16.5) 115 (14.5) <0.001 
 renal impairment  0 (0.0) 0 (0.0) 1 (5.3) 1 (4.3) 0 (0.0) 1 (2.8) 3 (6.1) 5 (7.8) 10 (11.4) 5 (4.7) 3 (2.2) 0.020 
 left ventricular dysfunction 32 (35.2) 38 (38.8) 55 (37.7) 106 (51.2) 124 (46.8) 203 (53.4) 240 (55.3) 279 (54.1) 291 (52.9) 346 (55.4) 349 (51.8) <0.001 
 multiple comorbidity - - 12 (6.1) 29 (13.3) 35 (13.0) 61 (16.0) 70 (15.7) 107 (19.0) 150 (21.9) 165 (21.9) 178 (22.5) <0.001 
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1998 
 
1999 
 
2000 
 
2001 
 
2002 
 
2003 
 
2004 
 
2005 
 
2006 
 
2007 
 
2008 
 
  n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) P value* 
  
previous PCI 
 
16 (16.7) 
 
14 (12.7) 
 
24 (15.8) 
 
34 (16.4) 
 
47 (17.9) 
 
57 (16.6) 
 
53 (12.8) 
 
82 (14.9) 
 
91 (14.6) 
 
93 (14.0) 
 
92 (12.7) 
 
0.730 
 previous CABG 15 (16.0) 12 (11.2) 27 (19.6) 29 (14.0) 46 (17.4) 72 (19.5) 67 (15.5) 93 (16.6) 90 (14.0) 123 (18.2) 107 (14.7) 0.710 
 previous AMI 48 (47.5) 49 (38.0) 58 (29.6) 101 (46.3) 132 (48.9) 159 (41.5) 166 (37.3) 221 (39.1) 256 (37.4) 260 (34.6) 229 (28.9) <0.001 
 family history 43 (46.7) 50 (47.6) 73 (50.7) 60 (30.8) 54 (23.6) 81 (25.2) 88 (22.3) 141 (26.1) 151 (24.5) 159 (23.9) 122 (16.9) <0.001 
<75 years  
 male 1,167 (62.5) 1,167 (67.7) 1,290 (67.2) 1,854 (68.3) 2,132 (70.7) 2,385 (72.4) 2,609 (72.3) 2,958 (71.5) 3,431 (70.9) 3,375 (72.2) 3,292 (73.0) <0.001 
 current smoker 664 (43.6) 810 (48.0) 705 (45.2) 829 (37.0) 835 (31.2) 923 (30.5) 985 (28.9) 1,305 (32.4) 1,435 (31.4) 1,267 (29.8) 1,115 (26.4) <0.001 
 MVD 859 (55.2) 995 (58.9) 847 (53.2) 1,026 (40.5) 1,061 (35.7) 1,223 (37.5) 1,473 (41.5) 1,656 (40.4) 1,920 (39.8) 1,835 (39.4) 1,733 (38.7) <0.001 
 obesity 294 (21.3) 380 (24.4) 362 (25.5) 567 (30.1) 637 (30.8) 647 (30.1) 576 (28.9) 946 (32.9) 1,185 (33.7) 1,085 (33.7) 916 (33.6) <0.001 
 diabetes mellitus 326 (18.9) 399 (20.8) 612 (30.2) 429 (16.9) 472 (16.9) 519 (16.3) 569 (16.0) 626 (15.4) 879 (18.6) 773 (17.6) 738 (17.3) <0.001 
 hypertension 490 (31.5) 606 (35.5) 595 (37.7) 916 (40.4) 1,015 (37.8) 1,300 (42.4) 1,450 (42.3) 2,005 (49.7) 2,403 (52.5) 2,193 (51.6) 2,177 (51.7) <0.001 
 extra-cardiac arteriopathy - - 97 (4.7) 222 (8.5) 246 (8.2) 276 (8.4) 250 (6.9) 336 (8.1) 434 (9.0) 402 (8.6) 364 (8.1) <0.001 
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1998 
 
1999 
 
2000 
 
2001 
 
2002 
 
2003 
 
2004 
 
2005 
 
2006 
 
2007 
 
2008 
 
  n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) P value* 
 renal impairment  0 (0.0) 2 (0.7) 3 (1.2) 6 (2.4) 2 (0.7) 3 (0.9) 12 (3.3) 6 (1.4) 22 (3.7) 13 (1.9) 18 (2.0) <0.001 
 left ventricular dysfunction 545 (39.9) 501 (33.2) 559 (35.1) 1,029 (41.1) 1,180 (40.1) 1,412 (43.5) 1,412 (40.2) 1,603 (41.8) 1,691 (42.1) 1,959 (48.9) 1,760 (45.1) <0.001 
 multiple comorbidity - - 162 (7.9) 313 (12.0) 360 (11.9) 415 (12.6) 453 (12.6) 616 (15.3) 788 (16.3) 730 (15.6) 724 (16.1) <0.001 
 previous PCI 246 (15.7) 290 (16.8) 331 (20.2) 439 (18.1) 569 (19.3) 440 (14.4) 453 (13.1) 541 (13.4) 696 (15.2) 661 (15.7) 628 (15.0) <0.001 
 previous CABG 192 (12.4) 228 (13.8) 211 (13.3) 334 (13.7) 339 (11.4) 371 (11.7) 358 (10.1) 425 (10.4) 427 (9.2) 396 (9.4) 363 (8.7) <0.001 
 previous AMI 673 (39.0) 718 (37.4) 597 (29.0) 992 (37.9) 1,148 (38.1) 1,251 (38.0) 1,214 (33.6) 1,390 (33.6) 1,635 (33.8) 1,396 (29.5) 1,221 (27.1) <0.001 
 family history 804 (52.9) 769 (46.2) 769 (49.4) 1,076 (48.3) 1,122 (42.2) 1,229 (41.1) 1,319 (39.0) 1,801 (44.8) 1,987 (43.6) 1,671 (39.6) 1,447 (34.7) <0.001 
*χ2 test for trend  
n number, PCI percutaneous coronary intervention, CABG coronary artery bypass grafting, AMI acute myocardial infarction, MVD multi-vessel disease  
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There was a four-fold increase in multiple comorbidity in elderly patients, compared with only a 
35% increase in younger patients. The elderly were also characterised by increasing severity of 
cardiac disease with the prevalence of left ventricular dysfunction increasing from 35.2% to 51.8% 
(p<0.001). The prevalence of MVD increased by 9.4% in the elderly, compared with a 16.5% fall 
in younger patients.  
 
The adjusted risk of MACE among the elderly referent to the young did not change significantly 
over time (Figure 15). Among younger patients, the crude risk of MACE within 30 days of PCI 
fell significantly over the ten-year period from 6.3% to 2.4% (Table 9). By contrast, there was no 
significant change among elderly patients. Overall, the crude risk of MACE fell from 5.8% to 
2.7% (χ
2 
test for trend, p=0.019).  
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Table 9. Time trends in crude 30 day outcomes following non-emergency percutaneous coronary intervention by age-group.  
  1998 1999 2000 2001 2002 2003 2004 2005 2006 2007  
P value* 
  n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) 
≥75 years 
 All-cause death 1 (1.0) 2 (1.6) 2 (1.0) 2 (1.0) 4 (1.5) 6 (1.6) 10 (2.3) 7 (1.3) 10 (1.5) 16 (2.1) 0.260 
 AMI 2 (2.0) 4 (3.2) 1 (0.5) 7 (3.5) 6 (2.3) 15 (4.0) 13 (2.9) 20 (3.7) 25 (3.7) 27 (3.7) 0.07 
 Cardiac surgery 2 (2.0) 1 (0.8) 2 (1.0) 0 (0.0) 2 (0.8) 1 (0.3) 2 (0.9) 4 (0.7) 3 (0.4) 3 (0.4) 0.213 
 MACE 4 (4.0) 6 (4.7) 5 (2.6) 7 (3.5) 10 (3.7) 18 (4.8) 20 (4.5) 29 (5.2) 31 (4.6) 36 (4.9) 0.216 
<75 years 
 All-cause death 21 (1.2) 10 (0.5) 10 (0.5) 10 (0.4) 12 (0.4) 18 (0.6) 26 (0.7) 27 (0.7) 26 (0.5) 25 (0.6) 0.357 
 AMI 53 (3.1) 39 (2.1) 25 (1.7) 34 (1.4) 54 (1.8) 65 (2.0) 83 (2.3) 98 (2.3) 104 (2.2) 83 (1.8) 0.909 
 Cardiac surgery 45 (2.6) 18 (0.9) 11 (1.1) 21 (0.8) 16 (0.5) 22 (0.6) 23 (0.6) 25 (0.6) 15 (0.3) 22 (0.5) <0.001 
 MACE 101 (6.3) 56 (3.1) 42 (2.2) 58 (2.4) 72 (2.5) 90 (2.8) 111 (3.2) 127 (3.2) 127 (2.7) 107 (2.4) <0.001 
*χ2  test for trend, n number, AMI acute myocardial infarction, MACE major adverse cardiovascular event 
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Adjusted for: sex, smoking status, diabetes, hypertension, extra- cardiac vascular disease, renal 
impairment, impaired left ventricular function, disease severity, SIMD deprivation quintile, urgency of 
the procedure, access site, year of procedure, and hospital.  
 
Figure 15. Unadjusted and adjusted risk of major adverse cardiovascular events within 30 days of non-
emergency percutaneous coronary intervention in the elderly referent to younger patients by year of procedure.  
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4.2.1. Strengths and Limitations 
The cohort used in this analysis comprised all patients undergoing PCI (between 1998 and 
2008) in Scottish NHS hospitals, this is not a selected sample and therefore avoids selection 
bias. The registry data are detailed and comprehensive, and are collected prospectively by 
clinical staff at the patient’s hospital. As discussed above, the SCRR has a high proportion of 
successful linkage (98% for this analysis) to follow-up databases (99%) and robust quality 
assurance mechanisms that make systematic bias is unlikely. Statistical methods were utilised 
to adjust for known differences in baseline characteristics between elderly and younger 
patients.  However, residual confounding due to unknown or unrecorded differences cannot be 
excluded. This is a recognised limitation of all observational studies. Age-stratified general 
population incidence rates were based on a single year being used as the denominator – 2006. 
This could have resulted in a modest underestimate of the incidence rate as the elderly 
probably increased in the overall population during the study period. In any cohort study, 
there is always the potential for loss to follow-up due to, for  example,  emigration  from  
Scotland.  Linkage with SMR01 and GROS would not provide admission data for events 
and deaths occurring outside Scotland. However, this is unlikely to impact significantly on 
the early (30 day) complications reported here. Unfortunately, it was not possible to assess 
long-term outcomes in this cohort.  
The vast majority of patients were successfully linked to the follow-up databases. Fourteen percent 
could not be linked but, as mentioned above, there is no reason to suspect a systematic bias in the 
success of linkage, and analysis confirmed no significant differences in case-mix according to 
whether or not linkage was achieved. We had baseline data up to March 2008 but outcome until 
only March 2007 due to follow-up data only being updated on an annual basis. Data on non-
cardiac arteriopathy were not collected in the first two years. Therefore, this could not be included 
as a covariate in the multivariate analysis and multiple comorbidity was only calculated for the 
subsequent years.  
 
 
  
178 
 
4.2.2. Discussion of the main findings 
Similar to the findings in the coronary angiography analysis, there was an increase in the number 
and percentage of PCIs undertaken in elderly patients - from 196 (8.7%) in 2000 to 752 (13.9%) in 
2007. Compared with younger patients, the elderly were more likely to have multivessel disease, 
multiple comorbidity, and a history of myocardial infarction or coronary artery bypass grafting (χ2
 
tests, all P<0.001).  
Over the 7 years, there was a significant increase in the proportion of elderly patients who had 
multiple comorbidity (χ2 test for trend, P<0.001). Despite this, the underlying risk of 
complications did not change significantly over time in the elderly (χ2 test for trend, P=0.142), or 
overall (χ2 test for trend, P=0.083). This suggests that even thought the threshold for undertaking 
PCI appears to have changed over time (likely as a result of earlier revascularization for milder 
disease and use PCI in patients with more severe disease but deemed high risk for surgery), the 
risk of complications after PCI has not.  
Compared with younger patients, elderly patients having PCI were more likely to have multivessel 
disease, multiple comorbidity, and a history of myocardial infarction or coronary artery bypass 
grafting (χ2 tests, all p<0.001). The elderly had a higher risk of MACE within 30 days of PCI 
(4.5% versus 2.7%, χ2 test p<0.001). However, similar to the findings in coronary angiography, 
crude risk was low.  
As discussed, PCI is generally undertaken in elderly patients to alleviate the signs and symptoms 
of CAD. Therefore, assessing the benefits of PCI on QoL is as important as investigating the risk 
of peri-procedural complications or the longer term MACCE outcomes found for follow on PCI in 
the coronary angiography analysis. To do this, QoL improvements following PCI were assessed as 
part of this thesis in the ReQoL study (for results, see Chapter 4.3 below).  
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4.3. ReQoL (Revascularisation and quality of life) 
Four hundred and fifty-one participants were recruited from consecutive patients attending the 
GJNH for elective PCI between September 2009 and August 2011. Of these, 437 fully completed 
the baseline questionnaire and had baseline characteristics and procedural information available. 
The Cardiac Research Nurses did not record actual response rate; however, based on data available 
from the National Golden Jubilee Hospital, this is likely to represent 18.2% of the eligible study 
population (based on ~1200 PCI procedures per year being undertaken as daycase procedures, 
with daycases being used as a proxy of the eligible population).  The average age of participant 
was 61.1 (SD 10.3), with a range from 26 to 86 years of age. The most common presentation was 
with a CCS angina score of III (44.7%). The participant characteristics are shown in Table 10.  
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Table 10. Baseline characteristics of participants enrolled in the ReQoL study (n= 437) 
  
Mean age (SD) 61.1 (10.3)  
Median age (range) 62 (26-86) 
 n(%)  
Male 318 (72.8) 
Smoker 117 (28.5) 
CCS angina score  
0 8 (1.9) 
I 12 (2.8) 
II 92 (21.8) 
III 187 (44.7) 
IV 124 (29.3) 
Obese 176 (43.7) 
Diabetes mellitus 73 (16.9) 
Hypertension 287 (68.5) 
Extra cardiac arteriopathy 56 (13.4) 
Renal impairment 4 (0.9) 
Left ventricular dysfunction 217 (57.3) 
Multiple co-morbidity 357 (81.7) 
Previous AMI 233 (56.3) 
Previous PCI 89 (22.6) 
Previous CABG 32 (8.1) 
Family History CAD 288 (69.1) 
  
SIMD Deprivation  
Most deprived 122 (28.2) 
Least deprived 72 (19.7) 
Severity of disease  
SVD 254 (58.1) 
MVD 183 (41.88) 
  
PCI percutaneous coronary intervention; CABG coronary artery bypass grafting; AMI acute myocardial infarction; SVD single 
vessel disease; MVD multi-vessel disease; CAD coronary artery disease; SIMD Scottish Index of Multiple Deprivation; CCS 
Canadian Cardiovasacular Society classification  
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There were 103 (23.6%) participants aged ≥70 years and 334 (76.4%) <70 years of age. Elderly 
participants were more likely to smoke, have more severe disease, a family history of CAD, and 
have had a previous CABG. They were less likely to smoke or live in a the most deprived SIMD 
quintile (see Table 11) 
Table 11. ReQoL: Baseline characteristics of 437 ReQoL patients by age group 
 ≥70 years <70 years P value* 
 n (%) n (%)  
 103 334  
Male 73 (70.9) 245 (73.3) 0.621 
Current smoker 9 (10.0)   
CCS angina score    
0 (none) 0 (0.0) 8 (2.5)  
I 3 (3.0) 9 (2.8)  
II 14 (14.1) 78 (24.1)  
III 52 (52.5) 135 (41.7)  
IV (severe) 30 (30.3) 94 (29.0) 0.122 
Obese 36 (37.5) 140 (45.6) 0.362 
Diabetes mellitus 22 (22.0) 51 (15.4) 0.124 
Hypertension 71 (73.0) 216 (67.1) 0.256 
Extra-cardiac arteriopathy 17 (17.5) 39 (12.1) 0.170 
Renal impairment 1 (0.0) 3 (0.9) 0.927 
Left ventricular dysfunction** 52 (60.5) 165 (56.3) 0.494 
Multiple comorbidity 85 (82.5) 272 (81.4) 0.183 
Previous AMI 32 (34.2) 74 (22.6) 0.082 
Previous PCI 27 (29.3) 62 (20.5) 0.077 
Previous CABG 18 (19.3) 14 (4.6) <0.001 
Family history of CAD 55 (57.3) 233 (72.6) 0.004 
Deprivation (SIMD quintile)    
Most deprived 16 (15.7) 106 (32.0) 0.001 
Least deprived 22 (26.5) 50 (17.7) 0.075 
Severity of disease    
SVD 49 (47.6) 205 (61.4)  
MVD 54 (52.4) 129 (38.6) 0.013 
    
* Person’s χ2 test/nptrend/ranksum for trend; **75% missing; PCI percutaneous coronary intervention; CABG coronary artery bypass grafting; 
AMI acute myocardial infarction; SVD single vessel disease; MVD multi-vessel disease; CAD coronary artery disease; SIMD Scottish Index of 
Multiple Deprivation; CCS Canadian Cardiovasacular Society classification  
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Three hundred and nine participants completed both the baseline and 3 months questionnaire. This 
equates to an attrition rate of 29.3%. There were 79 patients ≥70 years of age and 213 patients <70 
years of age. Patients who did not complete the 3 months assessment were more likely to be 
younger (32.6% vs 18.5% dropped out from younger and older groups respectively, p=0.006) and 
smoke (38.5% of the drop-outs vs 25.3, p=0.008); however, they were no more likely to have 
severe disease (p=0.469), or be from the most deprived SIMD quintile (0.063).  
 
 
Figure 16. Baseline and 3 months EQ-5D index utility score in all participants  
Baseline average EQ-5D index utility score was similar in elderly and younger patients (0.7, 
p=0.561). Overall, the score increased following PCI (0.7 to 0.8, p <0.001). The greatest increase 
appeared to be in younger patients (0.075 vs 0.071); however, this was not found to be statistically 
significant p=0.911.  
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Figure 17. Baseline and 3 months EQ-5D index utility score, by age group.   
 
The EQ-5D visual analogue scale showed that the mean score increased from 67.8 (SD 18.8) to 
73.9 (SD17.8), p<0.001, following PCI. The mean difference for older patients in the EQ-5D 
visual analogue was 3.2 (SD 19.8) compared with 7.2 (SD19.0) in younger patients; again, this 
was not found to be statistically significant (p=0.141) 
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Figure 18. Baseline and 3 months EQ-5D visual analogue scale, by age group.   
The breakdown of EQ-5D domains suggests that baseline anxiety and depression is much less in 
elderly patients (p=0.009). However, none of the other variables at baseline showed statistical 
significance.  
Overall mean SF
-
12v2 PCS and MCS increased following PCI (39.0 vs 44.6 and 47.8 vs 50.9, 
p<0.001). While baseline PCS appeared to be lower in elderly patients compared with younger 
(37.6 vs 39.7, p=0.106) and MCS higher (50.0 vs 46.7, p=0.027), only the MCS was statistically 
significant. Both elderly and younger patients showed statistically significant increases in both 
PCS and MCS following PCI (see table 12).  
 
 
 
0
20
40
60
80
10
0
EQ
5D
 
vi
su
a
l a
n
al
og
ue
 
sc
a
le
>=70 years <70 years
Baseline 3 months
 
  
185 
 
*paired ttest/Wilcoxon signrank test  depending on skewness of data 
** As a utility index score  
***low scores on the 5 items of EQ-5D reflect a favourable assessment of each component 
PCS: Physical component score; MCS: Mental component score; SF-12v2: Short Form Questionnaire 
 
Similar to the EQ-5D VAS, the MacNew showed that global baseline QoL score was better in 
elderly patients compared with younger patients (4.7 vs 4.4, p=0.024) and that all the MacNew 
domains (emotional, physical and social) showed statistically significant increases following PCI.  
There was no statistically significant difference between elderly and younger patients in the 
proportion of patients who achieved the MID (73.8% vs 77.9%, p=0.393) in MacNew score 
between baseline and 3 months.   
Table 12. Baseline and 3 months quality of life score, by measurement tool and age group 
 ≥ 70 years of age  < 70 years of age  
     
 Before After P value Before After P value* 
EQ-5D Index** 0.7 (0.3) 0.8 (0.2) 0.009 0.7 (0.3) 0.8 (0.0)  <0.001 
EQ-5D visual scale 67.7 (19.1) 70.9 (18.6) 0.187 68.0 (18.5) 75.3 (17.7) <0.001 
EQ-5D domains***       
Mobility 1.5 (0.5) 1.4 (0.5) 0.672 1.4 (0.5) 1.3 (0.5) 0.093 
Self-care 1.1 (0.3) 1.1 (0.3) 0.132 1.1 (0.3) 1.1 (0.3) 0.1797 
Usual activity 1.6 (0.6) 1.4 (0.5) 0.011 1.7 (0.7) 1.4 (0.6) <0.001 
Pain or discomfort 1.6 (0.7) 1.5 (0.6) 0.061 1.6 (0.6) 1.4 (0.6) <0.001 
Anxiety or depression 1.2 (0.5) 1.2 (0.4) 0.808 1.4 (0.6) 1.4 (0.6) 0.584 
       
SF-12 v2       
PCS 37.6 (10.1) 41.9 (10.1) <0.001 39.7 (10.0) 45.6 (10.8) <0.001 
MCS 50.0 (10.4) 53.0 (11.9) 0.035 46.7 (11.1) 49.7 (11.1) <0.001 
       
MacNew Global 4.7 (1.3) 5.6 (1.1) <0.001 4.4 (1.3) 5.4 (1.3) <0.001 
MacNew       
Emotional 4.9 (1.3) 5.7 (1.2) <0.001 4.5 (1.4) 5.3 (1.4) <0.001 
Physical 4.4 (1.4) 4.2 (1.4) <0.001 4.2 (1.4) 5.5 (1.4) <0.001 
Social 4.7 (1.4) 5.7 (1.1) <0.001 4.3 (1.4) 5.6 (1.4) <0.001 
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In the MacNew questionnaire there is an optional question asking: “How often during the last 2 
weeks have you felt your heart problem limited or interfered with sexual intercourse?” One 
hundred and twenty-five patients answered this question (15 aged ≥70 years) in the follow up 
questionnaire. Sixty–eight patients responded as “all the time” or “most of the time” at baseline 
compared with only 34 at 3 months (p<0.001) suggesting a significant improvement.  
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Figure 19. Scatterplot of baseline and 3 months EQ-5D utility index score, by age group.   
 
Following adjustment for baseline characteristics (sex, disease severity, smoking status, obesity, 
comorbidity, and deprivation) using multivariate linear regression there was no statistically 
significant difference between elderly and younger patients in mean increase in EQ-5D score, 
PCS, MCS or any of the MacNew domains.  
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Table 13. Multivariate linear regression (elderly referent to younger), by QoL measurement 
tool and with or without baseline score adjustment.  
 β coefficient (95% CI), p value 
QoL questionnaire Without baseline score   With baseline score  
 
EQ-5D utility index 
 
0.12 (-0.06, 0.09), 0.757 
 
0.03 (-0.60, 0.66), 0.917 
PCS  1.34 (-1.61,4.30), 0.373 2.27 (-0.35,4.89), 0.090 
MCS 0.77 (-2.58, 4.12), 0.652 0.70 (-3.80, 42.01), 0.546 
MacNew Global  0.20 (-0.28, 0.69), 0.406 0.01 (-0.43, 0.24), 0.992 
 
 
Likelihood ratio testing suggested a good fit for the model and that fit was not improved following 
the introduction of interaction terms e.g. sex and deprivation, age and sex 
Reliability testing suggested good internal consistency reliability for all the questionnaires: 
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Table 14. Cronbach alpha, by QoL measurement tool 
Questionnaire  Cronbach’s alpha  
EQ-5D  0.70 
PCS 0.86 
MCS 0.84 
MacNew Global  0.95 
Spearman’s correlation coefficient was assessed between EQ-5D utility index and MacNew 
global; PCS and MacNew Physical; and MCS and MacNew emotional.  
Table 15. Correlation matrix of QoL measurement tools 
 
 Spearman’s rho, p value  
 EQ-5D utility index  PCS MCS 
MacNew global  0.52, <0.001   
MacNew physical   0.65, <0.001  
MacNew Emotional    0.74, <0.001 
  PCS MCS 
 
 
The coefficients were found to be larger between the related dimensions (e.g. PCS and MacNew 
Physical functioning) than the global scores (EQ-5D and MacNew global). 
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At baseline, a small number of patients were found to have conditions associated with significant 
frailty: 5 had dementia (1 in the ≥70 year old group); 2 were confined to bed (1 in the ≥70 year old 
group); and 39 were incontinent of bowel or bladder (11 in the ≥70 year old group). Using the 
“usual activities” domain of EQ-5D as a proxy for ADL; 10.4% participants reported that they 
were unable to perform their usual activities at baseline. Overall, there was a statically significant 
difference in usual activities score between baseline and 3 months (10.4% vs 3.2%, p<0.001). 
Comparisons between change in score in elderly and younger patients was not possible due to 
small numbers (e.g. the assumptions of the statistical tests were not met).  
 
4.3.1. Strengths and Limitations 
Assessment of QoL was undertaken using both generic and disease specific QoL questionnaires. 
The aim was to recruit consecutive patients in real life practice.  Cardiac Research Nurses at 
GJNH were responsible for recruitment and baseline data collection. Although, the nurses did not 
record actual response rate, routine PCI data from the GJNH suggest that an estimated 18% of the 
eligible study population was recruited. Contributing factors to the lower than anticipated 
recruitment rates include the length of the questionnaire and the rapid same day discharge process. 
This resulted in loss of potential participants due to time constraints, which could potentially result 
in issues of generalizability. In addition, selection bias may have occurred, especially if there were 
systematic differences between participants and non-participants. However, in keeping with data 
from the secondary data analysis of SCRR (see Chapters 4.1 and 4.2), elderly patients enrolled in 
ReQoL were more likely to have severe disease, a family history of CAD, and have had a 
revascularisation procedure in the past, suggesting the sample could be reasonably representative 
of the target population. As discussed, there could be issues of generalisability in the study, 
finding similar patterns in the baseline differences between elderly and younger patients, suggests 
that comparisons in outcomes between elderly and younger patients can still be undertaken. This 
would allow comparisons in outcomes between elderly and younger patients. 
There were advantages associated with the administration of the baseline questionnaire by the 
Cardiac Research Nurses, for example improved completion rates.  Participants were able to ask 
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for clarification and assistance with questionnaire, factors that may be particularly important in 
elderly patients who may have problems with vision or who may have found the length of the 
questionnaire challenging.  While participants completed the 3 months questionnaire without such 
support, the initial facilitation may also have increased confidence in participants’ perceived 
ability to self-complete the same questionnaire three months later. However, potential limitations 
include information bias; the Cardiac Research Nurses were not blinded to the research question 
and their support may have influenced responses.  In addition, nurse facilitation of the 
questionnaire at baseline could have impacted on responses to potentially sensitive items, for 
example, the question about sexual activity in the MacNew questionnaire; or the question on 
continence.  
This was also a single-centre study, and it is possible that unique characteristics of the patients, the 
physicians, or the institution may limit the generalizability of these results. However, it does 
improve consistency of management and recording of baseline characteristics.    
 
An additional concern is that only 79.7% of the patients involved in baseline analyses completed 
3-months follow-up. However, loss to follow-up is not uncommon in studies of QoL following 
PCI. Sperus et al201 had an attrition rate of 31% and may be offset by the benefit of a cohort that is 
more representative of the general patient population undergoing PCI than a secondary analysis of 
patients enrolled in a clinical trial. Although conducting these analyses in the context of clinical 
trials may allow higher rates of follow-up, the selection bias of who gets enrolled into the clinical 
trials may significantly offset this benefit. 
 
Data on clinical outcomes, such as MACCE were not available for this cohort. these may 
wellhowever, these may well be influenced by adverse clinical outcomes such as MACCE. 
 
 
  
192 
 
4.3.2. Discussion of the main findings 
Following PCI, mean QoL improved in both elderly and younger patients. Using the SF-12v2, 
elderly participants had higher baseline MCS but lower PCS. After adjusting for baseline 
differences, QoL (both physical and mental component) in elderly patients improved as much as 
younger patients, following PCI: MCS 50.0(SD 10.4) to 53.0(SD 11.9) vs 46.7(SD 11.1) to 
49.7(SD 11.1), p=0.652; and PCS 37.6(SD 10.1) to 41.9(SD 10.1) vs 39.7(SD 10.0) to 45.6(SD 
10.8), p=0.373). Similar findings were seen when the  EQ-5D or MacNew tools were used to 
assess QoL. These findings suggest that elderly patients benefit just as much from PCI than 
younger patients, irrespective of the measurement tool.  
A Cronbach’s alpha of 0.95 was found for MacNew which suggests that the questionnaire had 
good internal consistency and the Spearman’s correlation coefficient suggests that the physical and 
emotional domains correlate well with the mental and physical domains of the SF-12v2.  
The questions designed to assess frailty were found to be of limited use in this population; given 
the small numbers with significant frailty. The likely explanations for this are (i) this is a group 
already selected to have an invasive procedure by their clinician; (ii) the question on incontinence 
failed to map to the Rockford levels as it did not distinguish between bowel and bladder 
incontinence, and (iii) no physical assessment of frailty, such as, grip strength or walk test was 
used. The usual activities question from the EQ-5D were used as a proxy of ADL and did show a 
statistically significant improvement after PCI; however, numbers were too small to allow 
comparisons between elderly and younger patients.  
The findings from the analysis of coronary angiography and PCI secondary data analysis suggest 
that there is a higher threshold for the investigation and management of CAD in elderly patients 
and that elderly patients have a higher risk of adverse outcomes. In keeping with the systematic 
review of the literature in Chapter 2.3, ReQoL confirms the QoL benefit of PCI for elderly 
patients. However, deciding who will most benefit vs risk is challenging. Currently many tools are 
used to assist with clinical decision making include, chronological age e.g. PTP. However, there is 
growing interest in the use of biological markers of ageing (such as LTL) to predict incidence, 
prognosis, and who would most benefit from invasive investigations and/or management of CAD. 
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The first stage in assessing whether LTL could be used for this purpose is to investigate the 
association between LTL and the presence and severity of CAD. This association was assessed in 
this thesis in the Biomarkers of Ageing in CAD study (for results of this study, see Chapter 4.4 
below).  
4.1.  Biological ageing in CAD 
One thousand eight hundred and fifty-two participants were recruited at the GJNH from 
Table 16. Baseline characteristics of study participants by presence or absence of 
 CAD No-CAD  
 1,350 (73.1) n=496 (26.9) P value* 
Age (mean, SD) 63.0 (10.7) 62.6 (11.4)  0.487 
Male 972 (72.0) 378 (59.2) <0.001 
Current smoker 374 (30.9) 94 (22.1) 0.001 
CCS angina score    
 0 (none) 128 (9.9) 151 (32.0)  
 I 124 (9.6) 54 (11.4)  
 II 486 (37.5) 169 (35.8)  
 III 424 (32.7) 66 (14.0)  
 IV (severe) 134 (10.3) 32 (6.8) <0.001 
    
Obese  505 (40.1) 193 (42.1) 0.541 
Diabetes mellitus 268 (20.3) 77 (16.0) 0.041 
Hypertension 899 (71.2) 297 (64.9) 0.011 
Extra-cardiac arteriopathy 236 (18.7) 82 (17.9) 0.707 
Renal impairment  23 (1.8) 7 (1.5) 0.671 
Left ventricular dysfunction ** 200 (43.1) 12 (15.6) <0.001 
Multiple comorbidity 1031 (76.4) 332 (67.0) <0.001 
Previous AMI  749 (63.5) - - 
Previous PCI 323 (29.4) - - 
Previous CABG 123 (11.4) - - 
Family history CAD 865 (70.1) 292 (65.2) 0.054 
Deprivation (SIMD2)    
 Most deprived quintile 467 (34.8) 162 (32.7) 0.406 
 Least deprived quintile 201 (17.5) 79 (18.4) 0.670 
*Pearson’s χ2  test  **70% values missing 
CCS Canadian Cardiovascular Society;  AMI: acute myocardial infarction; PCI: percutanteous coronary intervention; 
CAD: coronary artery disease; CABG: Coronary artery bypass grafting. SIMD: Scottish Index of Multiple Deprivation  
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consecutive patients attending for coronary angiography. Of these, LTL was successfully 
measured in 1846 participants. Of these 1846, 73.1% (n=1350) had evidence of CAD on 
angiography or were known to have had a history of AMI, PCI or CABG.  The baseline 
characteristics for these participants is shown in Table 16.  
Those with CAD were more likely to be male, currently smoke, have a higher CCS angina score, 
and have multiple comorbidity. They were no more likely to be older, have a family history of 
CAD or be from the most deprived SIMD quintile.  
Mean relative T/S for the whole cohort was 0.875 (SD 0.210) with a range of 0.160 to 2.208. 
Decreased relative T/S was associated with increasing age (see Figure 20) however only 3.3% of 
the variance in relative T/S can be attributed to age.  
 
 
 
Figure 20. Scatterplot of age and leukocyte telomere length (determined by by relative T/S) 
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On univaiate analysis, mean relative T/S appeared to be higher in patients with CAD compared to 
those without CAD (0.890 (SD 0.207) vs 0.869 (0.214). However, this was not found to be 
statistically significant, p=0.064.  
No statistically significant association was found between LTL and sex (p=0.068), smoking 
(p=0.239), deprivation (p=0.382), or comorbidity (p=0.268).  
 
Figure 21. Scatterplot of age and leukocyte telomere length, by presence or absence of 
coronary artery disease.  
 
After adjusting for age, sex, current smoking status, obesity, comorbidity, deprivation, and family 
history, no association was found between CAD and relative T/S y=-0.009x + 1.137, adjusted R2 
=0.033, p=0.365.  
 
No statistically significant difference was found after truncation at <=65 years of age or by 
stratifying by gender, either on univariate or multivariate analysis.  
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Figure 22. Scatterplot of age and leukocyte telomere length, by presence or absence of 
coronary artery disease (age truncated at 65 years). 
 
On univariate analysis, there was a statistically significant difference in the mean age of those with 
and without CAD: 55.9 (SD 6.74) years vs 54.8 (SD 7.10) years of age, p=0.007. However, no 
such difference was found in mean T/S ratio: 0.893 (SD 0.202) vs 0.918 (SD 0.226), p=0.063.  
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Figure 23. Scatterplot of age and leukocyte telomere length, by presence or absence of 
coronary artery disease: (a) females (b) males 
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Of the 1,350 patients known to have CAD (by angiograpghy or by clinical history of AMI, PCI, or 
CABG), 262 (19.5%) had no evidence of significant stenosis on angiography. Of the others, 508 
(37.7%) had single vessel disease; 445 (33.0%) had multivessel disease; and 132 (9.8%) had LMS 
involvement. There was no staistically significant difference in relative T/S length by severity of 
disease: 0.875 (SD 0.211) vs 0.875 (SD 0.212) vs 0.860 (SD 0.203) vs 0.867 (SD 0.200), p=0.670 
After adjusting for age, sex, current smoking status, obesity, comorbidity, deprivation, and family 
history, no association was found between CAD and relative T/S y=-0.002x + 1.086, adjusted R2 
=0.0217, p=0.891.  
 
Figure 24. Scatterplot of age and leukocyte telomere length, by severity of coronary artery 
disease (by number of stenosed vessels).  
0
.
5
1
1.
5
2
R
el
at
ive
 
T/
S 
(Te
lo
m
er
e
 
le
n
gt
h)
20 40 60 80 100
Age
No stenosis Multivessel w/o LMS
Single vessel LMS
Fitted values Fitted values
Fitted values Fitted values
  
199 
 
 
Overall there were 16 (0.88%) inlab complications. No deaths occurred in the cohort. There was 
one infarction leading to a VF/VT arrest which was sucessfully managed within the catherter lab.  
The most common comlication was occlusion or dissection of the coronary artery (n=9). No 
association was found between the occurrence of inlab complication and telomere length (0.874 
(SD 0.005) vs 0.915 (SD 0.542), p=0.4395).  
SYNTAX score was available for 922 of the participants who had evidence of stenosis on 
angiography. Syntax score ranged from 0 – 73.5, with a mean score of 17.7 (median 15).  On 
univarate and multivariate analysis, SYNTAX score was not found to be associated with relative 
T/S.  
 
 
Figure 25. Scatterplot of age and leukocyte telomere length, by severity of coronary artery 
disease (by SYNTAX score).  
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4.1.1. Strengths and Limitations 
This is a large cross-sectional study of unselected consecutive cases attending a single large 
regional institution. While this may raise issues around generalisability, it has the advantage that 
there is consistency of approach to managing patients (following the most up-to-date European 
guidelines from the ESC). In addition, consistency in approach to recruitment and data collection, 
reduces selection and information bias. Recruitment at the GJNH finished well within the 
timeframe expected, suggesting a high recruitment rate which will reduce selection bias.  
The analysis adjusted for common confounders (as highlighted in the introduction to this thesis, as 
being associated with both CAD and LTL) such as, age, sex, current smoking status, obesity, 
comorbidity, deprivation, and family history. However, it was not possible to adjust for those 
variables not routinely collected by the database. For example, individual socioeconomic status, 
rather than the area-based measures in the database have been associated with LTL.33 In addition, 
inflammatory markers (IL-6 and CRP) and lipid levels were not available at the time of analysis. It 
was also not possible to assess the influence of cardiovascular drugs on the association between 
LTL and CAD. Therefore, residual confounding in the study cannot be excluded. 
A limitation of the study is that the comparison group comprised of those undergoing angiography 
for symptoms suggestive of CAD, rather than using a sample from the general population. 
However, this study design has made it possible to assess the association between LTL and CAD 
in a real life population referred for, and attending for, an invasive investigation for CAD. In 
addition, coronary angiography is considered as the “gold standard” investigation for the diagnosis 
of CAD, therefore, reducing misclassification bias. 
Generally data completeness was >90% for most covariates, such as smoking status and quality 
assurance of the data in the clinical system is undertaken on a regular basis for audit purposes.  
However, not all patients had undergone echocardiography prior to coronary angiography, 
resulting in a low proportion of patients with a measurement of their left ventricular ejection 
fraction. This is likely to be less of an issue for future studies using this database because the ESC 
guidelines now recommend echocardiography prior to coronary angiography. The case definition 
of CAD took past medical history of AMI, CABG, and PCI into consideration as well as the 
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angiographic appearance. Severity of CAD was assessed using 2 methods: number of stenosed 
vessels and SYNTAX score.  
LTL was measured using Real-Time qPCR by Shiels lab. The CoV was found to be 0.51%, which 
shows a high degree of precision for the technique. The LTL was based on all populations of 
leucocytes rather than a specific sub-population; however, it is not clear if this is strength or a 
possible limitation of the study.  
 
4.1.2. Discussion of the main findings 
This cross sectional study design was used to investigate the association between LTL and the 
presence, and severity, of CAD. Those with CAD were more likely to be male, currently smoke, 
have a higher CCS angina score, and have multiple comorbidity. This suggests that males are more 
likely to be diagnosed with CAD in this population. Incidence and prevalence of CAD is known to 
increase with age; although, age was not associated with an increased likelihood of having a CAD 
in this study. However, this is a population who have presented with symptoms suggestive of 
CAD, been referred for coronary angiography, and agreed to be in the study; making comparisons 
with general population difficult. In addition, these findings suggest that the character and severity 
of pain (based on the CCS) is an important indicator of the presence of CAD on coronary 
angiography.  
No statistically significant difference was found in mean LTL T/S ratio between those with and 
without CAD (0.87 (SD 0.21) vs 0.89 (SD 0.21), p=0.91), even after adjusting for baseline 
characteristics. Therefore there is no evidence of an association between LTL and CAD in this 
population. LTL was no better than chronological age at predicting the presence of CAD; 
suggesting it would be of little use as a biomarker of ageing in this population. No significant 
difference was found between LTL T/S ratio and severity of disease irrespective of which method 
was used (number of stenosed vessels or SYNTAX score).  
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Similar to the findings in Chapter 4.1 of this thesis, there was a low complication rate (0.88%) 
associated with coronary angiography, suggesting that coronary angiography is a safe 
investigation.  
5. OVERALL DISCUSSION.  
5.1. Discussion of thesis findings 
Chapter 4.1 and 4.2, of this thesis, demonstrated that elderly people account for an increasing 
number and proportion of patients presenting for the investigation and management of CAD, 
however, Chapter 4.1 and 4.2 also demonstrated that the threshold for investigation, via coronary 
angiography, and subsequent intervention, using PCI, were higher among this increasingly large 
group of patients, even after taking account of co-morbidities. This suggests a chronological age-
based inequality in access to investigation and treatment. Inequality might, nonetheless, be 
justified if the risks were unacceptably high or benefits less among elderly patients. However, this 
is not the case. Section 4.2 demonstrated that elderly patients do have a higher risk of early 
complications than younger patients, but their absolute risk was, nonetheless, low suggesting that 
coronary angiography and PCI are safe procedures to perform in the elderly.  
 
PCI is performed to improve symptoms and thereby, QoL, rather than survival. The systematic 
review undertaken in section 2.3 demonstrated that QoL following PCI in octogenarians improves 
at least as much as younger patients. In addition, section 4.3 the primary research project, ReQoL, 
showed that following PCI, the QoL of elderly patients improved at least as much as in younger 
patients. Therefore, PCI is both a safe and effective procedure for elderly patients.   
 
There is currently much interest in whether biomarkers of ageing may provide a better 
measurement of “miles on the clock.”33 If so, biomarkers of ageing may be a better basis for 
clinical decision-making (than chronological age) and provide a better means of judging equality 
of access based on equivalent need or the potential for equivalent benefit. A number of biomarkers 
of ageing have been explored, including telomere length. However, Section 4.4 demonstrated that 
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telomere length is no better than age at predicting the presence of CAD and therefore is unlikely to 
be a useful biomarker of ageing in CAD. 
 
 
5.2. Comparison of thesis findings with the literature  
Chapter 4.1 demonstrated that the total numbers and rates of coronary angiography undertaken 
in Scotland had been increasing until the mid 2000s. This may be explained by increasing 
prevalence of CAD and changes in the threshold for investigation by coronary angiography.  
Other countries, such as the USA,374 Israel375 and Pakistan, have also seen similar patterns 
of increases  in coronary  angiography.376  
Also in keeping with other studies, Chapters 4.1 and 4.2 demonstrated that elderly patients 
(aged ≥75 years of age) represent an increasing number and proportion of those who 
undergo coronary angiography and PCI in Scotland.  Groarke  et  al.377  used comprehensive   
routine  national  Irish  hospital  inpatient   data  and  found  that  the proportion of those 
having coronary angiography who were aged  >70 years increased from 19% in 1997 to 31% in 
2007.  Rajani et al.378 also found that the number and proportion of elderly patients (defined as 
≥80 years of age) attending the Royal Sussex County Hospital between 2000 and 2008 for PCI, 
increased from 5.8% to 12.2%.   
In  common  with the findings of this thesis,  previous  studies  have  shown  that  older  age  
was associated with an increased likelihood of finding evidence of both, any CAD, and 
more advanced CAD.379,380,381,382 Kotecha et al.379 found that those with angiographically-
confirmed disease were older than those with no or non-obstructive CAD (mean age 
61.1±11.3 years vs 67.0±9.9 years, p<0.001) and the odds of having more severe disease 
increased with every 10 years of age (OR 1.57, 95% CI: 1.57 – 1.95, p<0.001). Their 
study used a 10% random sample (n=539) of coronary angiograms, from three interventional 
centres in Australia, which were reviewed by two experienced,  blinded operators  and 
defined stenosis  as ≥50% in a native major coronary artery or a main tributary. while in 
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Chapters 4.1 and 4.3 stenosis was defined as ≥70% diameter stenosis of at least one major 
epicardial artery segment or ≥50% diameter stenosis in the left main coronary artery.  
In a study by Veeranna et al.381 based on 631 consecutive patients aged 65 years or over 
who underwent coronary angiography, 21.7% were found to have a Dukes Myocardial 
Jeopardy (DMJ)353 score of <2. In our study, 24.2% of elderly patients were found to have no 
evidence of stenosis on coronary angiography; using a comparable definition of angiographic 
disease (significant stenosis: ≥70% diameter stenosis of at least one major epicardial artery 
segment; or ≥50% diameter stenosis in the left main coronary artery). DMJ score was not 
available in the data from the SCRR.  
The high rates of CAD and  more  severe  disease  in  the  elderly  likely  reflect  a 
combination of delayed presentation, delayed investigation and more stringent referral or 
investigation criteria. Sekhri et al383 found that, even when deemed  appropriate, coronary 
angiography was less likely to be performed in patients over 64 years of age compared 
with those aged under 50 years (HR 0.6, 95% CI: 0.4 – 1.0, p=0.031).  
As presented in Chapter 4.2, elderly patients were also more likely to have more severe 
disease when undergoing revascularisation. The time trends presented suggest that the 
prevalence of multivessel disease decreased only slightly in the elderly (p=0.098), compared 
with a 16.5% fall in younger patients (p<0.001). This suggests that the increasing numbers in 
younger patients may reflect use of PCI in less severe cases that may previously have been 
treated by medical therapy alone. However, no significant change in the threshold for 
management appears to exist for elderly patients undergoing PCI. In contrast, the Royal 
Sussex County Hospital cohort378 found an increase in the proportion of calcified, tortuous and 
LMS disease treated in the octogenarians over time. Detailed data on lesion characteristics 
were not available at the time of the analysis presented in Chapter 4.2 (therefore MVD or SVD 
was used) while the Royal Sussex County Hospital cohort380 used a different cut-off for elderly 
(≥80 years old) and included primary and rescue PCI. These may be responsible for the 
differences in findings.  
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Elderly patients have been shown to have an increased risk of early and late complications 
following coronary angiography and PCI. Studies have reported a 4-5 fold increased risk of in-
hospital death,
32,201
and a 4-6 fold increased risk of in-hospital MACE,
5,32,201 
among elderly 
patients undergoing PCI. This thesis adds to this literature by comparing their risk of early 
complications following coronary angiography. The evidence presented in Chapter 4.1 and 
4.2 confirms that elderly patients do have an increased risk of early complications following 
diagnostic angiography alone; follow-on PCI; and PCI. However, the crude risk is 
nonetheless low suggesting that coronary angiography and subsequent PCI are safe 
procedures to perform  in  the  elderly.  
Among elderly patients the baseline risk profile increased over time. For example, the presence of 
multiple comorbidity in elderly patients undergoing PCI increased more than 4-fold from 2000-
2007 (6.1% to 21.9%, p<0.001) and the increase in left ventricular dysfunction 37.7% to 55.4% 
(<0.001). In spite of these trends over time, the risk of adverse events has not increased in the 
elderly, and was shown to fall overall. This suggests increasing willingness to use PCI in patients 
who might previously have been managed with medical therapy alone. In contrast, Rajani et al378. 
found that rates of MACCE for elderly patients declined between 2000 and 2008; however, no 
information on trends in comorbidity is presented, only morphology of lesions.  
 
Over the period studied in both Chapter 4.1 and 4.2, many technical developments, new devices 
and adjuvant therapies, have been shown to be effective at improving coronary angiography and 
PCI outcomes,
6,32,260,271,272,273 
and have been adopted into routine clinical practice in Scotland, as 
elsewhere. For example, over the period studied, deployment of coronary stents increased from 
60% to 90% among elderly patients (47% to 93% among younger patients) and the use of 
ticlopidine or clopidogrel increased from 33% to 67% among elderly patients (19% to 68% among 
younger patients). In 1998, radial access was used in only one patient. In 2008, it was used in 37% 
of younger patients and 41% of elderly patients. These findings suggest that these advances have 
been sufficient to offset the effect of worsening risk profiles among patients.  
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In contrast to the USA based study by Good et al.384 in which 96% of patients had “ad 
hoc” (follow- on PCI), only 24.1-34.5% of Scottish patients with CAD had a follow-on PCI. 
European based clinical guidelines recommend that follow-on PCI is “reasonable for many 
patients but not desirable for all” following potential indications e.g. lesions with high risk 
morphology.3 Elderly patients were less likely to proceed to revascularisation, either as a 
follow-on procedure or over the subsequent year, suggesting a higher threshold for 
intervention even among those with angiography confirmed disease. This finding is also in 
keeping with the literature on referral and management patterns for CAD in elderly 
patients.300,386 
 
Most studies have only been able to report in-hospital complications.5,32,201,256
 
This has the 
potential to introduce bias, since length of stay in hospital is longer in elderly patients32
 
and has 
fallen over time due to an increase in day-case procedures.294
 
Through linkage to routine data 
we were able to obtain outcomes up to 30-days of follow-up for patients undergoing  PCI and 1 
year for those having coronary angiography, in both the elderly and younger patients. In 
Scotland, the follow-up information derived from SMR01 has been shown to be as complete 
and accurate as that obtained using conventional follow-up methods.294 Unlike previous 
studies,5,32,201,351
 
we excluded patients presenting with AMI since the use of primary and rescue 
PCI has significantly increased over time and varies by age.375  
Chapter 4.1 and 4.2 examine increased risks associated with coronary angiography and PCI. 
These are undertaken to either investigate CAD with a view to revascularisation or carry out 
the revascularisation itself. PCI is generally undertaken to relieve the signs and symptoms of 
myocardial ischemia. Therefore, given these risks, it is important to assess whether or not PCI 
improves symptoms and QoL in elderly patients. These effects of PCI are more critical 
considerations for patient and health service decision-making than survival – especially in 
elderly patients where longevity benefits could be limited. However, self-rated QoL has been 
shown to be of prognostic value for estimating risk of death.387 
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In Chapter 4.3, the overall mean QoL was shown to improve in all participants, irrespective of 
age, following PCI (e.g. EQ-5D: 0.7 to 0.8, p<0.001; SF-12
 V2 PCS and MCS: 39.0 vs 44.6 and 
47.8 vs 50.9, p<0.001). While follow up was limited to QoL measurement, data linakge with 
SMR01 and GROS may be possible to provide data to assess short and long-term clinical 
outcomes. Similar findings of improved QoL have been found in a large number of other 
studies which have demonstrated improvements in QoL following PCI 242,243, 307,308 
A number of these studies, including randomised controlled trials, have compared QoL outcomes 
for OMT, PCI and CABG. QoL outcomes of the Clinical Outcomes Utilizing Revascularization 
and Aggressive Drug Evaluation (COURAGE) Trial and were published in 2007.215 In this trial, 
2,287 patients with stable angina pectoris were randomly assigned to PCI with optimal medical 
therapy or to optimal medical therapy alone. A number of issues have been highlighted regarding 
this study: (i) it did not meet pre-specified assumptions about statistical power despite protocol 
changes made after the trial was underway that placed PCI at a disadvantage; and (ii) only a small 
percentage of screened patients were included, revascularization was incomplete, 2/3rds of 
patients had angina weekly or less frequently, and 32% of the medical therapy group needed 
revascularization. In contrast, the study presented in Chapter 4.3 recruitment was from routine 
patients attending for non-emergency PCI and 74% of them had a CCS of 4 or 5.  
COURAGE215 assessed SAQ and SF-36 at baseline and at 3 months, 53% of patients in the PCI 
group and 42% in the medical-therapy group remained angina-free. By 3 months, SAQ scores had 
increased in the PCI group as compared with the optimal medical therapy group for: physical 
limitations (p = 0.004); angina stability (p = 0.002); angina frequency (p<0.001); treatment 
satisfaction (p < 0.001); and QoL (p < 0.001). There was improvement in all domains of the SF-36 
in both groups between randomization and follow- up at 1 to 3 months (P<0.001 for all 
comparisons).  This is in keeping with the findings in this thesis which used the SF-12v2 because 
the shortened version SF-12 has been shown to correlate highly with the SF-36 in patients with 
CAD.388  While the SF-12 provides less detailed information and may not be appropriate to use as a 
clinical tool on an individual patient basis, it improves efficiency and lowers costs associated with 
QoL research. Three QoL tools were used in this thesis to allow comparisons to be made. Using 
the SF-36 rather than the SF-12v2 would have resulted in an even longer patient questionnaire.  
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RITA-2216 also used the SF-36 and had a 27% crossover rate from OMT to PCI. It demonstrated 
that greater improvement in Qol was seen in the PCI group compared with the OMT with 
significantly greater improvements in physical functioning, vitality and general health at both three 
months and one year, but not at three years. Participants in ReqoL showed similar improvements 
in QoL at 3 months. Longer follow up of participants was outwith the scope of this thesis.  
 
Following PCI, mean QoL was shown to improve as much as younger patients, even after 
adjusting for baseline differences. This is similar to the findings in the Trial of Invasive Versus 
Medical Therapy in Elderly Patients (TIME).244 This trial compared two strategies for treating 
symptomatic, stable angina in patients aged ≥ 75 years. Results confirmed that an invasive 
diagnostic angiography approach and, depending on the result, PCI or CABG, significantly 
improved QoL 6 months after the procedure. This improvement was similar for men and women 
with CAD despite the lower overall scores for women. However, after 1 year, no significant 
differences in mortality, MI, or symptom improvement were noted between conservative and 
invasive strategies. This was primarily because, at this time, 43% of patients who initially 
qualified for pharmacological treatment underwent revascularization because of recurring angina. 
The TIME study, which looked at individuals aged ≥ 75 years, attained similar results to those in 
the Randomised Intervention Treatment of Angina (RITA-2) study,216 which examined younger 
CAD patients with a mean age of 58 years. In both age groups, early improvement in angina 
symptoms and QoL after invasive treatment for CAD (by PCI or CABG) disappeared with time, 
after 1 year. Conversely, younger and older CAD patients treated conservatively were found to: 
have a greater incidence of non-fatal cardiovascular episodes and hospitalizations; use more anti-
anginal drugs; require revascularization more often. Hence, their QoL was poorer. 
 
 
Theile et al.389  used both SF-36 and MacNew to compare outcomes of minimally invasive direct 
coronary artery bypass surgery versus sirolimus-eluting stenting in isolated proximal left anterior 
descending coronary artery stenosis. Baseline MacNew scores in the 65 patients receiving stenting 
were similar to the population in the study in this thesis for the emotional domain of MacNew (4.9 
vs 4.9). However, physical and social domains of the study participants were lower (4.4 vs 4.9 and 
4.7 vs 5.2 respectively).  This is in keeping with the studies extensive exclusion criteria. There 
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were no significant differences in SF-36 and MacNew domains between stenting and surgery at 
follow-up, adjusted for baseline. However, patients after both stenting and surgery showed 
significant improvements from baseline to follow-up in all domains. 
While RCTs provide the highest quality evidence and reduce the effects of bias and confounding. 
However, they are primarily undertaken to allow comparisons to be made between PCI and 
alternative management. As discussed, elderly patients are underrepresented in them. 
Observational studies are more likely to provide a “real world” perspective. 
 
Using SF-36 and SAQ , Seto et al.308 did not find differences based on age in QoL after PCI. At 
observation times of 6 months and 12 months, they authors found similar levels of QoL in 295 
patients aged ≥ 70 years as in 1,150 patients aged < 70 years. Li et al.320 observed 624 elderly 
subjects with ACS admitted to hospital. QoL was assessed at baseline and after 6 months by SF-
36. The authors found that QoL at baseline decreased with advancing age. However, even though 
older patients were less likely to undergo angioplasty (56% of patients aged 60–79 years versus 
21% of patients aged > 80 years), subjects from the older group who underwent PCI experienced 
the most improvement in physical health as compared with younger ones. The investigators 
suggest that age should not be an argument against coronary revascularization with PCI due to the 
potential benefits in QoL. 
 
 
Spertus et al.225 assessed QoL in 1518 consecutive non-acutely presenting patients, attending a 
single centre in the USA, using the SAQ. This disease specific QoL 19-item instrument includes 
physical limitation, change in angina symptoms, angina frequency, satisfaction with treatment, and 
QoL. The QoL scale directly assesses patient’s perceptions of their QoL by measuring enjoyment 
with life, their satisfaction with current health status and their fear of dying or having a heart 
attack. Höefer  2003390 suggests that while both the SAQ and the MacNew questionnaires are 
valid, reliable, and responsive, the MacNew discriminates better between angina grades. In this 
thesis it was possible to assess the internal consistency of the MacNew Questionnaire in the study 
participants. The Cronbach’s alpha of 0.95 suggests that the questionnaire used in Chapter 4.3 had 
good internal consistency and the Spearman’s correlation coefficient suggests that the physical and 
emotional domains correlate well with the mental and physical domains of the SF-12v2.  
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Permanyer-Miralda et al.391found that, in a group of 106 patients. the Nottingham Health Profile 
and the DASI both statistically significantly improved at 1 month and 3 years following PCI. 
Baseline characteristics of this cohort shows that a higher proportion had milder symptoms at 
baseline compared with the study in this thesis  (11% vs 4.7% - based on CCS).  
 
Similar results were obtained in the study by de Quadros et al.392 Patients with stable angina (n = 
110) were assessed by the SAQ before PCI and followed up for 1 year. Authors demonstrate that 
there was an improvement in all SAQ scales after 1 year in most patients treated with PCI (68% of 
patients were free of angina 1 year after PCI). In multivariate analyses, QoL before the procedure 
was the main positive predictor of improvement in QoL. This confirmed the positive impact of 
PCI on symptom relief in chronic stable angina in everyday clinical practice. 
 
Nash et al.393 examined the baseline predictors of QoL in 1,182 patients before angioplasty. They 
found that poor QoL at baseline (low physical component (PCS) and low mental component 
(MCS) scores on SF-36) acted as an independent determinant of improvement from angioplasty 6 
months after the procedure. Suggesting that baseline QoL should be taken into consideration 
during multivariate analysis. However, there is much debate regarding the use of baseline QoL 
measures in models.371  Therefore, the multivariate models in this thesis were run with and without 
baselines measures with little impact on the overall findings.342 
 
With decreased incidence of restenosis associated with drug eluting stents and the consequent 
decrease in recurring angina symptoms; stents should lead to greater improvements in QoL. 
Recently published data from the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology 
Hospital (RESEARCH) Registry394 compared drug eluting and bare metal stents. More than 800 
consecutive patients (mean age, 62 years) treated with PCI with deployment of sirolimus eluting 
stents (SES) or BMS were involved. At inclusion, ~50% of participants suffered from stable 
angina. Patients were not randomized to stent type and QoL was measured with SF-36. At 1 month 
59% of patients had good health status after PCI. This was maintained until 12 months. In 
addition, they found that poor QoL at baseline was predictive of higher mortality at 6-year follow-
up, and this effect was independent of demographic and clinical characteristics.  The authors 
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recommend that patient-reported health status should be adopted in standard clinical practice for 
identification of high-risk CAD patients, who will be (or already have been) treated with drug 
eluting stents. In this thesis some 68% of participants had a drug eluting stent rather than a bare 
metal stent deployed. Including stent type deployed into the multivariate analysis in Chapter 4.3 
had little impact on the overall findings and did not improve the fit of the model.   
 
Pedersen et al.395 also assessed QoL using the MacNew questionnaire in 667 consecutive post PCI 
patients. They used global MacNew score to assess risk of MACE following PCI based on having 
a good or poor score. A poor score was defined as being in the lowest tertile. similar to the 
findings of the  RESEARCH  registry, they found that after a median follow up of 2 years 
incidence of early MACE was higher in patients with a poor score. While outwith the scope of this 
thesis, data linkage of ReqoL participants to SMR01 could be undertaken to assess short and long 
term MACCE outcomes.  
 
Sipötz et al.372 assessed Qol before and after PCI in 163 patients from 7 cardiovascular care units 
in Austria, using the MacNew questionnaire and HADS (Hospital Anxiety and Depression Scale). 
Participants were aged between 18 and 80 years and were treated with a drug eluting stent called 
Xience. Their main aim was to describe changes in HRQOL and mental distress. Improvement 
was seen in the MacNew score following PCI. They also found a strong correlation between 
MacNew score and HADS. While this thesis did not use HADS, this finding is in keeping with the 
strong correlation found between MacNew emotional score and the SF-12v2 mental component 
score (0.74), suggesting that the MacNew emotional score is a useful way of assessing emotional 
status.  In addition, the MCS derived from SF-36 has shown significant correlation with the 
MacNew emotional score in cardiac patients.390 Sipötz et al.372 also found that 48% of patients 
achieved or exceeded the MacNew MID of 0.5. In contrast,  ReQol found 73.8% of elderly and 
77.9% of younger patients achieved the MID. However, this may be because of differences in 
baseline characteristics, the wider age range, loss to follow up (which was 53% for the Sipötz et 
al.343 study), and that the MID was based on 1 months post PCI rather than 3 months.  
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Only a small number of studies have failed to demonstrate a benefit from PCI.396,397Hambrecht et 
al.396 randomised 101 male patients to receive either 12 months of exercise training or PCI 
following positive angiography. They demonstrated improvements in CCS class by physician 
blinded clinical assessment which were similar in both groups. However, no QoL tool was used 
and most of the patients in the study had only mild exercise-induced clinical symptoms and a 
preserved left ventricular systolic.  The second study, patients who were considered unsuitable for 
any revascularisation, salvage PCI (defined with advanced disease but faced with “no option” as 
they were experiencing ongoing intractable symptoms) did not improve QoL but did slightly 
improve angina status compared with baseline.397 Given the baseline characteristics of the 
participants, neither of these studies are directly comparable with the study in this thesis. So far, 
the MacNew hasn’t been used to compare differences in QoL following PCI in elderly and 
younger patients or in the UK to assess QoL improvements following PCI. 
 
 
In keeping with the systematic review of the literature in Chapter 2.3, ReQoL confirms the QoL 
benefit of PCI for elderly patients. In addition Chapter 4.2, shows that elderly patients are at 
increased risk of complications following PCI (although absolute risk is small).  However, 
deciding who will most benefit vs risk is challenging. Currently many tools are used to assist with 
clinical decision making include, chronological age e.g. PTP. There is growing interest in the use 
of biological markers of ageing (such as LTL) to predict incidence, prognosis, and who would 
most benefit from invasive investigations and/or management of CAD. The first stage in assessing 
whether LTL could be used for this purpose is to investigate the association between LTL and the 
presence and severity of CAD. In Chapter 4.4 no association was found between LTL and CAD in 
This finding is consistent with a number of other observational studies343,352, 337while others have 
found an inverse association between LTL and CAD.344,339,373 it has been suggested that telomere 
shortening might contribute to atherosclerosis through various biological ageing pathways, such as 
cellular senescence. For example, the accumulation of senescent cells, a prominent feature of 
atherosclerotic plaques, has reduces the regenerative potential of affected tissues and promotes 
apoptosis, which can further exacerbate inflammatory reactions, and endothelial dysfunction. 
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Also consistent with previous studies, an inverse relationship was found between LTL and 
chronological age344,339,343.  This is in keeping with what is known about age-related telomere 
attrition  and demonstrates validity of the quantitative real-time PCR undertaken by the Shiels lab. 
However, debate exists as to whether a variable such as LTL, that is related with age, can be a 
strong “age-independent” determinant of another variable, such as CAD.398 Despite this, age 
explained only 3.3% of the variation in telomere length and age was adjusted for, in the analyses.  
The comparison group used in Chapter 4.4 comprised of those with normal arteries on 
angiography or those who had a history of CAD based on having a previous PCI, CABG, or AMI. 
Angiography is undertaken primarily to investigate symptoms associated with CAD (73.1% of 
those attending for angiography) or as an investigation of another cardiac problem such as valvular 
heart disease (21.4%), often prior to surgical intervention. Similarly, Samani et al.341 compared 10 
cases with severe CAD and 20 controls, who had angiography undertaken to investigate valvular 
heart disease or chest pain of uncertain origin.  They used Southern Blot with an interassay 
variation of 0.8%. Unlike the study in this thesis, they found cases had mean terminal restriction 
fragments 303 bps shorter: equivalent to 8.6 years younger. However, the study in this thesis has 
much larger numbers and has been adjusted for common confounders such as sex and deprivation.  
A similar approach was also used by Carlquist et al362 who recruiting consecutive patients 
attending for angiography in Utah, USA. Similar to the population presented in Chapter 4.3, mean 
age was ~63 years of age and there weas a greater proportion of men than women. Sixty-two point 
two percent of the Utah patients were found to have CAD on angiography compared with 73.1% 
here. It is unclear from this conference abstract if this was solely based on angiographic 
appearance or if, like in the thesis, includeds those with a clear history of CAD based on history of 
PCI, CABG, or AMI. They found that longer LTL was associated with a decreased risk of CAD 
only in univariate analysis (OR=0.54, p<0.0001) but not in multivariate.  
Mukherjee et al.342 recruited 238 consecutive Indian patients admitted to a single centre hospital 
for coronary investigation or treatment of CAD (74% for diagnostic angiography, 20 for PCI and 
6% for CABG). Cases were matched to control for age, sex, BMI, and smoking history, with no 
statistically significant difference in fasting lipids. unlike the participants presented in Chapter 4.3 
Controls in this study were drawn from the general population rather than those used in Chapter 
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4.4, who had negative angiographic findings. They were assessed as being free from CAD based 
on self-reported history, Rose Angina Questionnaire, and medications list. In cases, CAD was 
defined as the presence of ≥50% stenosis of coronary arteries compared with ≥75% in the study in 
this thesis. No indication is given if participants could have had a previous history of PCI, CABG, 
or AMI Unlike the vast majority of studies, including the study in this thesis, the authors did not 
find an association with age. The authors suggest this surprising finding may be related the wide 
age range and Indian ethnicity of the subjects.  
 
Kurz et al.349 also recruited participants prospectively from patients undergoing elective coronary 
angiography. Cases (n=64, mean age 77.2±5.2 years) were those undergoing investigation of CAD 
prior to valve replacement surgery for critical calcific aortic valve stenosis (CAC). Controls 
(n=129) were those without CAC on direct measurement of the aortic valve pressures during 
coronary angiography (mean age 75.9±4.3 years). While there was an association between LTL 
and CAC, no significant association was found between CAD and LTL, in cases or controls, even 
after “investigating for possible confounding” (results not presented in the paper). LTL was 
measured using Southern Blot with an interassay variability of 7.8%±7%. In addition, to the 
validation provided through the inverse association with age, the CoV in this thesis was found to 
be 0.51%, which shows a high degree of precision for the technique (in comparison to the Kurtz et 
al. study). This is consistent with similar quantitative Real-Time PCR studies from Shiels the 
laboratory.8,180  It is also much lower than suggested by the literature generally for the for qPCR 
(6.45% suggested by Aviv et al.129), and even lower than the 1.74% attributed to Southern Blot. 
The CoV of other published studies assessing the association between LTL and CAD range from 
1.28-9%, as shown in Chapter 2.4.  
 
A number of populations based cohort studies have assessed incidence of developing CAD. 
344,339,343These longitudinal studies offer the benefit of assessing the temporal nature of the 
association thus providing more evidence towards a causal association. However, these studies are 
heterogeneous in nature with differences in study designs (e.g. retrospective or prospective), 
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populations (e.g. confined to elderly participants348); LTL analysis method; and CAD endpoints. 
Evidence from large high quality studies with robust adjustments for potential confounders 
suggest that there is likely to be a modest association between LTL and CAD outcomes.  
Weischer et al.337 using participants in the Copenhagen City Heart Study and the Copenhagen 
General Population Study, demonstrated multifactorially adjusted HR for the shortest versus the 
longest decile of telomere length of 1.24 95% CI 1.01-1.53 for CAD.  Suggesting only modest 
increased risk of CAD. Adjustment included inflammatory markers and lipids but also physical 
activity, alcohol intake and, in women, menopausal status and hormone replacement therapy. The 
CoV of quantitative real-time PCR was 2%. The study population consisted of 19,838 participants 
followed up for up to 19 years. There were 2,038 who developed CAD within the follow up 
period.   
There is increasing evidence to suggest that potential biomarkers of ageing may be influenced by 
early life factors399 (such as intrauterine and early years environment) with telomere length known 
to undergo rapid loss until ~5 years of age, after which it appears to plateau until gradual loss 
begins in middle age. Past studies have shown that 15%–25% of screened adult subjects might 
even increase their telomere length over time,178 This has been criticized because ageing is known 
to display a unidirectional progression, and therefore it is thought to be unlikely that LTL 
increases with age. Apparent lengthening may be a result of changes in peripheral blood stem cells 
or shifting patterns of leucocyte sub-populations. As a one off LTL measurement was used in this 
thesis, it is not possible to assess changes over time. In addition, data on early years life 
experiences were not assessed. Debate exists as to the benefit of measuring telomere length in 
different subpopulations of leucocyte cells.  However, in the study in this thesis, we measured only 
leucocyte telomere length as an average of total white cells rather than TL in separate leucocyte 
subpopulations.  
A number of studies have shown an association between LTL and adverse MACCE outcomes in 
those with existing CAD.356,357,358 Ruff et al358. and Perez-Rivera et al.357 used populations who 
attended with ACS and found that short LTL was strongly associated with subsequent AMI. 
However, Farzaneh-far et al.356 in the San Francisco based Heart and Soul Study found an 
increased risk of death and heart failure but not of a subsequent CV event. Exclusions included 
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those with a previous history of AMI in the last 6 months, those who deemed themselves unable to 
walk 1 block, or those planning to move out of the area. These exclusions limit the generalisability 
of the findings to a population of people with CAD attending clinics. Carlquist et al.361 followed 
up patients who had undergone coronary angiography for a median of 9.2 years and found that, 
after adjustment for a number of baseline characteristics (including medication use, number of 
stenosed vessels, and hyperlipidaemia), longer LTL was associated with decreased risk of death 
(HR=0.51, p<0.001) but not with AMI or CVA . It will be possible to link the cohort in this thesis 
by datalinkage to: SMR01, for hospital discharges; GROS, for death data; and to the SCCRR, for 
angiography and revascularization procedures.  In addition, for those without evidence of CAD on 
angiography, similar long term outcomes and incidence of CAD can be assessed. It has been 
hypothesised that, by reducing the proliferative potential of vascular smooth muscle cells, cellular 
senescence promotes the thinning of fibrous caps and the instability of atherosclerotic plaques, 
therefore making rupture and subsequent AMI much more likely.400 
 Calvert et al.359 included 170 patients with stable and unstable angina who were referred for PCI 
and underwent 3-vessel virtual histology intravascular ultrasound.  Shorter LTL was found to be 
associated with high-risk plaque morphology but not total 3-vessel burden; adding to the evidence 
that leucocyte ageing is involved in vulnerable plaque formation.  
The literature suggests that cardiovascular drugs may impact on telomere biology (eg, in relation 
to treatment by antihypertensive176,401). It was not possible to assess the influence of 
cardiovascular drugs on the association between LTL and CAD in this thesis. It should be possible 
to review clinical records and elicit such information on medications used by the participants in 
this study. However, this is outwith the scope of this thesis.  
Another limitation is whether using LTL reflects the tissue cell telomere length in coronary 
arteries. However, there is evidence to suggest that the correlation in telomere length between 
leucocytes and other tissues (including vascular tissue) in healthy humans is strong.123,124  In 
addition, LTL derived from peripheral blood has been associated with the presence of 
atheroscleric plaques in the carotid arteries; however, it was not found to be a proxy for local 
plaque telomere length.331 Further research is required to assess the correlation between LTL and 
coronary artery endothelial cells and/plaques, which may show stronger associations with CAD.   
  
217 
 
Further analysis of the blood collected in this sample could be undertaken to assess inflammatory 
markers (such as IL6 or CRP). As discussed in the introduction, although inflammatory markers 
are non-specific, abnormal values are thought to indicate clinical or subclinical levels of chronic 
inflammation that contribute to the ageing process – possibly through oxidative stress. Senescent 
cells are associated with a high level of intracellular ROS and accumulation of oxidative damage 
to DNA and proteins.78 Telomere shortening is considered to be one of the major cause of 
replicative cellular senescence and is increased as a result of mild oxidative stress.46,78,72  They are 
also thought to contribute to the development and progression of atherosclerosis.300,301,302,303,304, 
Controversy exists as to how appropriate the use of telomere length is as a biomarker of ageing, 
particularly as studies move from laboratory based to population based observational studies.8,96,97  
Therefore, exploring the association between alternative biomarkers of ageing and CAD would be 
useful. Particularly in this population where no association was found between LTL and CAD.  In 
addition to inflammatory markers, blood collected from the participants in this thesis can be used 
to measure other biomarkers of ageing such as CDKN2a, AEGs, Fetuin A, Sertuins 1-9, 
homocystine, and DNA methylation. All of which have been associated with ageing and 
atherosclerosis in humans (see Chapter 1.1.4 for a fuller discussion).97,98,99,100,101,104,105  
 
 
6. OVERALL CONCLUSION 
Population projections from GROS suggest that the phenomenon of population ageing will 
continue in Scotland for at least the next 25 years. This demographic trend is likely to result in a 
rise in the prevalence and complexity of degenerative disorders such as CAD. Therefore, elderly 
patients are likely to represent an increasing proportion of those presenting for investigation and 
treatment of CAD, with resultant implications for health services in the future. Chapters 4.1 and 
4.2 demonstrated that elderly people do account for an increasing number, and proportion, of 
patients presenting for the investigation and management of CAD and that over time the baseline 
risk profile has been increasing. This demographic trend, together with changes in patient selection 
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and case mix, will likely increase the underlying risk of periprocedural complications. However 
the time trend data for PCI complications presented in Chapter 4.2 suggests that we have managed 
to offset this effect, presumably as a result of technical improvements and the adoption of new 
devices and adjuvant therapies. However, further developments may be required if we are to avoid 
worsening outcomes in the future. 
 
Chapter 4.1 demonstrated that the threshold for investigation, via coronary angiography, and 
subsequent intervention, using PCI, was higher among this increasingly large group of patients, 
even after taking account of co-morbidities. This suggests a chronological age-based inequality in 
access to investigation and treatment. Inequality might, nonetheless, be justified if the risks were 
unacceptably high or benefits less among elderly patients. However, this was not found to be the 
case. Chapters 4.1 and 4.2 demonstrated that elderly patients do have a higher risk of early 
complications than younger patients, but their absolute risk was, nonetheless, low. This suggests 
that coronary angiography and PCI are safe procedures to perform in the elderly. These findings 
have significant implications for the delivery of cardiovascular clinical services to an increasingly 
important sub-group of patients.  Further investigation of referral patterns and apparent thresholds 
are required, using populations referred for CAD investigation and not receiving diagnostic 
coronary angiography.  
 
The current ESC guidelines 3 recommend that referral for investigation of CAD by non-invasive 
techniques is preferred except in those who would most benefit from revascularisation, (for 
example, high PTP, where it is used to assess the severity of CAD to inform future management 
options); in patients where the findings of non-invasive testing are inconclusive; in some 
professions who cannot have stress testing for regulatory reasons; or in those where optimal 
medical management fails to control symptoms. However, severity of clinical symptoms, the 
patient's risk of adverse events from coronary angiography, and patient preferences, are also taken 
into consideration in determining investigation of CAD. These recently changed guidelines are 
likely to have a significant impact on referral patterns for coronary angiography in the future. It 
may well off-set the effects of population ageing on the number and proportion of elderly patients 
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undergoing coronary angiography. However, the PTP is influenced by the prevalence of CAD in 
the population (as well as clinical features of an individual) and prevalence of CAD is known to 
increase with chronological age. Further investigation of this guideline change on referral patterns 
and apparent thresholds in elderly patients using populations referred for CAD investigation and 
not receiving non-invasive diagnostic testing, or diagnostic coronary angiography, is required.  
 
PCI is generally undertaken in elderly patients to alleviate the signs and symptoms of CAD. 
Therefore, assessing the benefits of PCI on QoL is as important as investigating the risk of peri-
procedural complications and longer term MACCE outcomes (as shown in Chapter 4.2.). QoL is 
used to measure an individual's experience of his or her health status and health-related well-
being. A number of QoL tools have been developed to document experience of illness and 
healthcare and to measure what effects of treatment are deemed to be of greatest importance to 
patients.  However, there is no consensus on the definition of QoL or what is the most appropriate 
measurement tool. In keeping with the systematic review of the literature in Chapter 2.3, the 
findings of ReQoL confirms that QoL (using generic and disease specific QoL measurement tools) 
following PCI in older patients improves at least as much as  in younger patients. 
Chapters 4.1, 4.2, 4.3 all used time from birth to define elderly. In contrast to chronological 
ageing, biological ageing involves variable structural and functional changes that take place at the 
cellular, tissue and organ level; these ultimately affect the overall performance of the body. 
Biological ageing is thought to vary between individuals of the same chronological age and 
increase susceptibility to ill health and disease. There is currently much interest in whether 
biomarkers of ageing may provide a better measurement of "miles on the clock" and whether 
biological age contributes to the development and progression of disease, such as CAD, and can 
explain socioeconomic inequalities in health. However, we found no association between LTL and 
either the occurrence of CAD, or its severity, on cross-sectional study. While LTL is considered a 
useful biomarker of ageing, the findings in this thesis suggest that LTL may not be as useful in 
CAD.  Longitudinal studies are required to assess the usefulness of LTL as a biomarker of ageing 
in CAD and to investigate whether LTL is associated with adverse outcomes in patients diagnosed 
with CAD.  
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This thesis has used a systematic review, one near systematic review, two secondary data analyses, 
and two primary research studies to explore both chronological and biological ageing in CAD. 
Overall, the findings suggest that: (i) the ageing population is likely to continue to have an impact 
on cardiovascular services for the near future; (ii) adverse outcomes following angiography and 
PCI are more common in elderly patients;  (iii) there appears to be different thresholds for 
investigation and management of CAD in elderly patients; (iv)  coronary angiography and PCI are 
safe procedures in elderly patients with PCI improving their QoL; and (v) LTL may not be as 
useful a biomarker of ageing in CAD.  
Population projections from GROS suggest that the phenomenon of population ageing will 
continue in Scotland for at least the next 25 years. This demographic trend is likely to result in a 
rise in the prevalence and complexity of degenerative disorders such as CAD. Therefore, elderly 
patients are likely to represent an increasing proportion of those presenting for investigation and 
treatment of CAD with resultant implications for health services in the future. Chapters 4.1 and 
4.2, confirm that elderly people do account for an increasing number and proportion of patients 
presenting for the investigation and management of CAD and that over time the baseline risk 
profile has been increasing. The demographic trend, together with changes in patient selection and 
case mix, will likely increase the underlying risk of periprocedural complications. However the 
time trend data for PCI complications presented in Chapter 4.2 suggests that we have managed to 
offset this effect, presumably as a result of technical improvements and the adoption of new 
devices and adjuvant therapies. However, further developments may be required if we are to avoid 
worsening outcomes in the future.  
 
Chapter 4.1 demonstrated that the threshold for investigation, via coronary angiography, and 
subsequent intervention, using PCI, were higher among this increasingly large group of patients, 
even after taking account of co-morbidities. This suggests a chronological age-based inequality in 
access to investigation and treatment. Inequality might, nonetheless, be justified if the risks were 
unacceptably high or benefits less among elderly patients. However, this is was not found to be the 
case. Chapters 4.1 and 4.2 demonstrated that elderly patients do have a higher risk of early 
complications than younger patients, but their absolute risk was, nonetheless, low suggesting that 
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coronary angiography and PCI are safe procedures to perform in the elderly. These findings have 
significant implications for the delivery of cardiovascular clinical services to an increasingly 
important sub-group of patients.  Further investigation of this referral patterns and apparent 
threshold are required using populations referred for CAD investigation and not receiving 
diagnostic coronary angiography, is required.   
  
The current ESC guidelines139 recommend that referral for investigation of CAD by non-invasive 
techniques is preferred except in: those those who would be most likely benefit from 
revascularisation (for example, high PTP, where it is used to assess the severity of CAD (rather 
than diagnose CAD) to inform future management options); in patients where the findings of non-
invasive testing are inconclusive; in some professions who cannot have stress testing for 
regulatory reasons; or in those where optimal medical management fails to control symptoms. 
However, severity of clinical symptoms, the patient’s risk of adverse events from coronary 
angiography, and patient preferences, are also taken into consideration in determining 
investigation of CAD. This change is likely to have a significant impact on referral patterns for 
coronary angiography in the future. It may well off-set the effects of population ageing on the 
number and proportion of elderly patients undergoing coronary angiography. However, the PTP is 
influenced by the prevalence of CAD in the population (as well as clinical features of an 
individual) and prevalence of CAD is known to increase with chronological age. Further 
investigation of this guideline change on referral patterns and apparent thresholds in elderly 
patients using populations referred for CAD investigation and not receiving non-invasive 
diagnostic testing or diagnostic coronary angiography, is required.  
 
PCI is generally undertaken in elderly patients to alleviate the signs and symptoms of CAD. 
Therefore, assessing the benefits of PCI on QoL is as important as investigating the risk of peri-
procedural complications and longer term MACCE outcomes (as shown in Chapter 4.2.). QoL is 
used to imply an individual’s experience of his or her health status and health-related well-being. 
A number of QoL tools have been developed to document experience of illness and healthcare and 
to measure what effects of treatment are deemed to be of greatest importance to patients.  
However, there is no consensus on the definition of QoL or the most appropriate tool to measure it 
with. In keeping with the systematic review of the literature in Chapter 2.3, the findings of ReQoL 
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confirms that QoL (using generic and disease specific QoL measurement tools) following PCI in 
older patients improves at least as much as younger patients.  
 
Chapters 4.1, 4.2, 4.3 all used time from birth to define elderly. In contrast to chronological 
ageing, biological ageing involves variable structural and functional changes that take place at the 
cellular, tissue and organ level; ultimately affecting the overall performance of the body. It is 
thought to vary between individuals of the same chronological age and increase susceptibility to ill 
health and disease. There is currently much interest in whether biomarkers of ageing may provide 
a better measurement of “miles on the clock.” and whether biological age contributes to the 
development and progression of disease, such as CAD, and can explain socioeconomic 
inequalities in health. However, we found no association between LTL and either the occurrence 
of CAD, or its severity, on cross-sectional study. While LTL is considered a useful biomarker of 
ageing, the findings in this thesis suggest that LTL may not be as useful in CAD.  Longitudinal 
studies are required to assess the usefulness of LTL as a biomarker of ageing in CAD and to 
investigate whether LTL is associated with adverse outcomes in patients diagnosed with CAD.  
This thesis has used: 1 systematic review, 1 near systematic review, 2 secondary data analysis, and 
2 primary research projects to explore both chronological and biological ageing in CAD. Overall, 
the findings suggest that: (i) the ageing population is likely to continue to have an impact on 
cardiovascular services for the near future; (ii) adverse outcomes following angiography and PCI 
are more common in elderly patients;  (iii) there appears to be different thresholds for investigation 
and management of CAD in elderly patients; (iv)  coronary angiography and PCI are safe 
procedures in elderly patients and PCI improves their QoL; and (v) LTL may not be as useful a 
biomarker of ageing in CAD.   
 
 
6.1. Recommendations for future research 
• Chapters 4.1 and 4.2 investigated the trends, case-mix, and adverse outcomes 
associated with coronary angiography and PCI. Results suggest that there appears to be 
  
223 
 
different thresholds for investigation and management of CAD in elderly patients. 
However, the findings are based on patients having these procedures. To determine the 
extent to which there are inequalities in referral threshold, as well as procedure 
threshold, further studies should be undertaken on patients referred to cardiology 
services for investigation of CAD rather than just those receiving it. In addition, 
populations attending GPs with symptoms suggestive of CAD should be studied to 
explore whether inequalities exist in referral to specialist services for CAD 
investigation.  
• The recent ESC guideline on managing stable CAD has updated the recommendation on 
who should be referred for invasive investigation and management. This change is likely to 
have a significant impact on referral patterns for coronary angiography and PCI in the 
future. It may well off-set the effects of population ageing on the number and proportion of 
elderly patients undergoing coronary angiography. However, further investigation of this 
guideline change is required on referral patterns and apparent thresholds in elderly patients 
using populations referred for CAD investigation but not receiving non-invasive diagnostic 
testing or diagnostic coronary angiography.  
• The ReQol study in Chapter 4.3 assessed QoL outcomes in patients undergoing PCI. 
However, patients were only followed up to 3 months post procedure, due to the 
constraints of data collection within a PhD programme. The systematic review in 
Chapter 2.3 suggests that improvements in quality of life may well extend to at least 3 
years. However, this review only included a small number of studies. Further research 
is required to assess the long term impact of PCI on QoL.  
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• ReQoL (in Chapter 4.3) assessed QoL outcomes; however, these may well be 
influenced by adverse clinical outcomes such as MACCE. Additional research should 
be carried out on this cohort by data linkage with SMR01 to assess short and long-term 
MACCE outcomes. This would also allow the investigation of the association between 
baseline QoL and frailty with MACCE outcomes.  
• Given the small number of participants included in ReQol, a larger study would be 
important to provide more robust evidence of the impact of PCI in elderly patients. 
Given the heterogeneity of studies included in the systematic review in Chapter 2.3, 
further research which assesses the most appropriate measurement tool for QoL in this 
group would be important. This would likely involve comparisons between 2 or more 
QoL life tools such as in ReQoL. However, given the low recruitment rate in ReQoL, 
care must be taken that the questionnaire length is not too onerous for participants. In 
addition, recruitment and consent for such a study would be best undertaken at the time 
of procedure consent; given the success of recruitment for the study in Chapter 4.4.  
• The findings in Chapter 4.4 suggest that LTL may not be as useful a biomarker of 
ageing in CAD as some studies have suggested.  However, the main limitations are the 
cross-sectional nature of the study and that that the comparison group comprised of 
those undergoing angiography for symptoms suggestive of CAD, rather than using a 
sample from the general population. Therefore, longitudinal studies are required to 
assess the usefulness of LTL as a biomarker of ageing in CAD.  
• In addition, Chapter 4.4. found no association between the occurrence of in-lab 
complication and telomere length and in keeping with Chapter 4.1 and 4.3 there were 
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only a small number of in-lab complications. It was not possible for this thesis to assess 
the association between LTL and short and longer-term adverse outcomes. Additional 
research should be undertaken to investigate whether LTL is associated with adverse 
outcomes in patients diagnosed with CAD. Data linkage with SMR01 would allow this 
to be undertaken in this cohort.  
• There is debate in the literature as to whether or not LTL is an appropriate biomarker of 
ageing. However, in Chapter 4.4 only LTL was used. Further analysis of the blood 
taken from participants should be used to investigate emerging biomarkers of ageing, 
such as those discussed in Chapter 1.1.3. For example, fetuin A, sirtuin 1-7, CDKN2a. 
In addition, inflammatory markers should be measured in the blood, given the 
association between inflammation and cellular senescence.  
• Chapter  4.4 used a cross-sectional study design to investigate the association between 
LTL and CAD, rather than longitudinal measurement of telomere length in the same 
individuals. Serial measurements of LTL in patients with and without CAD would 
allow assessment of telomere attrition of patients with CAD and the influence of 
interventions over time.  
• LTL is thought to correlate well with telomere length in somatic tissue, such as 
endothelial cells; however, further laboratory based research is required to confirm this 
correlation.  
• Given the debate as to whether telomere shortening is the primary abnormality, or a 
result of accelerated attrition of telomeres by cardiovascular risk factors and disease, 
further research is required to better understand the mechanisms involved. To do this, 
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research which assesses the lifetime trajectory of telomere length and its association 
with degenerative diseases, such as CAD, is required. For example, this should include 
the use of large longitudinal studies such as birth cohorts (which would ideally include 
an assessment of prenatal factors, given that prenatal factors could programme a foetus 
for increased risk of CAD) or cohorts comprising of healthy individuals. In addition, 
this approach is likely to provide a better understanding of the ageing process itself and 
its relationship to cardiovascular risk factors and disease.  
6.2. Lessons learned 
Undertaking this PhD has overall been a challenging and rewarding experience. It has afforded a 
valuable insight into the different theories and concepts of ageing and quality of life. This 
knowledge and understanding of these theories and concepts are very useful, and will be 
particularly as research in this area is likely to continue to be important in the future  
This PhD has allowed me the opportunity to apply all of the statistical techniques studied as part of 
my MPH course and many of those included in the FPH Part A syllabus.  
I was able to gain experience in coordinating and conducting two primary research projects. This 
included gaining NHS ethics, developing protocols, questionnaire design, and actively liaising 
with the cardiac research nurses at the Golden Jubilee National Hospital. In addition, I learned that 
undertaking primary research projects is a considerable undertaking and that it can be fraught with 
difficulties such as slow recruitment.  
I’ve learned that writing up a PhD is exponentially more challenging than an MPH, or even 5 
MPH projects (although equivalent in word count!). I also learned that referencing software is 
amazing useful until it isn’t.  
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8. APPENDICES  
8.1. Ethics approval letter for Revascularisation and 
Quality of Life (ReQoL) 
 
West of Scotland REC 2  
Western Infirmary  
Ground floor, Tennent Institute  
38 Church Street  
Glasgow G11 6NT  
Telephone: 0141 211 2123  
Facsimile: 0141 211 1847  
 
21 August 2009  
 
Dr Cathy Johnman  
Clinical Lecturer Public Health  
University of Glasgow  
1 Lilybank gardens  
Glasgow G12 8RZ  
Dear Dr Johnman Study Title:  ReQol: Revascularisation: Quality of life 
and clinical outcomes following 
revascularisation procedures.  
REC reference number:  09/S0709/58  
Protocol number:  1  
 
 
The Research Ethics Committee reviewed the above application at the meeting held on 18 
August 2009. Thank you for attending to discuss the study 
 
Ethical opinion 
 
The members of the Committee present gave a favourable ethical opinion of the above research 
on the basis described in the application form, protocol and supporting documentation, subject to 
the conditions specified below. As discussed at the meeting the following points require to be 
clarified through the Committee Co-ordinator before the favourable opinion is valid. 
1) Participant Information Sheet  
• The Researcher confirm that the study was looking at the quality of life in the over 75's 
population in comparison to the under75's but this was not reflected in the Participant 
Information Sheet. This should be made clear in the Participant Information Sheet.  
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• The final sentence at 'What will happen if I take part?' should be changed to read 'The 
Research Nurse will contact you only as a reminder or if we require further information 
about your health'.  
 
• At 'Contact for further information' as well as contact details for the Researcher, there should 
be contact details for someone independent from the study who could speak to 
participants.  
 
A revised Participant Information Sheet taking account of the above comments should be 
submitted.  
 
2) Consent Form  
 
• Each statement starts with 'I agree’. Each statement should begin with 'I understand'.  
• The final statement should be reworded to read 'I understand that the Research Team 
may wish to access my notes to provide additional follow-up information about my health'.  
A revised Consent Form taking account of the above comments should be submitted.  
 
3) Questionnaire  
• It is preferred that the section on 'Questions About You' at the end of the questionnaire 
should be on a separate page as these details are only required once and not at each 
follow up visit.  
A revised Questionnaire taking account of this comment should be submitted.  
 
Ethical review of research sites  
 
The favourable opinion applies to all NHS sites taking part in the study, subject to management 
permission being obtained from the NHS/HSC R&D office prior to the start of the study (see 
“Conditions of the favourable opinion” below).  
 
Conditions of the favourable opinion  
The favourable opinion is subject to the following conditions being met prior to the start of the 
study.  
Management permission or approval must be obtained from each host organisation prior to the 
start of the study at the site concerned.  
 
After ethical review  
Now that you have completed the application process please visit the National Research Ethics 
Service website > After Review  
You are invited to give your view of the service that you have received from the National 
Research Ethics Service and the application procedure. If you wish to make your views known 
please use the feedback form available on the website.  
The attached document “After ethical review – guidance for researchers” gives detailed guidance 
on reporting requirements for studies with a favourable opinion, including:  
• Notifying substantial amendments  
• Adding new sites and investigators  
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• Progress and safety reports  
• Notifying the end of the study  
 
The NRES website also provides guidance on these topics, which is updated in the light of 
changes in reporting requirements or procedures.  
We would also like to inform you that we consult regularly with stakeholders to improve our 
service. If you would like to join our Reference Group please email 
referencegroup@nres.npsa.nhs.uk. 
 
09/S0709/58  Please quote this number on all 
correspondence  
 
With the Committee’s best wishes for the success of this project  
Yours sincerely  
Liz Jamieson  
Committee Co-ordinator on behalf of Dr S Langridge, Chair  
 
Email: Liz.Jamieson@ggc.scot.nhs.uk  
 
Enclosures:  
 
 
List of names and professions of members 
who were present at the meeting and those 
who submitted written comments  
“After ethical review – guidance for 
researchers”  
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8.2. Participant information leaflet for 
Revascularisation and Quality of Life (ReQoL) 
Version 1 31/08/09 Code: AB/147118/1 
 
 
GOLDEN JUBILEE NATIONAL HOSPITAL   
NHS National Waiting Times Centre 
 
 
 
PARTICIPANT INFORMATION LEAFLET  
Revascularisation and Quality of Life Study (ReQoL)  
 
Introduction  
You are being invited to take part in a research study. Before you take part it is important for you 
to understand why the research is being done and what it will involve. Please take time to read 
the following information carefully and to discuss it with others if you wish. Ask us if there is 
anything that is not clear or if you would more information (contact details are at the end of this 
leaflet)  
 
What is the purpose of the study?  
We would like to collect information on the impact of this procedure on your general health and 
quality of life. We are particularly interested in how the health and quality of life of older patients 
are affected in comparison to younger patients, undergoing this procedure. We also want to 
determine which types of questions are most helpful in assessing your health and quality of life.  
 
Why have I been chosen?  
You have been chosen because you are having a cardiac procedure to treat the narrowing of the 
blood vessels of the heart in the Golden jubilee hospital.  
 
Do I have to take part?  
It is up to you to decide whether or not to take part. If you decide to take part you will be given the 
opportunity to discuss your involvement with the research nurse at the time of your admission 
where you will be asked to sign a consent form. If you decide to take part you are still free to 
withdraw at any time without having to give a reason. Whether you take part or not, will not affect 
the type or the standard of care you receive.  
 
What will happen if I take part?  
On admission, one of the research nurses will ask you some questions about your health and 
how your health affects your usual activities. We will then post out a similar questionnaire at 3 
months, 6 months and 12 months after you procedure (this should only take around 20 minutes to 
complete). The research nurse will contact you only as a reminder or if we require further 
information about your health. Version 1 31/08/09 Code: AB/147118/1  
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What are the possible benefits of taking part?  
Taking part in the study will be of no direct benefit to you but will be very useful in assessing the 
overall effect of cardiac procedures for narrowing of the blood vessels of the heart on your health 
and quality of life. It will give us valuable information which will be helpful in caring for future 
patients.  
 
Will my taking part in the study be kept confidential?  
All information which is collected about you during the course of the research will be kept strictly 
confidential.  
 
What will happen to the results of the research study?  
Only those directly involved in the study will have access to any information which has your name 
and address on it and then, only for the purposes of arranging the study follow up.  
Your name and other details will be removed from the questionnaire and will be kept separate 
from your answers.  
Any information which is then examined for this study will have your name and address removed 
so that you cannot be recognised from it.  
 
Who has funded the research?  
The research is jointly funded by the NHS and by the Alexander and Margaret Hutchison Trust 
(associated with the University of Glasgow) which was set up to help and support research which 
is likely to be of benefit to the health and welfare of the residents of the West of Scotland.  
 
Who has reviewed the study?  
The study was reviewed and approved by the West of Glasgow Ethics Committee.  
 
For independent advice on this study, if required please contact:  
Dr Hany Eteiba MD FRCP, FACC, FSCAI  
National Waiting Times Centre Board  
Golden Jubilee National Hospital  
Beardmore Street  
Clydebank  
G81 4HX  
 
Direct Study Contacts:  
 
Research Nurses:  
Joanne Kelly, Maureen Mason and Elizabeth Boyd  
Golden Jubilee National Hospital  
Beardmore Street  
Clydebank  
G81 4HX  
Tel: 0141 951 5256  
Email: joanne.kelly@gjnh.scot.nhs.uk 
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8.3. Participant consent form for Revascularisation and 
Quality of Life (ReQoL) 
GOLDEN JUBILEE NATIONAL HOSPITAL   
NHS National Waiting Times Centre 
CONSENT FORM 
 
ReQol (Revascularisation and Quality of Life) 
Study number: ____________ 
Name:       ____________________________   
Hospital:  Golden Jubilee National Hospital 
 
CHI Number:   
(Community Health Index) 
Please put your  
initials in boxes 
 
 
I confirm that I have read and understood the information leaflet 
 
 
 
I understand that I will be asked to complete an initial questionnaire on admission  
and that additional questionnaires will be sent to me at 3, 6 and 12 months after  
my procedure 
 
 
I understand that the research team may wish to contact me for follow up should  
it be required 
 
 
I understand that my GP will be informed of my involvement in this study 
 
          
 
 
 
 
  
273 
 
 
I understand that the research team may wish to access my notes to provide  
additional follow-up information about my health.  
 
 
   
Name of participant  
 
Date Signature 
   
Name and designation  of person 
taking consent   
 
Date  Signature 
Version 2  31/08/09  Code: AB/147118/1 
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8.4. Participant questionnaire for Revascularisation 
and Quality of Life (ReQoL) 
ReQoL Study number: XXXX 
Date:………………………………….. 
Study number:………………………. 
CHI number:………………………… 
Hospital number:…………………… 
Procedure date: …………………… 
Name:………………………………. 
Date of Birth:………………………. 
Address: 
 
 
 
Contact telephone number: 
GP details: 
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We would be grateful if you could help us by filling out this questionnaire about your 
health and quality of life.  Any information will have your name and address removed so 
that you cannot be recognised from it.   
Please try and answer all the questions.   
Overall general health  
 
 
 
 
 
  
1. Mobility                      TICK ONE 
I have no problems in walking about  
I have some problems in walking about   
I am confined to bed    
2. Self-Care  
I have no problems with self-care  
I have some problems washing or dressing 
myself 
 
I am unable to wash or dress myself  
 
3. Usual Activities (e.g. work, study, 
housework, family or  leisure activities) 
 
I have no problems with performing my usual 
activities 
 
I have some problems with performing my 
usual activities 
 
I am unable to perform my usual activities  
4. Pain/Discomfort  
I have no pain or discomfort  
I have moderate pain or discomfort  
I have extreme pain or discomfort  
 
 
By placing a tick in one box in each group below, please indicate which statements best 
describe your own health state TODAY 
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5. Anxiety/Depression                                         
                   TICK ONE 
I am not anxious or depressed  
I am moderately anxious or depressed  
I am extremely anxious or depressed  
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We would like you to indicate on this scale 
how good or bad your own health is 
TODAY, in your opinion. Please do this 
by drawing a line from the box below to 
whichever point on the scale indicates how 
good or bad your health state is today. 
Your own 
Your own 
health state today  
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Detailed general health  
1. In general, would you say your health is: (TICK ONE BOX ONLY) 
 
Excellent   Very good  Good  Fair  Poor  
 
The following two questions are about activities you might do during a typical day. Does YOUR 
HEALTH NOW LIMIT YOU in these activities? If so, how much?  
2. MODERATE ACTIVITIES, such as moving a table, pushing a vacuum cleaner, bowling, or 
playing golf: (TICK ONE BOX ONLY) 
 
Yes, limited a lot  Yes, limited a little  No, not limited at all  
   
3. Climbing SEVERAL flights of stairs: (TICK ONE BOX ONLY) 
 
Yes, limited a lot  Yes, limited a little  No, not limited at all  
   
During the PAST 4 WEEKS have you had any of the following problems with your work or other 
regular activities AS A RESULT OF YOUR PHYSICAL HEALTH? (Please tick one box per 
question) 
(TICK ONE BOX ONLY) 
All of 
the time 
A good bit 
of the time 
Some 
of the 
time 
A little 
of the 
time 
None of 
the time 
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4. ACCOMPLISHED LESS than you 
would like 
 
5. Were limited in the KIND of work or  
other activities 
 
During the PAST 4 WEEKS, were you limited in the kind of work you do or other regular activities 
AS A RESULT OF ANY EMOTIONAL PROBLEMS (such as feeling depressed or anxious)? 
                                                                                              
 
 
 
6. ACCOMPLISHED LESS than you would 
like 
7. Did work or activities less carefully than  
usual 
 
8. During the PAST 4 WEEKS, how much did PAIN interfere with your normal work (including 
both work outside the home and housework)? (TICK ONE BOX ONLY) 
Not at all  A little bit  Moderately Quite a bit  Extremely  
     
(TICK ONE BOX PER QUESTION) 
     
     
     
All of 
the time 
A good 
bit of 
the time 
Some of 
the time 
A little 
of the 
time 
None of 
the time 
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The next three questions are about how you feel and how things have been DURING THE PAST 
4 WEEKS.  
For each question, please give the one answer that comes closest to the way you have been 
feeling. How much of the time during the PAST 4 WEEKS – 
                                                                                                                             
(TICK ONE BOX PER QUESTION) 
 
 
 
 
9. Have you felt calm and peaceful? 
 
10. Did you have a lot of energy? 
 
11. Have you felt downhearted  
and depressed? 
 
 
 
 
 
 
All of the 
time 
A good 
bit of the 
time 
Some of 
the time 
A little of 
the time 
None of 
the time 
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12. During the PAST 4 WEEKS, how much of the time has your PHYSICAL HEALTH OR 
EMOTIONAL PROBLEMS interfered with your social activities (like visiting with friends, relatives, 
etc.)? (TICK ONE BOX ONLY) 
 
All of the time A good bit of the time Some of the time A little of the time None of the time 
     
 
Heart Health questions  
 
Please be sure to answer all questions. 
 
1. During the past 4 weeks, how much were you bothered by each of the following 
problems related to your heart condition?  
                                                                    (TICK ONE BOX PER QUESTION) 
 
 A lot Quite a bit Moderately A little Not at all 
Chest pain due to angina 
 
     
Discomfort in your chest due to 
angina 
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Shortness of breath 
 
     
Angina pain that radiates to 
other parts of your body (eg 
arms, shoulders, hands, neck, 
throat, jaw, back) 
 
     
Palpitations (strong or irregular 
heart beat) 
     
 
 
2. Over the past 4 weeks, on average, how many times have you had chest pain, chest 
tightness, or angina? (TICK ONE BOX ONLY) 
 
 
 4 or 
more 
times 
per 
day 
1-3 
times 
per day 
3 or more 
times per 
week but 
not every 
day 
1-2 
times 
per 
week 
Less than 
once per 
week 
None 
over the 
past 4 
weeks 
 
 
I get chest pain, chest 
tightness, or angina... 
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3. During the past 4 weeks, have you had chest pain, chest tightness or angina: (TICK 
ONE BOX ONLY) 
 
    At rest  On exertion  At rest and on exertion  Not at all  
    
 
4. During the past 4 weeks, how much trouble has your heart condition caused you?  
(TICK ONE BOX ONLY) 
 
     A lot   Quite a bit  Some A little     None  
     
 
1. The following questions ask about activities which you might do during a typical 
day. During the past 4 weeks, has your heart condition limited you in your usual 
daily activities? Please indicate whether your heart condition limits you a lot, limits 
you a little, or does not limit you at all in the activities listed below. 
          
                                                 (TICK ONE BOX PER QUESTION) 
 
 All of the 
time   
A good bit 
of the 
time 
Some of 
the time 
A little of 
the time  
None of 
the time  
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1. Moderate activities, such as 
moving a table, pushing a vacuum 
cleaner, bowling or playing golf 
 
     
2. Lifting or carrying groceries  
     
3. Climbing several flights of stairs  
     
4. Climbing one flight of stairs 
 
     
5. Bending, kneeling or stooping 
 
     
6. Walking half a mile 
 
     
7. Walking one hundred yards 
     
8. Bathing or dressing yourself 
     
 
Heart disease quality of life 
 
We would like to ask you some more questions about how you have been feeling DURING THE 
LAST 2 WEEKS (rather than 4 weeks) 
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Please tick the box        that matches your answer 
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Leave blank if you do not wish to answer 
this question 
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Additional questions about your health  
 
 
1. During the past 2 weeks, how much of the time did you:  
                                                                               (TICK ONE BOX PER QUESTION) 
 All of 
the time   
A good bit 
of the time 
Some of 
the time 
A little of 
the time  
None of 
the time  
Have difficulty reasoning and solving 
problems, for example making plans, 
making decisions, learning new 
things? 
     
Forget, for example things that 
happened recently, where you put 
things or appointments? 
     
Have difficulty doing activities 
involving concentration and thinking? 
 
     
2. Have you ever been diagnosed with dementia?  (TICK ONE BOX ONLY) 
 
        Yes                                         No                                   Not sure 
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3. How would you describe your current living arrangements? 
 
(TICK ONE BOX ONLY) 
 
4. When you need help with tasks, can you count on someone who is willing and able 
to meet your demands? 
 
(TICK ONE BOX ONLY) 
 
Always                               Sometimes                             Never 
                       
If yes who do you receive this support from? (TICK ANY THAT APPLY)  
 
Partner  
 
Other member of the family  
 
Living 
alone 
Living with 
partner/spouse 
Living 
with 
family 
Living in a 
residential 
home 
Living in a 
nursing home 
Living in supported 
accommodation (e.g. 
sheltered housing) 
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Friends  
 
Neighbours  
 
Statutory Organisation  
 
Voluntary Organisation  
 
5. Have you fallen in the last 3 months? 
     (TICK ONE BOX ONLY) 
 
        Yes                                         No                                   Not sure 
                       
                                    
6.  Do you have a problem with losing control of urine or your bowel when you don’t want 
to? 
(TICK ONE BOX ONLY) 
                       
        Yes                                         No                                   Not sure 
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   7.  Have you recently lost weight such that your clothing has become looser? 
(TICK ONE BOX ONLY) 
        Yes                                         No                                   Not sure 
                       
8.  At times, do you forget to take your prescription medications? 
(TICK ONE BOX ONLY) 
        Yes                                        No                                    Not sure 
                       
9. What medications are you currently taking? 
 
Type Dose How often do you take it?  
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Please check that you have answered all the questions 
on each page. 
 
THANK YOU FOR YOUR HELP 
 
Questions about you.   
 
1. a) To which Ethnic Origin group would you say you belong? :  
 
(TICK ONE BOX ONLY) 
 
Black (Caribbean)     Bangladeshi   
Black (British)     Black (African)  
Chinese      Indian    
Pakistani      White (British)  
White (European – non UK)   White (European)  
 
Prefer not to say   
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Other (please state)   ………………………………………… 
 
 b) Nationality  ………………………………………… 
 
 
2. Highest qualification achieved: (TICK ONE BOX ONLY) 
 
None  
      
GCSE / ‘O’ Level/grade / Standard grade/ (G)SVQ Level 2  
  
‘A’ Level / Higher/ (G)SVQ Level 3  
   
Diploma / SVQ Level 4 / HND  
  
Degree     
   
Post-Graduate Qualification    
 
Other (please state)   ………………………………………… 
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3. Employment: 
 
Please tick which category reflects most closely your employment status: 
 
Full-time – paid  
   
Part-time – paid 
    
Full-time – voluntary  
   
 Part-time – voluntary   
  
Unemployed due to age (retired)  
 
Never worked do to disability  
  
No longer work due to disability 
  
Training programme    
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Student 
 
House wife/home maker/house husband 
 
Unemployed 
 
If you work (or have worked), please state the type of work you do (or did) (be as precise 
as possible, e.g. teacher in primary school, clerk in accounts office) 
 
…………………………………………………………………………………… 
 
 
 
Please check that you have answered all the questions 
on each page. 
 
THANK YOU FOR YOUR HELP 
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8.5. Shiels lab protocol for telomere length analysis 
Telomere Assay Protocol 
 
This protocol is designed for use with the Roche Light Cycler 480. 
 
1.1.1.1 Reagents Needed 
 
 DNA 
 Nuclease free H2O 
 SYBR Green I Master – 2x SYBR Green I Master Mix 
                                                    H2O PCR Grade 
           (ROCHE # 04 887 352 001) 
 Telomere Primers 
 36B4 Primers 
 
2.1.1.1 Sample DNA Preparation 
 
For this assay 35ng of DNA is required per well. Each sample is assayed in triplicate in both the 
telomere and 36B4 plates. To each well 5µl of DNA is added (7ngDNA/µl). In total make 35µl 
(245ng DNA) of each sample (7x5µl 6 wells for two plates plus 1 well extra). DNA is diluted in 
nuclease free H2O.  
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 For each sample calculate the volume of DNA and the volume of H2O required: 
 
Volume of DNA reqd (µl) = 245/Concentration (ng/µl) of DNA sample 
Volume of H2O reqd (µl)  = 35 – Volume of DNA reqd 
 
e.g If your stock concentration of DNA is 18ng/µl, you need 13.61µl of DNA (245/18) and 
21.39µl of H2O (35-13.61). 
 
 Label eppendorfs with sample number and aliquot the required volume of H2O. 
 Before aliquoting the DNA, heat to 65oC for 10 minutes then vortex and centrifuge briefly 
to ensure DNA is thoroughly resuspended. 
 Aliquot the required volume of DNA, then vortex and centrifuge sample briefly. 
 Store samples at 4oC until required.  
 
 
3.1.1.1 Standards & Positive Control Preparation 
 
For absolute quantification analyses, serial dilutions of a standard with known concentration are 
used to create a standard curve. The standard curve is then used to determine the concentration of 
the the unknown samples. The crossing point (CP – the point at which the fluorescence of a 
sample rises above the background fluorescence) of the standards (with known concentration) 
and the samples are used to calculate the concentration of the sample DNA. 
 
As with the samples, each standard is assayed in triplicate in both the telomere and 36B4 plates. A 
reference sample with known DNA concentration is used to construct the standard curve. The 
DNA concentration of the standards for this assay range from 100ng to 3.125ng, they are prepared 
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by serial dilution (1:2).  To each well 5µl of standard DNA is added. Therefore need 35µl of each 
standard (7x5µl 6 wells for two plates plus 1 well extra). DNA is diluted in nuclease free H2O.  
If running a lot of plates within a short space of time try if possible to prepare a stock of standards 
for more uniformity between different plates. 
 
 
            1:2                1:2                1:2                   1:2                   1:2 
 
100ng           50ng              25ng             12.5ng             6.25ng             3.125  
 
            35µl             35µl             35µl                35µl                  35µl 
 
 
 e.g For a reference sample with concentration 40ng/µl. Begin by preparing 100ng (20ng/µl) 
standard (remember 35µl is needed for each standard but for 100ng need to make double the 
volume (70µl) since this is the starting concentration) 
 
100ng standard SD1: Volume SD1 reqd = 70µl (1400ng DNA) 
Volume reference DNA reqd (µl) = Amt of DNA reqd/Conc of reference sample 
                     = 1400/40 = 35µl 
 
  
304 
 
             Volume of H2O reqd (µl) = Vol SD1 reqd – Volume of DNA reqd 
                                = 70-35 = 35µl 
 
100ng standard SD1 = 35µl reference DNA + 35µl H2O 
50ng standard SD2 = 35µl SD1 + 35µl H2O 
25ng standard SD3 = 35µl SD2 + 35µl H2O 
12.5ng standard SD4 = 35µl SD3 + 35µl H2O 
6.25ng standard SD5 = 35µl SD1 + 35µl H2O 
3.13ng standard SD6 = 35µl SD1 + 35µl H2O 
 
 
 Label eppendorfs with standard number and aliquot the required volume of H2O. 
 Before aliquoting the DNA, heat to 65oC for 10 minutes then vortex and centrifuge briefly 
to ensure DNA is thoroughly resuspended. 
 Aliquot the required volume of DNA to SD1, then vortex and centrifuge sample briefly. 
 Aliquot the required volume of SD1 and add to SD2, then vortex and centrifuge sample 
briefly. 
 Add SD2 to SD3, SD3 to SD4, SD4 to SD5, SD5 to SD6. Ensure that each standard is 
vortexed and centrifuged before preparing the next one.  
 Store samples at 4oC until required. 
 
 
 
A reference positive control (calibrator) is required in each plate. Use the reference DNA that was 
used to create the standard curve. The concentration of this sample should fall within the range of 
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your standard curve (approximately half way). Therefore for this assay 50ng of DNA is required 
per well for the reference positive control. As with the samples, the reference sample is assayed in 
triplicate in both the telomere and 36B4 plates. To each well 5µl (10ng/µl) of reference DNA is 
added. Therefore need 35µl (350ng) of reference sample (7x5µl 6 wells for two plates plus 1 well 
extra). DNA is diluted in nuclease free H2O. If running a lot of plates within a short space of time 
try if possible to prepare a stock of reference DNA sample for more uniformity between different 
plates. 
 
Volume of DNA reqd (µl) = 350/Concentration (ng/µl) of DNA sample 
Volume of H2O reqd (µl)  = 35 – Volume of DNA reqd 
 
e.g If your stock concentration of reference DNA is 40ng/µl, you need 8.75µl of DNA (350/40) 
and 26.25µl of H2O (35-8.75). 
   
 Label eppendorfs with sample number and aliquot the required volume of H2O. 
 Before aliquoting the DNA, heat to 65oC for 10 minutes then vortex and centrifuge briefly 
to ensure DNA is thoroughly resuspended. 
 Aliquot the required volume of DNA, then vortex and centrifuge sample briefly. 
 Store sample at 4oC until required. 
 
 
4.1.1.1 Primer Preparation 
 
Telomere Primers 
 
  
306 
 
Telo 1 Sequence (5’ to 3’) 
CGG TTT GTT TGG GTT TGG GTT TGG GTT TGG GTT TGG GTT 
 
Telo 2 Sequence (5’ to 3’) 
GGC TTG CCT TAC CCT TAC CCT TAC CCT TAC CCT TAC CCT 
 
Always prepare a 100µM main stock of the primers (in the tube that they are supplied) as per 
Invitrogen instructions (depends on the nanomole quantity of the primers supplied). 
 
 From the 100µM main stock of primers prepare an 8µM stock (1 in 12.5 dilution). (Both 
telomere primers are used at a final concentration of 300nM. 300µls of 8µM primers is 
enough for 4 plates). 
8µM Telo 1: Add 25µls of primer to 287.5µls of H2O  
8µM Telo 2: Add 25µls of primer to 287.5µls of H2O 
 
      Vortex and centrifuge aliquots to ensure primers thoroughly mixed. Store      
      aliquots at –20oC. 
36B4 Primers 
 
36B4d Sequence (5’ to 3’) 
CCC ATT CTA TCA TCA ACG GGT ACA A  
 
  
307 
 
36b4u  Sequence (5’ to 3’) 
CAG CAA GTG GGA AGG TGT AAT CC 
 
Always prepare a 100µM main stock of the primers (in the tube that they are supplied) as per 
Invitrogen instructions (depends on the nanomole quantity of the primers supplied). 
 
 36B4d primer is used at a final concentration of 500nM (in 20µl). Prepare a 25µM stock 
from the main 100µM stock. (300µls of 25µM primer is enough for 4 plates). 
25µM 36B4d: Add 80µls of primer to 240µls of H2O 
 
    Vortex and centrifuge aliquots to ensure primers thoroughly mixed. Store       
          aliquots at –20oC.  
 
 36B4u primer is used at a final concentration of 300nM (in 20µl). Prepare an 15µM stock 
from the main 100µM stock. (300µls of 15µM primer is enough for 4 plates). 
15µM 36B4u: Add 48µls of primer to 272µls of H2O 
 
      Vortex and centrifuge aliquots to ensure primers thoroughly mixed. Store       
      aliquots at –20oC. 
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5.1.1.1 Master Mix Preparation 
 
This assay now uses the SYBR Green I Master from Roche. The kit contains 2x SYBR Green I 
Master Mix and H2O PCR Grade. The only other reagents that need to be added to the master mix 
are the primers. The total reaction volume per well is 20µl; 5µl of this is the sample/standard DNA 
therefore the remaining 15µl is comprised of the master mix. Consequently the total volume of 
master mix required is 1500µl (96 wells x 15µl plus 4 extra wells). The master mix is prepared as 
follow 
 
Per Well Total Reaction Volume = 20µl 
 
2x SYBR Green I Master Mix  
= 20/2 =10µl per well 
Telo1/Telo2 Primers (8µM stock – need final conc to be 300nM)  
= (300/8000) x 20 = 0.75µl per well 
36B4d Primer (25µM stock – need final conc to be 500nM) 
  =(500/25000) x 20 = 0.4µl per well  
36B4u Primer (15µM stock – need final conc to be 300nM) 
  =(300/15000) x 20 = 0.4µl per well 
H2O = Total reaction volume – Volume of Master Mix - Volume of primers 
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Master mix  TEL 
 
 Master mix 36 B4 
Reagent  
Vol reqd  
per well (µl) 
Vol Reqd  
  for 100 wells (µl) 
 Reagent 
    Vol reqd  
  per well (µl) 
Vol Reqd  
    for 100 wells (µl) 
      100 
2x master mix 10 1000  2x master mix 10 1000 
Telo 1 0.75 75  36B4d 0.4 40 
Telo 2 0.75 75  36B4u 0.4 40 
H2O 3.5 350   H2O 4.2 420 
total 15 1500   total 15 1500 
 
 
 Defrost all reagents on ice. SYBR Green I Master is light sensitive therefore make sure that 
it is protected from light at all times. 
 Prepare Telomere Master Mix. Label 1.5ml eppendorf tube and wrap in foil, aliquot 
required volume of H2O. 
 Add Telo 1 and Telo 2 primers to the H2O. 
 Add the correct volume of SYBR Green I Master. Thoroughly mix the master mix by 
pipetting up and down. DO NOT VORTEX OR CENTRIFUGE THE MASTER MIX!! 
 Keep the telomere master mix on ice until ready to use. 
 Prepare 36B4 Master Mix. Label 1.5ml eppendorf tube and wrap in foil, aliquot required 
volume of H2O. 
 Add 36B4d and 36B4u primers to the H2O. 
 Add the correct volume of SYBR Green I Master. Thoroughly mix the master mix by 
pipetting up and down. DO NOT VORTEX OR CENTRIFUGE THE MASTER MIX!! 
 Keep the 36B4 master mix on ice until ready to use 
 
6.1.1.1 Plate Construction 
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Telomere and 36B4 plates should both be prepared on the same day and preferably on the day they 
are going to be run. Prepare one plate at a time, generally telomere plate first then 36B4 plate. This 
prevents confusion and also allows you to run the first plate whilst preparing the second plate. 
Both plates should have the same layout ie all samples should have the same well position in both 
plates. In each plate there will be 6 standards, a reference sample (SC positive control), a no 
template control (negative control – no DNA is added to this well only master mix. The purpose of 
this is to make sure that there is no contamination of any reagents) and 24 unknown samples. Plate 
layout is normally as follows: 
 
 
 
 
 
 
 
 
 
  
             
 1 2 3 4 5 6 7 8 9 10 11 12 
te
lo
m
e
re
 
& 
36
B4
 
A SD1 SD1 SD1 1 1 1 9 9 9 17 17 17 
B SD2 SD2 SD2 2 2 2 10 10 10 18 18 18 
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C SD3 SD3 SD3 3 3 3 11 11 11 19 19 19 
D SD4 SD4 SD4 4 4 4 12 12 12 20 20 20 
E SD5 SD5 SD5 5 5 5 13 13 13 21 21 21 
F SD6 SD6 SD6 6 6 6 14 14 14 22 22 22 
G SC SC SC 7 7 7 15 15 15 23 23 23 
H ntc ntc ntc 8 8 8 16 16 16 24 24 24 
 
 
 Label the plate, with Telomere/36B4, study, date and your name. Take note of the plate 
barcode. 
 Set the 20µl pipette to 15µls and the 10µl pipette to 5µls, to prevent the set volumes 
from changing wrap the pipette dials in tape. 
 Carefully pipette 15µls of Telomere Master Mix into each of the wells. Change pipette 
tip after each well, ensures accuracy and also acts as a check that master mix is added 
to each individual well. Once master mix is added to all wells and you are preparing 
your standards/sample, remember to protect the plate from light by covering with foil. 
 Vortex and centrifuge briefly all standards and samples. 
 Heat all standards/samples to 95oC for 5 minutes, then transfer to ice. 
 Beginning with columns 1-3, carefully pipette 5µls of DNA to the triplicate wells (A1, 
then A2, then A3, then B1, B2, B3 etc etc etc). As with the master mix change pipette 
tip after each well.  Remember to add only H2O to the NTC well. Once DNA has 
been added to the 3 columns cover them to prevent confusion and pipetting into the 
wrong well. 
 Continue adding DNA to the columns in triplicate 4-6, 7-9 and 10-12. 
 Once all the wells have both master mix and DNA added cover the plate with the 
sealing film, making sure that is properly sealed to prevent loss of samples. 
 Wrap the completed plate in foil to protect it from light. 
 Centrifuge the plate at ~2000rpm for 2 minutes. 
 At this stage either run plate on Light Cycler 480 or store at 4oC until ready to use. 
 Once the telomere plate is finished begin the 36B4 plate, preparing it in the exact same 
way as the telomere plate. 
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7.1.1.1 Running Plates on LightCycler 480 
 
Defining Experimental Conditions 
 
 Once your plate is ready to be run on the Light Cycler 480, switch on the computer and 
machine. 
 Double click on the LightCycler 480 Software icon, login to the appropriate database.  
 Starting from the Overview window you can create a new experiment or open an existing 
file. 
 To start a new experiment click on the “new experiment” icon, this will take you to the 
Main Window, where you input your experimental conditions, plate layout, sample names 
etc. 
 The default opening screen is “Experiment” – input experimental conditions here. For the 
Telomere and 36B4 runs the conditions are as follows: 
 
TELOMERE RUNNING CONDITIONS 
 
Program Name 
Heat Start (HS) 
Cycles 
1 
Analysis Mode 
None 
Target (oC) Acquisition 
Mode 
Hold 
(hh:mm:ss) 
Ramp Rate 
(oC/s) 
Acquisitions 
(per oC) 
95 None 00:10:00 4.4  
 
Program Name 
Amplification (Amp) 
Cycles 
30 
Analysis Mode 
Quantification 
Target (oC) Acquisition Hold Ramp Rate Acquisitions 
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Mode (hh:mm:ss) (oC/s) (per oC) 
95 None 00:00:05 4.4  
59 None 00:00:10 2.2  
72 Single 00:02:00 4.4  
 
Program Name 
Melt 
Cycles 
1 
Analysis Mode 
Melting Curves 
Target (oC) Acquisition 
Mode 
Hold 
(hh:mm:ss) 
Ramp Rate 
(oC/s) 
Acquisitions 
(per oC) 
95 None 00:00:30 4.4  
65 None 00:00:30 2.2  
95 Continuous 00:02:00 0.29 2 
 
Program Name 
Cool 
Cycles 
1 
Analysis Mode 
None 
Target (oC) Acquisition 
Mode 
Hold 
(hh:mm:ss) 
Ramp Rate 
(oC/s) 
Acquisitions 
(per oC) 
40 None 00:00:10 2.2  
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36B4 RUNNING CONDITIONS 
 
Program Name 
Heat Start (HS) 
Cycles 
1 
Analysis Mode 
None 
Target (oC) Acquisition 
Mode 
Hold 
(hh:mm:ss) 
Ramp Rate 
(oC/s) 
Acquisitions 
(per oC) 
95 None 00:05:00 4.4  
 
Program Name 
Amplification (Amp) 
Cycles 
35 
Analysis Mode 
Quantification 
Target (oC) Acquisition 
Mode 
Hold 
(hh:mm:ss) 
Ramp Rate 
(oC/s) 
Acquisitions 
(per oC) 
95 None 00:00:05 4.4  
58 None 00:00:15 2.2  
72 Single 00:00:15 4.4  
 
Program Name 
Melt 
Cycles 
1 
Analysis Mode 
Melting Curves 
Target (oC) Acquisition 
Mode 
Hold 
(hh:mm:ss) 
Ramp Rate 
(oC/s) 
Acquisitions 
(per oC) 
  
315 
 
95 None 00:00:30 4.4  
65 None 00:00:30 2.2  
95 Continuous 00:02:00 0.29 2 
 
Program Name 
Cool 
Cycles 
1 
Analysis Mode 
None 
Target (oC) Acquisition 
Mode 
Hold 
(hh:mm:ss) 
Ramp Rate 
(oC/s) 
Acquisitions 
(per oC) 
40 None 00:00:10 2.2  
 
 
 For both telomere and 36B4 plates check that the reaction volume is 20µl 
 
Having set the experimental conditions these san be saved as templates to prevent having to input 
the conditions each time an experiment is run. To create a template, click “Save as Template” and 
select the location to save the template and enter a name for the template. To use this template in 
future runs, start a new experiment and click “Apply Template” icon and then select the required 
template. The template experimental conditions are then applied to the new experiment. 
 
Entering Sample Information 
 
 The next step is to input your sample information, depending on the number and type of 
samples (eg normal vs tumour) you may want to create subsets within the plate layout. This 
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is useful if you are not running a full plate but also allows you to analyse the plate as a 
whole and by individual subsets. To do this click on the “Subset Editor” icon, highlight the 
areas of the plate to be in a subset, then name this subset.  
 To input sample information click on the “Sample Editor” icon. At this stage you can 
either select to input data into the whole plate or into subsets, if they have been created.  
 Select either Abs Quant or Rel Quant depending on what type of analysis is required. 
 Highlight the triplicate wells, input the sample name, select the sample type (Unknown, 
Standard, Negative Control) and click “Make Replicate” Icon. (It is important to make 
the samples replicates so that when the analysis is performed, the average of all three 
triplicates is taken into account).  For standards enter the known concentration into the 
table. 
 
As with the experimental conditions you can save sample information as a template to prevent 
having to input the information each time. Follow the same steps as described for experimental 
templates. 
 
Running Experiment 
 
 Once all sample information is entered, return to the experiment window (click on the 
“Experiment” icon).  
 Load the prepared plate into the machine. Press the push button on the front of the 
machine (located next to the instrument status LEDs). Place the plate into the loading arm 
of the loader with the flat edge pointing towards the instrument). Press the plate loading 
push button again to retract the loader with plate into the machine. You are now ready to 
start the run. 
 Click the “Start Run” icon, you will then be asked to save your run (it wont start until you 
have saved the experiment). Once saved the run begins. 
 A status bar on the “Data” tab indicates the progress of the running experiment.  
 Once the run is finished press the plate loading push button and remove the plate, press the 
button again to close the loader. You are now ready to analyse your experiment or to begin 
a new experiment. 
 
Absolute Quantification 
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Absolute quantification enables you to quantify a single target sequence and express the final 
result as an absolute value. For absolute quantification analyses, serially diluted standards with 
known concentration are used to generate a standard curve. 
A perfect amplification reaction has an efficiency of 2 (every PCR product is replicated once in 
every cycle). The LightCycler 480 software automatically calculates the efficiency. An efficiency of 
2 corresponds to a standard curve slope = -3.3. For accurate analysis and calculation of telomere 
length (Relative T/S) it is necessary to ensure that telomere and 36B4 plates have similar 
efficiencies, slopes between –2.9 and –3.8 are generally deemed acceptable. 
 
 
 To perform absolute quantification analysis, click on the “Analysis” icon. In the Create 
New Analysis box select  “Abs Quant/2nd Derivative Max” or “Abs Quant/Fit Points”. 
(See the Roche LightCycler 480 Manual for more details on the differences between these 
two methods). 
 Click Calculate – the standard curve is generated.  
As well as the standard curve, the error, efficiency and slope of the reaction will be displayed. The 
error is a measure of the accuracy of the quantification result based on the standard curve, this 
value should be less than 0.2. The efficency should be as close to 2 and the slope close to -3.3 as 
possible. 
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Error: 0.0369 
Efficiency: 1.991 
Slope: -3.343 
YIntercept: 
20.29 
Link: 0.000  
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 Having generated the curve, the software then determines the DNA concentration of the 
unknown samples, by using the point at which the unknown sample Cp value falls on the 
standard curve. Cp data from the standards is used to convert the Cp data form the 
unknown samples into DNA concentrations.  
 Check the DNA concentration of your reference sample (SC), the concentration should be 
approximately 50ng in both the telomere and 36B4 plates. 
 Having ensured both telomere and 36B4 plates have worked, proceed to calculating the 
T/S and relative T/S of all samples. 
 
Melting Curve Analysis 
 
The purpose of melting curve analysis is to determine the characteristic melting temperature of the 
target DNA. It is also useful for checking your no template control (negative control) for 
contamination and for the formation of primer-dimers.  
 
 Click the “Analysis” icon 
 In the Create New Analysis box select  “Tm Calling” 
 Click Calculate, a melting curve chart and a melting peak chart will be generated. The Tm 
for the telomere products is ~83oC and for the 36B4 products is ~82.5oC. 
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8.6. Ethics approval letter for biological ageing and 
coronary artery disease 
 
 
           
  
 
 
 
Dr Cathy Johnman 
Public Health and Health Policy  
University of Glasgow  
1 Lilybank Gardens  
G12 8RZ 
 
 
West of Scotland REC 5 
Ground  Floor - Tennent Building 
Western Infirmary 
38 Church Street 
Glasgow  
G11  6NT 
 
 
Date 1 June 2011 
 
 
Direct line 0141 211 2482 
Fax 0141 211 1847 
E-mail WoSREC5@ggc.scot.nhs.uk 
 
Dear Dr Johnman 
Study title: Biomarkers of ageing in coronary heart disease. 
REC reference: 11/AL/0307 
The Research Ethics Committee reviewed the above application at the meeting held on 18 May 2011. 
Thank you for attending to discuss the study. 
Ethical opinion 
To summarise your discussion with the Committee, you confirmed the following main points: 
 WoSRES 
West of Scotland Research Ethics Service 
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• You plan to include all cardiologists and make the procedure routine.  This should therefore ensure 
that the patient numbers should be achieved.  
 
• The storage procedure of the patient top sheets, blood sheets and blood samples and that they will all 
be kept separately.  Permission has been obtained from the Data Protection Officer.  
 
• You expect to publish the results when the linkage data becomes available, which is usually at the 
beginning of each summer.  
 
• Some of the blood will be used for testing with the remainder retained for future research subject to 
consent by the participant.  It was also noted that future research on the retained blood would be 
subject to ethical approval.  
 
• Although follow up was planned for one year, this could be longer due to when linkage data became 
available. 
 
The members of the Committee present gave a favourable ethical opinion of the above research on the basis 
described in the application form, protocol and supporting documentation, subject to the conditions 
specified below. 
Ethical review of research sites 
The favourable opinion applies to all NHS sites taking part in the study, subject to management permission 
being obtained from the NHS/HSC R&D office prior to the start of the study (see “Conditions of the 
favourable opinion” below).  
Conditions of the favourable opinion 
The favourable opinion is subject to the following conditions being met prior to the start of the study. 
Management permission or approval must be obtained from each host organisation prior to the start of the 
study at the site concerned. 
Management permission (“R&D approval”) should be sought from all NHS organisations involved 
in the study in accordance with NHS research governance arrangements. 
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Guidance on applying for NHS permission for research is available in the Integrated Research 
Application System or at http://www.rdforum.nhs.uk.   
Where a NHS organisation’s role in the study is limited to identifying and referring potential 
participants to research sites (“participant identification centre”), guidance should be sought from 
the R&D office on the information it requires to give permission for this activity. 
 
For non-NHS sites, site management permission should be obtained in accordance with the 
procedures of the relevant host organisation.  
 
Sponsors are not required to notify the Committee of approvals from host organisations 
1)  The Consent Form requires to be amended as follows:  
 a) The standard footer should be added stating 1 copy to the participant and the other 
retained for the Research File.    
b) An additional clause is required for the DNA analysis to be carried out on the blood 
samples.  
 2)  The GP Letter should have the name of the Researcher at the bottom.  
 3)  The Participant Information Sheet requires to be amended as follows:  
 a) The standard statement regarding the complaints procedure should be added.  
b) In the section "Who has reviewed the study?", the name of the Ethics Committee should 
be changed to West of Scotland Research Ethics Committee 5.  
 4) All documentation should have the official logo and contact details. 
It is responsibility of the sponsor to ensure that all the conditions are complied with before the start 
of the study or its initiation at a particular site (as applicable). 
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You should notify the REC in writing once all conditions have been met (except for site approvals from 
host organisations) and provide copies of any revised documentation with updated version numbers. 
Confirmation should also be provided to host organisations together with relevant documentation  
Approved documents 
The documents reviewed and approved at the meeting were: 
 Document    Version    Date    
Covering Letter    28 April 2011  
GP/Consultant Information Sheets    13 April 2011  
Investigator CV       
Other: CV - Supervisor -        
Other: CV - Supervisor       
Participant Consent Form  1.0  13 April 2011  
Participant Information Sheet  1.0  14 April 2011  
Protocol  1  13 April 2011  
Questionnaire  1.0  13 April 2011  
REC application    28 April 2011  
 
Membership of the Committee 
 
The members of the Ethics Committee who were present at the meeting are listed on the attached sheet. 
 
Statement of compliance  
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The Committee is constituted in accordance with the Governance Arrangements for Research Ethics 
Committees (July 2001) and complies fully with the Standard Operating Procedures for Research Ethics 
Committees in the UK. 
 
After ethical review 
 
Now that you have completed the application process please visit the National Research Ethics Service 
website > After Review 
You are invited to give your view of the service that you have received from the National Research Ethics 
Service and the application procedure. If you wish to make your views known please use the feedback form 
available on the website. 
The attached document “After ethical review – guidance for researchers” gives detailed guidance on 
reporting requirements for studies with a favourable opinion, including: 
• Notifying substantial amendments 
• Adding new sites and investigators 
• Progress and safety reports 
• Notifying the end of the study 
 
The NRES website also provides guidance on these topics, which is updated in the light of changes in 
reporting requirements or procedures. 
We would also like to inform you that we consult regularly with stakeholders to improve our service. If you 
would like to join our Reference Group please email referencegroup@nres.npsa.nhs.uk. 
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11/AL/0307 Please quote this number on all correspondence 
 
With the Committee’s best wishes for the success of this project 
Yours sincerely 
 
On behalf of 
Mrs Liz Tregonning  
Vice-Chair 
Enclosures: List of names and professions of members who were present at the meeting and 
those who submitted written comments 
“After ethical review – guidance for researchers”  
 
Copy to: Dr Catherine Sinclair, National waiting Times Centre, Golden Jubilee National 
Hospital 
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8.7. Participant information leaflet for biological ageing 
and coronary artery disease 
 
 
 
 
PARTICIPANT INFORMATION LEAFLET 
Biological ageing and coronary heart disease 
Introduction 
You are being invited to take part in a research study.  Before you take part it is important for you 
to understand why the research is being done and what it will involve.  Please take time to read 
the following information carefully and to discuss it with others if you wish.  Ask us if there is 
anything that is not clear or if you would like more information (contact details are at the end of 
this leaflet or ask the cardiac research nurse)  
What is the purpose of the study?  
Physical ageing (also known as biological ageing) is faster in some people than others. People of 
the same age since birth can have different biological ages.  
We want to compare people with heart disease with people of the same age who do not have 
heart disease to see if they have a different biological age and, if so, why. In particular, we wish to 
investigate whether biological ageing is related to inflammation which can be more common in 
patients with heart disease.  
To do this, we want to take a small blood sample to measure markers of biological ageing (such 
as telomere length which is the length of the protective cap at the end of chromosomes) and 
Golden Jubilee National Hospital  
NHS national waiting times centre 
 
  
328 
 
markers of inflammation. Our aim is to use the findings of this study to benefit patients in the 
future by providing a better understanding of what causes heart disease and how we might 
prevent it.   
Why have I been chosen? 
You have been chosen because you are having a cardiac test at the Golden Jubilee to 
investigate whether or not you have coronary heart disease or you are having a procedure to 
treat narrowing of the blood vessels of the heart. 
Do I have to take part? 
It is up to you to decide whether or not to take part.  If you decide to take part you will be given 
the opportunity to discuss your involvement with your cardiologist or one of the cardiac research 
nurse at the time of your admission where you will be asked to sign a consent form.  If you decide 
to take part you are still free to withdraw at any time without having to give a reason.  Whether 
you take part or not, will not affect the type or the standard of care you receive.    
What will happen if I take part? 
We will take a small amount of blood (10millilitres - about 2 teaspoonfuls) to be tested for 
biomarkers of biological ageing.  The doctor will take this through the same needle that he/she 
will be using for your cardiac test therefore no additional jags are required. We will not feedback 
any information regarding blood results to participants as they will be analysed in an anonymised 
manner.  
We will ask you to complete a very short quality of life questionnaire which should take less than 
5 minutes to complete.    
 
We will use routine clinical information to follow up you up for 1 year after your test.   We can do 
this without having to contact you again.   
What are the possible benefits of taking part?  
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Taking part in the study will be of no direct benefit to you but will be very useful in providing 
valuable information which could be helpful in caring for future patients.   
Will my taking part in the study be kept confidential?  
All information which is collected about you during the course of the research will be kept strictly 
confidential.  If you agree, we will contact your GP to inform them that you are taking part in this 
study. 
Your information will be held within a secure environment both here and in the University of 
Glasgow Research Office.  
What will happen to the results of the research study? 
Only those directly involved in the study will have access to any information which has your name 
and address on it and then, only for the purposes of arranging the study follow up.   
Information will be transported to the University of Glasgow Research Office within a secure bag, 
which is locked, and taken by NHS transport services.  
Your name and other details will be removed from the questionnaire and will be kept separate 
from your answers.   
Any information which is then examined for this study will have your name and address removed 
so that you cannot be recognised from it.   
Results of the study will be published in medical journals and will form part of the Chief 
Investigator’s PhD thesis.  
Who has funded the research? 
The research is jointly funded by the NHS and by the University of Glasgow Patterson Bequest 
Fund.  
Who has reviewed the study? 
The study was reviewed and approved by the West of Scotland Ethics Committee 5.  
Direct Study Contacts: 
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Research Nurses:  
Joanne Kelly, Maureen Mason and Elizabeth Boyd 
Golden Jubilee National Hospital  
Beardmore Street  
Clydebank 
G81 4HX 
Tel: 0141 951 5256 
Email: joanne.kelly@gjnh.scot.nhs.uk 
Chief Investigator: 
Dr Cathy Johnman 
Hutchison Research Fellow/Clinical Lecturer/SpR Public Health 
Centre for Population and Health Based Sciences 
Public Health and Health Policy 
University of Glasgow 
1 Lilybank Gardens 
Glasgow 
G12 8RZ 
0141 330 8547 
Email: Cathy.Johnman@glasgow.ac.uk 
For independent advice on this study, if required, please contact: 
Dr Roy Gardener, Consultant Cardiologist 
National Waiting Times Centre Board  
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Golden Jubilee National Hospital  
Beardmore Street  
Clydebank 
G81 4HX 
 
What if I have a complaint about this study?  
If you have any concerns or complaints about any aspect of this study you should ask to speak to 
Dr Cathy Johnman, the Chief investigator of this study or one of the Cardiac Research Nurses at 
the Golden Jubilee National Hospital. If you remain unhappy and wish to complain formally you 
can do this through the usual NHS complaints procedure. 
 
 
 
 
 
 
 
 
 
  
332 
 
8.8. Participant consent form for biological ageing and 
coronary artery disease 
 
 
CONSENT FORM 
 
Biological ageing and coronary heart disease 
 
Study number:       ………………………………………………………. 
 
Name:        ………………………………………………………. 
 
Hospital:       Golden Jubilee Hospital 
 
 
 
CHI Number:   
(Community Health Index) 
Please put your  
initials in boxes 
 
 
I confirm that I have read and understood the information leaflet 
 
 
 
I understand that I will be asked to complete an initial questionnaire on admission  
and that additional questionnaires will be sent to me at 3, 6 and 12 months after  
my procedure 
          
Golden Jubilee National Hospital  
NHS national waiting times centre 
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I understand that the research team may wish to contact me for follow up should  
it be required 
 
 
I understand that my GP will be informed of my involvement in this study 
 
 
I understand that the research team may wish to access my notes to provide  
additional follow-up information about my health.  
 
 
   
Name of participant  
 
Date Signature 
   
Name and designation  of person 
taking consent   
 
Date  Signature 
Version 2.0 03/06/2011 
 
 
 
 
 
